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ABSTRACT 
 
Topical microbicides are being developed as a female-controlled method for preventing 
HIV-1 infection. Non-antiretroviral (ARV)-based candidates may be advantageous given 
increasing levels of ARV resistance in low and middle- income countries. 
MABGEL 1 was a phase 1 trial designed to evaluate the pharmacokinetics and safety of a 
vaginal microbicide containing the broadly HIV-1 neutralizing monoclonal antibodies 
(mAbs) C2F5, C4E10 and C2G12 in a hydroxyethylcellulose-based gel vehicle. It was the 
first study of topical mAb application to the human female genital tract. 
Twenty-eight healthy women were randomised to apply either high dose Mabgel 
(containing 20mg/g of each mAb) (n= 10), low dose Mabgel (containing 10mg/g of each 
mAb) (n=9) or placebo gel (n=9). Doses (2.5ml) were applied over 12 consecutive days. 
Genital tract sampling was performed at baseline, 1 hour, 8 hours and 24 hours post 1st 
dose and 12 and 36 hours post 12th dose with serum samples collected at baseline, 8 
hours post 1st dose and 12 hours post 12th dose. Safety was assessed through participant 
report and clinical examination, including colposcopy. 
Residence half-lives (t ½) in vaginal secretions (Weck-Cel samples) were estimated to be 
between 4 and 5.5 hours for C4E10 and C2F5. In contrast, vaginal levels of C2G12 did not 
conform to a single overall exponential decay, displaying a more rapid initial rate of 
decline, which then slowed at lower concentrations.  The estimated early t ½ of C2G12 
was 1.4 hours (95% CI 1.2 to 1.8).  There was no evidence of systemic absorption. 
Daily vaginal application of up to 50g of each mAb over 12 days was safe. Although 
adverse events (AEs) were reported by all but 1 participant, 95 % were mild, none were 
serious and only 4 were moderate. There was no statistically significant difference in the 
number of AEs reported per participant between the 3 study arms.  
Although there are a number of caveats, results demonstrate ‘proof of principle’ of the 
potential for combinations of HIV-1 neutralizing mAbs to be used as a coitally-dependent 
microbicide.  
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15 
 
IC90 Antibody concentration needed to achieve 90%  
virus neutralization in-vitro  
 
ID Identification number  
IDU Injection drug use  
IFN Interferon  
Ig  Immunoglobulin   
IL Interleukin  
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MHRA Medicines and Healthcare products Regulatory 
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MRC CTU Medical Research Council Clinical Trials Unit  
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MUC 
ND 
Men who have sex with men 
Glycoprotein constituent of mucin 
Not detectable 
N9 Nonoxynol 9  
NALT Nasal-associated lymphoid tissue  
NAb Neutralizing antibody  
Nef Negative regulatory factor (HIV accessory protein)  
NF-ĸB Nuclear factor kappa B   
NHP Non-human primate  
NHS National Health Service  
NK cell Natural Killer cell  
NKR NK cell receptor  
NMB Non-menstrual bleeding  
NNRTI Non-nucleotide reverse transcriptase inhibitor  
NRTI Nucleotide reverse transcriptase inhibitor  
OE On examination  
ORF Open reading frame  
OTC Over the counter  
PAMP Pathogen associated molecular pattern  
PBS Phosphate buffered saline  
PD Pharmacodynamics  
pDC Plasmacytoid dendritic cell  
PEP Post-exposure prophylaxis  
PHI Primary HIV infection  
PI Protease Inhibitor  
pI Isoelectric point  
PID Pelvic inflammatory disease  
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PIS Participant Information Sheet  
PHI Primary (acute) HIV  
PK Pharmacokinetics  
PMN  Polymorphonucleocytes  
Pol  HIV enzyme precursor protein  
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R & D Research and Development  
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Secreted 
 
RBCs Red blood cells  
RCT Randomised controlled trial  
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RNA Ribonucleic acid  
RR Relative risk  
RT Reverse transcriptase (HIV enzyme)  
RTI Reverse transcriptase inhibitor  
SAE  Serious adverse event  
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TLR Toll-like receptor  
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TMG Trial Management Group  
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U and Es Urea, creatinine and electrolytes  
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UM 
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URVI Unprotected receptive vaginal intercourse  
V1 to V5 Variable regions of HIV-1 gp120  
Vc Central volume of distribution  
VEC Vaginal-ectocervical tissue model  
VH Variable region of Ig heavy chain  
VL Viral load  
Vpr 
Vpu 
Viral protein R (HIV accessory protein) 
Viral protein U (HIV accessory protein) 
 
Vss Steady state volume of distribution  
WBC White blood cell  
Weck-Cel Weck-Cel ophthalmic sponge  
WHO World Health Organization  
WT Wild-type  
X4 CXCR-4 using (tropic) HIV-1 isolate  
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1. INTRODUCTION  
1.1 Overview of the state of the HIV-1 pandemic 
Thirty years have passed since the first cases of Acquired Immunodeficiency Syndrome 
(AIDS) were recognised by the United States Centres for Disease Control (CDC) [1,2] and 
there have now been over 30 million deaths from AIDS worldwide [3,4]. The past three 
decades have seen remarkable scientific and clinical progress in identifying the underlying 
causative agent, the retrovirus HIV-1 (human immunodeficiency virus type 1), 
understanding its role in pathogenesis and developing interventions to halt its 
progression [5,6]. Rapid and accurate HIV diagnosis is now possible at point-of-care and 
disease can be monitored through the measurement of CD (cluster of differentiation) 4-
expressing T lymphocytes (CD4+ T cells), the main target cell depleted by HIV infection, 
and HIV ribonucleic acid (RNA) copy number, or Viral load (VL), in plasma [7,8].  Since 
1996, combinations of antiretroviral agents (ARVs), known as highly active antiretroviral 
therapy (HAART), have been available in high-income countries with the ability, provided 
adherence is good,  of  suppressing HIV replication to  below the limits of detection (VL < 
50 copies/ml) in plasma  [9]. The prognosis of individuals receiving such treatment has 
been transformed and, with early diagnosis and guideline-recommended regimens, an 
HIV-1-infected individual can now achieve a near normal life-expectancy [10]. Between 
2001 and 2010, the number of people in resource-poor regions who had access to HIV 
treatment increased by 22 fold [3]. In 2011, another 1.4 million people started ARVs in 
these regions, bringing the total receiving treatment to 8 million [4]. However, although 
this represents a huge achievement, there are still currently another 9 million individuals 
who are not on treatment, but who require it based on clinical and CD4-count ≤ 350  
cells/mm3  thresholds, and there were 1.7 millon deaths from AIDS in 2011 [4,11]. 
Despite some significant advances we are a long way from controlling the HIV-1 
pandemic. Unfortunately,  opportunities to try to limit the spread of HIV in the early years 
after its discovery were not taken up, with the responses provided by most governments 
and global non-government organisations in the 1980s and 1990s being ‘too little, too 
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late’ [12]. This, coupled with increasing survival, mean there are now estimated to be     
34.2 million people living with HIV-1 world-wide, 97 % of whom reside in low or middle 
income countries [4]. Despite a gradual decline in the global annual HIV-1 incidence of 
almost 1/4 in the past decade, there are still 2.3 million new infections in adults per year, 
with 70% occurring in sub-Saharan Africa [3]. Indeed, for every 2 people started on ARVs, 
another 3 become newly infected [4]. At the current rate of growth, the costs attributable 
to caring for the HIV-1 infected population are not sustainable. Thus, development and 
implementation of effective HIV prevention strategies is a global research priority [13]. 
HIV-1 infections can be acquired through exposure to infected body fluids via three major 
routes.  Firstly, blood to blood, i.e. through transfusions, sharing needles and needle-stick 
injuries. Secondly, vertically from mother to child, either in-utero, during delivery or 
through breast feeding. Thirdly, via sexual intercourse. In adults, although HIV-1 
transmissions are increasing in association with injection drug use (IDU), especially in 
Eastern Europe and Central Asia, over 80% of infections are acquired through sex [3,4]. 
High rates of transmission continue to be seen in men who have sex with men (MSM), 
who were the initial population in whom HIV-1 was first detected in high-income 
countries. However, the overwhelming majority of infections world-wide occur in 
heterosexuals [4]. 
Young women, especially in Africa, appear particularly vulnerable to acquiring HIV. 
Globally, around half of all people living with HIV-1 are female.  In sub-Saharan Africa, 
women account for almost 60 % of HIV-1 infected adults, however, in the 15 to 24 year 
age group, this proportion rises to almost 3/4 [3]. In many of the most highly-affected 
regions, young women are up to 3 times more likely to be HIV-1 infected than men of the 
same age [4]. World-wide, women under 25 account for over a 1/4 of the total new HIV 
infections in those aged 15 or older [3]. The explanation for the excess of infections in 
young women is multi-factorial with inter-generational partnerships, gender inequalities, 
hygiene practices, sexually transmitted infections (STIs), hormonal contraceptive use and 
innate biological susceptibility all playing a role [4, 14, 15].  Understanding these factors 
and how they interact to enhance HIV-1 transmission will be crucial to developing 
successful HIV prevention strategies for this important target population [16].  
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A growing number of interventions have shown potential in reducing sexual transmission 
of HIV-1 [17]. Behavioural strategies, which are aimed largely at reducing high risk sexual 
encounters, include increasing HIV testing and knowledge of HIV serostatus, delaying 
coitarche, reducing the number and concurrency of sexual partnerships and encouraging 
correct and consistent condom use.  Biomedical methods, ideally used as an adjunct to 
the above, include measures both to reduce donor infectiousness, and to decrease 
recipient susceptibility.  Earlier initiation of ARV treatment of HIV infected individuals to 
reduce onward transmission is a particularly promising strategy. Examples of 
interventions which aim to directly protect HIV seronegative individuals are medical male 
circumcision, the use of systemic or topical ARVs (as pre-exposure prophylaxis (PrEP)), 
non-ARV-based topical microbicides, and, ultimately, once developed, an effective 
prophylactic vaccine.  
This thesis is primarily concerned with the first-in-human evaluation of a novel vaginal 
microbicide, MABGEL, containing three HIV-1 neutralizing monoclonal antibodies (mAbs) 
and its potential role in preventing HIV-1 transmission to women. The aims of the 
remainder of this introductory chapter are to: 1) Provide relevant background 
information regarding the virology and life-cycle of HIV-1, anatomy and physiology of the 
human female genital tract (FGT) and innate and adaptive mucosal immune defenses; 2) 
Give an overview of HIV-1 transmission via the FGT, including factors which influence its 
efficiency; 3) Discuss the current status of biomedical HIV prevention strategies and the 
rationale behind the development of an anti-HIV-1 mAb-based vaginal microbicide. 
1.2 Basic virology of HIV-1 
HIV-1 is a human lentivirus of the Retroviridae family [18,19].  It is closely related to HIV-2  
and both HIV viruses are believed to have originated in West-Central Africa as zoonoses 
from the Simian Immunodeficiency Viruses (SIV)  affecting chimpanzees (SIVcpz) and sooty 
mangabeys (SIVsmm) respectively [20, 21]. In comparison to HIV-1, HIV-2, is generally less 
pathogenic and has largely remained confined to its region of origin [22].   
Phylogenetic analysis of HIV-1 viral nucleotide and amino acid sequences has identified 
three separate groups, known as M (main), O (outlier) and N (Non-M, non-O), that are 
thought to have arisen through separate cross-species transmission events. Viruses in 
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group M, the only group to become widely established, have been further divided into 
subtypes (or clades), and circulating recombinant forms (CRFs) have also arisen through 
co-infections with two or more distinct subtypes [23].  HIV-1 subtypes are largely 
geographically separated, with subtype B predominating in MSM populations in high 
income countries (Europe, USA, Japan, Australia), South and Central America and the 
Carribean, C in Southern Africa and Asia (responsible for > 50% of all infections 
worldwide), A and D in Central and Eastern Africa, and CRF01_ AE and CRF02_ AG  in 
Thailand and Central Africa [24].  However, increased migration and air travel has resulted 
in the global dispersal of most subtypes.  
1.2.1 Viral genes, life-cycle and targets for intervention 
The general organization of the HIV-1 viral particle (virion) and genome are shown in 
Figure 1-1 and Figure 1-2. HIV-1 genes, resultant proteins and their main functions are 
outlined in Table 1-1. Each virion contains two copies of the full-length HIV-1 RNA 
genome. The HIV-1 genome is approximately 9 kb in length and is flanked at each end by 
single long terminal repeats (LTR). These are required for integration into the host cell 
nuclear deoxyribonucleic acid (DNA) and contain promoter sequences necessary for gene 
expression, including binding sites for the viral protein Tat and host transcription factors 
such as nuclear factor kappa B (NF-ĸB) [25]. Three of the nine open reading frames (ORFs) 
encode the Gag, Gag-Pol and Env polyproteins (later cleaved into individual proteins by 
the viral protease). The gag gene products are core structural proteins responsible for the 
assembly of the virion. In contrast, pol encodes three enzymes essential for viral 
replication: reverse transcriptase (RT) (an RNA-dependant DNA polymerase), integrase 
(INT) and protease (PR), which are also incorporated within the virion [26]. The env 
(envelope) gene encodes the viral glycoproteins which become embedded in the host cell 
membrane, through which the virion buds to derive its outer covering [25,26]. The 
products of the other six ORFs are accessory proteins with gene regulatory (Tat and Rev) 
[27,28] or virulence-enhancing (Vif, Vpr, Vpu and Nef) functions [29,30]. Vif, Vpr and Nef 
are also found in the viral particle [26]. 
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Figure 1-1  The HIV-1 virion 
 
Figure reproduced with permission from evolutionarymodel.com. Accessed at http:// 
www.evolutionarymodel.com/ERV_2.JPG  on 2 June 2012. 
 
Figure 1-2 The HIV-1 RNA genome 
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Table 1-1 HIV genes, proteins and their main functions 
Gene Protein Function 
Structural and enzymatic proteins [25, 26] 
Gag p24 Capsid Important for particle formation; encapsidates viral 
enzymes and genomic RNA. 
 p17 Matrix Forms a shell on inner side of membrane. Responsible for 
virion stability and maturation; role in uncoating and 
transport of pre-integration complex to the nucleus. 
 p9 Nucleocapsid Binds single stranded genomic RNA and ensures it is 
packaged into virions. 
Pol p6 Proline-rich 
protein 
Involved in virion assembly and release. 
 p10 Protease Mediates cleavage of Gag and Gag/Pol polyproteins. 
 p31 Integrase (IN) Mediates integration of reverse transcribed HIV-1 DNA 
(provirus) into the host cell DNA. 
 p66/p51  Reverse 
transcriptase (RT) 
Has DNA polymerase and RNAse H activity, copies viral RNA 
into DNA. 
Env gp41 
Transmembrane 
(TM) 
Anchors envelope glycoprotein complex to host/virion 
surface membrane; mediates fusion of virus and target cell 
membranes. 
 gp120 Surface (SU) External glycoprotein which forms complexes with gp41; 
major determinant of cell tropism and target of most 
neutralizing antibodies; binds CD4 and chemokine co-
receptors on target cells. 
Regulatory and virulence-enhancing proteins 
Tat p14      
Transcriptional 
activator 
Transcriptional and post transcriptional regulator of HIV-1 
gene expression; enhances expression of viral genes [28]. 
Rev p19 Regulator of 
virion expression 
Post transcriptional regulator of HIV-1 gene expression; 
promotes nuclear export, stability and translation of mRNA 
transcripts containing the Rev responsive element [27]. 
Nef p27 Negative 
regulatory factor 
Promotes activation of infected cells to help establish 
persistent infection; downregulates expression of surface 
major histocompatibility complex (MHC) and CD4 
molecules to assist infected cells in evading the host 
immune response [29]. 
Vpr p14 Viral protein R Helps regulate nuclear import of the HIV-1 pre-integration 
complex, and is required for virus replication in non-
dividing cells such as macrophages. Vpr also induces G2 cell 
cycle arrest and apoptosis in proliferating cells [29]. 
Vpu p16 Viral protein U Binds to BST2/tetherin on host cells to facilitate virion 
budding and release [30]. 
Vif p23 Viral infectivity 
factor  
Binds the cytidine deaminase enzyme APOBEC 3G and 
targets it for cellular degradation. APOBEC 3G mutates viral 
nucleic acids and prevents ongoing replication [31]. 
 
  
28 
 
 
Figure 1-3  HIV-1 Viral Life-Cycle 
 
Figure adapted from Boyer R, 2002 [32] 
The HIV-1 lifecycle can be divided into stages as depicted in Figure 1-3. These include: 1) 
Viral attachment to host cells; 2) Fusion of viral and host cell membranes; 3) Viral 
uncoating; 4) Reverse transcription of viral RNA to DNA; 5) Integration of viral DNA 
(provirus) into the host cell genome; 6) Transcription of provirus by host cell RNA 
polymerase II; 7) Translation of RNA transcript into viral proteins; 8) Virion assembly; and 
8) Budding and maturation of infectious virus.  Each of these stages represents a potential 
opportunity for intervention. Currently licensed ARV drugs for HIV-1 treatment fall into 
four main classes.  Examples from each class and their mode of action are given in Table 
1-2 [9]. 
A newly produced replication-competent HIV-1 virion can cause at least 3 types of 
infection event: 1) It may productively infect a target cell, e.g. an activated T Cell, which 
then rapidly produces a large quantity of virus prior to cell death; 2) It may infect a long-
lived cell, e.g. a macrophage, with capacity to produce virions at a slower rate but over a 
longer duration; 3) It may become integrated as a ‘latent’ provirus into a non-activated   
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Table 1-2  Current licensed antiretroviral agents 
Drug Class Target/Mechanism of 
Action 
Examples Licensed 
dosage 
form 
Entry inhibitors   
CCR5 inhibitors Small molecule.  Binds 
to small pocket on CCR5 
trans-membrane 
domain to Inhibit gp120 
- CCR5 interaction.  
Maraviroc (Celsentri® (ViiV) Oral 
Fusion 
inhibitors 
Bio-mimetic peptide. 
Inhibits gp41-mediated 
cell - viral membrane 
fusion. 
Enfuvirtide (T20, Fuzeon®, Roche) Subcut 
Reverse transcriptase inhibitors  
Nucleoside RT 
inhibitors  
(NRTIs) and 
nucleotide RT 
inhibitors 
(NtRTIs) 
Nucleoside/nucleotide 
analogues. Act 
intracellularly as 
competitive substrate 
inhibitors. Incorporated 
into the newly 
synthesized viral DNA 
strand as ‘faulty’ 
nucleotides causing 
chain-termination. 
Zidovudine (AZT, Retrovir®, ViiV);  
Lamivudine (3TC, Epivir®, ViiV);  
Emtricitabine (FTC,  Emtriva, 
Gilead); 
Abacavir  (ABC, Ziagen®, ViiV); 
Tenofovir (the only NtRTI) (TDF, 
Viread®, Gilead) 
Combinations include: 
Truvada® (TDF and FTC); Kivexa® 
(ABC and 3TC); Combivir® (AZT 
and 3TC); Atripla® (Truvada plus 
Efavirenz); Eviplera® (Truvada 
plus Rilpivirine) 
Oral 
Non-nucleoside 
RT inhibitors 
(NNRTIs) 
Non-competitive 
inhibitors. Bind to the 
RT enzyme at a site 
distant from its active 
site to inhibit function. 
Nevirapine (Viramune®, 
Boehringer Ingelheim);  
Efavirenz (Sustiva®, Bristol-Myers-
Squibb); 
Etravirine (Intelence®, Tibotec); 
Rilpivirine (Edurant®,Tibotec) 
Oral 
Protease 
inhibitors (PIs) 
Inhibit the HIV-1 
protease and block 
virion assembly. 
Ritonavir (Norvir®, Abbott)(used 
in low dose to boost levels of 
other PIs);  
Atazavavir (Reyataz®, Bristol-
Myers Squibb); 
Darunavir (Prezista®, Tibotec); 
Kaletra® (lopinavir plus ritonavir, 
Abbott) 
Oral 
Integrase 
strand –
transfer 
inhibitors 
(INSTIs) 
Inhibit the ‘strand 
transfer’ step of 
integration, in which 
the 3' ends of viral DNA 
are covalently ligated to 
host cell DNA. 
Raltegravir (Isentress®, Merck) 
 
Oral 
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cell, e.g. a memory T Cell, with potential for production of viral progeny on future 
reactivation. The establishment of latent reservoirs clearly reduces any ability to 
eradicate infection [33]. Thus, strategies to prevent initiation of HIV-1 infection must 
primarily act before or during the integration stage.  
1.2.2 Structure of HIV-1 envelope glycoproteins 
The glycoproteins on the surface of HIV-1 play a key role in virus-cell binding and fusion 
and determine its cellular tropism. In addition, they are the main targets of the host 
neutralizing antibody response (see section 1.4.4) [34,35]. The env gene encodes a 160 
kilodalton (kDa) polyprotein, gp160, which is cleaved intracellularly to produce two 
smaller proteins, gp 120 and gp41.  The heavily glycosylated gp120 is positioned on the 
surface of the viral particle, whereas the relatively hydrophobic gp41 is a transmembrane 
protein embedded in the lipid-bilayer of the viral envelope (see Figure 1-1). Each gp120 
molecule binds, non-covalently, to one of gp41 and, in their native state, form trimers 
with two other gp120-41 heterodimers. Cryoelectron tomographic studies suggest that 
each Env ‘spike’ consists of a globular ‘head’ formed from three gp120 molecules on a 
‘stalk’ made up of three, obliquely projecting gp41 proteins, similar to a tripod. As 
opposed to being evenly spaced, these spikes form clusters and there may be as few as 
14±7 spikes per virion [36].  
Gp120 contains five regions of high nucleotide and amino acid heterogeneity (designated 
V1-V5), and five more conserved areas (C1-C5). Crystal structures of gp120 show that it is 
folded into three major domains (see Figure 1-4). The inner domain, formed mainly by 
regions C4-C5, is the interface of interaction with gp41. The outer domain, comprised of 
the variable regions, forms the external portion, most accessible to antibodies, and 
contains potential sites for glycosylation.  Linking these major domains is a bridging sheet 
[34,35]. Of note, Env gp120 gene sequences can vary by > 25 % between different HIV-1 
clades. In contrast, being largely hidden within the viral membrane, the entire sequence 
and structure of gp41 is relatively conserved [34].   
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Figure 1-4  Schematic Representation of the crystal structure of gp120 both unbound 
and bound to CD4 
 
A. Structure of gp120 in its native state (from the perspective of CD4) 
B. Conformational changes induced in gp120 on binding CD4. 
Figure reproduced from Prabakaran P et al. 2007 [34].   
 
1.2.3 HIV-1- target cell tropism and entry 
Virus-cell attachment and fusion of viral and cell membranes occurs in a number of 
stages.  Initially, gp120 binds to the receptor CD4;  a molecule present on the surface of a 
number of cell types, including ‘helper’ T cells, macrophages and dendritic cells (DCs)[37].  
The CD4 binding site (CD4bs) is a deeply recessed region on gp120, formed by the 
interface between the inner and outer domains and the bridging sheet, and is partly 
shielded by the V1/V2 loops within a long cavity [34]. 
Binding to CD4 triggers conformational changes in gp120 leading to the formation of a co-
receptor binding site (consisting of a four stranded bridging sheet shaped from C4 and the 
V1/V2 stem and part of the V3 loop) [38]. Gp120/CD4 complex-co-receptor binding 
causes further conformational rearrangements in Env, resulting in the insertion of the 
hydrophobic amino-terminus of gp41 (the ‘fusion peptide’) into the host cell membrane. 
Gp41 then dissociates from gp120 and undergoes further re-folding, to produce a 6-helix 
bundle. This results in a complete fusion of cell and viral membranes, in which the fusion 
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peptide and the transmembrane segment of gp41 lie parallel on a contiguous bilayer [35].  
Recent evidence suggests that complete virus-cell fusion does not occur at the cell 
surface but instead, following CD4 and co-receptor mediated endocytosis, takes place in 
endosomes [39]. Virion contents are subsequently released into the cytoplasm in close 
proximity to the nucleus.  Although the interaction between a single Env spike and CD4 
plus co-receptor may be sufficient to enable HIV to enter cells, this has not been fully 
determined, and it is possible that the binding of multiple spikes to multiple receptors 
may be required. 
By far the most commonly used co-receptors are CC-chemokine receptor type 5 (CCR5) or 
CX-chemokine receptor type 4 (CXCR4). Most HIV-1 isolates utilize one of these in 
preference to the other, determined by the nature and distribution of charged amino 
acids in the V3 loop. Viruses binding to CCR5 are referred to as being R5 tropic, in 
contrast, CXCR4 using viruses are X4 tropic [40,41]. These chemokine receptors are 
expressed by a range of cell types, which, if also expressing CD4, constitute potential 
target cells for HIV-1.  Both CXCR4 and CCR5 are found on activated and memory (but not 
‘naive’) T cells and DCs, whereas ‘naive’ T cells (those which have not yet been exposed to 
cognate antigen) express only CXCR4 and macrophages only CCR5 [41,42,43,44]. In 
general, R5 tropic viruses predominate in early HIV infection, with X4 using isolates 
emerging with disease progression in some individuals [45,46,47]. However, the exact 
triggers of the R5 to X4 switch and its relationship to increasing HIV replication and 
immunosuppression are not fully understood. 
1.2.4 Reverse transcription and genetic heterogeneity 
Before the HIV-1 RNA genome can be integrated into the host chromosome it must first 
be reverse-transcribed into double-stranded DNA. Both RNA-dependent and DNA-
dependent polymerization steps are catalyzed by RT, with RNA-DNA hybrids cleaved by its 
RNase H domain [26]. Reverse-transcription and the subsequent copying of the integrated 
provirus by host RNA polymerase II are both error prone processes, promoting frequent 
mutations and recombinations in the HIV-1 genome [48].  In the absence of inhibitors, 
HIV-1 replicates at a high rate and, on average, one mutation will be incorporated into 
each virion produced [23]. Thus, HIV-1 exists as a mixture of genetically heterogeneous 
quasi-species, even within a single individual.  
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1.3 Basic anatomy and physiology of the human female genital 
tract 
The female genital tract (FGT) is primarily designed for the purpose of reproduction and 
the structure, lining epithelia and secretions of its constituent organs reflect their various 
roles in this process [49]. The lower FGT is comprised of the vagina and ectocervix 
whereas the upper tract consists of the endocervix, uterus, oviducts (Fallopian tubes) and 
ovaries (see Figure 1-5) [49,50]. Hormonal effects on these tissues have important 
implications both in the evaluation of a topical vaginal product and in influencing 
susceptibility to HIV transmission and are discussed in sections 1.3.1 and 1.3.2. 
The vagina is the part of the FGT into which seminal fluid and spermatozoa are ejaculated 
during sexual intercourse. It is also the conduit for menstrual blood and for the delivery of 
the neonate. The human vagina is a fibro-muscular tube, approximately 9cm long, leading 
from an exterior orifice, the introitus, to the uterine cervix. The axes of the upper and 
lower vagina differ, giving it a slight S-shape: whilst the lower vagina in relation to a 
standing woman is vertical and posterior, the upper part (from the pelvic diaphragm to 
the cervix) lies more horizontal, with the final portion curving towards the hollow of the 
sacrum (see Figure 1-6) [51]. The relaxed vagina is a collapsed, potential space. However, 
the mucosal tissue covering its walls forms a series of transverse folds, known as rugae, 
most prominent in the lower third of the vagina, allowing considerable distension during 
penile penetration and childbirth [49].   
The vaginal mucosa is composed of lamina propria, or stroma, covered by a largely 
nonkeratinized, pluristratified squamous epithelium. The lamina propria consists of 
fibrous connective tissue richly supplied by small blood and lymphatic vessels. The vaginal 
epithelium is about 150 to 200μm thick with 30 to 40 layers of cells. There are 5 different 
identifiable cell-types, namely the basal (adjacent to the lamina propria), parabasal, 
intermediate, transitional, and superficial (adjacent to the lumen) layers, reflecting 
increasing maturity and differentiation [52]. This provides mechanical protection against 
friction and trauma during sexual intercourse. The vagina is kept moist and lubricated 
through the presence of transudated fluid from the vaginal epithelium, secretions from 
Bartholin’s and Skene’s glands, located near the introitus and mucus and tubal fluids, 
produced by the epithelium of the upper FGT [49]. The constitution of vaginal fluid is 
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variable; it consists largely of water (90 – 95%) with smaller amounts of inorganic and 
organic salts, urea, carbohydrates, glycerol, mucins, fatty acids, albumin, 
immunoglobulins, enzymes, leukocytes, and epithelial debris [53]. During puberty the 
vagina becomes colonized by bacteria, the most important of which are Lactobacilli (see 
section 1.4.1). These are so-named because they produce lactic acid, which acidifies the 
vaginal secretions.  
The cervix is the lowest, narrowest portion of the uterus, forming a cylindrical body at the 
upper end of the vagina. It can be divided into two parts; ectocervix and endocervix. The 
ectocervix protrudes into the upper part of the vagina, dividing it into recesses, known as 
the anterior, posterior and lateral fornices. It is lined with mucosa which is contiguous 
with and similar to that of the vagina. The opening of the ectocervix, known as the 
external os, leads to the endocervical canal, which links the vagina with the uterine cavity 
[49]. The size and shape of the external os and the ectocervix vary widely with age, 
hormonal state, and whether the woman has delivered a baby vaginally. In women who 
have not had a vaginal birth the external os appears as a small, circular opening. In 
women who have had a vaginal birth, the ectocervix appears bulkier and the external os 
appears wider, more slit-like and gaping [50]. In contrast to the ectocervix, the endocervix 
is lined with a single layer of columnar epithelium. The junction between the ectocervix 
and endocervix, known as the transformation zone, varies in location depending on the 
age and hormonal status of the woman [52]. In the presence of high levels of oestrogen 
e.g. during puberty, pregnancy or exposure to high dose exogenous sources, the 
columnar epithelium of the endocervix  moves out of the endocervical canal, becoming 
visible on examination as a red area  known as cervical  ectopy.  Once exposed to the 
harsh acidic environment in the vagina, it subsequently undergoes metaplasia, 
transforming to pink squamous epithelium [49].  
The uterus is a hollow, pear-shaped structure which opens, at either side, into two 
Fallopian tubes at its upper end. The uterine epithelium, known as endometrium, is highly 
hormone responsive, and is shed periodically during menstruation. The Fallopian tubes 
act as a conduit between the uterus and the ovaries and are the site where oocytes, 
released by the ovaries, are potentially fertilized by spermatozoa. They possess a ciliated 
epithelium, which secretes tubal fluid and facilitates the transport of fertilized oocytes to 
the endometrium where they can undergo implantation [50]. 
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The adult ovaries are oval organs which contain numerous oocytes within follicles at 
various stages of development.  Dormant, primordial oocytes and follicles are present 
from birth but from puberty are gradually recruited into the maturation process known as 
folliculogenesis. Folliculogenesis takes around 375 days coinciding with thirteen 
menstrual cycles. The process begins with the recruitment of primordial follicles, 
continues through primary, secondary (pre-antral) and tertiary (antral) developmental 
stages and ends when a mature oocyte is released from the pre-ovulatory follicle in a 
process called ovulation [49]. 
Figure 1-5  Diagramatic representation of the human female genital tract 
 
Figure reproduced from Iwasaki A, Nat Rev Immunol 2010 [54]. 
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Figure 1-6 Sagittal view of the human female pelvis 
 
Figure reproduced from http//:www.qldscienceteachers.com. Accessed 4 June 2012. 
1.3.1 The human menstrual cycle 
Beginning during puberty (at menarche) until the 6th decade (menopause), women 
undergo a series of cyclical hormonal and physiological changes that are essential for 
reproduction [49]. Each of these cycles represents the period required for the selection 
and final maturation of tertiary (antral or Graafian) follicles, the emergence of a single 
dominant pre-ovulatory follicle, the process of ovulation, and the maintenance of the 
endometrium, for potential inplantation, by the corpus luteum (derived from the 
ruptured follicle).  The menstrual cycle is separately described for both the ovary and 
endometrium and is generally divided into pre- and post- ovulatory stages. The first half 
of the cycle, prior to ovulation, corresponds to the follicular phase of the ovary and 
menstruation and the proliferative phase in the endometrium. The second half, post-
ovulation, reflects the luteal phase of the ovary and the secretory phase in the 
endometrium. An average menstrual cycle lasts 28 days, beginning with the first day of 
menstrual bleeding. However the length of a woman's cycle will typically vary, with some 
shorter and some longer cycles.  A cycle length of between 21 and 35 days is considered 
normal and regular.  The menstrual period is variable, but usually lasts between 4 and 6 
days. The duration of the follicular phase also varies between and within individual 
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women, but in a 28 day cycle is around 14 days (including menstrual period). In contrast, 
the length of the luteal phase tends to be approximately 14 days regardless of cycle 
length. 
The menstrual cycle is under the control of the endocrine system [49]. Hormones 
participate in a complex system of positive and negative feedback to regulate the final 
stages of folliculogenesis and prepare the FGT for conception (see Figure 1-7). 
Gonadotrophin-releasing hormone (GnRH), produced by the hypothalamus, triggers the 
secretion of the gonadotrophins, follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH), from the pituitary which, in turn, act on the ovary to stimulate follicle 
development and, eventually, induce ovulation. Estradiol, an estrogen, is produced in 
increasing amounts by the developing follicles, with levels peaking at around day 12 of 
the cycle, 24 to 36 hours before ovulation. Post ovulation, estradiol levels decline and the 
ruptured follicle becomes a yellow corpus luteum. The corpus luteum secretes high levels 
of progesterone, a progestagen, and moderate levels of estradiol which prepare the 
endometrium for implantation of a fertilized oocyte and establishment of pregnancy. In 
the absence of a fertilized oocyte, the corpus luteum degenerates after approximately 10 
days and the consequent fall in progesterone and estradiol concentrations leads to 
menstruation and the start of a new menstrual cycle. 
During menstruation, the vascular endometrium is shed down to a basal layer (the 
stratum basalis) with resultant blood and tissue lost through the vagina. Subsequently, in 
response to the increasing estradiol concentrations from the developing follicles, the 
endometrium undergoes proliferation, developing a layer known as the stratum 
functionalis containing numerous glandular structures and arterioles [52].  High mid-cycle 
estradiol also impacts on the endocervix, where crypts produce mucus which is thin and 
watery, facilitating passage of sperm into the uterus. Post-ovulation, epithelial 
proliferation stops, but the endometrial glands secrete glycogen and become more 
tortuous. In addition, under the influence of high progesterone, endocervical mucus 
becomes viscous and thick, impeding sperm migration [49]. 
The characteristics of the ectocervical and vaginal mucosae are also influenced by the 
menstrual cycle, but the changes are more subtle than in the uterus. During the first half 
of the cycle, estradiol induces the proliferation of the ectocervical-vaginal epithelium, the 
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thickness of which peaks at approximately mid-cycle. In the secretory phase, 
progesterone opposes those actions, but, although there is increased sloughing of the 
superficial epithelial layers during this period, any change in overall epithelial thickness is 
small [55,56,57]. Estrogens also increase vaginal blood flow, which, together with 
alterations in epithelial permeability, facilitates the transudation of fluid [49]. Although 
quite variable between women, average daily production of vaginal fluid is estimated to 
be around 6 mL, increasing at midcycle and decreasing around menstruation [53].  
Figure 1-7 Human female menstrual cycle 
 
Figure reproduced from http://www.merckmanuals.com/media/ 
professional/figures/GYN_menstrual_cycle_PE.gif.  Accessed 4 June 2012. 
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1.3.2 Hormonal contraception 
Exogenous hormones are currently used as contraception by over 200 million women 
globally. The most common methods are combined oral contraceptive pills (COCP), with 
over 100 million users, and intramuscular (im) depot medroxyprogesterone acetate 
(DMPA, Depo-Provera®, Pfizer), with over 50 million users [58]. Most progestagen-only 
methods provide a continuous level of systemic progestagen sufficient to suppress 
ovulation (in most women) through inhibiting the release of GnRH.  These include DMPA 
[59], the levonorgestrel-releasing sub-dermal implant (Implanon®, Nexplanon®, Organon) 
[60,61] and high dose desogestrol-containing progestagen only pills (Cerazette®, 
Organon) [62].  The intra-uterine system (IUS, Mirena®, Bayer), which releases a lower-
dose of levonorgestrel directly into the uterus, has, in contrast,  been shown to inhibit  
ovulation in only 15 % of cycles and does not significantly reduce the production of 
endogenous oestradiol in the majority of women [63,64]. Unlike progestagen-only 
contraceptives, most COCPs are taken as a fixed combination of a progestagen with a low-
dose of synthetic oestrogen for 21 days. This is followed by a seven day break during 
which hormone levels fall to a level which causes endometrial epithelial shedding but 
maintains contraceptive efficacy. The contraceptive action of COCPs is largely mediated 
by the relatively high levels of progestagen (which inhibit ovulation), with the low dose 
oestrogen helping to stabilise the endometrium and prevent break-through bleeding 
[65,66].  
Exogenous progestagens have similar effects to natural progesterone. In addition to any 
inhibition of ovulation, they exert their contraceptive effects through increasing the 
viscosity of cervical mucus and by thinning the endometrium: impeding sperm passage 
and implantation respectively [59]. In contrast to what is seen in macaques (where there 
is considerable progestagen-induced cervico-vaginal epithelial thinning even during the 
normal cycle) [67,68], there is no evidence that even the highest doses of progestagens 
(in DMPA) produce significant thinning of the human cervicovaginal epithelium 
[69,70,71]. However, the potential for hormonal contraceptives to enhance women’s 
susceptibility to acquiring HIV-1 in other ways remains a controversial and on-going area 
of research (see section 1.5.1). 
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1.4 Defenses against HIV-1 infection in the FGT 
The mucosal immune system of the FGT is unique as it has evolved to perform conflicting 
functions.  Under the influence of estradiol and progesterone, it manages both to tolerate 
the passage of allogeneic sperm and the development of a hemi-allogeneic fetus, whilst 
also providing protection from STIs and other pathogens [72]. Although fully integrated, 
immune defenses are often broken down into two arms: innate and adaptive. The innate 
immune system is characterised by cells, mechanisms and molecules that are available 
immediately or are triggered rapidly to counteract invading pathogens and do not require 
a prolonged period of induction. In contrast, adaptive immunity takes days to weeks to 
develop, but provides a more complex and specific response [73].  In the context of HIV 
transmission, the innate defenses form the first line barrier and are largely responsible for 
preventing viral acquisition, replication, and dissemination in the FGT [54]. In contrast, 
adaptive immunity develops too late to inhibit initial infection but plays an important 
role in controlling subsequent viraemia. However, the creation of immunological 
memory, following a primary adaptive response to a specific pathogen, enables faster, 
enhanced responses to secondary encounters with the same pathogen, and forms the 
rationale behind vaccination [73]. 
1.4.1 Initial barriers to HIV-1 infection  
HIV is present in semen both as free virions and as integrated provirus within infected 
macrophages and T cells (measured as HIV RNA and DNA respectively). Although both 
forms have been shown experimentally to be capable of transmitting infection in-vitro 
[74,75,76,77], and in animal models [78,79,80,81], it is currently unclear whether one or 
both is operative naturally in-vivo.  In the absence of genital tract inflammation or 
infection, the quantity of free virus in human seminal fluid usually far exceeds the number 
of infected cells [82,83], but it has been suggested that much free virus may be replication 
incompetent [77]. Reliable non-human primate (NHP) models of cell-associated HIV 
transmission have proven more difficult to establish than those for cell-free virion 
transmission [80,81], hence the latter has been more widely studied (see section 1.5.2). 
However, once the epithelium has been breeched and target cells encountered, cell-
associated virus may establish and disseminate infection more efficiently than 
transmitted free virions [75,76,79,80,81]. 
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The initial defense against both cell-free and cell associated HIV-1, once deposited in the 
vaginal lumen, are FGT secretions. In addition to diluting the viral inoculum, these  
contain a number of chemical and biological factors, derived from the mucosa and 
commensal flora, that have broad activity against a range of pathogens. Such factors 
include mucus, antimicrobial peptides, lactic acid and hydrogen peroxide [84].  
Mucus is a complex and dynamic gel: consisting of 90 to 98 % water, small quantities of 
salts and lipids and variable amounts of mucins (MUC glycoproteins) (2-5%) [85,86]. In the 
FGT, mucins are primarily produced and exocytosed by goblet cells located in the 
columnar epithelium of the endocervix [85]. Hydration and expansion then occurs, 
extracellularly, through contact with transudated fluid [85,86].  Hydrated mucus forms a 
gel layer against the mucosa which performs important physiological functions. These 
include lubrication, and physical protection of the epithelium, during sexual intercourse, 
and regulation of water-balance and sperm transport.  It also acts as a mesh, trapping and 
carrying  cell debris and micro-organisms; thus restricting access to the mucosa and the 
upper FGT [87]. Acidified cervico-vaginal mucus, obtained from healthy women with 
normal vaginal flora, has been shown to trap HIV-1 virions and slow their diffusion by 
1000 fold compared to water [88]. In addition, certain purified mucins, including MUC5B, 
the most abundant in cervico-vaginal mucus, are capable, in–vitro,  of preventing  HIV 
infection of CD4+ cells [89]. Although not fully understood, charge-dependant interactions 
between fucosylated glycans on mucin and carbohydrate moieties on gp120 may lead to 
binding and aggregation of HIV virions; similar to that seen with Candida albicans and 
other mucosal pathogens [88,89,90].   
Several broadly-acting antimicrobial peptides are present in FGT luminal secretions, e.g. 
lactoferrin [91], alpha (α) and beta (β) defensins [92,93], the cathelicidin LL-37 [94], 
secretory leucocyte protease inhibitor-1 (SLP1) [95], and the serine protease inhibitor 
trappin-2/elafin [96]. These are expressed constitutively by epithelial cells (ECs) and 
immune cells and act through multiple, complex mechanisms to directly inactivate virions 
and/or interfere with HIV-1 binding and replication in target cells [97,98].  As with other 
FGT mucosal defenses, there is evidence that production of anti-microbials may be 
influenced by reproductive hormones, with some differences between sites in the upper 
and lower FGT in keeping with their differing roles [99].  
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Another component of the first-line defence against mucosal pathogens is the 
commensal bacterial flora. These organisms are not inhibited by antimicrobial peptides 
and have co-evolved to enhance mucosal barriers [100]. The healthy vagina is colonized 
by high concentrations of Lactobacillus species (108 colony forming units/ml) [101].  
Glycogen, produced by the vaginal epithelial cells, provides metabolic fuel for the 
generation of lactic acid by lactobacilli, which, in turn, reduces the pH of the vagina to 
less than 4.5. This low pH, together with additional anti-microbial agents produced by 
lactobacilli, such as hydrogen peroxide, prevents the potentially pathogenic overgrowth of 
other commensals, such as Candida albicans and Garderella vaginalis [102,103].   Such 
acidic conditions have also been shown to inhibit T cell activation and proliferation; thus 
may reduce the number of potential target cells for HIV [104]. Hydrogen-peroxide 
producing lactobacilli have been shown to be directly virucidal against HIV-1 in-vitro and 
are themselves being studied as a potential biomicrobicide [105,106,107,108]. 
In mucosal tissues, the primary physical barrier between the host and the external 
environment is provided by the epithelium.  As described in section 1.3, the entire luminal 
surface of the FGT is covered by epithelial cells (ECs),  with simple, columnar epithelium 
lining the upper FGT (endocervix, endometrium, Fallopian tubes, ovaries) and stratified 
squamous epithelium lining the lower FGT (vagina and ectocervix).  In most epithelia, the 
passage of polar molecules and micro-organisms between cells (paracellularly) is 
restricted by the presence of tight-junctions. These consist of a seal formed by 
intermembrane extensions of transmembrane proteins, such as occludins, claudins and 
junctional adhesion molecules (JAMs), across the intercellular space between the apical 
and basolateral membrane domains of adjacent ECs [109]. Not only do these provide a 
barrier to pathogen entry but they also polarize the cell, enabling the selective, 
directional transport of molecules between the mucosal lumen and the submucosa 
and/or blood stream.   
1.4.2 Cytokines and chemokines and pathogen recognition 
In addition to antimicrobial peptides, ECs and resident immune cells in the FGT stroma 
secrete a number of cytokines and chemokines, including: interleukins (IL) 6 and 8, 
Stromal cell derived factor (SDF)-1 (CX chemokine ligand 12)(CXCL-12)), macrophage 
inflammatory proteins (MIP) 1α, 1β, and 3α (CC-chemokine ligands (CCL) 3,4 and 20), 
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macrophage chemotactic protein (MCP)-1 and Regulated on Activation Normal T Cell 
Expressed and Secreted (RANTES) [84].  These are involved in a number of processes, 
from mediating endometrial proliferation, menstruation and implantation, to regulating 
cells of both the innate and adaptive immune systems [84,110].  Some of their actions 
may be important in protection from HIV.  MIP- 1α and β and RANTES are the natural 
ligands for CCR5, whereas SDF-1 binds the alternative co-receptor CXCR4, thus they may 
block binding by HIV-1 and prevent it entering target cells.  IL-6, IL-8 and MIP-3α promote 
the influx of type 1-interferon (Type 1 IFN) producing immune cells to the epithelium, the 
most important of which are plasmacytoid dendritic cells (pDCs), which play a key role in 
the defense against viruses [73].  
Type 1 IFNs are pleiotropic cytokines that mediate antiviral effects through increasing 
transcription of multiple IFN-stimulated genes (ISGs) [111].  Many ISGs encode ‘restriction 
factors’; proteins that act within infected cells to restrict viral replication. The three most 
well studied in relation to retroviruses are TRIM5α (tripartite motif 5-α), APOBEC3G 
(apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) and tetherin (BST-
2, CD317, or HM1.24) [30].  
The secretion of antimicrobial peptides, chemokines and cytokines is upregulated in 
response to pathogens. This is triggered by the recognition of conserved pathogen-
associated molecular patterns (PAMPs), derived from micro-organisms, by the pattern 
recognition receptors (PRRs) of immune cells [112].  Toll-like receptors (TLRs) are PRRs 
expressed on the surface and endosomal membranes of a wide variety of cells found in 
the FGT mucosa: including ECs, macrophages, neutrophils, myeloid (mDCs) and 
plasmacytoid dendritic cells, natural killer (NK) cells, B cells and T cells [72]. All 9 major 
TLRs identified in humans are expressed on the FGT epithelia, with vaginal and cervical EC 
lines expressing TLRs 1-3, 5 and 6, primary endocervical ECs TLRs 1-3 and 6, and primary 
uterine ECs expressing all TLR types (1-9) [113,114,115,116,117]; thus they can potentially 
respond to a wide-range of micro-organisms. The primary way HIV and other RNA viruses 
are recognized is via their nucleic acids. TLR3 and the cytosolic helicases RIG-1 and MDA5, 
all recognise double stranded RNA (dsRNA), whereas TLR7/8 and RIG-1 sense single 
stranded RNA (ssRNA) [112]. PAMP recognition initiates a signalling cascade, resulting in 
the activation of transcription factors, such as NF-ĸB, and an increase in the production of 
immune mediators. 
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1.4.3 Natural Killer Cells 
NK cells are key players in the host defense against viruses, acting both as effector and 
regulatory cells. Through production of cytokines and chemokines (including  IFN-γ, IL-12, 
MCP-1, MIP-1α/β and RANTES), and cell-cell interaction, they both inhibit viral entry into 
target cells and prime and recruit cells of the innate and adaptive immune system, in 
particular mDCs, pDCs, Th1 and CD8+ T cells (see section 1.4.4). In addition, they mediate 
direct cytolysis of infected cells through secretion of granzyme or perforin [118]. NK cells 
express a variety of different surface receptors (NKRs) which either stimulate or inhibit 
their activity.  An NK cell’s response is determined by the balance of inhibitory and 
stimulatory signals it receives from other cells via its NKRs [119]. Killer cell 
immunoglobulin-like receptors (KIRs) are a range of NKRs which recognise major 
histocompatibility complex (MHC) type I on host cells [120]. In humans, MHC molecules 
are also known as the human-leucocyte antigens (HLA).  Expression of MHC I is down-
regulated in host cells infected with many viruses, including HIV-1, as a means of evading 
cytolysis by CD8+ T cells [121]. Detection of ‘missing MHC I’ on such cells by inhibitory KIRs 
thus triggers their destruction by NK cells [120] as can recognition of any remaining MHC I 
(HLA) types by activating KIRs [119]. NK cells are activated in acute HIV-1 infection and 
can destroy infected cells in-vitro. However, efficiency of NK-mediated clearance of HIV-1-
infected cells is variable between individuals and is related to the number and types of 
KIRs expressed on NK cells, specific for different HLA molecules [122]. For example, HLA-C 
expression is not downregulated by HIV-1 [123]; thus stimulatory NKRs that recognise 
HLA-C [124] or KIRs which recognise specific HLA-A or B allotypes are more likely to 
respond to HIV-1 infected cells. Combinations of HLA and KIR allotypes which promote NK 
activity towards infected cells, e.g. KIR3DS1 (activatory) and HLA-B Bω4-801, KIR3DL1 
(inhibitory) and HLA B*57, KIR2DS2 (activatory) and HLA-C1 have been associated with 
lower VLs and delayed progression to AIDS in HIV-1 infected individuals [124,125,126]. In 
addition, there is evidence that some allele combinations (e.g. KIR2DL2 (inhibitory) 
without HLA-C1/C2, KIR3DL1 (inhibitory) and HLA B*57, KIR3DS1 (activatory) and HLA-B 
Bω4-801) may increase protection from initial HIV-1 infection [126,127,128].  
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1.4.4 Adaptive immunity  
Adaptive immune responses are initiated following interactions between naive CD4+, 
‘helper’ T cells (Th cells) and antigen presenting cells (APCs), such as macrophages and 
mDCs. Phagocytosis of pathogens induces maturation of APCs and the subsequent 
presentation of antigen on type II MHC.  Cognate antigen is then recognised by Th cells, 
which undergo stimulation and become activated [73]. Such encounters usually take 
place within organized lymphoid structures, containing large numbers of T cells, B-cells, 
and APCs in close proximity.  Examples of such secondary lymphoid organs include lymph 
nodes, spleen and mucosa-associated lymphoid tissue (MALT).  However, in contrast to 
other mucosal sites, such as the the nasal and GI tracts, which have well-defined 
lymphatic tissue (i.e. the nasal-associated lymphoid tissue (NALT), and gut-associated 
lymphoid tissue (GALT) respectively), the FGT tract lacks any specialised areas specific for 
antigen presentation. Instead, most priming encounters are thought to occur in the 
regional, draining lymph nodes [54]. Uniquely, lymphoid aggregates, consisting of a B cell 
core surrounded by CD8+ T cells and macrophages, are found within the uterine mucosa. 
These develop during the menstrual cycle, becoming maximal during the secretory phase 
[129]. The function of these is poorly understood, but they are believed to be involved in 
the suppression of cell-mediated immune responses prior to conception and implantation 
[130]. 
Different types of adaptive response are elicited according to the nature of the pathogen. 
Broadly speaking, T-helper type 1 (Th1) responses are directed against intracellular 
microbes, e.g. viruses and some bacteria; Th2, against extracellular parasites, e.g. 
helminths; and Th17 against extracellular bacteria and fungi [73].  Unsurprisingly, 
therefore, adaptive defenses against HIV-1 are primarily Th1 mediated [54].  Th1 cells, 
characterised by the expression of CCR5 and the secretion of IFN-γ, stimulate largely cell-
mediated responses [73].  However, in addition to follicular T-helper cells (Tfh), they also 
assist B-cells in producing (non-IgE) antibodies (see below). 
1.4.4.1 Cytotoxic, CD8+ T cell responses 
IFN-γ enhances production of antimicrobial compounds by macrophages, promotes the 
generation of opsonizing and effector antibodies and activates cytotoxic, CD8+ T cells 
(CTLs) [73]. The latter induce apoptosis of virus-infected cells expressing peptide-bound 
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MHC I, through perforin and granzyme-mediated cytolysis. CTLs have been proposed as 
playing a key role in the initial reduction of acute HIV-1 viraemia and in the maintenance 
of the VL set-point in chronic infection. Early anti-HIV/SIV CTLs, appearing from around 2 
weeks post initial infection, have been temporally linked with the fall in plasma VL 
[131,132,133] and HLA-alleles, restricted to specific CTL epitopes, have been linked to  
lower VL set-points and delayed progression to AIDS [134]. In macaques, in-vivo depletion 
of CD8+ T cells has been shown to abolish viral control in both acute and chronic SIV 
infection [135] and vaccines that induce SIV-specific CD8+ T-cell responses have 
attenuated later SIV infection [136].  Recently, a comprehensive modelling study, based 
on serial analysis of both genomic sequences of initial, transmitted viral isolates and T Cell 
isolates in 4 acutely, HIV-1 infected individuals, has lent support to the importance of CTL 
responses in reducing initial viraemia, and has provided valuable clarification and insight 
into the emergence and evolution of viral CTL escape mutants [137]. Despite being rapidly 
evaded, due to targeting variable regions of Env, most individual initial CTL responses 
were potent, with each accounting for between 15 and 35 % of the total elimination of 
virus-infected cells. CTL responses elicited against more conserved HIV-1 components, 
e.g. Nef, Pol or Gag, where mutations confer a reduction in viral fitness, take at least one, 
and often several months to emerge and are generally sub-dominant [138, 139,140,141]. 
Although broader and more chronically effective at controlling viral replication (after 
initial suppression) than earlier responses, whether these CTLs would be as efficient at 
controlling initial, high viraemia is unknown [137]. Ongoing studies looking at the impact 
of early conserved CTL epitope responses in more detail, e.g. in individuals with the 
favourable HLA B*5701 allotype, will have importance for vaccine design. 
1.4.4.2 Antibodies 
Antibodies are glycoproteins, belonging to the immunoglobulin (Ig) super-family, which 
enhance and complement cell-mediated defenses. They are produced by mature B-cells, 
known as plasma cells, following recognition and internalisation of their cognate antigen 
(via an Ig receptor molecule expressed on their surface), presentation as peptide-MHC II 
complexes and stimulation from peptide-MHCII-specific Tfh cells [73]. Each Y-shaped 
molecule is formed of an identical pair of heavy and light chains, with each chain 
containing a constant and a variable part (see Figure 1-8). The ‘fragment of antigen 
binding’ or Fab domain is composed of one constant and one variable domain of each of 
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both a light and a heavy chain. The variable portions of each Fab contain an area known 
as the complementarity-determining region (CDR), which determines the antigen 
specificity of the antibody molecule.  The CDR possesses a unique amino acid sequence 
and structure (known as the idiotope) which binds specific regions (epitopes) of a cognate 
antigen molecule. In contrast, the Fc (fragment, crystalizable) portion, formed by the 
constant regions of the heavy chains, binds to Fc receptors (FcR) on immune cells and 
complement proteins to mediate non-antigen-dependent effector functions [73,142].   
Figure 1-8  Typical structure of an antibody 
 
Figure reproduced from http://www.ebioscience.com/knowledgecenter/ 
antigen/immunoglobulin/structure.htm.  Accessed 25 May 2012. 
In humans, there are 2 types of immunoglobulin light chain (ĸ and λ) and 5 main types of 
heavy chain (α, δ, ε, γ, and μ); the constant region of the latter determining the class or 
isotype of the resulting antibody (IgA, IgD, IgE, IgG and IgM), its molecular mass, 
oligomerisation, and nature of its Fc effector functions (see Table 1-3). Exposure of the B 
cell to specific cytokines determines which class or sub-class of antibody is produced with 
the aim of eliciting effector functions that are appropriate to the antigenic challenge and 
location [73,142].   
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Table 1-3  Human immunoglobulin classes and major characteristics   
 IgG1 IgG2 IgG3 IgG4 IgM IgA1 IgA2 IgD IgE 
Heavy chain γ1 γ2 γ3 γ4 μ α1 α2 δ ε 
No. of constant domains 3 3 3 3 4 3 3 3 4 
Light chain ĸ or 
λ 
ĸ or 
λ 
ĸ or 
λ 
ĸ or 
λ 
ĸ or 
λ 
ĸ or 
λ 
ĸ or 
λ 
ĸ or 
λ 
ĸ or λ 
Molecular weight    
(kDa) (approx) 
150 150 170 150 970 160 160 175 190 
Susceptibility to 
proteolysis 
++ +/- ++++ +      
Oligimerisation (number 
of monomers in typical 
molecule) 
1 1 1 1 5 1/2 1/2 1 1 
Serum concentration 
(gL–1) (approx) 
7 3 0.5 0.5 1.5 3 0.5 0.05 5x10-4 
Half-life (days) (approx) 21 21 7 21 5 6 6 3 3 
Placental transfer + + + + - - - - - 
Binding to macrophages 
and other phagocytic 
cells via 
         
- Fcγ RI (ADCC, uptake, 
phagocytosis) 
+++ - +++ + - - - - - 
- Fcγ RIIa, RIIc (uptake, 
phagocytosis)  
Fcγ RIIb (inhibitory) 
++ 
+++ 
+++ 
++ 
+/- - - - - - - 
   - Fcγ RIIIa (ADCC, 
uptake, phagocytosis) 
  - Fcγ RIIIb (neutrophil/ 
eosinophil activation) 
++ - ++ - - - - - - 
Binding to basophils and 
mast cells (histamine 
granule release) 
- - - - - - - - +++ 
Complement activation 
(classical pathway via 
C1q) 
++ + +++ - +++     
     
    References: [73, 142,143,147] 
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Normally, over 80% of antibodies present in the body are of the IgG class and it is the 
most prevalent isotype in serum and non-mucosal tissues. In contrast, IgA is the 
predominant class in most mucosal tissues, including the GI and respiratory tracts [73]. 
Intriguingly, this is not the case in the FGT, where IgG is most abundant occurring at 
approximately two to four times the concentration of IgA, and six times that of IgM 
[144,145]. 
IgG antibodies are the most important class in terms of anti-HIV-1 immunity and can 
contribute in several ways [146,147].  Firstly, they can neutralize free virions directly, e.g. 
through binding to a critical portion of Env to prevent binding to CD4 and infecting target 
cells; such antibodies are called neutralizing antibodies (NAbs). Secondly, even if non-
neutralizing (non-NAbs), they can bind to and coat virions to mediate opsonization and 
phagocytosis by macrophages, neutrophils and mDCs (via their surface FcγRIIa 
molecules). Thirdly, they can trigger complement-mediated lysis of free virions and 
infected cells, following specific antibody-antigen binding and complement activation.  
Lastly, they can destroy infected cells and/or limit viral spread, through triggering 
antibody-dependent cellular cytotoxicity (ADCC) or antibody- dependent cell-mediated 
virus inhibition (ADCVI) [148]. These are mainly effected by NK cells (through binding to 
FcyRIIIa) and to a lesser extent neutrophils, macrophages and mDCs (via FcyRIIIa and 
FcyRI) [143,147]. 
Vigorous antibody responses to HIV-1 are generated at all stages of infection, with 
antibodies detectable in plasma within a few weeks of acquisition [149]. However, initial 
antibodies are non-neutralizing: being directed at sites on gp120 and gp41 that are 
present in monomeric forms (shed from virions/infected cells), but not functional trimeric 
Env [150]. The Env spike displays a number of features which aid HIV in evading the 
adaptive immune system (see section 1.2.2). Firstly, the sugar moieties, which cover the 
most accessible, external, upward facing regions of gp120, are derived from the host cell 
and are, in general, poorly recognised by antibodies, forming a ‘glycan shield’[151]. 
Secondly, conserved regions are ‘protected’ from antibodies by conformational masking 
or steric occlusion, e.g. interfaces are housed within deep or narrow pockets (CD4bs) or 
shielded by highly variable, flexible loops (gp120/41) [38,152,153].  Thirdly, sparsely 
distributed clusters of targets are less likely to allow binding of two epitopes 
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simultaneously than regular, dense arrays, reducing the avidity of bivalent IgG NAbs 
[36,154]  Finally, many regions of gp120, including N-linked glycosylation sites, can vary 
widely without detriment to CD4/co-receptor binding, hence facilitating the generation of 
escape mutants when errors are produced by RT [34,35,151].  
Antibodies that neutralize transmitted founder isolates are not detected until several 
months after HIV-1 acquisition [151,155] and it generally takes years before robust 
neutralizing activity is established [156].  However, even at this stage, the antibody 
response is continuously overcome by viral mutation and selective pressure, as is 
reflected by the lack of control of HIV-1 replication by autologous NAbs [155]. That said, 
10 to 30 % of chronically-HIV-1 infected individuals have sera which is capable of broadly-
neutralizing a range of cross-clade viral isolates [156,157,158,159]. Of these, fewer than 
10% are ‘elite neutralizers’: neutralizing more than one HIV-1 strain within a clade group, 
across at least four different clades, at serum IC50 (median antibody concentration 
required to inhibit HIV activity by 50%) titres of 1/300 [158]. Such neutralizing capacity 
can be generated through two separate mechanisms, which can co-exist: the presence of 
a wide-range of antibodies targeting different HIV-1 epitopes (polyclonal) [160,161], or 
the production of a single (monoclonal) or limited (oligoclonal) number of potent, broadly 
NAbs against specific conserved regions of Env [162]. Identifying individuals with the 
latter responses has enabled the isolation and characterization of specific NAbs with the 
potential for use in preventative strategies (see sections 1.6.8 and 6.2.6).  In addition, this 
approach has allowed new conserved epitopes to be determined in the Env trimer that 
could be used as immunogens in future vaccines [163].  
Antibodies are likely to have the best chance of successfully neutralizing HIV-1 the earlier 
in infection they are present [164]. If pre-existing (e.g. due to passive administration or 
prior vaccination) they would have the potential to enhance innate protective effects and 
act on small viral inocula near the site of entry to prevent establishment of infection. 
Evidence that infection is established with a limited number of founder variants lends 
support to this concept [165,166], as does data correlating in-vitro anti-HIV-1 activity with 
anti-gp160 IgG levels in female genital tract secretions (obtained from healthy HIV-1 
infected women)[167]. 
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1.5 HIV-1 transmission via the FGT 
1.5.1 Factors influencing efficiency of of HIV-1 transmission 
Compared to viruses spread via the respiratory and/or faecal-oral route or others 
affecting the genital tract mucosa, such as herpes simplex virus (HSV) or human 
papillomavirus (HPV), sexual transmission of HIV-1 is relatively inefficient [168]. In 
general, being the receptive rather than the insertive partner carries at least a 2-fold 
greater risk, with probabilities of transmission varying with the nature of the sexual act. 
Estimates from meta-analysis of cohort studies of HIV-1 transmission, suggest that 
transmissions to women from HIV-1 infected male partners, who are not taking ARVs, 
may occur in fewer than 1 in 1000 episodes of unprotected vaginal intercourse (URVI), 
particularly in the context of high-income countries and stable relationships, with per-
contact risks being up to 10 fold higher in low-income settings [169]. In contrast, the 
average risk of acquiring HIV following unprotected receptive anal intercourse (URAI) is 
estimated to be greater, at around 1.4%, with no significant difference in per act risks of 
URAI for heterosexuals and MSM [170,171]. However, although anal intercourse is 
practiced by heterosexuals as well as MSM world-wide, and should not be ignored in the 
development of prevention strategies [172,173,174,175], the extent to which it is 
contributing to the generalized HIV epidemics of southern Africa is yet to be fully 
determined [176,177].   
Although the above estimates reflect the general inefficiency of HIV-1 transmission across 
mucosal barriers, and the relatively low rates of acquisition per act from individuals in the 
chronic, asymptomatic phase of HIV-1 infection, they are not representative of all 
scenarios.  A number of biological co-factors are known to facilitate HIV transmission, by 
increasing the quantity of infectious virus in donor secretions, impairing mucosal 
defences and/or increasing target cell availability in the recipient.  Those co-factors with 
greatest relevance to women (and associated increase in relative risk (RR) of HIV 
transmission (if known)) are summarised in Table 1-4. In the presence of one or more of 
these, HIV could be transmitted as frequently as once every 10 URVI acts or every 3 URAI 
acts [169,178].  
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Primary, or acute HIV infection, (PHI) represents the first 6 months post acquisition of 
infection and is characterised by very high HIV VLs in plasma and genital tract secretions, 
the former often being > 1 million RNA copies/ml in the first few weeks, before gradually 
declining to a chronic set-point [179,180].  Analyses of data from heterosexual HIV-1-
serodiscordant couples, obtained, in the pre-HAART era, from a population cohort in 
Rakai, Uganda, identified donor HIV-1 plasma VL as being the most important 
determinant in predicting transmission [181,182].  However, onward transmission in PHI 
is higher than would be predicted based on VL alone and may reflect better adaptation of 
recently acquired viral isolates to initiate infection [183], and/or the influence of other 
factors, such as concomitant STIs.  Estimates from the Rakai cohort suggest that 
individuals with PHI are at least 8 to 10 times, and may be up to 26 times more infectious 
than those in the chronic, asymptomatic phase of the disease [184,185].  The majority of 
recently infected individuals will experience only a brief, non-specific seroconversion 
illness and be generally well, and unaware of their HIV status. This has profound public 
health consequences, the severity of which will be influenced by the phase of the HIV 
epidemic and rates of partner change within a population. In mathematical models, PHI 
accounts for a greater proportion of transmissions in early phase epidemics, where a 
higher proportion of HIV positive individuals are newly infected, and in populations where 
there are high rates of partner change [186]. That said, in a recent study conducted in 
Lilongwe, Malawi, which utilized both behavioural and biological data, 38 % of incident 
HIV cases were attributed to sexual transmissions from partners who had been infected 
within the previous 5 months [187]. Malawi, like most of sub-Saharan Africa, has a long-
standing epidemic, thus these findings may be representative for much of the region.  
Further evidence that both host and viral factors play a role in determining likelihood of 
HIV-1 transmission comes from studying viruses isolated from newly HIV-1 infected 
individuals.  Use of the technique of single- genome amplification (SGA), together with a 
mathematical model of viral evolution, has revealed that approximately 80 % of 
heterosexually acquired infections are initiated by a single virion [165,166,188,189, 
190,191].  In contrast, this is only true of about 60% of infections in MSM and 40% in 
IDUs, the latter being associated with as many as 16  transmitted virions [192,193,194]. In 
heterosexuals, transmission of multiple variants (up to 5) is more likely in the presence of 
inflammatory STIs [195].   
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It has long been recognised that the vast majority of founder viruses are R5 tropic 
[165,166,192,196,197], explaining why individuals who lack CCR5 expression, due to 
homozygosity for the Δ32 mutation, are virtually resistant to acquiring HIV-1 [198,199].  
However, recent research supports selection even within CCR5-using isolates.  
Comparison of viruses found in newly infected individuals with those in the donor show 
that, in 90% of cases, the most closely related donor variant comprises < 5% of their total 
quasispecies [195].  Although there is some evidence emerging of differences in the 
length or charge distribution of the gp120 variable loops, amino acid changes in the signal 
peptide and cytoplasmic domains of Env and/or reduced Env glycosylation, clear 
‘transmission signatures’ of founder isolates are yet to be defined [200,201,202].  
Elucidating the sites and mechanisms responsible for CCR5 restriction and the viral 
‘genetic bottle-neck’ may provide clues on how to enhance barriers against HIV 
transmission [203]. In addition, identification of unique genetic or phenotypic 
characteristics in transmitted viruses could facilitate the development of vaccines by 
highlighting important targets.   
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Table 1-4 Biological co-factors which facilitate HIV-1 transmission 
Co-factor RR of HIV-1 acquisition  if  co-
factor present in recipient 
RR of HIV-1 transmission if co-factor 
present in donor 
Biological Explanation 
Plasma HIV-1 VL 
 
- RR =2.5-3.0 per log10 copies/ml 
increment 
(no/very low risk of transmission if VL 
< 1500 copies/ml)[181,182,184,204]. 
Risk of transmission proportional to quantity of 
infectious virus in the inoculum (indirect measure). 
Genital tract HIV-1 VL - RR = 1.7 per log10 copies/ml increment 
[205]. 
As above but direct measure. 
Acute HIV-1 infection 
(within 1st 6/12) 
- RR= 8-10 but may be up to 26 
[184,185]. 
Very high plasma and genital VL (> 1 million copies/ml); 
early CCR5 tropic viral strains potentially better 
adapted to initiating infection [202,203]. 
HIV-1 subtype C 
(accounts for > 50% of 
infections world-wide). 
- unknown Predominant CCR5 usage even in late stages, prolonged 
high-viraemic phase, 3 rather than the usual 1 or 2 
binding sites for NF-ĸB on its LTR [206,207,208]. 
STIs 
- HSV-2 
- Gonorrhoea 
 
- Chlamydia 
- Candidiasis 
- TV 
- BV 
 
RR= 3-7 (highest in acute, 
symptomatic infection) 
[209,210,211]. 
 
RR=1.5-3 [211,212,213].  
 
RR=1.5-2 [14,211,214,215,216]. 
 
 
Around a 2-3 fold increase in HIV 
detection in genital tract secretions in 
presence of STI [217]. 
 
RR= 3 in presence of BV [218]. 
Increased genital tract VL. Possibly increased cellular 
/blood-blood transmission. 
(i) Generation of a clinical or sub-clinical pro-
inflammatory response through the activation of TLRs; 
(ii) Increased recruitment of target cells; (iii) Disruption 
of the cervico-vaginal epithelium and (iv) Perturbation 
of  the normal protective vaginal microflora,  pH and/or 
antimicrobial peptide activity [219,220]. 
Hormonal status 
-Adolescence 
-Menopause 
-Day 14-23 of cycle 
- Hormonal 
contraceptive use  
-Pregnancy 
 
Unknown but likely  
RR= 4-8 [221,222]. 
Possibly  [99,223]. 
DMPA RR= 2 ?COCP [15,224] 
 
RR= 2 [225,226,227]. 
 
 
 
Possibly  [15]. 
RR= 2 [224]. 
 
RR=2 [227]. 
 
-cervical ectopy, trauma during early coitus 
-reduced lubrication/increased mucosal friability 
-Progestagen-dominant environment 
-controversial:? epithelial thinning, lactobacilli, 
innate immune effects (antimicrobial peptides,  
target cells), cell-mediated immune suppression, HIV 
replication/shedding [15,99,228]. 
Trauma Unknown but likely  Unknown but likely  Disruption of the cervico-vaginal epithelium 
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1.5.2 Early events in HIV-1 transmission and dissemination  
Given the practical and ethical difficulties of studying acutely HIV-1 infected people, most 
of what we know regarding the initial stages of HIV-1 infection and dissemination has 
been ascertained using Simian Immunodeficiency Virus (SIV) macaque NHP models of 
vaginal HIV-1 transmission [79,229,230,231]. These have traditionally been high dose 
vaginal challenge studies in which rhesus macaques (or other susceptible macaque 
species, e.g. cynomolgus, pig-tailed) are atraumatically exposed once, or  twice in the 
same day,  with two 105 TCID50 (50% tissue culture infectious dose) inocula containing 
billions of virions [230,231]. Although convenient in that they provide reliable access to 
tissues infected in-vivo, within a known time-scale, they may only approximate to what 
happens naturally in women, where HIV-1 infection generally occurs after much lower 
viral exposures, even from donors with the highest  seminal VLs [232]. Recently, low-dose 
SIV challenge models have been developed, where animals receive repeated 
physiologically-congruent viral inoculae over several weeks, to initiate infections with 
only 1 or 2 viral variants [233,234,235].  HIV-1 strains encoding Vif proteins derived from 
SIV/HIV-2 isolates have also been developed which can establish productive infection in 
NHPs [236].  In addition, improvements in culture systems for studying intact human 
cervical or vaginal mucosal tissues (known as explants) have facilitated the study of 
complex HIV-cellular interactions ex-vivo [74,237].  By more closely recapitulating events 
in natural HIV-1 transmission, it is hoped such models will generate reliable insights and 
provide a more realistic system for evaluating the pre-clinical efficacy of prevention 
methodologies in humans [238].  
Knowledge to date regarding the initial steps in the establishment of HIV-1 infection via 
the FGT mucosa is summarised in Figure 1-9. In male-to-female transmission, epithelial 
penetration and initiation of viral replication has been shown to be possible in the 
vaginal, ectocervical, endocervical and endometrial mucosa [239,240]. However, it is 
unclear which sites predominate in natural infection.  Given its relatively huge surface 
area, the ectocervical-vaginal mucosa has been proposed as the likely site for most HIV-1 
transmission [15,239,240].  Although its multi-layered, squamous epithelium  generally 
presents a much thicker barrier against trauma and pathogen entry than the columnar 
epithelium of the upper tract, tight-junctions are restricted to its lower 2/3, in the basal, 
parabasal and intermediate layers [241]. The epithelium is also penetrated by numerous 
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stromal papillae, which may be covered by only 1 or 2 layers of cells [242].  While 
containing fewer HIV-1 target cells than the TZ, in the absence of inflammation [242], the 
vagina and ectocervix are the regions most commonly affected by coital trauma [243] and 
are the main sites of several genital infections known to facilitate HIV-1 acquisition, 
including Herpes Simplex Virus (HSV), bacterial vaginosis (BV), Trichomonas vaginalis (TV) 
and Candida species [220]. HIV-1 infection occurs in women with congenitally absent 
uteri [244] and SIV can be transmitted to macaques following hysterectomy [245]. In 
addition, contraceptive diaphragms, which shield the cervix and upper FGT but not the 
vagina, were shown to be ineffective at reducing rates of HIV-1 acquisition in a large 
randomised trial. That said, it is noted that there was a significantly lower rate of reported 
condom use in the intervention arm (54% of visits) compared with the control arm (85 %) 
[246].  
Several possible mechanisms may be involved in the translocation of HIV-1 virions across 
the FGT epithelium and these may vary at different sites.  HIV-1 enters the body most 
easily at sites where the mucosal barrier has been disrupted e.g. where there is an area of 
microtrauma resulting from sexual intercourse, or ulceration from infection, and it can 
gain direct access to the submucosa [243,247].  However, free virus could also penetrate 
between the squamous cells of the superficial layers of the intact vaginal and ectocervical 
epithelium, before being restricted by the tight-junctions of deeper layers.  In addition, 
the interdigitating dendrites of Langerhan’s cells and mDCs can cross several epithelial 
layers thus may bind HIV virions close to the the vaginal/ectocervical  lumen [240,248]. 
Tight-junctions, together with adjacent, supporting, adherens junctions and desmosomes, 
are coupled to the cytoskeleton.  They can mediate changes in permeability, measured in-
vitro as transepithelial resistance (TER), in response to cytokines, hormones and other 
stimuli [249]. Reduction in vaginal and endocervical TER mid-cycle, in response to high 
levels of estradiol, increases the transudation of fluid into the FGT lumen and helps to 
reduce the viscosity of ovulatory mucus [250].  Although designed to assist the passage of 
sperm into the uterus, this may also facilitate pathogen entry, both through the 
epithelium and into the upper FGT. Interestingly, Nazli et al. have shown that direct 
exposure of ECs to gp120 can cause a 30 to 60 % decrease in TER, which is associated with 
a reduction in the number of junctional proteins [251]. 
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There is also in-vitro evidence that HIV-1 can transcytose ECs without infecting them 
productively [252,253,254,255,256,257]. Although trancytosis of virions through 
squamous ECs has been suggested, it most classically occurs in-vivo through single-celled, 
columnar epithelia [258].  Some ECs lining the FGT have been shown to express CD4, 
CCR5 and CXCR4, which may enable HIV to enter.  Although there is little evidence that 
CD4, CCR5 or  CXCR4 are expressed on the superficial and mid-zone layers of the vaginal 
and ectocervical epithelium that would be most easily accessible, CD4+ CCR5+ ECs  are 
brought closer to the lumen within the stromal papillae [259]. There is some evidence 
that expression of these receptors may be influenced by hormones. Recognised as being 
important for implantation, apical expression of CCR5, CXCR4 and CD4 by uterine ECs has 
been found to be low during the 1st half of the cycle, peak around ovulation and decline 
(CCR5) or plateau (CD4, CXCR4) thereafter [250]. Similar, but less pronounced, changes in 
receptor levels have been seen in parabasal and basal ECs in the ectocervix. 
In the absence of classical  receptors, HIV entry into ECs may be facilitated by cell surface 
glycosphingolipids, such as sulphated lactosylceramide expressed by vaginal ECs and 
galactosylceramide expressed by ectocervical ECs, as well as transmembrane heparin 
sulphate molecules, e.g. syndecans [255,256,260,261].  In addition, interaction with the 
DMBT (deleted in malignant brain tumours)-1 gene encoded glycoprotein gp340, found in 
mucosal secretions, has been shown to promote HIV-1 transcytosis in FGT-derived EC 
lines and primary endocervical epithelium [262,263].  It has also been proposed that 
through binding to molecules on ECs, e.g. the human mannose receptor, HIV-1 per se may 
trigger an increase in the production of matrix metalloproteinases and/or inflammatory 
cytokines, impairing the integrity of the FGT epithelium  and facilitating migration of virus 
and/or target immune cells across the mucosa [264]. The extent to which these 
mechanisms play a role in HIV transmission in-vivo has yet to be determined. 
Semen and its constituents have complex effects on the immunologic milleu of the FGT, 
which facilitate conception and may potentially enhance HIV transmission. Seminal fluid is 
alkaline (pH 7.2-8.0), so neutralizes the acidic pH of the vagina. It also reduces the activity 
of SLPI, defensins, and other antimicrobial proteins [265]. Semen contains several 
cytokines and chemokines, including IL-7, IL-8, SDF-1, MCP-1 [266], enhances the 
production of further inflammatory cytokines, e.g. IL6 and MCP-1, by the FGT epithelium 
[267] and promotes the migration of leukocytes, including macrophages and mDCs into 
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the cervico-vaginal epithelium and endometrial stroma [268]. It may also directly increase 
HIV infectivity through the action of prostatic acidic phosphatase, which forms amyloid 
fibrils that capture HIV particles and facilitate their subsequent attachment to target cells 
[269]. 
Being sentinels to invading pathogens, mDCs and Langerhans cells are among the first 
cells to encounter HIV within the FGT epithelium [239]. mDCs possess receptors on their 
surface known as C-type lectins which recognise polysaccharide moieties on pathogens 
not commonly found on mammalian cells [270]. Langerhans cells express Langerin 
(CD207) whereas other mDCs express dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) (CD209). Both Langerin and DC-SIGN bind 
HIV gp120 with high affinity causing it to be taken up into Birbeck granules and 
endosomes respectively where it is protected from destruction [271]. Research using ex-
vivo vaginal explant tissue has demonstrated the rapid uptake of HIV-1 virions into both 
CD4 + T cells and mDCs [272].  However, whereas HIV enters T cells via CD4 and CCR5 
mediated binding and fusion, leading to productive infection, virions remain intact within 
DC endosomes for up to 3 days, inducing maturation and migration to the deeper 
submucosa or regional lymph nodes [272,273]. It thus appears that, in addition to directly 
infecting available target cells, HIV may be initially captured by mucosal mDCs, and 
harboured as infectious virus for later transfer to CD4+ T cells. 
Cell-cell propagation, or trans-infection, occurs via a cytoskeletal-based virological 
synapse (VS), which, in the case of mDC to CD4+ T cell transmission, is enhanced by DC-
SIGN mediated signalling [274,275,276,277].  Within an hour of HIV binding DC-SIGN, and 
undergoing endocytosis, extensions form over the entire mDC cell membrane [277]. 
Subsequently, HIV is transferred to microvillar extensions from T cells which make contact 
with virions beneath the mDC cell surface [278]. Such transfer is thought to be dependent 
on HIV-CD4/co-receptor interactions [274,279].  Similar cell-cell trans-infection also takes 
place between CD4 +T cells, and has been shown to be around 10 times more efficient 
than cell-free viral spread [279].  
Increasing evidence points to the interactions of HIV-1 per se with the inate immune 
system as being critical to tipping the balance between aborting and promoting infection. 
An example is its subversion of the type 1 IFN response.  RNA viruses are taken up by 
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pDCs into endosomes, where they are recognised by TLR7 and trigger type 1 IFN 
production.  However, HIV-1 is abberantly trafficked to early endosomes resulting in 
induction of a partially matured pDC phenotype, which secretes IFN-1, MIP1α and 1β and 
other chemotactic factors persistently [280]. This amplifies the pool of locally available 
CD4+ T cells, facilitates cell-cell spread and enables the rapid expansion of the ‘founder 
population’ necessary for dissemination to lymph nodes and secondary lymphoid organs 
to generate a systemic infection [281]. 
Over 90% of detectable productively infected cells in the initial and locally expanding foci 
in the FGT stroma are CD4+ T cells [282,283,284]. Yet, rather than being activated, they 
are predominately of a ‘resting’ or ‘memory’ phenotype, with residual rather than high 
levels of CCR5 expression. Recent research suggests that a subset of mucosal memory 
CD4+CCR5+ Th17 cells, expressing the chemokine receptors CCR6 and CXCR3 with and 
without integrin α4β7, may be particularly permissive to HIV-1 infection and replication 
[285,286,287,288] and that Env glycans may play a role in determining specificity of initial 
target cells and selective transmission [289].  α4β7, CXCR3 and CCR6 are homing 
receptors, controlling cell migration into the GALT.  Preferential infection of these cells 
may explain how HIV-1 disseminates from the site of entry to the GI tract, and why the 
latter becomes an early focus for HIV-1 replication and CD4+ T cell depletion [283]. 
The ‘eclipse’ period, before widespread viral dissemination takes place, ranges from 4 
days to several weeks, and is lengthened by reducing viral exposures [234]. Typically, in 
humans, and following low dose SIV challenge, HIV/SIV RNA becomes detectable in 
plasma (at concentrations > 50 copies/ml) from around 7 to 10 days post infection with 
levels peaking around the end of the second week [229,234,290]. However, although the 
adaptive immune system begins to control replication by 1 month post acquisition, 
reflected in a gradual reduction in plasma and tissue VL, this is too weak and too late to 
eradicate infection [229,137].  By this stage, a large reservoir of virus has already been 
established in lymphatic tissues, with ongoing replication and CD4+ T cell depletion. In 
addition, a potential pool of  proviruses have become integrated into the DNA of resting T 
cells [291,292].  
It is clear that there is just a brief window of opportunity to block the establishment of 
HIV-1 infection. To be successful, prevention measures must act at the time, or within a 
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few days, of HIV-1 exposure, to prevent the infection and expansion of founder 
populations [229].  Recent  research efforts have focused on improving understanding of 
these initial key steps, to elucidate vulnerabilities in host defenses that may be exploited 
by HIV, and identify new potential strategies for prevention. 
Figure 1-9 Initial steps in the establishment of HIV-1 infection in the FGT mucosa 
 
Figure reproduced from Kelly CG and Shattock RJ, J Intern Med 2011 [293]. 
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1.6 Strategies for Preventing Sexual Transmission of HIV-1 
At a population level, sexual transmission of HIV-1, like that of other STIs, can be 
described using the formula:   Ro =  ßcD + ßcГ  
Where: Ro = the basic reproductive rate and will determine the risk of spread of new 
infectious cases;  ß represents the efficiency of transmission, c the number of new sexual 
partners per unit time, D the duration of infectiousness of the index case and Г the 
average partnership duration [294].  If Ro > 1 new, secondary cases of HIV will occur, and 
the epidemic will grow.  Conversely, any strategy that reduces Ro to ≤ 1 will lead to a 
slowing of epidemic spread.  As can be seen from the formula, reducing any of the 4 
factors ß, c, D, or Г will decrease the spread of HIV, however, minimising ß and/or c will 
potentially have the greatest impact. 
Transmission probability per partnership (ßp) is related to the transmission probability per 
act (ßa) and the number of unprotected acts (Na):  ßp = 1-(1- ßa) 
Na   [294]. 
A number of different approaches are being taken to reduce sexual transmission of HIV-1 
(see Table 1-5) [17,295]. The aim of biomedical prevention methods is largely to reduce 
the efficiency of HIV transmission and, in the case of identifying and providing ARVS to 
HIV seropositive individuals, the duration of infectiousness.  In contrast, behavioural 
interventions are mostly concerned with reducing numbers of sexual partners and, in 
particular, concurrency (multiple, overlapping sexual partners) and age-disparate/ 
transactional sex, which have been proposed to be important in influencing the size and 
speed of growth of an HIV epidemic within a population [296,297,298].  Although 
important, and likely to be utilized in combination with successful biomedical strategies, 
behavioural interventions and those of a structural nature, e.g. implementing changes to 
the legal or economic framework and/or healthcare infrastructure of societies, are 
beyond the scope of this thesis but have been reviewed elsewhere [17,299,300].  
 
 
 
62 
 
Table 1-5  Strategies for preventing sexual transmission of HIV-1 
Uninfected individuals to reduce own susceptibility  
Time window for initiating 
activity 
Behavioural Biomedical 
Pre-exposure, lasts 
months/years 
Delay coitarche Prophylactic Vaccine 
(acquired immunity) 
 Reduce number/ concurrency 
of partners 
Medical male circumcision 
 Reduce inter-generational  
partnerships 
Treatment of  STIs 
  Long-acting/slow-release 
ARV technologies e.g. 
Intravaginal rings (IVRs), 
intramuscular depots. 
Prior to and during coitus  Correct and consistent use of 
condoms 
Oral ARVs (PrEP) 
  Topical ARVs  and/or other 
microbicides 
Post coitus  Oral  ARVs (PEP, ?PrEP) 
  ? Topical ARVs and/or other 
microbicides 
HIV-1 infected individuals to reduce onward transmission 
Time window for activity Behavioural Biomedical 
Years/lifelong Knowledge of HIV positive 
serostatus 
HAART 
Years/lifelong  Reduce number/ concurrency 
of partners 
Therapeutic vaccination 
Prior to and during coitus Correct and consistent use of 
condoms 
 
Structural Interventions 
Economic Legal (Laws and Policies) Healthcare Infrastructural 
Conditional cash transfers Protecting  sex workers, 
tackling gender-based 
inequality and violence 
Improved access to HIV 
screening, prevention and 
treatment 
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1.6.1 Treatment of HIV infected individuals to prevent transmission  
Given its proven ability to substantially reduce plasma HIV viral load (VL) [9], and the 
correlation between VL and risk of sexual and vertical HIV transmission 
[181,182,184,204,301,302],  great emphasis is currently being placed on using HAART as a 
prevention tool. The provision of ARVs to HIV infected pregnant women and their 
neonates has reduced mother to child transmission rates from around 20 % without 
intervention to below 2 % [303,304]. Likewise, observational studies in both developing 
and Western countries have demonstrated that initiation of HAART by HIV infected 
individuals within sero-discordant heterosexual relationships can dramatically reduce the 
incidence of HIV infection [305,306,307,308]. In a cohort analysis of a recent randomised 
controlled trial (RCT) involving 3381 HIV-1 and HSV-2 sero-discordant heterosexual 
couples, starting ARVs reduced the risk of HIV transmission from infected individuals to  
uninfected partners by 92 % [309].  A phase III RCT (HPTN 052) was established (at sites in 
9 countries; 5 in Africa, Brazil, India, Thailand and USA) specifically to evaluate the 
benefits,  with regards to reducing heterosexual HIV transmission, of earlier HAART 
initiation at  CD4 counts between 350 and 550 compared with at  CD4  counts < 250 or  
AIDS-related illness. This has recently been halted prematurely as it was clear there was a 
96 % reduction in phylogenetically linked transmissions between sero-discordant couples 
if the HIV positive partner was taking ARVs [310]. Although, it remains to be determined 
how well these benefits will translate outside of a trial setting, where adherence 
counselling, condoms and STI treatment were also provided on a regular basis, the use of 
ART as ‘couples prevention’ could have a significant public health impact; in some regions 
up to 50% of HIV transmissions occur within HIV discordant relationships lasting more 
than 1 year [311,312,313].  
Such is the faith in the power of suppressive HAART to prevent onward transmission that, 
the Swiss Federal AIDS Commission issued a declaration stating “if an HIV positive 
(heterosexual) individual has had a VL < 40 copies/ml for at least 6 months, remains 
adherent to HAART, free of sexually transmitted infections and under regular follow up by 
their HIV physician, then they should be considered to be ‘not sexually infectious’” [314]. 
However, this has proven to be controversial.  Although it is acknowledged that there is 
evidence in heterosexuals for a significantly reduced risk of onward HIV transmission if an 
individual maintains an undetectable plasma VL on HAART, there is as yet no conclusive 
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evidence to prove that it eliminates the risk of transmission.  Of some concern is the fact 
that it has been shown that whilst there is a correlation between HIV VL measured in  
plasma and that found in cervico-vaginal secretions and semen, it does not always follow 
that an individual with an undetectable plasma VL will also have an undetectable VL in 
their genital secretions. Numerous studies have reported discordance between blood and 
seminal VLs, with between 5 and 48 % of men with fully suppressed blood plasma HIV VLs 
continuing to have detectable levels in seminal plasma, even in the absence of STIs 
[315,316,317,318]. Such shedding can occur intermittently; thus a single undetectable 
measurement of genital tract HIV VL does not preclude transmission from that individual.   
In HIV infected women, discrepancies in VL between the genital and systemic 
compartments may be even more common than in men, with cervico-vaginal shedding 
being influenced by additional factors such as reproductive hormones and the vaginal 
flora [319].   Degree of inhibition of HIV-1 replication in the genital tract could potentially 
be influenced by choice of oral ARVs used, with protease inhibitors generally penetrating 
the genital tract less well than other classes of agent [320].  Recovery of different viral 
phenotypes and genotypes from blood and genital tract secretions, and determination of 
localised replication within the genital tract, suggest that differential compartment 
alisation of HIV-1 infection can occur [321,322]. Thus, poor genital tract penetration by 
certain agents could give rise to distinct drug-resistant HIV-1 variants from those found in 
plasma, with potential for onward transmission. As yet, no study has conclusively shown 
that ARV drug regimens which contain several agents which concentrate in the genital 
tract are any more likely to maintain undetectable genital VLs than regimens that 
penetrate poorly. That said, most research to date has looked at HAART combinations 
including at least 1 drug which is likely to penetrate the genital tract well [320]. Genital 
penetration of specific agents may be of greater importance if used individually as HIV 
treatment or as pre-exposure prophylaxis (PrEP) by HIV-1 uninfected individuals (see 
section 1.6.2). 
Another factor which needs to be taken into account when prescribing ARVs is the 
balance of risk to benefit for the individual.  There is now clear evidence from cohort 
analyses and randomized controlled trials that starting HAART in asymptomatic HIV 
positive individuals before their CD4 count falls below 350 offers a benefit in terms of 
reducing morbidity and mortality from AIDS and non AIDS conditions 
[323,324,325,326,327]. Significant reductions in morbidity have also been demonstrated 
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through starting ARVs at CD4 counts between 350 and 500, although there is no clear 
evidence of reductions in mortality [310,325,328,329,330]. There is currently conflicting 
evidence from cohorts regarding the benefits:risks to individuals of starting at higher CD4 
counts [325,327,328,329]. A randomized controlled trial (START) has been set up to 
establish differences in outcome between initiating treatment at CD4 counts of 500 or 
above compared with at 350 [331]. Even if it is shown that there is an undisputed 
advantage to initiating HAART in all asymptomatic HIV-1 infected individuals, there will 
undoubtedly be a significant sub-set of HIV-1 infected people who will wish to delay 
taking ARVs until they are absolutely essential for their immediate health. Many ARVs are 
associated with significant side effects which can greatly diminish an individual’s quality 
of life [9]. There is also the potential for long term toxicities and sequelae which, in view 
of the relatively short period of clinical experience of using some agents, are as yet not 
fully determined. In addition, there is the burden of needing to take treatment for life: as 
interruptions following initiation are detrimental to the individual [330] and may increase 
the risk of onward transmission. Worryingly, due to the rapid, error prone replicative 
ability of HIV, poor adherence can quickly result in the development of ARV resistance 
mutations, which render drugs less effective at controlling VL and can be transmitted to 
subsequent individuals [23]. Thus, people on HAART require frequent monitoring and 
follow up by healthcare professionals. 
In addition to using HAART to prevent transmissions between individual couples, 
modelers have attempted to estimate the potential impact on populations of  establishing 
universal  annual HIV testing programmes coupled with immediate initiation of HAART in 
those found to be HIV infected:- the ‘Universal Test and Treat’ approach. Although 
receiving criticism for some of their assumptions (for example that all transmission of HIV 
is heterosexual and treatment coverage quickly reaches 90% with few drop-outs), Granich 
et al. predicted that in generalized HIV epidemics such as that in South Africa it would be 
possible to reduce HIV incidence to fewer than 1 case per thousand per year within 10 
years [332].  However, despite the potential for significant long-term financial and health 
benefits [333], there will be enormous economic, organizational and infrastructural 
challenges in trying to implement increased testing and ARV provision in the low and 
middle-income countries where it is needed most, particularly given that only 54 % of 
individuals requiring HAART for their immediate health are currently receiving them [4].  
PopART (HPTN 071), a three-arm, cluster randomised trial of 1) a combined intervention 
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(community-wide house-to-house voluntary testing for HIV, the offer of medical 
circumcision to men who test HIV-negative and immediate initiation of ARVs for all 
individuals testing HIV-positive) compared with; 2) an intervention where ARV initiation is 
restricted to those meeting current national guidelines; and 3) standard of care, has 
recently been initiated in 24 communities in Zambia and South Africa [334]. Final results 
are expected in 2017. 
Even if shown to be feasible and effective, through the results of PopART and other 
studies, there are likely to be considerable delays to the widespead roll-out of ‘Test and 
Treat’ programmes in low and middle income countries and ongoing restrictions on the 
availability of ARVs. Thus, many of the poorest, most vulnerable people will continue to 
remain unprotected.  As is currently evident in some resource-rich regions, where policies 
for targeted, routine HIV testing and early ART initiation are already being implemented, 
e.g. Australia and San Francisco, USA, a significant proportion of HIV infected individuals 
continue to remain undiagnosed or decline testing or HAART [335,336].  These include 
individuals with acute HIV infection who are at highest risk of transmitting the virus 
[185,186].  Thus, even if the average per individual infectiousness is reduced, there are 
still likely to be significant numbers of new HIV-1 infections occurring at the population 
level each year [337,338].  Although there are differences between these relatively 
concentrated, largely MSM focused epidemics, and more generalized heterosexual ones, 
such ‘natural experiments’ have highlighted a number of logistical barriers which may 
limit the effectiveness of the ‘Test and Treat’ approach on a population level [335].  
Despite the undeniable potential of HAART for prevention, it seems unlikely that it will be 
possible to simply ‘treat ourselves out of the epidemic’ [339,340]. Thus, there remains a 
need to develop additional, complementary HIV prevention strategies. 
1.6.2 Interventions to reduce individuals’ susceptibility to HIV 
Thus far, the majority of HIV prevention interventions have been aimed at reducing 
susceptibility in people at risk of acquiring infection. The ideal scenario would be the 
development of a cheap, easy to deliver intervention capable of providing long-lasting, 
high-level protection to both men and women following a single application. To this end, 
a prophylactic vaccine, providing sterilizing immunity against all routes of transmission, 
remains the ultimate goal. However, development of an effective prophylactic HIV 
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vaccine has presented an enormous challenge, not least because of the huge diversity of 
HIV isolates and the difficulty in eliciting broadly cross-neutralizing antibodies [341, 
342,343, 344,345].  A shift in focus to  the generation of CD8+ T Cell responses, with the 
aim of attenuating HIV replication in those who become infected and reduce onward 
transmission, has also been met with major disappointments [346,347,348].  Although 
the results of the RV144 trial (of a replication-defective canarypox vector (ALVAC) ‘prime’ 
containing an AE_01 recombinant gp120 membrane anchored insert followed by a clade 
B/E recombinant gp120 protein (AIDSVAX B/E) ‘boost’) in 16,402 heterosexuals in 
Thailand, are encouraging,  the efficacy shown was modest (31 %) with apparent greatest 
protection in those at lowest baseline risk [349]. The characteristics of protection, with a 
trend to decreased efficacy after 6 months and the lack of any reduction in HIV VL in 
those vaccinees who became infected, were suggestive of a short-lived, antibody-
mediated response [343]. Plasma IgG antibodies against gp120 V1/V2 have subsequenctly 
been found to correlate significantly with the HIV-1 infection rate in RV144 vaccine 
recipients.  Presence of these antibodies conferred a 43% reduction in HIV-1 incidence.  
Individuals with high titres had a 71% lower rate of HIV-1 acquisition than those with 
medium- or low-level responses [350]. However, although able to bind some vaccine-
specific HIV-1 subtype E epitopes, these antibodies are incapable of neutralizing most 
primary isolates to any meaningful degree [351]. Since no mucosal samples were 
collected in this trial, it is unclear what responses were elicited in the genital tract.  
Despite recent insights and a more rational approach to immunogen design we are still 
likely many years away from developing a vaccine able to induce strong and sustained 
immune responses capable of preventing infection with a diverse range of viral subtypes 
[163,352]. Thus, other approaches have been taken to protect individuals from HIV. 
Currently, the most effective, one-off, HIV prevention intervention is medical male 
circumcision (MMC), which was demonstrated in three randomised trials to reduce HIV 
incidence among African heterosexual men by around 60 % [353,354,355]. The benefits of 
this procedure have been shown to be long-lasting and large-scale implementation 
programmes are already underway in some countries [356]. However, any benefit of 
MMC in decreasing women’s risk of HIV acquisition is indirect and is dependent on their 
male partners having undergone the procedure [357]. In addition, circumcision does not 
reduce HIV transmission from men who become HIV positive to their uninfected female 
partners [358].  
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The strong association between bacterial and viral STIs and both the transmission and 
acquisition of HIV-1 have led to calls for STI treatment to be an essential part of HIV 
prevention strategies. Enhanced syndromic treatment of curable STIs achieved a 
reduction in HIV incidence of almost 40% in a large community study in Mwanza, 
Tanzania in the early 1990s [359].  However, such an impact has failed to be reproduced 
in subsequent trials, conducted in regions with more generalized epidemics 
[360,361,362].  Identified as a key driver of some HIV epidemics, HSV-2 has been 
particularly targeted for intervention. Unfortunately, in several large RCTs in discordant 
couples, providing  acyclovir for people with HSV-2 infection  did not  protect them from 
acquiring HIV and likewise treating HSV in those with HIV-1/HSV-2 dual infection failed to 
prevent onward HIV transmission [363,364,365]. There has been much speculation as to 
why these disappointing findings arose. Significant reductions in genital ulcers [363,365], 
and plasma HIV-1 VL (through a direct effect of acyclovir on HIV-1 RT) [365] were 
achieved in some studies suggesting that adherence was good. However, it has been 
suggested that the dose of acyclovir used in these trials (400mg bd) was inadequate and 
that 800mg bd or valacyclovir 500mg bd may have achieved greater HSV2 +/- HIV-1 viral 
suppression [366].  Interestingly, increased populations of both ‘resting’ and ‘active’ T 
cells are detectable in the genital mucosa of HSV-2 infected individuals even in the 
absence of visible inflammation or ulceration [367,368]. Thus, subtle changes may persist 
which enhance HIV susceptibility even when HSV is well-controlled. 
Correct and consistent use of penile latex condoms has been shown, in observational 
studies, to reduce the probability of HIV-1 acquisition by heterosexual men and women 
by around 80% whilst also providing variable degrees of protection against other STIs 
[369,370]. In addition, although none have yet been demonstrated to reduce HIV-1 
incidence, a number of behavioural interventions, in HIV positives, MSM, adolescents and 
women, have been found, in meta-analyses, to significantly decrease HIV transmission 
risk behaviours [371,372,373,374].  However, even if they wish to use them, approaches 
such as ‘ABC’ (Abstinence, Be faithful, use Condoms) are outside of the control of many 
women in resource-poor settings, who lack power and influence over their partners’ 
behaviour [375]. 
At present, the only HIV prevention method that is ostensibly marketed as being under 
the complete control of women is the female condom. Although there is some evidence 
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to suggest that these are effective at preventing STIs, including HIV, they are not widely 
used, having been subject to issues with cost, acceptability and lack of availability 
[376,377,378]. They also invariably require some co-operation from men, and can be 
noisy and difficult to use. Although a new, lower cost version (the FC2) was approved by 
the US Food and Drug Administration (FDA) in 2009, it is still 10 times more expensive 
than the male condom making provision difficult in the developing world [379]. In 
general, there is little robust evidence of the effectiveness of initiatives to promote use of 
male or female condoms [380] and neither are a viable option for women who wish to 
become pregnant. 
1.6.3 Potential Role of Microbicides in HIV prevention 
Microbicides are topical agents that are designed to be applied by the receptive partner 
to protect against sexual transmission of HIV. They are particularly seen as having 
potential as a key, female-controlled defence against HIV acquisition [381,382]. It is 
envisaged that microbicides could provide women with a simple way to protect 
themselves, independent of whether their partner agrees to use condoms, undergoes 
circumcision, is HIV tested or initiates HAART. They could also be used in combination 
with these other strategies to increase protection. Although primarily intended for vaginal 
use by women living in areas with high HIV prevalence, it is increasingly recognized that 
products should also be developed for use by women and MSM for anal intercourse 
[383,384]. Although a dual-use product would offer greatest convenience, given the 
marked differences in the mucosal environments of the vagina and rectum, specific, 
separate formulations may be required for each compartment [385,386,387]. 
A microbicide is designed to be used in advance of sexual intercourse.  Topical application 
should, in theory, enable high, protective doses of an effective agent to be administered 
directly to the site of action and have a lower propensity for systemic toxicity and 
inadequate genital tract compartmentalization than oral dosing. However, these 
advantages are balanced by a higher potential for local adverse effects, which may impact 
on womens’ willingness to use the product, or even enhance the risk of HIV infection.   
An ideal product would be well tolerated, effective against multiple HIV subtypes, 
inexpensive to produce for use in developing countries, stable to storage in the absence 
of a cold chain, provide long-duration protection for use independent of time of coitus, be 
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durable in the presence of vaginal secretions and semen and, not least, be acceptable to 
potential users [388,389].   
1.6.4 Microbicide Development 
Like other biomedical interventions, potential microbicides are identified and evaluated 
pre-clinically, in-vitro and in animal models, before proceeding to trials in humans. At 
present, neither the FDA nor any other regulatory authorities, including the UK Medicines 
and Healthcare products Regulatory Agency (MHRA), have issued specific guidance for 
the development of topical anti-HIV microbicides; however, detailed and extensive 
recommendations for pre-clinical assessment were devised by the International Working 
Group for Microbicides (IWGM) in 2004 [390]. Essential laboratory mile-stones, adapted 
from FDA requirements for systemic antimicrobials, include definition of the mechanism 
of action of the active pharmaceutical ingredient (API), efficacy and toxicity testing in cells 
or explants relevant to the site of transmission, range-of action testing against a wide 
diversity of HIV subtypes and isolates, and evaluation of the APIs ability to both prevent 
infection with, and generate/select for, HIV strains which are resistant to the agent and 
other products [391]. 
Should an API be selected, it will be formulated as a gel, or other administration form, 
which will be then be tested for its safety, drug-release and distribution abilities (physic-
chemical properties), pharmacokinetics (PK), pharmacodynamics (PD) and efficacy, in 
cellular, tissue and animal models [392].  The latter have classically involved rodents for 
initial toxicity testing, followed rabbits for assessment of vaginal irritation [393,394], and 
finally, NHPs for evaluation of safety, PK, PD and efficacy. Challenge studies are generally 
performed in macaques, using SIV or chimeric simian/human immunodeficiency virus 
(SHIV) isolates (SIV virions that contain genes derived from HIV-1 and, therefore, express 
HIV-1 proteins e.g env-containing SHIVs express gp120/41 on their surface) as a surrogate 
for HIV-1 infection [79,230]. Although no defined cut-offs exist (reflecting, in part,  
variability, in the virulence and applicability of different challenge isolates, and use of 
DMPA, between studies), a viable candidate would generally be expected to protect 
against at least 70%, and ideally 90%, of high dose (300 TID50) virus exposures to warrant 
progression to clinical trials [392]. 
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Preliminary trials in humans (phase I and IIa; involving approximately 20 to 100 
participants) are largely concerned with evaluating toxicity and/or pharmacokinetics with 
subsequent larger trials (phase IIb and III, involving hundreds to thousands of 
participants) assessing extended safety and efficacy. Acceptibility evaluations can be 
conducted within or in parallel to clinical trials [391]. Reflecting the complexities and 
expense involved in the evaluation, formulation and manufacture of potential 
microbicides, of over 100 candidates identified thus far, only 8 have progressed to human 
efficacy trials [391, 392].   
1.6.5 Early Microbicide Candidates 
Initial research was focused on developing microbicides from established vaginal products 
or excipients that had demonstrated anti-HIV activity in-vitro. These were compounds 
with non-specific mechanisms of action against a range of micro-organisms +/- sperm, 
and included surfactants, polyanions, and vaginal pH buffering agents (see Table 1-6). Six 
of these early candidates were tested in efficacy trials with disappointing results [395].  
The first product to be tested, the surfactant nonoxynol-9 (N-9), was widely available as a 
spermicide and lubricant.  Results of initial trials of N9-containing microbicides (a vaginal 
sponge in Kenya [396] and film in Cameroon [397]) in HIV-negative female sex workers 
were inconclusive.  However, in a more definitive trial, involving female sex workers in 
Benin, Cote D’Ivoire, South Africa and Thailand, an association was found between 
frequent use of an N9-based gel (> 3 per day) and an increased risk of HIV acquisition 
[398]. A suggestion of an increased number of HIV seroconversions was also seen in the 
active arm compared with the placebo arm in a phase III efficacy study of another 
surfactant C31G  (Savvy®, Cellegy Pharmaceuticals, Quakertown, Pennsylvania, USA). This 
result was not conclusive as both this study, in Nigeria, and another study in Ghana were 
halted because of a lower than expected HIV incidence rate in the study population 
[399,400]. With hindsight, the mechanism of action of surfactants, disruption of cellular 
and microbial lipid membranes, should have perhaps led to earlier questioning of their 
safety. N-9 has subsequently been shown to be toxic to the genital mucosa, with 
associated epithelial disruption, inflammation, immune cell recruitment and alterations to 
the vaginal flora, which may help explain the clinical observations [401,402]. 
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Table 1-6  1st Generation HIV-1 Microbicides 
Category of 
Microbicide 
Mechanism of 
Action 
Examples in Class Stage of Development 
Surfactants 
 
Non-specific 
disruption of 
phospholipid 
membranes on 
cells and micro-
organisms 
 
Nonoxynol- 9 (N9) 
 
 
 
Savvy® (C31G) 
 
 
 
Sodium lauryl sulfate 
(Invisible condom®) 
 
No longer under consideration 
due to safety concerns 
[398,401,402]. 
 
2 Phase III trials halted due to 
low HIV incidence in study 
population [399,400]. 
 
Phase II safety study 
completed [403]. 
 
Negatively 
charged 
(Anionic)  
Polyanions 
Interact with HIV 
gp 120 (envelope), 
CD4 and CXCR4 to 
inhibit viral 
attachment and 
entry into cells 
 
Carageenan 
(Carraguard®) 
 
Cellulose sulfate 
(Ushercell®) 
 
 
 
Naphthalene 
sulfonate (PRO 2000®) 
 
 
Cellulose acetate 
phthalate 
 
 
Dendrimers (Vivagel®) 
 
Completed phase III trial 
[410].Safe, but not efficacious. 
 
2 phase III trials [411,412] 
halted early due to possibility 
of increased HIV incidence in 
one study [411]. 
 
Phase IIb and III trials 
completed [415,416]. Safe, but 
not efficacious. 
 
Phase I trial halted due to 
heavy vaginal discharge 
(osmotic effect) [404]. 
 
Phase I trials completed 
[405,406]. 
 
Acidifying 
agents 
Act to maintain 
acidic vaginal pH 
by buffering 
effects of alkaline 
semen 
Carbopol 974P 
(Buffergel®) 
Acidiform (Amphora®) 
Lack of efficacy in phase IIb 
trial [415]. 
Phase I and II/IIb studies 
completed  (with 
diaphragm)[407,408].  
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The next group of compounds to be tested were polyanions. These bind to positively 
charged regions on HIV gp120 to inhibit binding to target cells [409]. Carraguard® (R515, 
Population Council, New York, USA) a gel containing the seaweed derived polysaccharide 
carageenan, was shown to be safe, but not efficacious when applied by 3011 women over 
a 2 year period. However, the reliability of the findings have been questioned since self-
reported adherence, from which estimates of total sex acts were derived,  was much 
higher than that calculated from  testing of returned applicators,  the latter of which 
suggested that gel had been used in  only 42.1 %  of sex acts [410].  Two phase III efficacy 
studies of another polyanion cellulose sulfate (Ushercell®, Polydex Pharmaceuticals, 
Toronto, Ontario, Canada and Topical Prevention of Conception and Disease [TOPCAD], 
Chicago, Ilinois, USA) were halted prematurely after an interim analysis of one suggested 
a higher HIV incidence among participants in the cellulose sulfate arm than in the placebo 
arm. On final analysis, the HIV incidence was 5.29/100 woman-years in those receiving 
cellulose sulphate compared with 3.33/100 woman years in placebo users; a difference 
which did not reach statistical significance (hazard ratio 1.61 95 % confidence interval (CI) 
(0.86-3.01)) [411,412]. Subsequently, it has been demonstrated, in-vitro, that cellulose 
sulphate generates a sustained drop in TER, reducing the integrity of the genital epithelial 
barrier. It also induces activation of NF-ĸB, which may promote HIV-1 replication [413]. 
Subversion of TLR mediated pathways may underlie this and may also affect levels of 
other cytokines [414]. 
Initial findings with PRO 2000® (naphthalene sulfonate, Indevus Pharmaceuticals, 
Lexington, MA, USA), the final polyanion to undergo efficacy trials, were encouraging. 
HPTN 035 was a 4 arm phase IIb trial in which 3087 women were randomized 1:1:1:1 to 
receive PRO 2000, BufferGel® (Carbopol 974P, Reprotect, Baltimore, MD, USA)- a gelling 
agent which acts to preserve low vaginal pH), placebo gel or no gel. No effect of BufferGel 
on HIV acquisition was detected (hazard ratio 1.1, 95 % CI 0.8-1.6); however, PRO 2000 
(0.5 %) gel was 30 % effective at reducing HIV incidence compared with placebo gel  
(hazard ratio 0.7, 95 % CI 0.5-1.1) and 33%  (hazard ratio 0.7, 95 % CI 0.4-1.1) compared 
with no gel [415]. However, since this positive effect was not statistically significant, it 
may possibly have occurred by chance. The Microbicides Development Programme (MDP) 
recruited over 9,000 women from different population groups (the general population in 
South Africa and Zambia), those at high risk in Tanzania and Ugandan HIV serodiscordant 
couples) to the MDP301 trial. This phase III trial was designed to compare two 
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concentrations of PRO 2000 (0.5 % and 2 %) against placebo; however, the 2 % arm was 
stopped for futility following a Data and Safety Monitoring Committee review in February 
2008. The final results, released in December 2009, indicated that whilst both 
concentrations of PRO 2000 were safe neither was any better than placebo at preventing 
HIV acquisition (hazard ratio for 0.5 % gel 1.05, 95 % CI 0.82-1.34; for 2 % gel 1.21, 95 % CI 
0.88-1.68)[416]. 
These initial failures called into question whether the concept of microbicides for HIV 
prevention was viable and highlighted deficiencies in the processes for evaluating 
potential candidates [417,418].  In the face of these challenges, and with enhancements 
in our understanding of mucosal HIV transmission, new models, assays and biomarkers 
have been developed to provide better, and earlier insights into the likely safety and 
efficacy of the next generation of microbicides [392] (discussed further in section 6.2.2). 
1.6.6 Antiretroviral microbicides and oral pre-exposure prophylaxis 
Although some agents with similar mechanisms of action to 1st generation microbicide 
candidates remain in the development pipeline, including the dendrimer SPL7013 
(VivaGel®, Starapharma, Australia) [405,406], the focus has shifted towards more potent 
molecules, which specifically inhibit a particular stage of the HIV life-cycle (see Table 1-7).  
Currently, the leading microbicide candidates are ARVs, although more novel, non-ARV 
agents are also being evaluated (see section 1.6.7) [293].  As well as topical application, 
use of oral ARVs as pre-exposure prophylaxis (PrEP) is  also being explored, given that the 
latter are already provided to HIV negative individuals in Western healthcare settings as 
post-exposure prophylaxis (PEP) following high-risk occupational (needle-stick) or sexual  
exposures [419]. 
The most advanced candidates for both topical and oral PrEP are reverse transcriptase 
inhibitors. Proof of concept for microbicides was demonstrated following the results, in 
2010, of a phase IIb safety and efficacy trial of 1% tenofovir gel (Gilead, Foster City, USA).  
This study (CAPRISA 004) was conducted over a 30 month period in 889 women, recruited 
in both an urban and a rural clinic in KwaZulu Natal, South Africa.  Women were asked to 
apply a dose of tenofovir gel within 12 hours before vaginal intercourse with a second 
dose immediately afterwards with no more than 2 doses in 24 hours (the BAT24 
regimen). The trial was end-point driven, with participants due to be followed until at 
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least 92 HIV infections were observed, providing 90% power to detect a 50 % effect.  
When the trial was terminated, there were 38 HIV infections in the tenofovir arm and 60 
in the placebo arm with incidence rates of 5.6 and 9.1 per 100 woman years respectively. 
Overall, the intervention was found to reduce HIV transmissions by 39% (rate ratio 0.61 
95 % CI 0.40-0.96) [420]. HIV infection trends show that the tenofovir gel effect was 
evident soon after initiation of gel use and decreased over time. The HIV incidence rate in 
the tenofovir gel arm was 50% (P=0.007) lower compared to the placebo arm after 12 
months and only 40 % lower (P=0.013) after 24 months follow up. This apparent reducing 
efficacy likely  resulted from the effect of a declining number of reported coital acts (7.2 
acts/month in 1st 6 months to 3.1 acts/month in months 18 to 24) as the study went on 
and a declining HIV incidence rate in the placebo arm over time whilst that in the 
tenofovir arm remained stable. As might be predicted and reflecting the robustness of the 
data, efficacy was greatest in those with the highest adherence (> 80 % gel adherence, 54 
% lower HIV incidence) and least in those with the lowest adherence (< 50 % gel 
adherence, 28 % lower HIV incidence). This was also reflected in pharmacodynamic data. 
There was a clear correlation seen between cervico-vaginal fluid (CVF) levels of tenofovir 
and intracellular levels of the active metabolite tenofovir–diphosphate (measured at first 
study visit post infection, in 34/38 women in tenofovir arm who seroconverted, or 
random study visit in 303 women who remained HIV negative) and these in turn 
predicted rates of HIV seroconversion. In those women who remained HIV negative 
throughout the trial in the tenofovir arm, 96% had detectable concentrations in CVF, 
compared with 45 % of those who seroconverted [421]. HIV incidence in women with CVF 
levels > 1000ng/ml  (n=82) were significantly lower than those in the placebo group (2·4 
vs 9·1 per 100 person-years; incidence rate ratio (IRR)=0·26, 95% CI 0·05–0·80, p=0·01) 
whereas those with with CFV levels < 1000ng/ml (n = 253) were similar (7·8 vs 9·1 per 100 
women-years; IRR=0·86; 95% CI 0·54–1·35, p=0·51) [422].  
In safety analyses, there was no statistical difference between the overall numbers of 
adverse events reported in the tenofovir arm compared to in the placebo arm (3.55 and 
3.44 per woman year P=0.265) and no safety concerns in pregnancy, although gel use was 
discontinued in those women found to be pregnant. One theoretical concern with using 
ARVs for PrEP is that users who become HIV positive whilst still exposed to the drug could 
develop resistance mutations. One advantage of using topical microbicides over oral PrEP 
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is that systemic levels of drug are likely to be much lower which may make the 
development of resistance less likely.    
No NRTI resistance mutations, including those particularly associated with tenofovir use 
(K65R, K70E), have been found using standard population sequencing in plasma samples 
from women in the tenofovir arm with breakthough HIV infection. Although low levels of 
resistance mutations, in particular K65R, were detected in women from both study arms 
using deep 454 pyrosequencing, frequencies were not increased in those exposed to 
tenofovir gel suggesting it had no appreciable effect [423] .  However, one participant was 
also found to have very low levels (~ 1%) of the K65R mutation in cervicovaginal fluid 
using sensitive proviral DNA PCR assays. This woman had the highest vaginal aspirate 
tenofovir level of any participant who seroconverted (213,000 ng/mL), with an estimated 
infection duration of 13 days, and a CVL viral load of 740 copies. This level of K65R falls 
within a frequency that has been reported to be natural quasispecies error for subtype C 
in the absence of drug; thus, although it has raised concern, it might also simply reflect 
background levels of mutation and not tenofovir-induced resistance [424,425]. Of note, 
samples for resistance testing were performed on average 20 weeks after the estimated 
date of HIV seroconversion when many participants were no longer exposed to tenofovir. 
There therefore remains a small chance that some other mutations may have been 
archived and may emerge at a later date if the individual is re-exposed to the drug.  
An additional beneficial finding from a sub-study within CAPRISA 004 looking at women 
who were HSV-2 serologically negative at enrolment, was that women in the 1% tenofovir 
arm displayed a 51 % reduction in their incidence of HSV2 (95 % CI: 22-70%) [420]. This 
finding was a surprise bonus, and is linked to the anti-HSV activity exhibited by  tenofovir 
(which is structurally related to the drug Cidofovir used to treat HSV and 
Cytomegalovirus) at high concentrations [426]. As for HIV, there was a correlation 
between tenofovir levels in cervico-vaginal fluid and incidence of HSV2 [421].  Although 
numbers were too small for a formal statistical analysis, tenofovir appeared to protect 
women from HIV-1 independent of their baseline HSV status; thus, it is thought unlikely 
that its HIV protective effect was mediated through the prevention of HSV2 acquisition. 
Initial results of the iPrEX study, a Phase III trial of oral PrEP in 2,499 sexually active MSMs 
and transgendered women who have sex with men, were also released in 2010. The 
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strategy showed promise, with 43.8 % fewer HIV infections reported in participants 
randomised to daily oral Truvada (tenofovir plus emtricitabine, Gilead) than those who in 
the placebo arm (95% CI 15.4 to 62.6%; P=0.005) [427]. Detectable levels of the study 
drugs in participants’ blood strongly correlated with the prophylactic effect, suggesting 
efficacy was directly related to adherence. In the final intention-to–treat (ITT) analysis, 
Truvada PrEP was shown to be 42 % effective overall. However, modelling, based on 
detected drug levels, suggested a 92 % reduction in HIV infection was achieved with high 
adherence to daily dosing [428]. 
Findings from four other important PrEP studies, all in heterosexuals, were announced in 
2011.  The TDF-2 Study was a Phase IIb trial of daily oral Truvada vs placebo, conducted in 
1,200 HIV uninfected men (54.7%) and women (45.3%) in Botswana. Nine of 601 
participants became HIV-1-infected in the Truvada group and 24 of 599 in the placebo 
group.  Overall protective efficacy of Truvada was 62.2% (95% CI 21.5 to 83.4, p=0.0133). 
Although not designed and powered for such, ITT analysis by gender suggested the 
intervention was protective in men (p=0.026) but not in women (p=0.107) [429].  The 
Partners PrEP study was a 3 arm phase III trial comparing daily use of oral tenofovir alone, 
oral Truvada, and placebo in preventing HIV transmission in serodiscordant couples. 4,758  
couples were enrolled in Uganda and Kenya, between July 2008 and November 2010, 
with study follow-up planned until 2012. However, following an adhoc review of the data 
up until May 2011, the DSMC concluded that there was clear evidence that both tenofovir 
and Truvada were effective at preventing transmission and that individuals in the placebo 
arm should be offered active product. In the final published results, 82 participants 
acquired HIV-1 after enrolment, n= 52 placebo arm, n= 17 tenofovir arm, and n= 13 
Truvada arm. Overall, compared to placebo, there were 67 % fewer infections in the 
tenofovir arm (95 % CI 0.44- 0.81) and 77% fewer in the Truvada arm (95 % CI 0.55- 0.87). 
There was no significant difference in the efficacy of tenofovir and truvada. Both 
tenofovir and Truvada significantly reduced risk of HIV acquisition in both men and 
women [430].  
In contrast with the findings from CAPRISA 004, suspected ARV-induced resistance 
mutations have been detected in several PrEP trial participants who were subsequently 
found to already have been recently HIV-1 infected (HIV-1 antigen (p24)/antibody 
negative/RNA positive) at baseline. In the iPREX trial 2 such particpants randomised to the 
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Truvada arm were subsequently found to have mutations associated with resistance to 
emtricitabine; 1 was confirmed to have become detectable during the study, i.e. the HIV-
1 genotype was wild-type at baseline, but M184I positive at 4 weeks; in the other patient, 
the baseline RNA sample was too low to perform resistance testing [431].  In the TDF-2 
study, 1 acutely HIV-1 infected participant who received Truvada developed K65R, M184V 
and A62V RT mutations at high levels (approximately 100%), having previously had a wild-
type genotype [429]. In the Partners PrEP trial, 2 of 8 participants with acute HIV-1 at 
enrolment developed mutations on treatment, 1 in the tenofovir arm developed K65R 
and 1 in the Truvada arm developed M184V [430].  However, although resistance induced 
by taking the study ARVs is suspected it cannot be proven and there is a possibility that 
the mutations may have been present at low level as archived transmitted resistance 
which was then selected out under drug pressure. In particular the presence of A62V, a 
broad-spectrum NNRTI mutation, is supportive of this theory. Evidence of transmitted 
drug resistance was found in patients in the placebo arms of both iPREX (1 individual with 
M184V, T215Y and K103N at baseline; the latter being an NNRTI mutation) and 
potentially in TDF-2 (1 participant had a K65R mutation intermittently and at very low 
levels (<1%) after seroconversion, although the mutation was not detected in the blood 
sample that had been obtained closest to the estimated date of seroconversion and may 
just reflect natural Subtype C variation [425]).  Resistance appears to be uncommon in 
individuals seroconverting after randomisation, a minority of whom had detectable drug 
levels, although further analyses are awaited. These findings, and the small but significant 
decreases in bone mineral density induced through tenofovir use in 2 of the studies (in 
populations with lower than average bone mineral density at baseline) [430,432] are 
potentially worrying and could have long term consequences. What is certain is that if 
PrEP is rolled out widely as a prevention methodology, every effort should be made to 
identify those individuals at risk of being in the serological detection ‘window period’ for 
acute infection, and PrEP deferred, and/or triple drug PEP offered as appropriate, until 
HIV infection can be definitively excluded. 
Interestingly, the efficacy of oral tenofovir and Truvada as PrEP in the above studies is in 
contrast to findings from two others. The FEM-PrEP trial, in which daily oral Truvada was 
compared to placebo in high risk African women, was terminated early in April 2011 
having enrolled 1,951 participants and accrued 75 % of the planned study endpoints (56 
HIV infections, 68 in final analysis). With virtually equal numbers of HIV transmissions 
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occurring in both arms of the study, the DSMC decided that it was futile to continue as it 
was highly unlikely to be able to demonstrate effectiveness of the intervention  [433]. 
Despite a requirement for all women to be using a reliable method of contraception (66 % 
were using injectables and 30 % were using oral contraceptives at enrolment) there was 
an overall pregnancy rate of 9 %. This in itself is not unusual, since conception is a 
common occurrence in trials involving young African women. Interestingly, among study 
participants assigned to the Truvada arm, observed pregnancy rates were higher than 
among women in the placebo arm. This is unexpected and inconsistent with known drug 
interactions involving tenofovir or emtricitabine and contraceptive hormones. Results 
suggest that, despite intensive counselling, drug adherence within the trial was generally 
poor. Among women assigned to Truvada, drug was detectable in plasma in < 30% of 
infected cases and < 40% of uninfected controls matched on time of infection [434].  This 
contrasts with adherence levels reported from the Partners PrEP study where drug level 
analyses indicated adherence rates of > 80 % in uninfected controls in both treatment 
arms. Adherence was found to be much lower in iPREX, where tenofovir was detected in 
only 44% of uninfected controls. Evidence from pharmacokinetic studies suggests that 
active tenofovir and emtricitabine metabolites concentrate in greater quantities in the 
rectum than in vaginal tissues following oral dosing [422]. Thus, tenofovir and Truvada 
may be more forgiving of poor adherence in protecting against rectal compared with 
vaginal HIV exposures. 
The Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial was designed to 
directly compare safety, efficacy and acceptability of topical and oral ARVs for HIV 
prevention in women [435].  Participants were randomly assigned to one of five study 
groups; three tablet groups: tenofovir, Truvada, or oral placebo; and two gel groups: 
tenofovir 1% gel or placebo gel. Interventions were to be used once daily at any time. 
VOICE was designed to enroll approximately 5,000 women, about 1,000 in each group. 
Enrolment of 5,029 women was completed in June 2011 with follow up expected to 
continue until mid-2012. However, similar to the FEM-PrEP trial, two study arms, first oral 
tenofovir, then tenofovir gel, have been stopped early due to a lack of difference in HIV 
incidence between the intervention and placebo arms [436]. 
On the basis of the findings from iPREX, Partners PrEP and TDF-2 Trials, the FDA has very 
recently granted a change of license for Truvada to be used as PrEP. As a condition of this 
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license, Gilead Sciences is required to “collect viral isolates from individuals who acquire 
HIV while taking Truvada and to evaluate these isolates for the presence of resistance. 
Additionally, the company is required to collect data on pregnancy outcomes for women 
who become pregnant while taking Truvada for PrEP and to conduct a trial to evaluate 
drug adherence and its relationship to adverse events, risk of seroconversion, and 
resistance development in seroconverters. Gilead has committed to provide national drug 
utilization data in order to better characterize individuals who utilize Truvada for a PrEP 
indication and to develop an adherence questionnaire that will assist prescribers in 
identifying individuals at risk for low compliance” [437].  
Following the promising results of CAPRISA 004, the FDA indicated that it would review 
data from VOICE as the second pivotal trial to support possible fast-track licensure of 
tenofovir gel, and a deal was brokered between CONRAD (the HIV and women’s health 
research organization who manufactured and supplied the 1% tenofovir gel for CAPRISA 
004) and the South African Government’s Technology Innovation Agency to grant the 
latter the right to manufacture and distibute the gel in Africa if it were to be approved 
[438]. However, instead of affirming the efficacy of tenofovir gel, VOICE has provided 
clear evidence that gel use was not effective in the women in the study. Although 
disappointing, this information adds a new dimension to discussions about the future of 
tenofovir gel.  Of particular interest is the potential for the different dosing regimens (pre 
and post coital dosing vs once every day) to have played a part in observed efficacy 
differences.  A Phase III trial (Follow-on African Consortium for Tenofovir Studies (FACTS 
001)), testing the same BAT24 regimen of tenofovir gel used in CAPRISA 004, began 
enrolling participants in October 2011 [439]. This study will involve approximately 2,200 
women at up to nine sites in South Africa, with results expected in 2014. Unfortunately, 
plans for another trial, led by the MDP, that would have compared tenofovir 1% gel 
administered via the BAT24 regimen vs tenofovir 1% in a single pre-coital dose, have been 
put on hold due to funding constraints. This is a pity since the latter would potentially 
make for a more convenient and realistic ‘real world’ dosing regimen. However, a phase I 
study comparing the post-coital pharmacokinetics and pharmacodynamics of 1% 
tenofovir gel applied in one of 3 ways (once daily, in a BAT24 regimen or peri-coitally) is 
going ahead (ClinicalTrials.gov identifier: NCT01369303). 
81 
 
 Two other ARVs which are currently being tested clinically for use in HIV-1 pre-exposure 
prevention strategies are the NNRTI Dapivirine (Tibotec BVBA, Mechelen, Belgium and 
International Partnership For Microbicides) and the CCR5 inhibitor Maraviroc (Pfizer, New 
York, USA). Dapivirine is a highly lipophilic molecule which was not suitable for oral 
dosing. It has been formulated both as a gel and as an intravaginal ring (IVR). The latter 
are capable of controlled release of agents over a prolonged period, enabling continuous, 
coitally-independent delivery of a high concentration of active drug [440].  Studies in 
rabbits and macaques of dapivirine vaginal gel demonstrated drug accumulation in the 
keratinized epithelial layer of the vagina with some penetration of the superficial cell 
layers. Dapivirine was detectable in tissue at 48 h post administration [441]. Dapivirine gel 
has subsequently been tested in women and found to be well-tolerated with low-level 
systemic absorption ( < 1.1ng/ml) and a long terminal half-life (t ½) in both plasma (72-73 
hours) and genital fluids (15-17 hours) [442,443,444]. The dapivine-loaded IVR has also 
been tested in a number of phase I and II pharmacokinetic, safety and acceptability 
studies [445,446], and a phase II study of long-term safety plus efficacy (The Ring Study) is 
on-going [447]. A phase III efficacy trial (ASPIRE) began recruitment in July 2012 [448].   
As shown in Table 1-7, maraviroc is currently the only inhibitor of CCR5 licensed for HIV 
treatment. Its action early in the HIV lifecycle, favourable safety and pharmacokinetic 
profile and relatively limited use in current ARV therapeutic regimens make it an ideal 
candidate both as a microbicide and as oral PrEP [449]. A randomised, double-blind trial 
of oral maraviroc (300mg OD), vs maraviroc plus either emtricitabine or tenofovir, vs 
Truvada as daily PrEP in MSM (Novel Exploration of Therapeutics for PrEP (NEXT-PrEP), 
HPTN 069/ACTG 5305), has just been initiated [450]. A vaginally applied gel formulation 
of maraviroc, which effectively protected against infection with SHIV in a macaque model, 
is currently undergoing phase I trials [451]. Maraviroc is also being assessed, both alone 
and in combination with dapivirine, in an IVR [452]. A combined maraviroc /tenofovir film 
is also being developed. 
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Table 1-7 Specific anti-HIV-1 agents with potential for use as microbicides or oral PrEP 
Category of 
Microbicide 
Mechanism of 
Action 
Examples in Class Stage of Development of Most 
Advanced Candidate(s) in Class 
Reverse 
transcriptase 
inhibitors 
 
Inhibit HIV 
reverse 
transcriptase 
enzyme to block 
viral replication 
Nucleoside/Nucle
otide e.g. 
Tenofovir  
 
 
 
Tenofovir +/- FTC 
(Truvada®) 
 
 
 
 
Non-nucleosides 
(NNRTIs) e.g. 
Dapivirine (TMC-
120), UC-781, 
MIV-150 
Microbicide:  
1 % tenofovir gel;-Phase IIb (CAPRISA 
004)- overall 39% efficacy [420]. 
VOICE- gel arm halted by DSMC [435]. 
 
Oral PrEP: Phase IIb/III 
iPREX, TDF-2, Partners PrEP:-  
Overall 42% (MSM) and 73% 
(heterosexual) efficacy [428,429,430]. 
FEM-PrEP, VOICE  
(tenofovir) Not protective [434,436]. 
 
Microbicide: 
Dapivirine:-Phase I/II studies 
completed (gel and IVR). Phase II 
studies ongoing; Phase III study 
started (IVR) (ASPIRE) [448,452].  
Entry 
inhibitors: 
 
 
CCR5 ligands 
 
 
 
 
 
 
Fusion 
inhibitors 
 
 
 
 
Lectins 
 
 
 
Monoclonal 
Antibodies 
 
 
Prevent HIV-1 
binding/entering 
cells 
Bind to CCR5 to 
inhibit binding of 
co-receptor to 
gp120 
 
 
 
Prevent  gp41 
helical bundle 
formation and 
fusion 
 
 
Bind to mannose 
moieties on 
gp120  
 
Bind to a range of 
different targets 
on  gp 120 or 41, 
or to cellular 
receptors (e.g. 
CD4, CCR5, 
CXCR4)  
 
 
 
 
Maraviroc 
 
 
 
PSC RANTES, 
5P12 RANTES 
 
T20, BMS806 
 
 
 
 
 
Cyanovirin-N, 
Griffithsin 
 
 
 
 
2G12, 2F5, 
4E10,b12, VRC01, 
PGV04, PGT NAbs 
 
 
 
 
Oral PrEP: Study in MSM started [450] 
Microbicide: 
Phase 1 studies ongoing (gel and IVR 
(latter combined with 
Dapivirine)[452]. 
Microbicide: 
Pre-clinical [456,457]. 
 
Microbicide: 
Pre-clinical[293]. 
 
 
 
 
Microbicide: 
Pre-clinical [459,460,461,463], phase I 
trial in development (Griffithsin) (C 
Lacey, personal communication, 
2012). 
 
Microbicide: 
Pre-clinical and phase 1 [500] 
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Other classes of ARVs, which act during (integrase inhibitors) or post-integration 
(protease inhibitors), are also being considered for HIV-1 prevention. These could 
potentially contribute to eliminating the initial founder infection foci, especially if used in 
combination with an entry blocker or RT inhibitor. Given the demonstrated success of 
combination therapy in HIV treatment, multi-target ARV formulations are being evaluated 
as microbicides or PrEP [293]. Indeed, a dedicated European project (Combined Highly 
Active Antiretroviral Microbicides (CHAARM)) has been established to specifically develop 
new combination ARV-based microbicides [453]. 
1.6.7 Current non-ARV microbicides 
Despite the undoubted potential of ARVs as PrEP, there remains a concern that 
intermittent dosing of oral agents could give rise to resistance mutations in users who 
acquire or who are already infected with HIV.  This could theoretically occur even with the 
low levels of systemic absorption seen with topical agents (In CAPRISA 004, blood plasma 
tenofovir concentrations measured at a mean of 4.5 days of gel use were < 1ng/ml (0-0.8 
ng/ml) in women using tenofovir gel, similar to levels seen with dapivirine) [420,421]. The 
efficacy of ARVs for PrEP may also be reduced in the presence of drug-resistant HIV 
strains in an infected partner. ARV-resistance has become a widespread problem with the 
increasing availability of HAART and relative lack of resources for detecting virological 
failure in developing countries [454,455]. Thus, there remains an impetus to develop 
microbicides based on classes of molecule which differ from those used in therapy. 
Most non-ARV agents in the potential microbicide pipeline act through various 
mechanisms to inhibit HIV attachment and entry into cells.  Many of these are peptides or 
proteins related to molecules involved in innate immune defenses [391]. PSC-RANTES, a 
synthetically produced analogue of the natural CCR5 ligand RANTES, displayed 
remarkable potency in- vitro and in macaque vaginal challenge studies [456], but was 
thought to be too costly to develop as a microbicide. It also acted as a CCR5 agonist, with 
potential for inducing inflammation. However, a fully recombinant compound, 5P12-
RANTES, displays potent cross-clade anti-HIV-1 activity, without any signalling effects, and 
is compatible with cheaper, biosynthetic production [457].  
Several non-mammalian lectins have been identified which, through binding mannose 
residues on gp120, inhibit both attachment of HIV-1 virions to target cells and onward 
84 
 
transfer via transcytosis [458]. The first of these, cyanovirin–N, is derived from 
cyanobacteria. It has broad and potent in-vitro anti-HIV-1 activity and has been shown to 
protect macaques from both vaginal and rectal SHIV challenge [459 ,460].  Scientists have 
expressed cyanovirin-N in Lactobacilli to produce a ‘living-microbicide’; a concept which 
may hold promise for the future [461]. Unfortunately, cyanovirin-N has been found to 
stimulate lymphocyte proliferation and cytokine production, raising safety concerns 
[462].  Griffithsin, a red algal protein, is another candidate. It has even more potent HIV 
inhibitory activity than cyanovirin-N in-vitro and displays no mitogenic or inflammatory 
properties, either in-vitro or on rabbit vaginal irritation testing. In addition it has been 
expressed in the tobacco plant Nicotiana Benthamiana, with potential for large scale 
affordable production [463].   
1.6.8 Broadly neutralizing monoclonal antibodies against HIV-1 
The ability to induce protective neutralizing antibodies has long been considered an 
optimal goal of candidate HIV vaccines as they have been shown to offer protection 
against many other viral infections [146,464,465,466]. More recently, interest has 
developed in the potential of applying combinations of neutralizing monoclonal 
antibodies topically as a vaginal microbicide. 
1.6.8.1 Definition of monoclonal antibodies (mAbs) 
Antibodies may be characterized as ‘polyclonal’ or ‘monoclonal’, according to the nature 
of the B-lymphocyte population from which they are derived. Naturally produced sera is 
polyclonal, containing antibodies with a broad range of different antigen affinities and 
specificities, which have been secreted by a large number of genetically distinct B-cells.  
However, it is possible to combine individual Ig –producing B cells with myeloma cells to 
create hybridomas, which can replicate indefinitely in culture and be cloned.  Antibodies 
produced in such systems are identical in their isotype, antigen affinity and specificity and 
are termed monoclonal [467].  
There are currently more than 20 IgG mAbs approved for the treatment of a variety of 
conditions, including autoimmune and inflammatory disorders, transplant rejection and 
malignancies [468].  At present, only one mAb is licensed for preventing an infection in 
humans; Palivizumab (AstraZeneca, London, UK), a humanized murine IgG1 against 
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respiratory syncytial virus, which is administered intramuscularly (IM). Topical 
administration of mAbs has been shown to have the potential to prevent a number of 
mucosally-transmitted infections [469,470]. However, to date, this strategy is yet to be 
tested in humans. 
1.6.8.2 b12, 2F5, 4E10 and 2G12 
A number of antibodies have been identified in the sera of selected individuals with long-
standing HIV-1 infection which are individually capable of neutralizing a broad range of 
isolates. These NAbs inhibit various stages of HIV attachment and fusion though binding 
to gp120, gp41, CD4 or co-receptors (see Figure 1-10). Among the earliest to be 
discovered (and produced as mAbs) and the best characterised are b12, 2G12, 2F5 and 
4E10.  Results of key research involving these (and other early anti-HIV mAbs, where 
relevant) is summarised below: 
Figure 1-10 Binding sites of NAbs on gp120 and gp41 
 
Figure reproduced from Burton et al. Nat Immunol 2004 [465]. 
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1.6.8.3 In-vitro evaluation 
b12 binds to the CD4 binding site (CD4bs) of gp120 [471,472]. In contrast to non-
neutralizing CD4bs mAbs (e.g. b3, b6, F105, 15e, and F91), b12 is able to interact not only 
with monomeric gp120 but also with functional oligomeric gp120 at the virion surface 
[472]. 
2G12 recognises a conformational dependent epitope on gp120. Binding of 2G12 to 
monomeric gp120 is abolished by amino acid substitutions removing N-linked 
glycosylation in the C2, C3, V4 and C4 regions of gp120 [473].  Using crystal structures of 
Fab 2G12, it was demonstrated that this antibody binds to an unusually dense cluster of 
carbohydrate moieties on the "silent", outer face of gp120 by a previously unappreciated 
mechanism for high affinity recognition of carbohydrate [474].  2G12 binds to the surface 
of native virions and has been demonstrated to inhibit gp120 binding to both CD4 and 
CCR5.  It has been proposed that binding of 2G12 to its epitope (which includes glycan 
residues on opposite borders of the V3 loop) restricts conformational changes involving 
V3, which are induced through CD4 and CCR5 binding, and weakens the affinity of these 
receptors for their binding sites  [475].  
2F5 and 4E10 recognise neighbouring, conserved epitopes (amino acid sequences 
ELDKWA and NWFDIT respectively) on the portion of gp41 which is extracellular and 
adjacent to the viral membrane in the native virion (the membrane proximal external 
region (MPER)), with 4E10 binding closer to the C-terminus [476,477,478].  Peptides 
corresponding to this region are largely unstructured in aqueous solution, but, acquire α- 
helical secondary structure within lipid bilayers [479]. The MPER has 2 α- helices linked by 
a kink with the N-terminus more exposed to the external, aqueous medium and the C-
terminal region inserted in a shallow position in the lipid membrane [480]. The 
mechanism by which 2F5 and 4E10 mediate neutralization in-vitro appears more complex 
than that for 2G12 and is incompletely understood.  MPER antibodies have been shown 
to preferentially bind to the pre-hairpin intermediate that forms upon receptor 
engagement and it has been proposed that their binding interferes with the process of 
virus-cellular membrane fusion, preventing target cell entry [479, 481, 482, 483]. 
However, although this may play a role in their neutralization activity, it may not be their 
only mode of action (see section 6.2.3.2).  It has been demonstrated that 2F5 and 4E10 
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can bind and interact with their epitopes, in their lipid-bound state, prior to receptor 
engagement and that this may be a requirement for successful neutralization [479].  
Although all 4 mAbs were isolated from individuals infected with HIV-1 subtype B, the 
conserved nature of their epitopes enables them to bind HIV-1 strains from other clades.  
However, differences exist between the mAbs with regards to the breadth and potency of 
their in-vitro neutralization capabilities. The most broadly neutralizing are the MPER 
antibodies, in particular 4E10. In a cross-clade neutralization study, 4E10 neutralized 
100% and 2F5 neutralized 67% of a diverse panel of 93 primary isolates compared to 50% 
for b12 and 41% for 2G12 [484]. Results from an even more comprehensive study showed 
that out of a panel of 162 viruses, 4E10 neutralized 159 isolates (98%), 2F5, 97 isolates 
(60%) b12, 57 isolates (35%) and 2G12, 52 isolates (32%) [485]. Similar neutralization 
breadth for 4E10, 2F5 and 2G12 was seen against 91 sexually transmitted HIV-1 isolates 
cloned from acutely infected patients [486].  
It has been observed in the above studies that b12, 2G12 and 2F5 are individually less 
capable of neutralizing non-clade B subtypes than 4E10. However,  triple or quadruple 
combinations of mAbs  (2G12, 2F5 and F105, b12 +/- 4E10) have been shown to  
demonstrate synergistic effects against  primary HIV clade C isolates (BW11, 1084i) as 
well as against clade B isolates [487,488,489]. Results suggest that the presence of two or 
more mAbs in combination reduces the levels of each antibody needing to be present in 
order to achieve the same level of viral neutralization. 
1.6.8.4 Studies in animal models 
Intravenous (IV) passive transfer of the above mAbs, in varying combinations, has 
protected macaques from infection following intravenous, oral, rectal and vaginal SHIV 
challenge [487,490,491,492,493,494,495,496, 497,498].  mAb concentrations for infusion 
were defined based on neutralization studies with primary isolates. Recently, Hessel et al.  
demonstrated clear protection by 2F5 and 4E10 used individually against rectal SHIV Ba-L 
challenge [499]. Macaque mucosal challenge studies involving mAbs 2F5, 4E10 and 2G12 
+/- b12 are summarised in Table 1-8. 
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Table 1-8  Summary of mucosal SHIV challenge studies in macaques involving anti-HIV-1 
neutralizing mAbs  2F5, 4E10 and 2G12 +/-b12 
mAb 
combinations 
Dose (route)  
and time of mAb 
relative to challenge 
SHIV challenge 
(dose) +route 
Monkeys  
protected/ 
treated 
Reference 
HIVIG/2F5/2G12 
400mg/kg HIVIG 
+15mg/kg each of 2F5, 
2G12; -24hr  (i.v) 
SHIV89.6P 
(10-50 AID50) 
vaginal 
4/5 
Mascola et al. 1999 
[491], 2000 [492] 
2F5/2G12 
15mg/kg each mAb -
24hr (i.v) 
SHIV89.6P 
(10-50 AID50) 
vaginal 
2/5 As above 
2G12 15mg/kg  -24hr (i.v) 
SHIV89.6P 
(10-50 AID50) 
vaginal 
2/4 As above 
Total macaques protected from vaginal challenge by iv 
mAbs 
Control animals (irrelevant IVIG) 
8/14 
0/5 
 
2G12+2F5+F105 
10 mg/kg (i.v.)5d 
before birth, d0 (-1hr), 
+d8 
SHIV-vpu+  
(10 AID50) oral 
4/4  
Baba et al. 2000 
[487] 
2G12+2F5+F105 
10 mg/kg (i.v.) d0  
(-1hr), +d8 
SHIV-vpu+ 
(10 AID50) oral 
2/2 
 
Hofmann et al. 
2001[494],2002 
[495] 
2G12+2F5+F105 
10 mg/kg (i.v.)  
PEP +1hr,+d8 
SHIV-vpu+ 
(10 AID50) oral 
2/2 
 
Hofmann et al. 
2002[495] 
2G12+2F5+b12 
10 mg/kg (i.v.) d0  
(- 1hr ), +d8 
SHIV89.6P 
(15 AID50) oral 
1/4 
 
Hofmann et al. 
2001[494] 
2G12+2F5+4E10
+b12 
30 mg/kg (i.v.)  
PEP: +1hr, +d8 
SHIV89.6P 
(15 AID50) oral 
2/4 
 
Ferrantelli et al. 
2003[496] 
2G12+2F5+4E10
+b12 
30 mg/kg (i.v.)  
PEP: +1hr, +d8 
+12hr, +d8 
SHIV89.6P 
(15 AID50) oral 
 
 3/4 +1/3 
Ferrantelli et al. 
2007[498] 
2G12+2F5+4E10
+b12 
30 mg/kg (i.v.)  
PEPi: +1hr, +d8 
SHIV-1157ip 
(15 AID50) oral 
3/4  
 
Xu et al. 
unpublished 
2G12+2F5+4E10 
40 mg/kg (i.m.)  
PEP: +1hr, +d8 
SHIV89.6P 
(15 AID50) oral 
4/4 
 
Ferrantelli et al. 
2004[497] 
Total protected macaques from oral challenge by iv mAbs 
Control animals (untreated) 
22/31 
0/31 
 
2F5 50mg/kg (i.v) –d1, +1d 
SHIVBa-L (2000 
TCID50) rectal 
5+/6 
Hessell et al. 2010 
[499] 
4E10 50mg/kg (i.v) –d1, +1d 
SHIVBa-L (2000 
TCID50) rectal 
6/6 As above 
Total protected macaques from rectal challenge by iv 
mAbs 
Control animals (2 untreated, 2 isotype control IgG) 
11+/12 
4/4 
 
 
PEP = Post-exposure prophylaxis; hr = hour(s); d = day(s); AID50 = 50 % animal infectious 
doses; TCID50 = 50 % tissue culture infectious doses; HIVIG= HIV immune globulin 
(polyclonal). 
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Proof of concept that vaginally-applied mAbs could prevent SHIV transmission was 
provided by Veasey et al [500].  Only 2 of 8 (25%)  DMPA treated macaques became 
infected with SHIV 162P4 (following 300 TID50 vaginal challenge up to 2 hours later) after 
vaginal application of 5mg b12 in saline compared with 9 of 10 (90%) controls. However, 
results using a gel were less clear-cut.  1 of 2 animals became infected post application of 
5mg b12 in a 2.5 % hydroxyethyl-cellulose (HEC) based gel, after a similar challenge, 
compared with all of 3 controls.  
1.6.8.5 Studies in humans:  passive immunotherapy in HIV infected individuals 
In addition to the above animal studies, the mAbs 2F5, 2G12, and 4E10 have been used in 
passive immunotherapy studies in humans (see Table 1-9). 4 studies involving a total of 
39 HIV-1 positive individuals have been conducted [501,502,503,504,505, 506].  Subjects 
received a dose of each mAb, ranging from 1 to 5g per infusion, at weekly intervals for 
between 4 and 16 weeks. Overall, the mAbs were shown to be safe, with no serious 
adverse events or thrombotic complications reported.  In the latter 2 studies, where all 
participants had stored, pre- HAART viral isolates which were sensitive to neutralization 
by at least 2 of the mAbs (all 3 mAbs in the majority), some efficacy in temporarily 
delaying viral rebound after cessation of HAART was observed in 14/16 individuals who 
had initated HAART during acute/early HIV-1 infection, with 4 maintaining VL suppression 
to < 50 copies/ml during the entire infusion period. However, in keeping with the limited 
efficacy of natural broadly neutralizing sera in controlling HIV-1 in most chronically 
infected individuals (in view of their more varied quasi-species), the mAbs had less effect 
in those participants who had initated HAART later in the course of their HIV-1 infection, 
with only 2/8 showing any delay in VL rebound, and only 1 maintaining VL suppression 
until the end of the infusion period.  Viral mutants emerged during rebound which were 
resistant to 2G12 in 19/22 participants, providing additional evidence that it produced a 
neutralizing effect causing a selective pressure [504, 505].  Interestingly, although no 2F5 
or 4E10 resistant mutants were generated, one acutely infected individual who displayed 
prolonged VL suppression displayed 2G12 resistance pre-HAART suggesting that  
suppression of his virus during the study was mediated by the MPER mAbs [504]. It is not 
known whether resistance to 2G12 alone arose because it was more active in these 
studies than 2F5 and 4E10, e.g. because of pharmacokinetic or mechanistic differences, or  
whether perhaps resistance to 2G12 (due to loss of one or more glycosylation site(s) 
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within its epitope) is generated more easily, with less impairment of viral fitness, than 
changes to the MPER (reflected in the lower proportion of cross-clade isolates sensitive to 
neutralization by 2G12 than by 2F5, and in particular 4E10) [484].  Laboratory studies 
have shown that generating resistance to all 3 of 4E10, 2F5, 2G12 is difficult and is 
associated with reduced viral replication [507].   
The results of the above pre-clinical and clinical studies suggest that,  although limited in 
their ability to control HIV-1 infection in the long-term,  if present at the time of infection 
(when the quasi-species is limited) combinations of HIV-1 NAbs may have the potential to 
prevent the establishment or expansion of the founder population. 
Table 1-9 Summary of clinical trials using C2F5, C4E10 and C2G12 to date 
 Study 
1 
Armbruster et 
al. 2002 [501] 
2 
Armbruster et 
al. 2004 [503] 
3 
Trkola et al. 
2005 [504] 
4 
Mehandru et al. 
2006 [505] 
No. of patients 7 8 14 10 
Male/Female 4/3 4/4 10/4 10/0 
mAbs C2F5, C2G12 C2F5,C2G12, 
C4E10 
C2F5, C2G12, 
C4E10 
C2F5, C2G12, 
C4E10 
Dose of mAb 
per infusion 
(g) 
1/1 1/0.5/1 1.3/1/1 1/1/1 (n = 6) 
2/1/2 (n =4) 
No. infusion 
days 
8 4 13 16 
Length of 
dosing  
4 weeks 4 weeks 13 weeks 16 weeks 
 
SAEs 0 0 0 0 
Thrombotic 
complications 
0 0 0 0 
Possible ADRs  
None 7/7 8/8 7/14 7/10 
Myalgia 0 0 5/14 3/10 
Arthralgia 0 0 4/14 1/10 
Skin rash 0 0 1/14 1/10 
 
1.6.8.6 Antibody isotypes of the commercially produced mAbs 
To generate the original hybridomas producing 2G12, 2F5 and 4E10 mAbs, B- 
lymphocytes isolated from asymptomatic HIV-infected subjects were fused with 
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heteromyeloma cell lines by a combined polyethylene glycol/electrofusion method [508].   
2G12 was initially produced as IgG1, whereas 2F5 and 4E10 were originally IgG3 
antibodies.  Subsequently, to enable safe mass production for use in research studies, and 
to maximise their plasma half-life, the mAbs were all expressed recombinantly in Chinese 
Hamster Ovary (CHO) cells as IgG1 (k)[509]. Clinical-grade mAbs, suitable for 
administration in humans, are produced commercially by this method by Polymun 
Scientific, Vienna; a company established by the immunologist who first discovered them.  
Such mAbs are given the prefix ‘C’ to distinguish them from mAbs produced in other 
systems. 
1.6.8.7 Mabgel 
A potential vaginal microbicide containing a combination of the 3 mAbs, C4E10, C2F5 and 
C2G12, in a hydroxyethylcellulose (HEC)-based matrix (Mabgel) was developed and 
evaluated by scientists working within the European Microbicides Project (EMPRO). 
EMPRO was a network of 24 partners consisting of academic institutions and small and 
medium sized enterprises from across Europe and Africa. It was funded for 5 years (2004-
9) by the European Commission as part of its Sixth Framework Programme.  
The culmination of the work of EMPRO was a Phase 1 clinical trial (MABGEL 1), which 
aimed to assess the pharmacokinetics and safety of Mabgel in healthy, HIV negative, 
female volunteers.  Two doses of the Mabgel would be studied; high dose Mabgel, which 
was evaluated in preclinical studies, contained 20mg/g of each mAb, whereas the low-
dose Mabgel contained 10mg/g of each mAb. A comparator placebo gel was also 
produced, which would be used to increase the validity of safety endpoint analyses. A full 
description of all 3 study gels is given in section 2.6.2.   
The design, conduct, results and conclusions from the MABGEL1 study (and relevant pre-
clinical evaluations) are the focus of the remainder of this thesis, which will also consider 
the potential of Mabgel as an effective vaginal microbicide and ideas for future research.  
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2. MABGEL1:  CLINICAL TRIAL DESIGN AND 
METHODOLOGY 
 
2.1 Overview of Clinical Trial Design and Conduct 
The MABGEL 1 study was a single centre, Phase 1, randomised, double-blinded, 
prospective clinical trial with the overall aim to assess the pharmacokinetics and safety of 
the anti-HIV-1 monoclonal antibodies (mAbs) C2F5, C2G12, and C4E10 when administered 
together in a gel vehicle as a vaginal microbicide. The trial was conducted from 29th 
September 2009 until the 29th July 2010 on the HYMS Experimental Medicine Unit (HYMS 
EMU), York Hospital. It was the first study to be conducted in this unit, which opened in 
April 2009. Professor Charles Lacey was the Chief Investigator (CI).  
2.1.1 Involvement of the author in trial design, conduct and data 
interpretation  
The author of this thesis was the principal Study Physician (SP) and co-ordinating 
investigator, responsible for overseeing recruitment, dosing, sampling and evaluation of 
all study participants and liaison with laboratory investigators and third parties. In 
addition, she was involved in producing the trial protocol, patient information sheets and 
revised statistical analysis plan. Although the author performed the microscopy at 
screening and assisted the laboratory technician with initial processing of samples, she 
did not perform the main laboratory analyses. However,  analysis and interpretation of 
the data arising from the pharmacokinetic assays and vaginal flora analyses was 
performed by the author, in addition to evaluation of the safety data, and she 
participated in the qualitatative analysis of transcripts from the interview sub-study. 
2.2 Research Governance and Approvals 
The trial was co-Sponsored by the University of York and York Teaching Hospital NHS 
Foundation Trust.  Prior to study commencement, Clinical Trials Authorisation was sought 
and obtained from the MHRA and a favourable opinion was granted by Cambridgeshire 1 
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NHS Research Ethics Committee (REC). NHS permissions were obtained from the North 
and East Yorkshire Research and Development (R &D) Alliance. 
 All advertisements, patient information sheets, consent forms and instruction leaflets 
used in the study were pre-approved by the Sponsor and the REC. 
The trial was conducted in accordance with the UK Clinical Trials Regulations and all study 
staff were trained in Good Clinical Practice (GCP). Monitoring and data management was 
performed by Covance Clinical Research Unit, Leeds in line with GCP requirements. All 
study gels were manufactured to EU Good Manufacturing Practice (GMP) standards by 
Polymun Scientific, Vienna. 
The Trial was registered on the European and International Clinical Trials Databases- 
EudraCT (2008-000312-32), ISRCTN: 64808733. 
2.3 Research Question and Rationale 
2.3.1 Primary Study Objective: Assessment of local mAb 
pharmacokinetics following vaginal application 
The primary objective of the study was to assess the pharmacokinetics of C2F5, C4E10 
and C2G12 when applied vaginally, as this would be crucial in guiding future development 
of such mAb combinations as microbicides. Specifically, we wished to investigate how 
long the antibodies persisted in the lower FGT, and at what concentration, as this would 
provide an indication of the potential duration of efficacy and recommended dosing 
frequency of the mAbs.  An ideal microbicide would have a long duration of activity to 
allow dosing independent from time of coitus [388]. At present, there is very limited 
published data relating to the pharmacokinetics of passively applied antibodies within the 
FGT.  Studies in mice suggest that, excluding leakage, the residence t ½ of IgG applied to 
the vagina is 5 ± 2 hours [510]. In the only previous study in humans, the residence t ½ of 
polyclonal human anti-D IgG solution (RhoGAM®, Ortho-Clinical Diagnostics, Raritan, New 
Jersey, USA) applied directly to the posterior vaginal fornix via a catheter, was 
approximately 9 hours [511].  
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The pharmacokinetics of the mAbs applied as a single 2g vaginal application of 20mg/g 
Mabgel was investigated in six cynomolgus macaques by collaborators within the EMPRO 
consortium. All animals were sampled at baseline, then two animals were sampled at 
each of three time-points; 1, 4 and 12 hours post gel administration, using Weck-Cel 
ophthalmic sponges and cervico-vaginal lavage (CVL).  mAb levels were 3.5 ± 2.3 fold 
higher in Weck-Cel samples than CVLs performed at the same time-points, with good 
correlation between both sampling methods (data not shown). In a separate experiment, 
following a 3 day wash-out period, a second dose of gel was applied to all six animals and 
samples obtained using Weck-Cels alone at baseline, 1, 4, 8, 12, 24, 48 and 72 hours. As 
shown in Table 2-1, concentrations of the 3 mAbs were maximal 1 hour after 
administration and were still detectable, in the nanogram range, at 72 hours. 
Concentrations up to 24 hours are displayed in Table 2-1. The investigators did not derive 
any estimates of t ½ for each mAb [Dereuddre-Bosquet et al. study THE0703, CEA animal 
facilities, Fontenay-aux-Roses, France, personal communication]. 
Table 2-1 Median, minimum and maximum mAb Concentrations detected using Weck- 
Cels in macaques (CEA study THE0703) following application of 20mg/g Mabgel 
Time post 
gel use 
(hours) 
C2F5(μg/ml) C4E10 (μg/ml) C2G12 (μg/ml) 
Med Min Max Med Min Max Med Min Max 
Pre dose 0.07 ND 0.69 ND ND ND 0.25 0.07 1.02 
1 1535 944 2351 1505 1045 1969 2008 1689 3882 
4 691 564 1317 793 713 1529 1046 812 2002 
8 91 65 525 181 54 471 153 136 992 
12 30 22 105 18 14 154 35 21 390 
24 1.7 0.40 3.70 1.40 0.59 2.40 3.6 0.60 9.5 
48 0.15 0.08 4.4 0.21 0.12 4.40 0.35 0.20 16 
72 0.06 ND 1.6 0.30 0.06 1.60 0.06 ND 0.13 
ND = not detectable 
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Figure 2-1 Median mAb concentrations in Weck-Cel secretion samples in macaques 
 
 
In view of the invasive nature of sampling, there was a need to space out and limit the 
number of vaginal examinations performed on the human participants to the time-points 
most likely to provide the most valuable information. It was thus decided to perform 
sampling at baseline, then at 1, 8 and 24 hours after administration of the 1st dose of gel 
and perform additional samples at 12, and 36 hours post 12th dose of gel. Levels of mAbs 
detected at 48 and 72 hours in macaques were so low that it was decided to limit the 
sampling period to 36 hours post gel dose. The primary sampling method chosen was 
Weck-Cel ophthalmic sponges (Medtronic, Xomed), to be performed at all time-points,  
with CVLs  providing a secondary measure at baseline and the final time-point per dose 
(24 hours post 1st dose, 36 hours post 12th dose). In addition, participants would be asked 
to perform self-taken samples, using an aspirator, at the same time-points as CVLs. 
Sampling is discussed further in section 2.4.1 in relation to the vaginal sampling sub-
study. The schedule of study visits and procedures is displayed in Table 2-2.  
2.3.2 Primary Study Objective: Determination of evidence of systemic 
absorption of the mAbs following vaginal application 
In addition to local pharmacokinetics, we wished to establish whether there was any 
evidence of systemic absorption of the mAbs following vaginal application. Our 
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hypothesis was that the mAbs would not be systemically absorbed because of the 
thickness of the vaginal mucosa and their relatively large molecular weight. In support of 
this, no systemic absorption was detected (at limit 15ng/ml) after repeated topical 
application to rabbits in toxicology studies [Polymun Scientific, Mabgel Investigator 
Brochure (IB)].  In macaques, very low serum levels of the mAbs C4E10 and C2F5, but not 
C2G12, were detected following vaginal application [Dereuddre-Bosquet et al. study 
THE0703, CEA animal facilities, Fontenay-aux-Roses, France, personal communication]. 
These levels were very close to the quantification limit of the assay and in all but one 
animal were not significantly higher than baseline (pre-dose) levels suggesting that they 
may represent spurious background detection by the assay rather than a true ‘in-vivo’ 
result.  However, in a single animal, a significant increase (around 100μg) was detected at 
12 and 72 hours post dose; thus, leaving open the possibility that some minor systemic 
absorption may have occurred.  
It is noteworthy, that the primates, but not the rabbits, had all been pre-treated with 
DMPA to synchronise their menstrual cycles. This has the secondary effect of thinning the 
vaginal mucosa and may have facilitated absorption into the blood-stream.  It was 
therefore decided that it was necessary to investigate whether there was any evidence of 
systemic absorption in healthy women and blood samples would be obtained at baseline, 
8 hours post 1st dose and 12 hours post 12th dose. The latter two time-points were felt to 
cover the time-period where peak absorption was most likely to occur. 
2.3.3 Secondary Study Objective: Assessment of the local and systemic 
safety of the mAbs when applied vaginally 
This trial was designed to assess both the pharmacokinetics and the safety of the mAb 
combination when applied vaginally. However, given that the antibodies had already 
been administered systemically to HIV infected men and women without any serious 
adverse events [501,502,504,505,506], and gels with similar compositions and 
formulations as the gel vehicle and placebo had been evaluated previously in microbicide 
safety and efficacy studies [512,513,398,399,415], it was expected that the IMP would be 
safe when applied vaginally. Repeat dose toxicity evaluation in rabbits, and application in 
macaques, in the CEA studies, suggested the Mabgel was generally well tolerated 
97 
 
[Polymun Scientific, Mabgel IB].  Thus, assessment of the local and systemic safety of 
Mabgel was a secondary objective of the study. 
One concern that had been raised previously was the potential auto-reactivity of the 
mAbs.  Although the generation of individual broadly-NAbs during chronic HIV-1 infection 
is more common than previously appreciated, antibodies against the MPER region are 
relatively rare [162,514,515162], with most NAbs targeting gp120 [156,157,158,160,161].   
It has been suggested, therefore, that they may arise as a result of atypical B cell 
induction pathways and potentially bind host (‘self’) epitopes [515,516,517]. Initially it 
was shown that both 2F5 and 4E10, but not 2G12, displayed auto-reactivity in-vitro 
through binding to various phospholipids, histones and other auto-antigens [516]. Further 
analyses and experiments in relation to the human clinical trials were thus performed to 
investigate the possibility of in-vivo autoreactivity and possible thromboembolic disorders 
associated with 4E10, 2F5 and 2G12. During the last trial the study design was modified to 
collect prospective data from the last four high dose patients. Very mild (<1.25 x ULN) 
prolongation of the activated partial thromboplastin time (APTT) 30 minutes post-infusion 
was observed which rapidly remitted, but there was no effect on the prothrombin time 
(PT). In-vitro experiments indicated that the effect on coagulation profile was mediated 
by 4E10. Further analyses have indicated that 4E10, but not 2F5 or 2G12, shows low-level 
cross-reactivity with cardiolipin, and that infusion of 4E10 resulted in transient low anti-
cardiolipin antibody titres [506,518]. Of interest similar transient rises in anti-cardiolipin 
antibodies are a recognised feature of some viral infections, including HIV-1, and are 
rarely pathogenic, in contrast with the ‘classical’ anticardiolipin associated with 
autoimmune diseases such as systemic lupus erythematosus [519,520,521,522]. It was 
concluded that there was little evidence that the mAbs conferred an increased risk of 
thrombosis or other autoimmune phenomena, but that monitoring of both coagulation 
parameters and anti-cardiolipin antibodies (aCL) should be carried out in any further 
clinical trials [506]. 
  
 
Table 2-2 Study Schedule 
 
Screening cycle Dosing cycle Follow-up cycle 
Visit number 1 t/c 2 (1st dose) 3 4 t/c 5 t/c 6 7 t/c 8 
Day of menstrual cycle 
 
 1 7-13 7-13 7-13 8-14 
 
8-16 11-19 14-22 19-25 20-26 1 7-21 
Study day relative to first dose -42 to -14 -6 to -12 1 1 1 2 2-4 5-7 8-10 13 14   
Time of visit (pre/post dose)   pre-1
st  1hr post-
1st  
8 hrs 
post-1st  
24 hrs 
post-1st  
   12 hrs 
post-12th  
36 hrs 
post-12th  
  
Informed Consent x             
Randomisation   x           
Medical & other history x            x 
Physical examination x            x 
Cervico-Vaginal examination x  x x x x  x  x x  x 
Colposcopy x  x x x x  x  x x   
GU infection 
screen 
CT cervical NAAT x             
GC cervical culture x             
Vaginal pH x          x  x 
Gram stain cervix x             
Gram stain vagina x          x  x 
Wet mount x             
Candida culture   x           
HIV antibody test   x             
Syphilis serology x             
Laboratory 
parameters 
Pregnancy test X  x          x 
Urinalysis x             
FBC and Biochemistry x         x   x 
Hepatitis B/C serology x             
APTT/aCL  x  x  x     x   x 
Pharmacokinetic 
parameters (for 
MAbs) 
Serum sample   x  x     x    
Vaginal self-sample x     x     x   
Vaginal Weck-Cel   x x x x    x x   
CVL supernatant   x   x     x   
Vaginal swab for vaginal flora substudy x          x  x 
Side-effect, compliance check       x x x x    
Qualitative interview             x 
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2.4 Sub-Studies 
In addition to the main study aims and objectives outlined above, some additional 
exploratory objectives were identified and investigated by means of 3 sub-studies 
conducted alongside the main study. 
2.4.1 Investigation of the reliability of the Weck-Cel technique for 
collection of vaginal secretions (for antibody quantification) post gel 
application and comparison of participant self-sampling to sampling 
by clinicians  
A range of techniques have been used to sample genital tract secretions in HIV prevention 
trials, each with their own advantages and disadvantages [523,524]. Two of the most 
widely utilised methods for collecting secretions for the analysis of antibodies or 
cytokines are  Weck-Cel  Ophthalmic sponges (Weck-Cels) and CVL.  Weck-Cels have the 
advantage over CVL in that they enable the collection of neat secretions, and provided 
that the collected secretion volume is measured and a known volume of buffer is used 
during processing, allow accurate quantification of mucosal immune factors 
[525,526,527]. However, correction for ‘dilution factors’ is not performed universally and 
has not been formally evaluated on samples obtained following the application of a gel. 
CVL involves the introduction of a known volume of saline (normal or phosphate-
buffered) into the vagina but results in a range of different recovered volumes due to 
variability in clinician technique, absorption and amount and consistency of secretions 
already present in the vagina [528,529]. Lithium chloride can be added as a tracer to CVLs 
to help quantify the dilution factor in recovered fluid but its analysis is time-consuming 
and requires the use of specialized equipment such as a flame atomic absorption 
spectrophotometer, hence is not routinely performed [523,528]. In addition, since 
introduction of saline washes the vaginal mucosa, CVL is unsuitable for obtaining serial 
pharmacokinetic samples of topically applied agents such as microbicides. Both 
techniques require the insertion of a speculum by a clinician, which, whilst enabling 
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greater standardization and concurrent clinical evaluation, restricts sampling to clinic 
visits and can be poorly tolerated by participants. 
Several collection devices have been developed to allow patients and trial participants to 
sample their own genital tract secretions. Some, such as tampons, swabs and self-lavages, 
have been shown to produce reliability and validity for the detection of infections that is 
equal to or, in the case of gonorrhoea and chlamydia, better than that of clinician taken 
samples, and are deemed acceptable by most users [530,531,532,533,534,535]. Others, 
such as aspirators and vaginal cups, have the potential to allow the collection of up to 10 
times greater volumes of neat secretions than current methods, including Weck-Cels 
[536,537]. 
A volumetric vaginal aspirator was developed (Rovumeter; Recipe Pharmaceuticals, 
Munich, Germany) and has been shown to produce adequate, reproducible volumes of 
vaginal secretions for analysis in studies measuring ARV drug levels [538,539]. These 
studies were conducted by Professor Angela Kashuba and co-investigators at the Center 
for AIDS Research, University of North Carolina, Durham, North Carolina, USA and 
involved samples being collected both by clinicians (via speculum) and participants (self-
collection) at different time-points using the aspirator.  However, the device has not been 
validated by comparison with Weck-Cel or CVL sampling.  
Thus, the objectives of this sub-study were to: 
1) Quantify the degree of variability in weights/volumes of secretion samples obtained 
using Weck-Cels and explore the relationship between sample weight/volume and 
detected 2F5, 4E10 and 2G12 mAb concentrations 
2) Compare the concentrations of mAbs measured in clinician-obtained CVL and Weck-Cel 
samples with those in participant self-taken aspirate samples and; 
3) Ascertain whether self-sampling with the aspirator was ‘user-friendly’ and acceptable 
to study participants. NB: this was performed as part of the interview sub-study (see 
section 2.4.3 and Chapter 5). 
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 Ascertaining that Weck-Cel sampling was reliable in our study would support its 
continued use in microbicide trials for obtaining mucosal secretions (for analyses of both 
natural and topically applied immune mediators) post gel application. If self-sampling 
using the aspirators was found to be effective and acceptable, then it could broaden their 
use in subsequent studies, allowing sampling outside of clinic visits and fewer invasive 
examinations. 
2.4.2 Investigation of the impact of Mabgel on vaginal flora 
As described in section 1.4.1, commensal vaginal bacteria, in particular lactobacilli, are 
an important defense against pathogens, including HIV-1. Various different species of 
lactobacilli have been isolated from the human vagina, the most dominant being the 
hydrogen peroxide-producing species L. crispatus and L. jenseni [540,541]. Other 
common species include L. gasseri, L. iners and L. vaginalis [542,543].  
Bacterial vaginosis (BV) is a perturbation of the normal vaginal flora characterized by 
an overgrowth of mostly anaerobic bacteria and a decreased prevalence of 
Lactobacillus species. It is symptomatic in half of affected women, causing a white 
homogenous discharge with a ‘fishy’ smelling odour [544]. Although associated with a 
number of different bacteria and mycoplasma, Gardnerella vaginalis, Atopobium 
vaginae and Mobiluncus curtisii are considered to be the most characteristic organisms 
for BV [545]. In contrast to lactobacilli, BV associated bacteria produce amines as 
opposed to lactic acid, resulting in an increased vaginal pH, and secrete a number of 
immunomodulatory and pro-inflammatory substances, including sialidases, proteases, 
lipopolysaccharides, lipoteichoic acids and peptidoglycans [546,547,548].   
BV can cause sequelae such as post-procedural pelvic inflammatory disease (PID), post-
partum endometritis, and pre-term delivery [549,550,551]. It has been associated with 
increased incidence of Chlamydia trachomatis and Neisseria gonorrhoeae infection, and 
related PID [552], and a greater risk of both HIV-1 acquisition [14,211,214,215,216] and 
transmission [218]. 
It is, therefore, important to assess any effects on the vaginal flora when determining 
the local safety of a microbicide [553]. To date, this has been performed primarily 
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through the serial evaluation of vaginal pH, microscopy (using Nugent scoring) and 
culture, before, during and after product use [554,555]. However, studies using 
molecular, culture-independent techniques have shown that the flora in many human 
microbial environments, including the vagina, are much more complex than previously 
appreciated and that conventional culture techniques may only detect a small fraction of 
the microbes in the environment [556]. In addition, there remains incomplete 
understanding of the failure of early microbicide candidates and it is possible that even 
subtle perturbations of the vaginal flora may have an impact on HIV acquisition, 
particularly in areas of high HIV prevalence [557].  Since it is now possible to identify and 
quantify individual organisms in the vaginal flora using the polymerase chain reaction 
(quantitative (q) PCR) [558,559,560] it was felt prescient to utilize such techniques in the 
assessment of Mabgel.  
Dr Tania Crucitti and Dr Vicky Jespers (Institute for Tropical Medicine, Antwerp, Belgium) 
are colleagues from within the EMPRO Consortium who have been developing qPCR 
techniques for the analysis of vaginal flora in microbicide trials and agreed to perform the 
laboratory analyses for this sub-study. 
The working hypothesis for the sub-study was that there would be no difference in the 
vaginal flora at the species level between participants in the placebo and Mabgel arms 
throughout the trial. A single additional vaginal swab and a vaginal secretion smear (slide) 
for microscopy were taken in all participants (i) before dosing (Screening Visit), (ii) at the 
end of dosing (Visit 7), and (iii) during the next menstrual cycle (Visit 8), to assess any 
changes in the vaginal flora caused by the use of the study gels. The slides were Gram-
stained and interpreted according to the standard methodology described by Nugent et 
al. [561], whereas the swabs were processed for assessment of Lactobacillus species by 
qPCR. Methodology is described in more detail in section 2.11.4. Further analysis of the 
swab samples for BV associated organisms is planned, but due to logistical and time 
constraints, this will be performed in conjunction with samples from another microbicide 
trial and reported separately. 
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2.4.3 Investigation of participants’ experience of taking part in the clinical 
trial 
The third sub-study was designed to evaluate participants’ experience of taking part in 
the MABGEL 1 trial. This took the form of a qualitative interview conducted at the final 
follow up visit by a member of the research team who had no other involvement with the 
trial. This sub-study is discussed and its findings presented in Chapter 5. 
2.5 Selection of Study Participants 
2.5.1 Number and Source of Study Participants  
As this was the first intra-vaginal administration of the mAbs in humans, there was no 
information on which to base power calculations. We aimed to recruit and randomise 30 
healthy HIV negative female volunteers (10 per arm) as this seemed reasonable and 
achievable given the nature of the study. Women were recruited from York and 
surrounding areas via advertisements placed at the University of York, York Teaching 
Hospitals NHS Foundation Trust, and in local media (websites, newspapers, magazines, 
radio interviews). The advert mentioned the need for healthy volunteers, the age and 
gender of volunteers required, and the main purpose of the study. It also explained that 
participants would be ‘reimbursed for their time and expenses’; however, the actual 
amount of money available was not stated in the advert. For details of financial 
reimbursement to participants see section 2.10. 
2.5.2 Informed Consent and Screening Procedures 
Women aged between 18 and 45 who responded to the advertisements by email or 
telephone were sent detailed written information about the study (the ‘full’ participant 
information sheet (PIS)). In view of the relatively intimate and complex nature of the 
study, an abridged, ‘brief’ version of the PIS containing a summary of key facts about the 
study and the procedures involved was also provided. Both versions were also available 
to download from the York HIV Research Group website, details of which were provided 
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on the adverts. Having been given at least 24 hours to read the study information, women 
who remained interested in taking part were invited to attend for screening. 
At the screening visit, following an in-depth discussion about the trial and an opportunity 
to ask questions, written informed consent was obtained from potential participants by 
the SP.  This took place prior to commencing any trial-related procedures.  Following 
consent, details of socio-demographic characteristics and a thorough medical history 
were taken. A physical examination was performed including an evaluation of the lower 
genital tract by colposcopy (see section 2.8.3). An assessment of vaginal pH, a wet mount, 
and a slide for Gram stain and microscopy were performed as were cervical samples for 
Neisseria gonorrhoea (GC) (culture) and Chlamydia trachomatis (CT) (nucleic acid 
amplification test). 
A urine sample was provided for urinalysis (blood, protein, leucocytes, nitrites and 
glucose) and pregnancy testing. Blood tests were performed for baseline haematological 
(full blood count (FBC), coagulation profile (PT, APTT)), biochemical (urea and electrolytes 
(U and Es), liver function tests (LFTs)), and serological (HIV, hepatitis C virus (HCV), 
hepatitis B virus (HBV), Syphillis, anti-cardiolipin (aCL)) testing. Permission was obtained 
from participants to inform their general practitioner (GP) regarding their involvement in 
the study and to seek verification from their GP of their medical suitability via a short 
questionnaire. Participants were informed of any infections or other abnormalities 
detected on screening and offered treatment in the York Sexual Health Clinic or referral 
to their GP as deemed appropriate. 
2.5.3 Eligibility 
Eligibility was determined by the SP, in accordance with the inclusion and exclusion 
criteria for the study, on receipt of results from screening investigations and GP response. 
Participants were eligible for the study if they were HIV negative, at low risk of acquiring 
HIV and using a reliable method of contraception as defined in the study protocol 
(combined oral contraceptive (COCP), desogestrel-containing progesterone only oral 
contraceptive (POP) (Cerazette®, Organon), etornogestrol inplant (Implanon®, Organon), 
depot medroxyprogesterone acetate (DMPA) injections  (Depo-Provera®, Pfizer), intra-
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uterine contraceptive device (IUCD) or levornogestrel-releasing system (IUS) (Mirena®, 
Bayer) or condoms with every coital act).  They had to be in good health, as determined 
by medical history, clinical examination, and GP report, with no clinically significant 
abnormalities on baseline blood tests.  In view of the mild transient prolongation of the 
APTT seen previously when high doses of the mAbs were given intravenously [506], any 
history of thrombotic or other coagulation disorders, or baseline aCL IgG antibody 
positivity was considered a bar to study entry. Also for safety reasons, women who were 
pregnant, within 12 weeks postpartum, or breast feeding and those who had participated 
in another clinical trial within the previous 2 months were also unable to take part. 
To minimise the risk of cervico-vaginal bleeding during the dosing phase of the study, only 
women who had a regular menstrual cycle (>26 days) or had been amenorrhoeic for at 
least 3 months (as a result of contraceptives) were included.  Women who gave a history 
of post-coital or inter-menstrual bleeding, previous or current genital ulceration, or had 
another condition that in the opinion of the SP and/or CI might interfere with the 
evaluation of study objectives, were considered ineligible. Also excluded were those who 
had received treatment for cervical-intraepithelial neoplasia (CIN) or undergone 
gynaecological instrumentation of the cervix within the past three months. Women with 
untreated urinary tract infections, GC, CT, trichomonas or BV were also ineligible 
(although participants were eligible after successful treatment and re-screening).  To 
minimise the risk of interfering with gel pharmacokinetics or creating any trauma that 
could be falsely attributed to gel use, participants had to be willing to abstain from using 
tampons or any genital preparations, other than the study gel, during the period of gel 
administration until after the final pharmacokinetic sampling visit (36 hours after the last 
dose). They also had to agree to abstain from any receptive oral or vaginal intercourse 
from 48 hours before using the first dose of gel until after the final pharmacokinetic 
sampling visit.  
Participants were allowed to be taking concomitant medications at study entry provided, 
in the opinion of the SP and/or CI, they had no significant current medical problems that 
would render them ineligible. 
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2.6 Study Interventions 
2.6.1 Randomisation and blinding 
Participants who provided informed consent and were still eligible after screening were 
invited to attend in their next menstrual cycle for the first dose of the vaginal gel. 
Participants enrolled into the dosing phase of the study were allocated consecutive 
subject numbers (MAB001 onwards) at their first dosing visit. The subject numbers were 
recorded on the participant log in the trial master file. This subject number was used to 
identify the participant throughout the trial and was used on Case Report Forms (CRFs), 
samples for external analysis and study documentation. Note: participants were also 
allocated a separate number, the screening identification number (SIN), for the purposes 
of performing investigations at the screening visit only. In this report, to avoid confusion, 
participants will be referred to by their subject number only. 
Randomisation was carried out by the York Trials Unit, University of York. Subject 
numbers 01 to 30 (MAB001 to MAB030) were randomised to Mabgel (high dose), Mabgel 
(low dose) or placebo using blocked randomisation of mixed block sizes. Randomisation 
was in the ratio of 1:1:1. The randomisation program was generated using Microsoft 
Visual Basic and a copy of the generated data stored in Microsoft SQL Server. The 
randomisation list was forwarded to the Qualified Person (QP) at Polymun Scientific for 
the purposes of labelling the study gel. However, laboratory personnel carrying out 
subsequent analyses, including Dr Vcelar, did not have access to this list. 
An emergency unblinding website was established by the York Trials Unit so that 
individual participants could be unblinded in the event of a serious adverse event (SAE) 
where knowing the treatment group of the participant might be of benefit in terms of 
treating them or protecting other participants. Access to the website was password 
protected. If accessed, the website was set-up to generate an email notification to the 
study Sponsors and CI and the password would be changed. Where possible, every effort 
was to be made to avoid unblinding any Clinical Investigators. 
 107 
 
2.6.2 The Study Gels 
The gels were manufactured by Polymun Scientific in accordance with Good 
Manufacturing Practice (GMP), supplied in 3ml luer lock syringes as a single batch and 
stored in a refrigerator (2 to 8 °C) prior to being dispensed. Syringes were individually 
labelled and each one was separately packaged. Twelve syringes were provided per 
participant in a re-sealable plastic bag.  
The study gels consisted of 2.5ml of extractable volume of gel per dose containing 
20mg/g (Mabgel high dose), 10mg/g (Mabgel low dose) or zero (placebo) of each of the 
mAbs in a 1.6 % HEC-based gel. Each of the formulations had the same quantitative 
composition of excipients and differed only in their antibody contents (Table 2-3). Each 
syringe of gel dispensed contained one dose and the gel was transferred into an Ortho® 
vaginal applicator (Janssen- Cilag) before use. 
As the gel was labelled as needing storage at 2 to 8 °C it was a requirement that each 
participant should have access to a refrigerator for storage of the study gels to be eligible 
for the study and they were instructed to keep the gels in the refrigerator until shortly 
before administering each dose. 
Table 2-3 Composition of Study Gels 
 Composition (per 1g) 
 
 Mabgel (high dose) 
 
Mabgel (low dose) Placebo 
mAbs 20 mg C2F5  
20 mg C2G12 
20 mg C4E10 
10 mg of C2F5 
10 mg of C2G12  
10 mg C4E10 
0 
Hydroxyethylcellulose 
cellulose 
16 mg 16 mg 16 mg 
Glycerin 25 mg 25 mg 25 mg 
Methylparaben 1.8 mg 1.8 mg 1.8 mg 
Propylparaben 0.2 mg 0.2 mg 0.2 mg 
Maltose 50 mg 51 mg 52 mg 
Purified water 847 mg 876 mg 905 mg 
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2.6.3 Administration of the Study Gel (Gel Dosing) 
Dosing with the randomised study gel began between days 7 and 13 of the menstrual 
cycle following the screening visit (2 to 6 weeks after screening). Women who were 
amenorrhoeic were assigned an arbitrary 28 day cycle to ensure visits occurred within the 
specified schedule (see Table 2-2). The first dose of the study gel was administered in the 
HYMS EMU under the supervision of the SP. Before being issued with the remaining 11 
gels and Ortho® applicators, participants were given a demonstration by the SP on how to 
transfer the gel into the Ortho® applicator, and were witnessed performing a practice 
transfer using a ‘dummy’ gel. They were also provided with written instructions on 
storing, preparing and administering the gel. Provided there were no safety concerns, the 
participant proceeded to use the study gel at home on a daily basis for the following 11 
days. 
 Due to scheduled evaluations at 1 and 8 hours post gel administration, the initial dose 
was applied in the morning. The 12th dose was applied at a pre-arranged time in the 
evening in accordance with when each participant was scheduled to attend for their 12 
and 36 hour post 12th dose visits e.g. the gel was applied at 10pm if they were due to 
attend at 10am. Participants were instructed to apply other doses at night at bedtime as 
this was thought to be the most convenient time.  
All participants were offered daily text message reminders from the research team as an 
aide memoire. They were advised to contact the EMU before their next scheduled visit if 
they encountered any problems with using the gel or had any queries. In addition they 
were provided with a contact card containing details of how to contact the research team 
outside of normal working hours. They were advised to always contact the team if they 
had an urgent problem or if an emergency situation arose and to inform any health care 
professionals treating them of their involvement in the study. 
2.6.4 Measures of Compliance and Adherence 
Compliance/adherence with using the gel was assessed by history, diary cards and by 
inspection of returned syringes. At each visit and in telephone calls, participants were 
asked whether they had remembered to use the gel and if they had encountered any 
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difficulties with applying it. Participants were issued with a diary card and asked to record 
the time and date each time they used the gel. All participants were asked to retain used 
syringes and return them and any unused syringes to the clinic at the 12 hours post 12th 
dose sampling visit. All returned syringes were inspected by the SP or Research Nurse and 
assessed to see whether they had been fully or partially emptied or not emptied at all. All 
used syringes were stored at the trial site until after the trial monitor had verified their 
return, and were subsequently disposed of as clinical waste.  
Compliance with sexual abstinence and avoiding tampons and vaginal products was 
assessed by history at visits and telephone calls.  Cervico-vaginal lavage samples were also 
assessed for the presence of spermatozoa prior to processing. In addition, women were 
asked regarding sexual activity during the study as part of the qualitative interview (see 
Chapter 5). 
2.7 Pharmacokinetic Evaluations 
As discussed in section 2.3 the primary objective of the study was to assess the local and 
systemic pharmacokinetics of C2F5, C2G12 and C4E10 when applied vaginally. In addition, 
one of the exploratory objectives was to compare participant self-taken samples with 
those taken by a physician. The time-points for sampling and hence outcome measures 
were chosen with the aim of providing an adequate number and spread of samples for 
analysis whilst minimising the number of invasive genital examinations and 
venepunctures required for each participant. 
2.7.1 Pharmacokinetic Outcome Measures 
The primary pharmacokinetic end-points for this study were defined as: 
1. Levels of mAbs in Weck-Cel vaginal secretions 1, 8 and 24 hours post-1st dose, 12 
and 36 hours post-12th dose 
The secondary pharmacokinetic end-points for this study were defined as: 
1. Levels of mAbs in cervico-vaginal lavage samples 24 hours post-1st dose, and 36 
hours post-12th dose  
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2. Levels of mAbs in participant self-taken vaginal aspirate samples 24 hours post-1st 
dose, and 36 hours post-12th dose.   
3. Levels of mAbs in serum samples 8 hours post-1st dose, and 12 hours post-12th 
dose. 
2.7.2 Pharmacokinetic Sampling Procedures 
This section describes the methodology for collecting samples for mAb pharmacokinetic 
analysis. Laboratory procedures for processing and analysis of samples are described in 
section 2.11. 
2.7.2.1 Overview of sampling procedures 
Women were examined in the lithotomy position using a disposable plastic vaginal 
speculum and samples were taken for measurements of mAbs at baseline (pre- 1st dose of 
the study gel), 1 hour, 8 hours and 24 hours post- 1st dose, 12 and 36 hours post-12th dose 
(see Table 2-2). 3 different sampling methods were used to collect genital secretions at 
times corresponding to the pharmacokinetic end-points outlined above. Weck-Cel and 
Cervico-vaginal lavage samples were performed by the SP and vaginal aspirates were 
taken by the study participants themselves. Standard Operating Procedures (SOPs) were 
devised and followed to try to minimise any variability. 
Note: baseline pharmacokinetic samples were performed shortly before administration of 
the 1st dose of study gel, except for the 1st vaginal aspirate which was performed at the 
screening visit. This was done for logistical reasons to provide more time to instruct 
participants on the sampling method, and also to allow colposcopic evaluation to be 
carried out following the procedure to assess whether the aspirator caused any visible 
trauma. All sampling at other time-points was performed after initial colposcopic 
assessment (see section 2.8.3). This enabled appearances to be assessed before any 
samples were taken to avoid any trauma or bleeding that may have arisen as a result of 
the sampling procedure being erroneously attributed as having been caused by the study 
gel. 
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2.7.2.2 Order of sampling 
To further standardise the sampling procedure, samples were taken in the following   
specified order, according to which were required at each visit.  
1. Vaginal participant self- collected aspirate sample 
2. Vaginal Weck-Cel 
3. High vaginal swab and slide for the vaginal flora sub-study (see section 2.4.2) 
4. High vaginal swab for candida culture and speciation (see section 2.7.2.6) 
5. Cervico- vaginal lavage 
2.7.2.3 Weck-Cels 
Vaginal secretions were sampled primarily using Weck-Cel Ophalmic Sponges (Medtronic 
Xomed) (referred to as Weck-Cels), which were used at all pharmacokinetic sampling 
time-points.  Weck-Cels are sterile, triangular- shaped cellulose sponge swabs on a 
polypropylene stem designed for wicking secretions during eye surgery. They have 
previously been used successfully by other research groups for measuring antibody levels 
in genital secretions following vaccination [525,526,527] and in HIV-1 positive individuals 
[562]. 2 Weck-Cel samples were taken per participant at each time point. Each Weck-Cel 
was grasped using a pair of disposable sponge forceps, placed inside the lateral fornix and 
held against the vaginal mucosa for 1 minute. Weck-Cels were placed in succession, one 
into each of the vaginal fornices.  After removal, each Weck-Cel was placed sponge- end 
down into a Spin-X centrifuge tube (Corning) containing 300μl of extraction buffer. Each 
Spin-X tube was housed inside a 15ml centrifuge tube (Corning).  Following sample 
collection, each Weck-Cel stem was removed to allow tube closure and avoid spillage but 
was retained to enable a post collection, pre-processing weight to be measured. 
2.7.2.4 Cervico-vaginal lavages 
CVLs were performed using 5ml of sterile normal saline at baseline, 24 hours post 1st dose 
and 36 hours post 12th dose. These were performed using a 10ml syringe with a plastic 
universal Kwill attached. Taking care to avoid contact between the vaginal mucosa and 
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the tip of the Kwill, the saline was gently expelled from the syringe to irrigate the lateral 
and posterior vaginal walls and fornices. The lavage fluid was then aspirated from the 
pool in the posterior fornix and transferred into a 15ml centrifuge tube. 
2.7.2.5 Participant self-taken vaginal aspirates 
Participant self-taken vaginal aspirates were performed using syringe-based volumetric 
devices (Rovumeter; Recipe Pharmaceuticals, Munich, Germany) which were designed for 
this purpose and were obtained from Professor Angela Kashuba, Centre for AIDS 
Research, University of North Carolina, Chapel Hill, North Carolina, USA. As mentioned in 
section 2.4.1, these aspiration devices have previously been used successfully to collect 
vaginal secretions for the analysis of levels of antiretroviral agents [538,539]. Participants 
were given verbal instructions and a demonstration by the SP on how to perform the 
procedure before being asked to self-sample their own vaginal secretions. These 
instructions were based on written instructions obtained from Professor Kashuba which 
had been provided to participants in one of her studies [539]. Before sampling, 
participants were required to lie supine on a couch for 15 minutes to allow time for 
pooling of secretions in the posterior fornix.  
After removing the syringe from the packaging, the participants were advised to pull the 
plunger of the aspirator up and down to loosen the plunger and prevent it from sticking 
to the syringe. With the plunger pushed to the bottom of the syringe, the participants 
were instructed to gently insert the device  into the vaginal canal until it touched the back 
of the posterior fornix - ‘push backwards but not upwards as far as the applicator with go 
until you feel it touch the posterior vaginal wall’. To perform the aspiration, the advice 
given was to ‘pull the entire syringe out slightly to avoid suction of tissue. With one hand 
holding the syringe in place, use the other hand to gently pull out the plunger to aspirate 
fluid. Stop pulling on the plunger if excess pressure causes discomfort. Continue to pull 
back on the plunger with one hand as you remove the syringe from the vagina with the 
other hand’. 
After removing the syringe from the vagina, the participant handed the syringe to the SP 
or a research nurse who placed the tip into a 15ml centrifuge tube (Corning). Any 
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secretions collected were expelled by fully depressing the plunger, making sure the tip 
touched the side of the tube. 
2.7.2.6 High Vaginal Swab for Candida Culture and Speciation 
Species of the yeast Candida are common commensal organisms which colonise the 
vagina in 10 to 20 % of women of reproductive age without causing overt signs or 
symptoms (candidosis) [563,564]. The occurrence of clinical signs or symptoms related to 
candida e.g. vulvovaginitis (redness, soreness, itching, curdy adherent vaginal discharge), 
known as candidiasis, may result from a high organism load or from an interplay between 
the host immune system and Candida [565,566,567,568]. As many of the features of 
clinical candidiasis can mimic side-effects caused by topical microbicides it was important 
to screen for this infection at baseline and consider it as a differential cause of local 
adverse events (AEs) (see section 4.1.1.12).  
 In addition, Dunlop et al. have reported cross-reactive binding of C2G12 to the most 
common species of candida, C. albicans, and to the less common C. tropicalis, but not to 
C. glabrata or the related yeast Saccharomyces cervisiae [569]. It is therefore theoretically 
possible that the presence of certain Candida species in the vagina could have an impact 
on measurable levels of C2G12 due to a sequestration effect. 
Thus, in our study, as is standard in microbicide trials, women with clinically or 
microscopically apparent Candida infections detected at screening were deemed screen 
failures and, unless treated and successfully re-screened subsequently, were not enrolled 
into the dosing phase. In addition, in view of the delay between screening and dosing (up 
to 6 weeks) and the possible pharmacokinetic interaction, it was decided to perform a 
high vaginal swab for quantitative Candida culture and speciation just before the 1st gel 
dose was given. It was envisaged that results of this test would not be available until the 
end of the dosing period, thus the presence of Candida would not exclude someone from 
dosing. However, the results would enable any potential impact on C2G12 analyses to be 
subsequently determined and could also be used as an adjunct in evaluating clinical AEs. 
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2.7.2.7 Serum 
Serum samples for mAb analysis were obtained at the specified time-points by the SP or 
Research Nurse. 7.5ml of blood were collected into a brown top S-Monovette® (Sarstedt, 
NHS Supplies) serum blood collection tube. 
 At time-points where blood samples for safety analyses were also required, the samples 
were collected in the order recommended by the Clinical and Laboratory Standards 
Institute (formally the National Committee for Clinical Laboratory Standards (Standard 
H3-A6, 2007) to ensure minimum potential interference of tube additives on subsequent 
sample analyses [570].   
2.7.3 Sampling windows 
Sampling windows were determined in advance for each pharmacokinetic time-point:  
 For the pre-1st dose samples, sampling had to be carried out on the same day as 
and prior to the delivery of the 1st dose. 
 For the 1 hour post-1st dose time-point, sampling had to be carried out within 15 
minutes less and 30 minutes more than the time indicated. 
 For the 8 and 24 hour post-1st dose, and 12 and 36 hour post-12th dose time-
points, sampling had to be  carried out within 1 hour (either more or less) than the 
time indicated. 
2.7.3.1 Timing of sample taking 
The time to the nearest minute at which samples were taken was recorded from the start 
of each sampling procedure. That is from when the participant inserts the vaginal 
aspirator, the first Weck-Cel is inserted, the syringe and Kwill are inserted for CVL 
irrigation, or the needle is inserted into a vein for venepuncture.  
Any samples taken outside of the sampling windows for each time-point were 
documented as protocol deviations. 
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2.8 Safety Evaluations 
As discussed in section 2.3, the secondary objective of the study was to assess the safety 
of C2F5, C2G12 and C4E10 when applied vaginally.  
2.8.1 Safety-Related Outcome Measures 
The main safety-related secondary end-points for this study were defined as: 
1. The number of grade 3 or above genital AEs during the dosing or follow up period.  
2. The number of grade 3 or above other clinical or laboratory AEs confirmed at 
examination or on repeat testing respectively during the dosing or follow up 
period. 
3. The number of events attributable to the study gel (i.e. adverse reactions (ARs)) 
leading to discontinuation of gel. 
Additional safety end-points that would be analysed were: 
 All grades of genital AEs. 
 All grades of non-genital AEs (clinical or laboratory findings). 
 Coagulation parameters (APTT and aCL)- if systemic absorption of the 
mAbs was detected in serum samples. 
 Identification of Lactobacillus species, in vaginal secretions (to be analysed 
and reported as part of the vaginal flora sub-study). Gardnerella vaginalis 
and Atopobium vaginae (to be reported later). 
2.8.2 Safety-Related Definitions and Classifications 
Unless stated otherwise, all definitions followed for the purposes of safety-reporting in 
this study were obtained from the UK Medicines for Human Use (Clinical Trials) 
Regulations 2004 [571]. 
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2.8.2.1 Definition of an Adverse Event 
An Adverse Event is any ‘untoward medical occurrence in a subject to whom a medicinal 
product (in this case, study gel) has been administered, including occurrences which are 
not necessarily caused by or related to that product’.  
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of an 
investigational medicinal product (IMP), whether or not considered related to the IMP. 
In this study, however, in line with the North and East Yorkshire R & D Alliance Research 
Related Adverse Event Reporting Procedures, we were requested by the trial Sponsors to 
collect details of any untoward events arising in all trial subjects from the time of their 
providing informed consent at screening, whether the study gel had been administered to 
the subject or not. However, any AEs occurring prior to 1st gel administration were to be 
considered to be unrelated to use of the study gel and excluded from the main analyses. 
2.8.2.2 Determination of Causality in Relation to Study Gel Administration 
A judgment was made by the SP, in consultation with the CI, for each AE in relation to 
expectedness and likely relationship to the study gels. This was based on clinical 
judgement with reference to AEs observed in the previous human trials, where the mAbs 
were administered intravenously, and to data from animal studies (rats, rabbits and non-
human primates) in which the Mabgel was applied vaginally, as reported in the MABGEL 
IB. 
2.8.2.3 Definition of an Adverse Reaction  
‘Any untoward and unintended response in a subject to an IMP related to any dose 
administered to that subject’ is defined as an adverse reaction (AR).  Therefore, any AE 
for which there is at least some evidence or argument to support at least a possible causal 
relationship to the study gel qualifies as an AR.  
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2.8.2.4 Classification of AE Severity 
All AEs were classified according to severity based on a pre-defined grading system. This 
system was based on the genital tract and clinical gradings devised and used by the UK 
Medical Research Council Clinical Trials Unit (MRC CTU) in the Microbicides Development 
Programme [572] and the laboratory gradings defined by US National Institute of Health 
Division of AIDS [573]. Common genital, other clinical and laboratory AEs were listed in 
tables with clearly defined cut-off boundaries for each grade. 
2.8.3 Procedures for Assessing Safety 
Clinical AEs were broadly categorised according to whether they were local to the genital 
tract, or affected an organ or body system outside.  
Data on clinical AEs were collected through open questions at face-to face visits and 
during telephone calls. In addition, genital AEs were specifically solicited using questions 
related to unexpected vaginal bleeding, genital discomfort (itching, burning, soreness), 
discharge, dysuria and dyspareunia and from findings on colposcopy including erythema, 
oedema, and epithelial disruption. Findings were recorded on study proformas then 
transcribed onto CRFs. 
Colposcopy was performed by the SP on all occasions using a Zeiss model 22/024282 
colposcope. This was conducted in general accordance with the CONRAD/WHO Manual 
for the Standardization of Colposcopy for the Evaluation of Vaginal Products (2004), 
however no saline lavages or swabs were used apart from the study samples specified in 
the protocol to avoid impacting on pharmacokinetic evaluations [574].  Images were 
recorded using a USB200 Medicapture Unit to allow comparison across subsequent visits 
and verification by the CI. 
Laboratory AEs were detected through blood or urine tests performed at scheduled time-
points. Results were provided by York Hospital Pathology Laboratories as printed reports 
which were reviewed by the SP within 48 hours of receipt. 
Details of any medications taken by participants during the trial were recorded, and 
where related, used in assessing the severity of AEs. 
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2.8.3.1 Timing of Safety Evaluations 
Genital examination, including colposcopy, coagulation assays and serum aCL antibody 
titres were performed before the first dose of study gel, and repeated 8 hours after the 
first dose to check for any immediate genital AEs or aCL reactogenicity.  Colposcopy was 
also performed at 1 hour post the first dose at the time of pharmacokinetic sampling visit.  
In addition to the pharmacokinetic sampling visits, where safety data were also obtained, 
follow up face-to face safety evaluations were carried out on day 5 (+/-1 ) post 1st dose 
(colposcopy) and between days 7 and 21 of the subsequent menstrual cycle (10 days to 4 
weeks after the 12th dose) (clinical examination, colposcopy, blood sampling, urinalysis 
and pregnancy test). Questions regarding AEs and concomitant medications were also 
asked during telephone calls at 2 days (+ /- 1) and 8 days (+ /- 1) post 1st dose. 
2.8.3.2 Safety Data Derived from Sub-Study Analyses 
As outlined in section 2.4.2 the impact of the study gels on vaginal flora was assessed by 
Dr Vicky Jespers and Dr Tania Crucitti, Institute of Tropical Medicine, Antwerp through 
analysis of vaginal swabs and Gram-stained slides taken at  baseline, 36 hours post 12th 
gel dose and in the subsequent menstrual cycle. Results of these analyses were provided 
at the end of the trial and are summarised in Chapter 4. 
At the end of the dosing period, as part of the qualitative interview sub-study, 
participants were asked whether they had experienced any problems with using the gel, 
had noticed any abnormal vaginal discharge or whether any features of the gel (such as 
consistency, smell) had bothered them. Data from the interviews was analysed separately 
from that from the main study and is presented in Chapter 5. 
2.9 Dosing Interruptions, Withdrawals and Study Termination 
As a condition of providing Informed Consent, any participant was free to withdraw from 
the study at any time, without giving a reason, and without their clinical care being 
affected. Interruption or discontinuation of gel use could also occur if the participant 
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desired to stop using the study gel.  Interruptions to dosing or study withdrawal could 
also be initiated by the CI for safety reasons. 
According to the trial protocol, a temporary cessation of study gel use should have taken 
place following a grade 2 or above solicited genital AE.  Dosing could be recommenced 
after interruption following any AE at the discretion of the CI.  A permanent cessation of 
study gel use would have taken place following a grade 3 or above solicited genital other 
clinical or laboratory adverse event.  In the case of 3 women experiencing either a grade 3 
or above genital AE or grade 3 or above clinical or laboratory AE, the study would have 
been temporarily halted pending unblinded review by the Data and Safety Monitoring 
Committee (DSMC) (see section 2.12.3). The decision to stop the study rested with the CI, 
with recommendations from the DSMC. The Sponsor also reserved the right to terminate 
the study at any time. 
Wherever possible, participants who discontinued study gel use either by choice or 
following advice would be encouraged to continue to adhere to the follow up schedule up 
to the final visit.  In the event of a discontinuation due to an SAE or AE, the participant 
would have been followed up by the study team until completion of the event.  
If a participant was considered a screen failure, discontinued dosing or withdrew from the 
study at any time, data and samples collected up to that point were to remain available 
for analysis in accordance with the trial protocol. 
2.10 Financial Re-imbursement of Study Participants  
Participants were re-numerated to cover their time and expenses during the trial. A 
maximum of £565 was paid to each participant, having been pre-approved by the REC, 
based on the following breakdown: 
 Screening visit, 1st dosing visit and final visit: £80 per visit. 
 Other clinic visit requiring colposcopy and/or vaginal sample collection: £65 per 
visit. 
Payment was made by cheque at the final study visit. 
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2.11 Laboratory Procedures 
2.11.1 Screening and Safety Specimens 
Screening microscopy was performed by the SP in the EMU according to SOPs based on 
those used in the York Sexual Health Clinic. Wet mounts were examined at x 400 
magnification using a dark-field setting for Trichomonas vaginalis, clue cells and yeast. 
Gram-stained slides, examined with a bright-field under oil at x 1000, were considered 
indicative of Candida species infection in the presence of spores and /or hyphae. A 
Nugent score ≥7 was considered indicative of BV as was a vaginal pH > 4.5 in the presence 
of clue cells and compatible white homogeneous discharge (see section 2.11.4). For safety 
reasons, it was not possible to use potassium hydroxide to perform an ‘amine whiff test’ 
in the EMU. 
Vaginal pH testing was performed at screening and subsequent visits using a 3cm strip of 
pH paper (range 4.0 to 7.0, Whatman) grasped in sponge-holder forceps and held against 
the lateral vaginal wall. pH was determined by comparing the resulting colour change 
with a chart supplied with the pH paper. 
Cervical swabs for Chlamydia trachomatis (PCR, Roche), Neisseria gonorrhoea (culture, 
chocolate agar, Oxoid (PB0963A)) and vaginal swabs for Candida culture and speciation 
(cultured on Sabouraud dextrose agar plus chloramphenicol, Oxoid (PO0161A); speciation 
by bioMerieux API 20 C AUX (20210)) were processed by the Microbiology Section of the 
York Hospital Pathology Laboratories according to their SOPs. 
Mid-stream urine samples were tested for protein, nitrites, leucocytes and blood 
(Multistix®, Siemens) and for evidence of pregnancy (QuPID®-One Step, Stanbio) by 
research nurses in the EMU. 
Blood specimens were processed for U and E, LFT, FBC, Clotting profile (APTT, PT), 
serology (HIV (4th generation combined antibody (Ab) and antigen (Ag) enzyme-linked 
immunoassay (ELISA)); Syphilis (Treponema pallidum enzyme immunoassay (EIA)); HCV, 
HBV (surface Ag), and aCL IgG) by the York Hospital Pathology Laboratories according to 
their SOPs. 
 121 
 
2.11.2 Initial Processing and Storage of Specimens for mAb Analysis 
2.11.2.1 Overview of Procedures for Initial Processing and Storage 
Initial preparation of reagents and sample collection equipment took place either in the 
HYMS EMU laboratory or in the Immunology and Infections Unit (IIU), University of York. 
Vaginal and serum samples obtained for mAb pharmacokinetic analysis were initially 
processed and stored in the HYMS EMU laboratory or transported and stored in the IIU in 
accordance with study-specific SOPs. Following collection, all vaginal samples were 
transported to the relevant laboratory on ice and stored at 2 to 8 °C to be processed 
within 2 hours.  Serum samples were kept at room temperature for 1 hour then stored at 
2 to 8 °C and processed within a 4 hour window of collection.  After initial processing by a 
laboratory technician, samples were stored in fridges and freezers which were alarmed 
and data-logged to ensure they were kept within the designated temperature ranges.  
Subsequently, samples were transported to Polymun Scientific in two batches, the first 
containing samples from the first 11 participants, the second containing samples from the 
remaining participants. Samples were transported by cold-transport courier on dry ice. 
2.11.2.2 Preparation of Extraction Buffer Required for Vaginal Sample Processing 
Processing of Weck-Cel, CVL and vaginal aspirate samples required use of an extraction 
buffer which was prepared as follows. Firstly, 1 vial of protease inhibitor (PI) cocktail set 1 
(100x solution) (Calbiochem, Cat. Nº 539131) was reconstituted in 1ml sterile distilled 
water and vortexed for 30 seconds so that it dissolved completely. When diluted to 1x 
concentration this contained 500M AEBSF, 150nM aprotinin, 1M E-64 PI, 0.5mM EDTA,  
1M leupeptin. 1ml of the reconstituted PI cocktail was mixed with 20l of a 10 % 
solution of sodium azide (Sigma, Cat. Nº 2002-25G), 1.5g Sodium Chloride (0.25 M final 
concentration) (BDH, Cat. Nº 102415k) and 1X Dulbecco’s phosphate buffered saline 
(PBS)(pH 7.4)(prepared from 10X stock solution)(Sigma, Cat. Nº D148)) to make a final 
volume of 100ml. The resulting extraction buffer was filter sterilised and stored at 2 to 
8C for up to 1 month.  
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2.11.2.3 Preparation of Weck-Cel Sampling Kits 
For Weck-Cel sampling, 300l of the extraction buffer was pipetted into each Spin-X 
centrifuge tube (Corning Cat .N º 8160), 2 per participant per sampling time-point, prior 
to sample collection. Each Spin-X tube contained a 22μm pore filter insert. Each complete 
sample collection kit containing the Weck-Cel sponge plus the Spin-X tube containing 
300l extraction buffer was placed in a 15ml centrifuge tube (Corning Cat.Nº 430766) and 
weighed on a fine balance (Mettler-Toledo) so a pre sampling weight could be recorded.  
Weck-Cel sampling kits were stored at 2 to 8C until sample collection. 
2.11.2.4 Weck- Cel Sample Processing 
Before processing, the sample collection kits were re-weighed on the same fine balance 
as before to determine the post-sampling weight. As mentioned in section 2.7.2.3 Weck-
Cel stems which were removed to allow lid closure were retained and weighed with the 
rest of the sampling kit. After re-weighing, the Spin-X tubes containing the Weck-Cel 
sponge-heads were removed from the 15ml Corning tubes, placed in a bench-top 
refrigerated centrifuge (Fisher Scientific) and spun at 13,000xg for 15mins at 4C. After 
centrifugation, another 300l of extraction buffer was added to each of the Spin-X tubes 
containing the Weck-Cel sponge-heads and they were spun again. If the buffer had not 
been completely drawn through the filter, using forceps, the sponge head was transferred 
to a new filter, placed in the original Spin-X tube and centrifuged again for 5 minutes at 
the same speed and temperature as before. Filtered buffer and secretions eluted from 
both samples taken per time-point per participant were then combined into a single 2ml 
sterile-capped microtube (Sarstedt, Cat N º72-694-005).  5l was removed and applied to 
Hemastix® (Bayer) testing strip for 1 min to test for blood contamination. 8l of heat-
inactivated fetal calf serum (HI-FCS) (Invitrogen, Cat. Nº 10108-165) was then added and 
the tube inverted gently 15 times to mix. The processed sample was then divided into 
200l aliquots in 2ml Sarstedt tubes, labelled with the participant’s subject ID, visit 
number/sampling time point and sample type and stored at -80C. 
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2.11.2.5 CVL sample processing 
Sample volumes were recorded prior to processing. Samples were gently vortexed for 10 
seconds. 10μl of each sample was then placed on a KOVA® slide (Hycor, Biomedical) and 
assessed for presence of red blood cells (RBCs) or spermatozoa by microscopy. Following 
the addition of 50 μl of the extraction buffer, each sample was transferred to a 15ml 
Corning tube and centrifuged for 6 minutes at 1000 x g at 4C to pellet the cells. A 10μl 
aliquot of supernatant was assessed for presence of RBCs and sperm as before. 5μl of 
supernatant was applied to a Hemastix testing strip for 1min to test for the presence of 
blood. The supernatant was divided into 200μl aliquots in 2ml Sarstedt tubes, labelled 
with the participant’s subject ID, visit number/sampling time point and sample type and 
stored at -80C. The cell pellet was kept in the original 15ml Corning tube, labelled with 
the participant’s subject ID, visit number/sampling time point and sample type and stored 
at -80C. 
2.11.2.6 Participant Self-Taken Vaginal Aspirate Processing 
Aspirators were placed inside a 15ml Corning tube. The plunger was suppressed to eject 
any secretions, ensuring the tip of the aspirator touched the side of the tube to remove 
any residual sample. The tube was gently vortexed to ensure the sample collected at the 
bottom of the tube and the volume of sample obtained recorded.  Samples taken at visits 
other than screening (i.e. post-baseline samples) were then diluted 1:1 with extraction 
buffer. Baseline samples obtained at the screening visit were stored neat. Samples were 
divided into 200μl aliquots in 2ml Sarstedt tubes, labelled with the participant’s subject 
ID, visit number/sampling time point and sample type and stored at -80C. 
2.11.2.7 Serum Processing 
S-Monovette® tubes (Sarstedt) containing blood samples were centrifuged at 1000 xg for 
10 mins to ensure the serum was separated from the clotted blood. Serum was then 
removed and divided into 500μl aliquots in 2ml Sarstedt tubes labelled with the 
participant’s subject ID, visit number/sampling time point and sample type and stored at  
-80C. 
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2.11.3 ELISAs for Quantifying mAb Concentrations 
Serum and vaginal secretion samples were analysed according to established SOPS at 
Polymun Scientific. The methodology has been used in the previous clinical studies 
involving the mAbs [501,502,504,505]. 
Briefly, C2F5 and C4E10 concentrations were determined by enzyme-linked 
immunosorbant assays (ELISA) systems using the peptides GGGLELDKWASL and 
KKWNWFDITNWGGG respectively for coating, and goat anti-human IgG gamma chain 
antibody (Zymed Laboratories Inc. 62-8420, USA) conjugated with horseradish peroxidise 
(HRP)  for detection. Highly purified internal C2F5 and C4E10 antibodies were used as 
standards. 
C2G12 concentrations were determined by an ELISA using the anti-idiotypic antibody 
M1G1 (in-house) for coating and goat anti-human IgG gamma chain antibody (Zymed 
Laboratories Inc. 62-8420, USA) conjugated with (HRP) for detection. A highly purified 
internal C2G12 antibody was used as a standard. 
Quantification was performed in pre-coated 96-well microtiter plates. The standard and 
samples were run in a 28-fold dilution row. The concentration range of the standard was 
1.563 - 200 ng/ml.  After incubating the pre-coated plates with the added samples for one 
hour at room temperature and washing with PBS pH 7.2 including 0.1 % Tween 20, the 
conjugated antibody was added. After incubation for one hour at room temperature and 
washing with PBS pH 7.2 including 0.1 % Tween 20, the enzymatic colour reaction was 
started by addition of the chromogene substrate o-phenylenediamine dihydrochloride 
(OPD) and hydrogen peroxide and stopped by adding 2.5 M sulphuric acid. The 
absorbance was measured at 492 nm (reference wavelength 620 nm) and the results 
were evaluated with a fourth-degree polynomial (Software: Biolise for Windows).  
The test was considered valid if the well with the highest standard protein concentration 
displayed an absorbance of at least 1.0 and if the absorbance of the blank vials was below 
0.1. In addition, recovery of the standard must be within +/- 20% and the coefficient of 
variance between repeat sample wells on the same plate had to be below 15%. 
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2.11.4 Specimens for Vaginal Flora Sub-study 
2.11.4.1 Initial processing and storage of swabs and slides 
Glass slides containing vaginal secretion smears were heat-fixed then stored at room 
temperature. High vaginal swabs (flocked dacron swabs, Copan) were stored at -20°C. 
Swabs and slides were transported to Dr Vicky Jespers in a single shipment after all 
participants had completed the study.  
2.11.4.2 Analysis of the slides 
Slides were Gram stained, examined by bright-field microscopy and interpreted according 
to the method described by Nugent [561]. As shown in Table 2-4, this scoring system 
grades vaginal smears according to the visual quantification of characteristic bacterial 
morphotypes per oil immersion field (0 = no morphotypes; 1+ = less than 1 morphotype; 
2+ = 1 to 4 morphotypes; 3+ = 5 to 30 morphotypes; 4+ = 30 or more morphotypes). 
Scores assigned for each morphotype are added together to give an overall Nugent Score 
between 0 and 10 for each sample. Nugent Scores between 0 and 3 indicate the presence 
of normal flora; scores of 4 to 6 indicate an intermediate flora; scores ≥ 7 are graded as 
BV. 
Table 2-4 Scoring System for Bacterial Morphotypes on Gram-stained Vaginal Smears 
Score Lactobacillus 
Morphotypes 
(large Gram 
positive rods) 
Gardnerella and 
Bacteroides 
Morphotypes 
(small Gram 
variable rods) 
Mobiluncus 
Morphotypes 
(curved Gram-
variable rods) 
0 4+ 0 0 
1 3+ 1+ 1+ or 2+ 
2 2+ 2+ 3+ or 4+ 
3 1+ 3+  
4 0 4+  
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2.11.4.3 Quantitative PCR for Lactobacillus Species 
Real-time, quantitative PCR was performed for Lactobacillus species present in the 
vaginal secretions collected on the dacron swabs.  Deoxyribonucleic acid (DNA) was 
isolated through capture by magnetic silica particles (BOOM-technology) (NucliSENS® 
easyMAG®, Biomérieux) according to the manufacturer’s instructions [575]. PCR was 
performed using SYBR® Green PCR Mastermix (Applied Biosystems) on 5μl samples of 
extracted DNA. Specific primers were selected to detect Lactobacilli generally and also the 
individual species Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, 
Lactobacillus vaginalis and Lactobacillus iners (see Table 2-5). Primers were designed in-
house for L. vaginalis but have been described elsewhere for generic Lactobacilli and for 
the other L. species [542,543,560,576]. 
Table 2-5 Lactobacillus Specific PCR Primers 
 
2.12 Data Management and Quality Assurance 
2.12.1 Data Management and Trial Monitoring 
Responsibility for managing trial data and monitoring trial conduct was sub-contracted by 
the Sponsor to Covance Clinical Research Unit, Leeds. Monitoring was undertaken before 
any participants were enrolled in the study and at regular intervals by suitably qualified 
 127 
 
and trained personnel in accordance with their own SOPs. The purpose of monitoring was 
to ensure: compliance with the protocol, adherence to regulatory and GCP obligations, 
proper maintenance of all study documentation, the completeness and exactness of the 
data entered on the CRFs, source data verification, accurate reporting of all adverse 
events,drug accountability and to maintain close liaison with the Investigators to clarify 
any problems which may arise during the study. Formal reports were sent to the Sponsor 
by the Monitor after every visit. Completed CRFs were forwarded to the Covance Data 
Manager by the Monitor after verification. Any data queries generated were forwarded to 
the Trial Management Group for clarification. 
2.12.2 Trial Management Group 
A Trial Management Group (TMG) was formed comprising the CI, the SP (i.e. the author) 
and the EMU Co-ordinator.  The TMG was responsible for the day to day running of the 
trial and discussed the progress of the trial at least once a month. The TMG provided 
feedback to the Data and Safety Monitoring Committee 
2.12.3 Data and Safety Monitoring Committee (DSMC) 
A DSMC was established by the CI to review safety and pharmacokinetic data as the study 
progressed. This consisted of two Consultant GUM/HIV Physicians with appropriate 
research experience (Dr Steven Taylor, Heart of England NHS Trust and Professor George 
Kinghorn, Sheffield Teaching Hospitals NHS Trust) and Martin Bland, Professor of Health 
Statistics, Department of Health Sciences, University of York (Committee Chair).  The 
DSMC met by teleconference on 2 occasions, 19th April and 14th June 2010, after 11 and 
22 participants had been randomised and dosed respectively. On both occasions interim 
blinded AE data was made available by the TMG. For the initial meeting, interim blinded 
pharmacokinetic data was also provided by Polymun for the first 11 participants. The 
TMG attended part of the meeting to answer questions regarding the progress of the 
study, however the majority of the meeting was conducted in private. The Committee 
had access to the unblinding list for the trial in order that they be in a position to fully 
assess the data, however no unblinded results were communicated to the CI, Sponsor or 
any investigators involved in recruiting or reviewing participants during the study.  Having 
reviewed the data, the Chair issued a report to the CI and Sponsor that the DSMC had no 
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concerns regarding the integrity of the pharmacokinetic data or safety of participants and 
were happy for the study to proceed. A final review of study data was conducted by the 
Committee Chair at the end of the trial. 
2.13  Planned Statistical Analyses 
An initial Statistical Analysis Plan (SAP) for the Mabgel Trial had been devised in June 2008 
by the then Statistician for the trial, Dr Victoria Allgar (Statistician at HYMS and the 
Department of Health Sciences, University of York) when the study was first submitted for 
Sponsor approval.  However, in the interim, the protocol had undergone a number of 
revisions without adjustment of this plan. On reviewing the SAP on his appointment as 
DSMC Chair, Professor Bland identified areas which employed statistical methods which 
were impractical given the expected nature of the data. In addition, the author and 
Professor Lacey had thought of several analyses that they felt ought to be included but 
which had been omitted from the original SAP.  Thus, it was decided to produce a revised, 
final SAP for the trial, prior to performing any analyses. This final SAP and the rationale 
behind the chosen statistical methods, is outlined in section 2.13.1 
As a result of the work put in by Professor Bland in his role on the DSMC and his 
consequent familiarity with the data, it was agreed by Dr Allgar, Professor Lacey and the 
Sponsor that he take over as Trial Statistician and complete the final analyses.  In view of 
Professor Bland’s dual roles, an independent expert medical statistician from another 
institution was asked, by the Sponsor, to review and approve the revised SAP, prior to its 
implementation.  In addition, verification of all completed analyses was performed by 
both Dr Allgar and the independent statistician. 
2.13.1 Final Statistical Analysis Plan 
The revisions to the original SAP related to the analysis of pharmacokinetic data described 
in section 2.13.4.  All other elements of the original SAP remained unchanged. Study 
objectives and end-points are described in sections 2.3,2.4,2.7.1 and 2.8.1 respectively. 
Key details from the SAP that aren’t provided elsewhere in this thesis are given below. 
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2.13.2 Analysis Populations 
Presentation of summary statistics for the mAb levels at each time point and comparison 
between arms was to be conducted on an intent-to-treat basis according to allocated 
treatment arm. Providing that all participants in the placebo arm were negative for all 
pharmacokinetic endpoints at all time-points, only data from those in the active arms 
(low dose and high dose mAbs) were to be included in subsequent analyses. 
Analysis of safety data would also be carried out on an intent-to-treat basis; all 
participants who are randomised and thus entered into the dosing phase of the study 
were to contribute data to the safety analyses. 
2.13.3 Data Derivations and Data Handling 
For the purposes of the analyses, sampling time was to be presented according to the 
intended time of each visit but deviations from sampling windows were to be reported. 
Missing data was not to be imputed. Any missing data was to be explored, and unless 
there was any reason to believe otherwise, missing data was to be assumed to be missing 
at random and therefore cases were to be excluded from analyses where their data are 
required but unavailable.  Should a participant withdraw from the study any data and 
samples collected up to the point of withdrawal were to be analysed. 
2.13.3.1 Rules for Handling Safety Data 
AE definitions and grading are provided in section 2.8.2. In accordance with the North and 
East Yorkshire R & D Alliance SOP on Adverse Event Reporting, all untoward occurrences 
that arose in a participant following informed consent had to be recorded as AEs. 
However, any events that were detected in a participant prior to them being exposed to 
study gel would be considered to be not related to study gel for the purposes of analysis 
unless they increased in severity and /or grade during the study. 
For every AE, the duration of the event was defined as the number of days from the first 
occurrence to the first event free day. The grade reported would be the maximum grade 
reached during that period. Events were only to be considered to be AEs if detected and 
recorded during the required period of follow up for each participant described in the 
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study protocol, i.e. up to and including the final evaluation (visit 8), except for any 
participant experiencing a grade 3 or above event who was required to be followed up 
until resolution of the event. 
2.13.4 Pharmacokinetic Analyses 
2.13.4.1 Non-parametric vs parametric tests 
Given the fact that no mAbs would be expected to be detected in the baseline samples in 
any of the 3 study arms, or any samples from recipients of placebo, the complete mAb 
ELISA data for all sample types was likely to be highly skewed with many observations 
recorded as being “<0.06”, meaning not detectable (ND) within the limits of the assay. 
Thus, a non-parametric statistical approach, using the Kruskal-Wallis Rank and Mann 
Whitney-U tests [577], was felt to be the most appropriate way of comparing mAb levels 
between all 3 study arms and for direct comparisons between the 2 active Mabgel arms. 
However, for more complex comparisons of mAb levels, involving other variables, it was 
thought justifiable to use parametric methods, such as analysis of variance (ANOVA), or 
regression, after transforming the data (using log10) so that it approximated a normal 
distribution [578].  Such analyses would only utilise mAb levels expected to be detectable, 
i.e. from post-dose visits in the 2 Mabgel arms, thus avoiding the difficulties of obtaining  
log10  of values which are ND (impossible)  or < 1 (negative log).  Should any observations < 
1 be encountered, they would be assigned the value 1, becoming 0 after log10 
transformation. 
2.13.4.2 Primary and Secondary End-point Analyses (mAb concentrations detected in 
Weck-Cel, CVL, aspirate and serum samples) 
For the mAb levels in all sample types, results would be summarised for each treatment 
group (high dose Mabgel, low dose Mabgel and placebo) as minimum, median, and 
maximum at each time-point. All 3 treatment groups would first be compared using the 
Kruskal-Wallis Rank test corrected for ties. Since this test uses only ordinal data, it copes 
well with zero or “ND” values. 
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Where the Kruskal-Wallis test is statistically significant, P<0.05, the two active treatment 
groups would be compared using a Mann Whitney- U test, to check for evidence as to 
whether the higher dose produces higher antibody concentrations. The test would be 
conditional on the Kruskal-Wallis test result to avoid multiple testing problems and the 
need to adjust P values for these [577]. 
2.13.4.3 mAb Half-lives 
Drug levels in pharmacokinetic studies are often expressed in terms of t ½ (t ½) and the 
two previous studies of passive application of IgG to the FGT have both provided t ½ 
estimates [510,511]. It seemed sensible therefore to attempt to estimate the t ½ of each 
of the mAbs in this study, with the caveat that the accuracy would be restricted by the 
relatively limited number of sampling time-points. 
Using data from Weck-Cel samples, t ½ would be estimated for each mAb using only the 
groups which received an active dose, and observations at 1, 8, and 24 hours after the 
first dose. The method would assume an exponential decay curve. If the data cannot be 
assumed to fit an exponential decay curve, a t ½ is not a meaningful estimate [579]. A log 
transformation of the observed mAb concentration was to be used and an analysis of 
covariance (ANCOVA) model fitted with time as a continuous predictor and participant as 
a categorical factor [577]. Two checks on the assumptions were to be made. Firstly, 
linearity would be checked by including and testing a time squared term. Uniformity of 
the t ½ would then be checked by testing an interaction between time and participant. If 
the assumptions are met, the t ½ could be estimated by log(2)/slope. The 95% confidence 
interval (CI) would be found from the usual CI for the slope. If the assumptions are not 
met, analysis would then be data-driven. 
2.13.4.4 Adjustment for Dilution Factor  
Analyses of mAb levels in all samples would be carried out using the ‘raw’ ELISA data, as 
reported by Polymun. In addition, antibody concentrations in Weck-Cel samples would 
also be analysed after application of a standard ‘dilution factor correction’ to adjust for 
variability in volumes of collected secretions and dilution occurring during processing. 
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This is discussed in section 3.6.3.  All “not detectable” observations were to remain “not 
detectable” and would not be adjusted.  
2.13.5 Safety Analyses 
2.13.5.1 Grade 3 or Above AEs 
The number of grade 3 or above genital, other clinical and laboratory AEs were to be 
reported for each participant and according to treatment arm. Attributed causality would 
also be provided. The proportion of participants in each arm experiencing a grade 3 or 
above AE was to be compared using Fisher’s exact test for appropriate combinations. 
2.13.5.2 Events Leading to Discontinuation of the Gel 
The reasons for any participants discontinuing or interrupting gel use were to be 
presented. Any reasons attributable to the study gel were to be reported according to 
treatment group however no statistical testing was to be performed. 
2.13.5.3 All AEs 
Data was to be reported according to treatment arm and attributed causality. For each 
type of event, the number of events experienced as well as the number and proportion of 
participants experiencing the event were to be presented. If AEs were recorded in a 
minority of participants overall, then the proportion of participants in each arm 
experiencing an AE of any grade was to be compared using Fisher’s exact test. However, 
should AEs be recorded in the majority of participants, the number of AEs per woman 
would be more important and relevant than their presence or absence for a woman. In 
this situation, counts of AEs per participant in each study arm were to be compared using 
negative binomial regression. Analyses would be performed for all events and for events 
classed as possibly or probably treatment related i.e. the latter would exclude all events 
that occurred before administration of study gel and any events that were deemed by the 
SP, in conjunction with the CI, to be unrelated to study gel. 
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2.13.6 Sub-Studies 
2.13.6.1 Exploration of the variability of weights/volumes of vaginal secretion samples 
obtained using Weck-Cels and the relationship between sample weight/volume 
and mAb concentration 
Given that the reliability of the Weck-Cel sampling method was key to the accurate 
determination of the primary end-point and the ‘dilution factor correction’ had never 
previously been applied in the context of secretions collected after application of a gel, it 
was decided to try to quantify the degree of variability in weights/volumes of secretion 
samples obtained and explore the relationship between sample weight/volume and 
detected mAb levels. Weights of Weck-Cel samples would be analysed to estimate the 
variation between paired samples for the same woman at the same visit, between 
women, and between visits, using the method of components of variance. Weights would 
be found by subtraction of the weight of a dry Weck-Cel sponge (in the sample collection 
kit) from the weight of the sponge plus sample (in the sample collection kit) (see sections 
2.11.2.3 and 2.11.2.4). Assumptions of ANOVA would be checked and a data 
transformation used if appropriate. The relationship between weight of sample and 
Weck-Cel mAb level would be estimated for levels detected on samples taken after 
administration of active gels, using multiple regression. Data transformations were to be 
applied if required. 
2.13.6.2 Comparison of participant self-sampled to clinician sampled vaginal secretions 
It was planned that a comparison would be made between the levels of mAbs detected in 
secretions obtained using the participant self-sampling aspirator and those obtained 
using Weck-Cel and CVL sampling. Using data for the active treatment arms only, 
regression analysis would be performed to see how well the mAb levels detected by the 
Weck-Cel and CVL methods could be predicted from those obtained in the aspirates. 
2.13.6.3 Investigation of the Impact of Mabgel on Vaginal Flora 
A line listing of Nugent score, vaginal pH, and Lactobacillus species detected would be 
presented for each participant, for each sampling point. Treatment groups were to be 
compared by 2 methods. Firstly, the proportion of women in each study arm at each visit 
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who had were positive for each Lactobacillus species by PCR would be compared using 
Fisher’s Exact test.  In addition, quantitative counts for all Lactobacillus species would be 
compared across all 3 study arms using the Kruskal Wallis rank test, allowing for ties. 
2.13.6.4 Investigation of the Experience of taking Part in the Clinical Trial 
The analysis plan for this sub-study was devised separately from that for the remainder of 
the Trial and is described in Chapter 5. Analysis of the interview transcripts was to be 
performed qualitatively using the framework approach. 
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3. PHARMACOKINETIC RESULTS AND ANALYSES 
3.1 Data Sets Analysed 
After completion and verification by the study Monitor, carbon-copies of CRFs were 
forwarded to Covance Data Management for data extraction. A database was created by 
Covance using Oracle Clinical Version 4.5 software, with all ancillary data programmed, 
read and reconciled with the CRF data using SAS version 9.0.  Final data sets were 
provided as Excel spreadsheets on 8th October 2010 following database lock on 5th 
October 2010.  
3.2 Data Analysis and Reporting 
Final data sets provided by Covance were analysed and interpreted by the author with 
reference to source data for clarification where required. Statistical analyses were 
performed in conjunction with Professor Martin Bland, Professor of Health Statistics, 
Department of Health Sciences, University of York, in accordance with the Final Trial SAP 
(see section 2.13). 
Results are reported below in accordance with the CONSORT (Consolidated Standards of 
Reporting Trials) 2010 Statement [580]. An overview of the conduct of the trial from 
participant recruitment to analysis of results is depicted in Figure 3-1. 
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Figure 3-1 CONSORT Diagram Depicting the Passage of Participants Through the 
MABGEL 1 Clinical Trial 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrolment 
Screened for Eligibility (n= 49)  
Excluded after screening (n= 21) 
Not meeting inclusion criteria (n=20) 
Declined to participate (n= 1) 
 
Analysed (n= 9) 
Excluded:                       
Weck-Cel samples 8 hours 
post 1st dose (n=1)                             
–  processing error 
Placebo  (n=9) 
 
Randomised (n= 28)  
White (n=27); Black African (n=1) 
Median age 25 
 
 
Low dose mAbs (n=9) 
 
High dose mAbs (n=10) 
 
Allocation 
Completed follow up 
(n=9)  
Applied all 12 Doses (n=8)  
11 Doses Applied (missed 
dose 9) (n=1) 
 
 
 
 
 
Follow-up 
Completed follow up 
(n=9) 
Applied all 12 doses (n=8)  
11 Doses Applied (dose 3 
omitted due to SEs)(n=1) 
possible side-effects (n=1) 
       
 
 
 
Completed follow up 
(n=10) 
Applied all 12 doses (n=9)  
11 Doses Applied (missed 
dose 4) (n=1) 
 
 
 
Analysed (n= 9) 
Excluded: None 
Analysed (n= 10) 
Excluded:                   
Pharmacokinetic Samples 
24 hours post 1st dose 
(n=1)   – participant had 
already applied 2nd dose 
Analysis 
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3.3 Study Participants 
3.3.1 Accrual and Retention 
49 women provided consent for the study and underwent screening to determine 
eligibility. Of these, 28 were enrolled into the dosing phase of the study. 4 women were 
initially ineligible and were enrolled after successful re-screening, thus there were a total 
of 53 screening visits (see section 3.3.3). All 28 women attended all study visits and 
completed the study (for protocol deviations see section 3.5). The study was terminated 
early on 29th July 2010 due to the expiry of the study gels at the end of July 2010. 
3.3.2 Baseline Characteristics 
A summary of the main baseline characteristics of enrolled participants is given in Table 
3-1.  Overall, 27 women described themselves as white and one as black African.  The 
median age at enrolment was 25 years (range 19 to 43).  Participants in the Low dose 
Mabgel arm had an older median age than the other two arms, and perhaps reflecting 
this, this arm had a larger proportion of women who had had children, with 2 women 
having had more than 2 children.  However, the majority of participants in all 3 study 
arms were nulliparous.  All current medical problems were mild in nature and considered 
insignificant by the SP and CI. 
Although required to refrain from sexual intercourse during the dosing period, in view of 
the lack of safety data on exposure to the mAbs during pregnancy, all women had to be 
using a reliable form of contraception (as defined in the study protocol:- see eligibility 
section 2.5.3) at time of screening and agree to do so for the duration of the study. 13 
women were using condoms consistently, 6 were using etonogestrel implants, 4 were 
taking a COCP, 2 had a levonorgestrel- releasing IUS in- situ, 1 had a copper IUCD, 1 was 
taking the desogestrel-containing POP and 1 was using DMPA injections. One of the 
participants using condoms (MAB014) was in addition taking a progestagen-only pill 
(Etynodiol, Femulen®, Pharmacia) that, if used alone, fell outside the contraceptive 
requirements of the protocol. Distribution of non-hormone (IUCD and/or condom) and 
hormone (IUS, DMPA, desogestrel POP, or COCP) users was fairly balanced overall 
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between study arms, however there were a preponderance of COCP users (3 of a total of 
4) and fewer users of progestagen-based methods (2 vs 4 in each of the Mabgel arms) 
randomised to placebo compared to Mabgel. In view of this, fewer women in this arm 
had been amenorrhoeic > 3/12 before enrolment. 
Table 3-1 Summary of Baseline Characteristics of Enrolled Participants 
 
Study Arm 
Demographic High Dose (n=10) Low Dose (n=9) Placebo (n=9) 
Ethnicity 
White British 
White Other 
Black African 
 
9 
0 
1 
 
8 
1 
0 
 
9 
0 
0 
Age (years) 
Number in Range 
 18-24  
25-34  
35-44  
Median  Age 
 
 
4 (40 %) 
6 (60%) 
0 (0%) 
25 
 
 
3 (33%) 
3 (33%) 
3 (33%) 
32 
 
 
4 (44 %) 
1 (11%) 
4 (44 %) 
25 
Height (metres) 
Mean 
 
1.68 
 
1.68 
 
1.68 
Weight (kg) 
Mean 
 
73.15 
 
75.67 
 
62.28 
Contraception 
Condoms 
IUCD 
COCP 
Cerazette (POP) 
IUS 
Implant 
DMPA 
 
4 (40%) 
1 (10%) 
1 (10%) 
1 (10%) 
1 (10%) 
2 (20%) 
0 (0%) 
 
5 (56%) 
0 (0%) 
0 (0%) 
0 (0%) 
1 (11%) 
3 (33%) 
0 (0%) 
 
4 (44%) 
0 (0%) 
3 (33%) 
0 (0%) 
0 (0%) 
1 (11%) 
1 (11%) 
Number of 
Pregnancies (Term) 
0 
1 
2 
>2 
 
 
7 (70%) 
2 (20%) 
1 (10%) 
0 (0%) 
 
 
5 (56%) 
0 (0%) 
2 (22%) 
2 (22%) 
 
 
6 (67%) 
1 (11%) 
2 (22%) 
0 (0%) 
Day of Cycle at 1st Gel 
Dose 
Number in Range 
7-10 
11-13 
Amenorrhoea > 3/12 
Median Day 
 
 
 
2 (20 %) 
4 (40%) 
4 (40%) 
11 
 
 
 
4 (44%) 
1(11%) 
4 (44%) 
9  
 
 
 
5 (56%) 
2 (20%) 
2 (20%) 
12 
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3.3.3 Screen Failures 
Twenty four women were found to be ineligible for the study following initial assessment. 
Of these, 4 were subsequently re-screened and enrolled into the dosing phase; 3 after 
successful treatment of infections detected on their initial screening (1x CT, 1x BV, 1x 
urinary tract infection) and 1 following renewal of her contraceptive implant.  An 
additional 3 women were also found to have infections (2x BV, 1x CT) and were referred 
for treatment but did not wish to be re-screened. 
 Eleven women were judged by the SP or CI to have a significant current general medical 
illness and/or condition that had the potential to interfere with the evaluation of study 
objectives (i.e. current respiratory infections, recent diagnosis of genital HSV, severe 
depression with evidence of recent self-harm,  severe  recurrent headaches,  recent 
transverse myelitis, significant vaginal prolapse, severe asthma requiring recent 
hospitalisation, diabetes, uncontrolled hypertension, latex allergy, severe allergic reaction 
of unknown aetiology). One woman was found to have a significantly elevated alanine 
transferase (ALT) level on LFTs at screening requiring investigation by her GP. Two women 
were deemed ineligible due to not using a reliable method of contraception. Another 
participant was judged to be unlikely to be able to comply with study procedures required 
in the protocol due to needle-phobia. Two women could not be enrolled into the dosing 
phase due to study investigators being unable to obtain a response from their GP within 
the required time-frame. One subject declined to be enrolled following successful 
screening having recently started a new job. 
3.4 Blinding and Randomisation 
Twenty eight women received the study gel; 9 received placebo, 9 low dose mAbs and 10 
high dose mAbs.  There was no indication to access the unblinding website during the 
study. All clinical investigators, including the SP, research nurses and the CI remained 
blinded until after database lock. Thus, double blinding was maintained for the duration 
of the study. 
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3.5 Compliance with Protocol 
3.5.1 Gel usage and sexual abstinence 
As far as could be ascertained from participant report, diary cards, and returned syringes, 
16 women completed dosing in accordance with the study protocol. With the other 12 
women there were either dosing-related protocol deviations or inconsistencies detected.  
In the case of 2 women there was an apparent discrepancy between the different 
measures of compliance. 1 woman (MAB004) returned a blank diary card at the end of 
dosing but verbally reported that she had applied all 11 doses in the evening and 
returned 11 empty syringes. Another woman (MAB013) stated both verbally and on her 
diary card that she had correctly used all doses of gel, however she only returned 10 
empty syringes having discarded one by mistake.   
Three women (participants MAB014, 018 and 023) returned 1 unused syringe with 10 
empty ones. In all 3 cases the missed doses were reported to have occurred in the middle 
of the dosing period (doses 3, 4 and 9 respectively), thus minimising any impact on 
pharmacokinetic and safety analyses. In addition, by chance, each of these women had 
been randomised to a different arm of the study, further reducing any influence on study 
outcomes. In the case of MAB018 and 023 the doses were missed due to the participant 
simply forgetting to use the gel. With MAB014, the participant omitted the gel due to 
feeling unwell. This will be discussed further in section 4.1.1.4.  
Participants were instructed to apply the gel at night at bedtime as this was thought by 
the Study Investigators to be the time that would be most convenient and impact least on 
their activities of daily living. However, it became clear as the study progressed that some 
participants were not following this instruction. This appears to be for two reasons. 
Firstly, we had inadvertently caused confusion as bed-time was not the same as night-
time for some of our participants. We recruited a number of healthcare workers to the 
study who worked variable shifts, thus bed-time for them could be in the morning or 
early afternoon following or preceding a night-shift. In addition, a couple of participants 
reported that they preferred to use the gel in the morning as they actually found this to 
be more convenient. Following discussion with the DSMC and study Monitor, it was 
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concluded that since only the first and 12th doses were considered to be time critical with 
regards to pharmacokinetic sampling and analysis, provided that participants had applied 
each of the other successive doses within a calendar day of the previous one they would 
be unlikely to have reduced the integrity of the pharmacokinetic or safety data derived 
from the study. 
No women reported having had oral or vaginal sexual intercourse during the specified 
abstinence period. This requirement was explored further in the qualitative interview 
study (see chapter 5). 
3.5.2 Deviations Relating to Sample Collection or Analysis 
3.5.2.1 Samples not obtained 
MAB015 attended for visit 4 (24 hours post 1st dose) having mistakenly applied the 2nd 
dose of study gel that morning. Consequently, it was decided not to perform any 
pharmacokinetic sampling at that time since results would have been difficult to 
interpret. 
3.5.2.2 Samples obtained outside of sampling windows 
MAB019 attended for her 12 hours post 12th dose evaluation (Visit 6) at the scheduled 
time of 10.30. However, she had mistakenly administered the 12th dose of gel at 21.20 
the night before rather than 22.30 as planned. Weck-Cel samples were obtained at 10.36 
and venepuncture for serum performed at 11.15 (16 minutes and 55 minutes respectively 
outside the allowed sampling window of an hour either side of the 12 hour time-point). 
The scheduled time for this participant’s Visit 7 the following day was brought forward by 
1 hour to allow 36 hour post dose samples to be taken at the correct time in relation to 
the timing of administering the 12th dose. 
2 other participants attended late for their 36 hours post 12th dose evaluations (Visit 7). 
As a result, the CVL sample for MAB007 was taken 4 minutes outside the allotted time 
window and the self-taken aspirate, Weck-Cel, and CVL samples for MAB023 were taken 
22, 28 and 30 minutes outside respectively. 
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In accordance with the SAP (see section 2.13.3), results are presented according to the 
intended time-point of each visit.  
3.5.2.3 Samples not Analysed 
Weck-Cel samples from MAB006 visit 3 were collected, stored and transported, but were 
not analysed by Polymun as they arrived unlabelled and could not be confidently 
identified. 
3.6 Pharmacokinetic Sampling and ELISA Data 
3.6.1  Samples Obtained 
Samples were obtained and processed in accordance with the study protocol and relevant 
SOPS except where outlined in section 3.5.2 above. 
3.6.1.1 Weck-Cel Vaginal Secretion Samples 
2 Weck-Cel samples were obtained per participant per sampling visit, except for MAB015 
visit 4 where no sampling was performed.  As described in sections 2.11.2.3 and 2.11.2.4, 
entire Weck-Cel sampling kits were weighed (in g) on the same fine balance before and 
after sampling; the difference in the weights (the difference between a ‘dry’ pre- and a 
‘wet’ post-sampling Weck-Cel sponge) was calculated to be the weight of secretion 
obtained. Vaginal fluid has been shown to have a composition which is around 99% water 
[53], hence with the density of water being approximately 1g/ml, 1ml of collected 
secretion has been assumed to weigh 1g. Original values in g (corresponding to ml) were 
converted to μl by multiplying by 1000. 
3.6.1.2 CVL Samples 
As described in section 2.7.2.4, CVL samples were obtained through irrigating the vaginal 
walls with 5ml of saline, which was then re-aspirated, together with any cervico-vaginal 
secretions that had pooled in the posterior fornix. Recovered volumes were recorded to 
the nearest 0.5ml. 
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3.6.1.3 Participant-Self taken Vaginal Aspirate Samples 
Participants were asked to collect samples of their own vaginal secretions using a 
volumetric aspirator as outlined in section 2.7.2.5. Unfortunately, due to difficulties 
encountered with the self-taken aspirator (discussed in section 3.8.6.5), measurable 
samples were only obtained at 36 (43%) of the 84 possible time-points.   
3.6.1.4 Serum Samples 
1 x 7.5ml of blood was obtained (as described in section 2.7.2.7) per participant at each 
time-point required in the protocol. Between 2 and 7, 500μl aliquots of serum were 
extracted from each sample (see section 2.11.2.7). 2 x 500 μl aliquots were sufficient for 
performance of the ELISAs, hence a more than adequate volume of serum was obtained 
at each time-point for each participant. 
3.6.2 mAb Concentrations Detected on ELISAs 
As outlined in section 2.11.3, concentrations of C2F5, C4E10 and C2G12 were analysed in 
Weck-Cel, CVL, vaginal aspirate and serum samples by Dr Brigitta Vcelar and technicians 
at Polymun Scientific, Vienna, Austria. All investigators involved in evaluating mAb ELISA 
results were blinded to participant treatment allocation. The lowest quantifiable standard 
concentration was 3.126ng/ml. To reduce non-specific background signals, all samples 
were diluted at least 1:20, resulting in a lower limit of quantification of 60ng/ml 
(0.06μg/ml). For reasons that Polymun were unable to determine, the ELISA for C2F5 
resulted in background signals below or close to the quantification limit whereas the 
assays for C4E10 and C2G12 produced background signals above this limit. 
As discussed in section 3.5.2, no samples were available for analysis for participant 
MAB006 visit 3 or MAB015 visit 4.  For participant MAB010 no value was obtained for 
C4E10 on Weck-Cel sample analysis at visit 4 due to failure of the ELISA to produce a valid 
test result.  ELISA data was only available for 27 (32%) of the 84 possible aspirate samples; 
for the others either no sample had been obtained or it was too small or thick to be 
pipetted out of the storage tube for analysis at Polymun. 
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3.6.3 Dilution Factor Correction For mAb Concentrations Detected in 
Weck-Cel Samples 
The mAb concentrations reported by Polymun did not take account of the variable  
‘dilution factor’ which exists as a result of variability in the volumes of vaginal secretions 
collected by Weck Cels and the addition of buffer during processing of these samples. An 
adjustment is commonly applied when using Weck-Cels to collect mucosal secretions for 
measurement of antibodies or cytokines occurring naturally or induced through 
vaccination [525,526,527,581]. It has also been applied, by some researchers, to levels of 
mAbs detected in vaginal and rectal secretions in macaques following i.v. administration, 
prior to SHIV challenge [K Klein and R Shattock, personal communication]. Thus, in order 
to enable more accurate comparison of our data with that from other studies, it was 
decided to apply a ‘dilution factor correction’ to the mAb concentrations detected by 
ELISA. 
The dilution factor correction  =  (Processing buffer volume + Secretion volume (in μl))   
  Secretion volume (in μl)   
 
As detailed in sections 2.11.2.3, 2.11.2.4 and 3.6.1.1, a total of 600 μl of buffer was used 
to process each sample and sample weights were calculated through weighing the entire 
sampling kits, containing the Weck-Cel sponge, processing tubes and filter and initial 300 
μl of buffer, before and after sampling. 1 μl of secretion was assumed to weigh 1mg.  
Each adjusted mAb concentration (per participant, per time-point) was derived by 
multiplying the reported ELISA value by an individually calculated dilution factor 
correction. As the eluants of the two Weck-Cel samples taken per participant per time-
point were pooled after processing, before being divided into aliquots for analysis by 
ELISA, each calculated dilution factor correction used the mean of the two Weck-Cel 
sample volumes.  
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3.7 Statistical Analysis of Pharmacokinetic Data  
All statistical analyses were performed in conjunction with Professor Martin Bland using 
STATA version SE 10.1, Stata Corp., College Station, Texas, released 1st October 2009. All 
analyses were conducted on an intention-to treat basis and in accordance with the final, 
revised SAP, outlined in section 2.13.1, unless specified otherwise.  
3.7.1 Handling of Missing Data 
As discussed in sections 3.5.2 and 3.6.2 above, Weck-Cel sample data was missing from 
MAB006 visit 3 (8 hours post 1st dose), Wecks, CVL and self-sampled aspirate data was 
missing from MAB015 visit 4 (24 hrs post 1st dose) and the C4E10 result from the Wecks 
samples was missing from MAB010 visit 4. There was no reason to consider that these 
data were not missing at random therefore analyses were performed without them using 
existing data. 
3.7.2 Primary and Secondary Pharmacokinetic End-Point Analyses  
The primary pharmacokinetic end-points for this study (as given in section 2.7.1) were the 
levels of mAbs detected in samples of vaginal secretions collected using Weck-Cels at all 
time-points post-gel use (1,8 and 24 hours post 1st dose of study gel and 12 and 36 hours 
post 12th dose of study gel), with a baseline (pre-1st dose) sample obtained for reference. 
mAb levels detected in CVL, self-sampled aspirate and serum samples, at fewer time-
points, were secondary end-points. 
3.7.2.1 Summary Statistics 
As discussed in section 2.13.4.1, for all sample types, the full data -sets of detected mAb 
concentrations display highly skewed distributions, with the lowest observations reported 
as < 0.06. It was thus considered more appropriate to use the median as the average 
measure and the range (minimum and maximum values) to describe the spread of the 
data than the mean and standard deviation respectively.  
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The ELISA-derived mAb concentrations were reported by Polymun to a varying number of 
decimal places and significant figures. For consistency, median, minimum and maximum 
mAb concentrations are provided, in Table 3-2 to Table 3-5, to the following degree of 
accuracy: values > 10 are given to zero decimal places, values > 1 but < 10 to one decimal 
place and numbers < 1 to one significant figure. Values recorded as < 0.06 are reported as 
ND = not detectable.  
3.7.2.2 Statistical Tests Employed 
Since the full-data set could not be assumed to be normally distributed, a non-parametric 
approach was followed. The Kruskal-Wallis rank test was performed initially, for each 
mAb at each sampling point, to determine whether there was evidence of a difference 
between the concentrations   detected across the 3 study arms generally. If the result of 
the Kruskal-Wallis test was found to be statistically significant, the Mann Whitney U test 
was performed to determine whether the mAb levels in the high dose Mabgel arm were 
significantly higher than those in the low dose Mabgel arm. As the Mann Whitney U test 
was conditional on the result of the Kruskal Wallis test, no adjustments were needed to 
take account of multiple testing. Being based on ranked observations, neither test is 
affected by ND values. Allowances were made for ties [577]. 
P values (given to 1 significant figure), obtained using STATA, are displayed in Table 3-2 to 
Table 3-5.  Any P value < 0.05 would be considered to be significant at the 95 % 
confidence level. 
3.7.2.3 Primary End-Point Analyses of Data Obtained from Weck-Cel Samples 
Analyses were performed both for the unadjusted concentrations as reported by Polymun 
and for concentrations that had been adjusted to correct for the variable dilutional 
effects of vaginal secretions and processing buffer. This ‘dilution factor correction’ is 
explained in section 3.6.3.   
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Table 3-2 Median, Minimum and Maximum Values for Concentrations of Each of C2F5, 
C4E10, C2G12 Detected in Weck-Cel Samples By Study Arm (Unadjusted Values 
  
Table 3-2a Median, Minimum and Maximum C2F5 Levels Detected in Weck-Cel Samples 
C2F5 (μg/ml) 
Visit 
Visit 
Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 Groups Low  vs High 
2 (pre) ND ND ND ND ND ND ND ND ND ---- ---- 
2 (post) ND ND 0.7 542 156 1207 1505 122 2709 0.0001 0.01 
3 ND ND ND 126 30 424 220 1.5 614 0.0002 0.2 
4 ND ND ND 9.5 3.8 33 15.4 3.2 61 0.0001 0.6 
6 ND ND ND 34 8.8 337 154 2.2 1464 0.0001 0.4 
7 ND ND ND 0.7 ND 23 0.3 ND 10 0.007 0.7 
Number 9 9 10   
 
Table 3-2b Median, Minimum and Maximum C4E10 Levels Detected in Weck-Cel 
Samples 
C4E10 (μg/ml) 
 
Visit 
Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 Groups Low vs High 
2 (pre) 0.1 ND 0.4 ND ND 0.2 0.06 ND 0.09 ---- ---- 
2 (post) ND ND 0.3 239 103 767 987 326 2116 0.0001 0.001 
3 ND ND 0.1 56 26 357 148 11.1 600 0.0002 0.3 
4 ND ND 0.2 6.3 ND 25 11 1.87 91 0.0009 0.4 
6 ND ND 0.09 33 4.0 400 96 1.5 281 0.0001 0.6 
7 ND ND 0.5 0.4 ND 4.7 0.5 ND 11 0.01 0.9 
Number 9 9 10   
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Table 3-2c Median, Minimum and Maximum C2G12 Levels Detected in Weck-Cel 
Samples 
C2G12 (μg/ml) 
Visit 
Visit 
Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 Groups Low vs High 
2 (pre) ND ND 0.6 ND ND 0.14 ND ND 0.3 ---- ---- 
2 (post) ND ND 0.4 619 123 2596 1620 138 4328 0.0001 0.07 
3 ND ND 0.2 5.2 1.7 135 23 0.1 690 0.0002 0.07 
4 ND ND 0.5 0.7 0.2 2.2 0.6 0.1 29 0.004 0.5 
6 ND ND 0.3 1.3 0.2 45 4.5 0.5 360 0.0002 0.6 
7 ND ND 0.3 0.1 ND 2.5 ND ND 8.1 0.6 ---- 
Number 9 9 10   
 
Median concentrations of each mAb over time have been plotted for both of the active 
gel arms in Figure 3-2 and Figure 3-3. 
 
Note: The time quoted is the time since the previous dose of study gel was given.  Graphs 
were created by combining data from sampling at 1, 8 and 24 hours post 1st dose and 12 
and 36 hours post 12th dose. Obviously it is possible that there could be residual mAbs 
remaining from previous doses in addition to dose 12 detected at the latter 2 sampling 
time points, however, it is clear from the concentrations detected that the mAbs were 
virtually eliminated from the lumen by 36 hours post application (which would coincide 
with the 12 hr sampling point). 
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Figure 3-2 Median Concentrations (Unadjusted for Dilution Factors) of C2F5, C4E10, 
C2G12 Detected in Weck-Cel Samples Over Time in Participants Randomised to High 
Dose Mabgel Arm (20μg/ml of each mAb) 
 
Figure 3-3 Median Concentrations of C2F5, C4E10, C2G12 (Unadjusted for Dilution 
Factors) Detected in Weck-Cel Samples Over Time in Participants Randomised to Low 
Dose Mabgel Arm (10μg/ml of each mAb) 
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Table 3-3 Median, Minimum and Maximum Values for Concentrations of Each of C2F5, 
C4E10, C2G12 Detected in Weck-Cel Samples By Study Arm (After Adjustment for 
Dilution Factors) 
 
Table 3-3a Median, Minimum and Maximum C2F5 Levels Detected in Weck-Cel Samples 
(post dilution factor adjustment) 
C2F5 (μg/ml) 
Visit Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
groups  
Low vs. 
High  
2 (pre) ND ND ND ND ND ND ND ND ND ---- ---- 
2 (post) ND ND 3.8 2715 941 6073 7737 903 14377 0.0001 0.009 
3 ND ND ND 910 342 3715 3161 30 6102 0.0001 0.06 
4 ND ND ND 93 36 530 196 31 729 0.0001 0.4 
6 ND ND ND 451 105 2146 1376 41 25334 0.0001 0.5 
7 ND ND ND 8.1 ND 161 4.8 ND 118 0.006 0.6 
number 9 9 10   
 
Table 3-3b Median, Minimum and Maximum C4E10 Levels Detected in Weck-Cel 
Samples (post dilution factor adjustment) 
C4E10 (μg/ml) 
Visit Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
groups 
Low 
vs. 
High 
2 (pre) 1.1 ND 5.9 ND ND 2.0 0.2 ND 1.6 ---- ---- 
2 (post) ND ND 2.7 1175 583 3849 5277 1442 13580 0.0001 0.002 
3 ND ND 1.6 547 302 3128 2505 176 6612 0.0001 0.1 
4 ND ND 1.6 64 ND 297 171 18.2 1088 0.0006 0.2 
6 ND ND 1.7 427 47 2548 870 28 2198 0.0001 0.7 
7 ND ND 4.8 5.8 ND 159 4.7 ND 119 0.008 0.8 
number 9 9 10   
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Table 3-3c Median, Minimum and Maximum C2G12 Levels Detected in Weck-Cel 
Samples (post dilution factor adjustment) 
C2G12 (μg/ml) 
Visit Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
groups  
 
Low 
vs. 
High  
2 (pre) ND ND 8.6 ND ND 6.8 ND ND 6.7 ---- ---- 
2 (post) ND ND 3.3 3314 742 12622 7479 1021 27882 0.0001 0.06 
3 ND ND 3.0 63 19 1183 538 2.4 6953 0.0001 0.06 
4 ND ND 4.3 5.6 1.1 25 12 1.5 182 0.002 0.2 
6 ND ND 5.2 17 2.3 283 52 5.4 1982 0.0002 0.8 
7 ND ND 27.7 1.3 ND 17 ND ND 160 0.7 ---- 
number 9 9 10   
 
Figure 3-4 Median Concentrations (Adjusted for Dilution Factors) of C2F5, C4E10, C2G12 
Detected in Weck-Cel Samples Over Time in Participants Randomised to High Dose 
Mabgel Arm (20μg/ml of each mAb) 
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Figure 3-5 Median Concentrations (Adjusted for Dilution Factors) of C2F5, C4E10, C2G12 
Detected in Weck-Cel Samples Over Time in Participants Randomised to Low Dose 
Mabgel Arm (20μg/ml of each mAb) 
 
The overall pattern in MAb levels was the same for both the unadjusted concentrations 
and those adjusted for dilution factors. Concentrations of all 3 mAbs were maximal at 1 
hour post dose and still detectable at low (nanogram) level at 36 hours post 12th dose in 
some participants.  Although variable, on average, adjusting for dilution factors increased 
mAb levels by 5 times at visit 2 (1 hour post dose) and 12 times at other visits. For each 
antibody, there was strong evidence of a difference in levels  between the three groups at 
visits 2 (1 hour post dose), 3, 4, and 6.  For C2F5 and C4E10 there was strong evidence for 
a difference at visit 7, but not for C2G12.  For C2F5 and C4E10 there was statistical 
evidence for a difference in the levels found between  the high and low dose  Mabgel 
arms at visit 2, 1 hour post dose, but not for C2G12.  However, although the median 
antibody concentration was greater for the high dose arm than the low dose arm at most 
other visits, except for visit 7, these differences were not statistically significant. 
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3.7.2.4 Secondary End-Point Analyses of Data Obtained from CVL and Self-aspirate 
Samples 
Analyses were performed for the mAb concentrations, as reported by Polymun, obtained 
from CVL samples. In view of the paucity of ELISA data available for samples obtained 
using the vaginal aspirator it was considered futile to perform any statistical analysis of 
the aspirate data or any formal comparison of the mAb levels obtained using the different 
sampling methods. 
As detailed in section 3.7.2.2 above, P values (to 1 significant figure) were derived using 
the Kruskal Wallis rank test, allowing for ties, to compare all 3 treatment groups for each 
visit and, if this result was significant, using the Mann Whitney U test to compare low and 
high dose Mabgel arms  for each visit. 
Table 3-4 Median, Minimum and Maximum Values for Concentration of Each of C2F5, 
C4E10, C2G12 Detected in CVL Samples By Study Arm 
Table 3-4a Median, Minimum and Maximum C2F5 Levels Detected in CVL Samples 
C2F5 (μg/ml) 
Visit Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
Groups 
Low vs. 
High 
2 (pre) ND ND ND ND ND ND ND ND ND ---- ---- 
4 ND ND ND 2.3 0.1 3.9 1.03 0.07 3.3 0.0001 0.5 
7 ND ND ND 0.1 ND 1.6 0.09 ND 0.7 0.02 0.7 
Number 9 9 10   
 
Table 3-4b Median, Minimum and Maximum C4E10 Levels Detected in CVL Samples 
C4E10 (μg/ml) 
Visit 
 
Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
Groups 
Low 
vs. 
High 
2 (pre) ND ND 0.2 ND ND 0.3 ND ND 0.1 ---- ---- 
4 ND ND 0.08 4.5 0.2 14 2.9 0.3 13 0.0001 1.0 
7 ND ND 0.07 0.4 ND 4.1 0.3 ND 2.3 0.004 0.6 
Number 9 9 10   
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Table 3-4c Median, Minimum and Maximum C2G12 Levels Detected in CVL Samples 
C2G12 (μg/ml)  
Visit 
 
Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
Groups 
Low 
vs. 
High 
2 (pre) ND ND 0.21 ND ND 0.2 ND ND 0.09 ---- ---- 
4 ND ND 0.09 0.3 ND 1.5 0.4 ND 3.6 0.009 0.6 
7 ND ND 0.1 0.1 ND 1.2 ND ND 0.7 0.2 ---- 
Number 9 9 10  
There was statistical evidence of a difference between the three study arms for all 3 
mAbs, at visit 4, but only for C2F5 and C4E10 at visit 7.  There was no evidence for a 
difference between high and low Mabgel doses at visits 4 or 7. 
3.7.2.5 Secondary End-Point Analyses of Data Obtained from Serum Samples 
Overall, looking at the minimum, median and maximum values (Table 3-5), there were no 
apparent changes from baseline levels for any of the mAbs, although this was not tested 
statistically. There were no statistically significant differences in the levels of any of the 
mAbs between the 3 study arms at any time-point. 
Table 3-5 Median, Minimum and Maximum Values for Concentration of Each of C2F5, 
C4E10, C2G12 Detected in CVL Samples By Study Arm 
Table 3-5a Median, Minimum and Maximum C2F5 Levels Detected in Serum Samples 
C2F5 (μg/ml) 
Visit Placebo Low Dose High Dose P values 
 
ss 
Med Min Max Med Min Max Med Min Max 3 
Group
s 
Low 
vs. 
High 
2 (pre) ND ND 0.09 ND ND 0.2 ND ND 0.1 ---- ---- 
3 ND ND 0.09 ND ND 0.1 ND ND 0.09 0.8 ---- 
6 ND ND 0.08 ND ND 0.2 ND ND 0.08 0.2 ---- 
Number 9 9 10   
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Table 3-5b Median, Minimum and Maximum C4E10 Levels Detected in Serum Samples 
C4E10 (μg/ml) 
Visit Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
Groups 
Low 
vs. 
High 
2 (pre) 0.4 0.3 2.5 0.5 0.2 1.6 0.4 0.2 1.3 ---- --- 
3 0.4 0.2 2.0 0.5 0.2 1.3 0.5 0.1 0.9 0.9 --- 
6 0.3 0.3 1.9 0.5 0.2 1.2 0.5 0.3 1.3 0.8 --- 
Number 9 9 10   
 
Table 3-5c Median, Minimum and Maximum C2G12 Levels Detected in Serum Samples 
C2G12 (μg/ml) 
Visit Placebo Low Dose High Dose P values 
Med Min Max Med Min Max Med Min Max 3 
Groups 
Low 
vs. 
High 
2 (pre) 0.5 0.3 1.1 0.8 0.4 1.3 0.8 0.5 1.9 ---- --- 
3 0.5 0.4 0.9 0.9 0.5 1.1 0.8 0.4 1.7 0.2 --- 
6 0.6 0.3 1.2 0.8 0.4 1.7 0.8 0.4 2.0 0.3 --- 
Number 9 9 10   
 
3.7.3 Analysis of mAb half-lives 
In addition to the primary and secondary end-point analyses, several additional analyses 
were identified in the final, revised SAP (see section 2.13.1). The first of these was to 
provide estimates of the residence half-life (t ½) of each mAb i.e. the time needed for half 
of the administered antibody present to be eliminated from the vagina. 
This analysis was conducted in conjunction with Professor Bland, using data from Weck-
Cel samples obtained at 1, 8 and 24 hours post 1st dose of study gel in the 19 participants 
who received either dose of the Mabgel. Data from all participants receiving either of the 
two doses were combined for this analysis.  Estimates were derived both from the 
unadjusted concentrations as reported by Polymun and from concentrations that were 
adjusted to account for the ‘dilution factor’. 
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3.7.3.1 C2F5 (unadjusted for dilution factor) and Methodology 
A meaningful estimate of the t ½ of each mAb can only be obtained if its decay curve 
matches an exponential decay, implying that its elimination follows 1st order kinetics 
[579]. The decay curve for C2F5 is shown in Figure 3-6. 
Figure 3-6  C2F5 Concentration Since Application of 1st Dose of Mabgel 
   
Each line represents a different participant.  If decay is exponential, i.e. if the rate of 
decay is proportional to the amount present, the log of concentration should have a 
straight line relationship with time.  This looks very plausible: 
Figure 3-7  Loge of C2F5 Concentration Since Application of 1
st Dose of Mabgel 
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An analysis of covariance model can be fitted to the log transformed data with time as a 
continuous predictor and participant as a categorical factor.  Evidence of deviation from a 
simple straight line for each participant can be assessed by adding an hours squared term 
to the model, to fit a curve [577].  In this case, the added quadratic term has P = 0.02, so 
there is evidence that the linear fit is inadequate.  Inspection of the graph suggests that 
that there are two outliers, Participants MAB015 and MAB028.   MAB015 has the lowest 
C2F5 level at 8 hours, MAB028 has the lowest at 24 hours. If data from these 2 
participants is excluded, the quadratic term has P = 0.1, so there is evidence that the 
linear fit is adequate in the reduced data set. 
Evidence that the same slope does not fit all participants can be sought by including an 
interaction between participant and slope.  This gives P = 0.1 for the full data set and P = 
0.2 without MAB015 and MAB028.  We have little evidence therefore that the slope is not 
uniform.   
The half-life (t1/2) is calculated as follows:   
The equation of the decay curve is  
 btay )log(  
where y is the antibody concentration and t is the time, or 
 
btaeey   
If y2 is half y, so that the time from y to y2 is t, then 
)(
2
2/1ttbaeey
  
Dividing one equation by the other gives 
  2/12/1 )(
2
2
btttbbt
ee
y
y
   
Hence 2/1)2log( bt , bt /)2log(2/1         [577].
   
 The 95% CI is found by putting 95% confidence limits for b into this formula. 
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For C2F5, using the full data, the estimated slope of the line on the log scale is   −b = 
−0.1882865, 95% CI for b = 0.1669421 to 0.209631.  Hence the t ½  is estimated by log(2)/ 
0.1882865 = 3.681343  = 3.7 hours, with 95% CI log(2)/0.209631 = 3.3065109 = 3.3 hours 
to log(2)/0.1669421 = 4.1520215 = 4.2 hours.  These estimates appear quite plausible 
from the graph.  If MAB015 and MAB028 are excluded, the estimated slope of the line on 
the log scale is −b = −0.1840464, 95% CI for b = 0.1651004 to 0.2029923.  Hence the t ½ is 
estimated by log(2)/0.1840464 = 3.7661545 = 3.8 hours, with 95% CI log(2)/0.2029923 = 
3.4146477 = 3.4 hours to log(2)/ 0.1651004 = 4.1983374 = 4.2 hours.  There is little effect 
on the estimate and the full data estimate of 3.7 hours (95% CI 3.3 to 4.2 hours) can be 
taken as a reasonably robust estimate. 
3.7.3.2 C4E10 (unadjusted for dilution factor) 
Repeating the above procedure for C4E10 yields the following results: 
The decay curve for C4E10 is shown in Figure 3-8 and the graph of loge concentration of 
C4E10 over time in Figure 3-9. 
Figure 3-8 Concentration of C4E10 Since Application of 1st Dose of Mabgel 
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Figure 3-9 Loge of C4E10 Concentration Since Application of 1st Dose of Mabgel 
   
Evidence of deviation from a simple straight line for each participant: P = 0.2, so there is 
no evidence that the linear fit is inadequate.   
Evidence that the same slope does not fit all participants: P = 0.08.  There is a little 
evidence that the slope is not uniform, but it is not significant and it was felt reasonable 
for it to be ignored. 
Estimated slope of the line on the log scale is −b = −0.1891694, 95% CI for b = 0.1622713 
to 0.2160676.  Hence the t ½  is estimated by log(2)/0.1891694 = 3.6641612 =3.7 hours, 
with 95% CI log(2)/ 0.2160676 = 3.2080107 = 3.2 hours to log(2)/ 0.1622713 = 4.2715328 
= 4.3 hours.  These estimates appear quite plausible from the graph.  Thus the estimated  
t ½ of C4E10 = 3.7 hours (95% CI 3.2 to 4.3) which is essentially the same as that for the 
other MPER mAb C2F5. 
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3.7.3.3 C2G12 (unadjusted for dilution factor) 
The same procedure was also repeated for C2G12. 
Figure 3-10 Concentration of C2G12 Since Application of 1st Dose of Mabgel 
   
Figure 3-11 Loge of C2G12 Concentration Since Application of 1st Dose of Mabgel 
    
Unlike with the other 2 mAbs, there is good evidence that the decay curve of CG212 is not 
a simple exponential decay. The linear fit of the relationship between loge of 
concentration and time is inadequate as addition of an hours squared term gives P 
<0.001. This is clearly shown in the graph.  For most participants the log lines clearly get 
less steep from left to right.  The t ½  has therefore been fitted to the 1 and 8 hour data 
only.  Hence it is the early t ½.   
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Evidence that the same slope does not fit all participants: P = 0.9.  There is little evidence 
that the slope is not uniform.  However, using the 1 and 8 hour values only there are too 
few data points for this to be reliable. 
For the early t ½ , estimated slope of the line on the log scale is −b = −0.5949343, 95% CI 
for b = 0.486288 to 0.7035806.  Hence the t ½  is estimated by log(2)/0.5949343 = 
1.1650819 =1.2 hours, with 95% CI log(2)/0.7035806 = 0.98517097 = 1.0 hours to 
log(2)/0.486288 = 1.4253841 = 1.4 hours.  The estimated early t ½  of C2G12  = 1.2 hours 
(95% CI 1.0 to 1.4). 
3.7.3.4 C2F5 adjusted for dilution factor 
Analyses were repeated on the mAb values adjusted for the dilution factor 
Figure 3-12 Concentration of C2F5 (Adjusted for Dilution Factor) Since Application of 1st 
Dose of Mabgel 
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Figure 3-13 Loge of C2F5 Concentration (Adjusted for Dilution Factor)  Since Application 
of 1st Dose of Mabgel 
     
The linear model appears quite plausible and checking with a time squared term we get  
P = 0.9.  However, there is evidence that there is an interaction between participant and 
time, P = 0.002, i.e. the same slope does not fit all participants. Unlike with the 
unadjusted levels, taking out MAB015 and MAB028 does not remove this, P = 0.008. 
There is no easy way of dealing with this interaction, so the final model was fitted without 
it and for all participants, leaving the interaction to be included in the error.  Hence the CI 
for the mean t ½  will be wider because of it, and it should be borne in mind that the t ½  
will vary between women. 
The estimated slope of the line on the log scale is −b = −0.1554724, 95% CI for b = 
0.1384918 to 0.172453.  Hence the t ½ is estimated by log(2)/ 0.1554724 = 4.4583295 = 
4.6 hours, with 95% CI log(2)/0.172453 = 4.0193396 = 4.0 hours to log(2)/0.1384918 = 
5.0049691 = 5.0 hours.  We have estimated t ½ = 4.6 hours (95% CI 4.0 to 5.0).  This is 
around an hour longer than the 3.7 hours (95% CI 3.3 to 4.2 hours) estimated for the 
unadjusted C2F5 concentrations. 
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3.7.3.5 C4E10 adjusted for dilution factor 
Figure 3-14 Concentration of C4E10 (Adjusted for Dilution Factor) Since Application of 
1st Dose of Mabgel 
  
 
Figure 3-15 Loge of C4E10 Concentration (Adjusted for Dilution Factor)  Since Application 
of 1st Dose of Mabgel 
  
The linear model appears quite plausible, with one possible outlier, and checking with a 
time squared term we get P = 0.4.  However, there is evidence that there is an interaction 
between participant and time, P = 0.01.   If we omit the outlier, MAB007, the interaction 
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has P = 0.1, so we can try the estimate with and without MAB007, whose 24 hour post 
dose level was anomalously low. 
Without MAB007, the estimated slope of the line on the log scale is −b = −0.1462686, 95% 
CI for b = 0.1260151 to 0.1665222.  Hence the t ½  is estimated by log(2)/ 0.1462686 = 
4.7388652 = 4.7 hours, with 95% CI log(2)/0.1665222 = 4.1624911 = 4.2 hours to 
log(2)/0.1260151 = 5.5005089 = 5.5 hours.   
If MAB007 is included, the estimated slope of the line on the log scale is −b = −0.1622861, 
95% CI for b = 0.1311617 to 0.1934105.  Hence the t ½  is estimated by log(2)/0.1622861 
= 4.2711432 = 4.3 hours, with 95% CI log(2)/0.1934105 = 3.5838136 = 3.6 hours to 
log(2)/0.1311617 = 5.2846767 = 5.3 hours.  As expected, this CI is considerably wider, 
thus the estimate without MAB007 is preferable.  Hence we have estimated t ½  = 4.7 
hours (95% CI 4.2 to 5.5) for the dilution factor adjusted C4E10 concentrations.  This is 
around an hour longer than the estimate of 3.7 hours (95% CI 3.2 to 4.3 hours) for the 
unadjusted C4E10 concentrations and is remarkably similar to the findings for C2F5. 
 
3.7.3.6 C2G12 adjusted for dilution factor 
Figure 3-16 Concentration of C2G12 (Adjusted for Dilution Factor) Since Application of 
1st Dose of Mabgel 
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Figure 3-17 Loge of C2G12 Concentration (Adjusted for Dilution Factor) Since Application 
of 1st Dose of Mabgel 
  
As with the unadjusted 2G12 concentrations, there is evidence to suggest that these data 
do not fit with an exponential decay model. The linear fit does not appear plausible and 
checking with a time squared term gives P < 0.001.  There is no evidence that there is an 
interaction between participant and time, P = 0.8 and most participants exhibit the non-
linearity.  As before, the 1 and 8 hour observations only will be used to estimate the early 
t ½. 
The estimated slope of the line on the log scale is −b = −0.4804366, 95% CI for b = 
0.3822727 to 0.5786004.  Hence the t ½ is estimated by log(2)/0.4804366 = 1.4427443 = 
1.4 hours, with 95% CI log(2)/0.5786004 = 1.1979722 = 1.2 hours to log(2)/0.3822727 = 
1.813227 = 1.8 hours.  Thus the estimated early t ½ for the dilution factor adjusted CG12 
levels = 1.4 hours (95% CI 1.2 to 1.8).  This is similar to the 1.2 hours (95% CI 1.0 to 1.4) 
estimated for the unadjusted C2G12 concentrations. 
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3.7.4 Analysis of Variability in Weck-Cel Sampling and relationship 
between sample weight and mAb concentration 
The second of the additional pharmacokinetic analyses outlined in the final SAP (see 
section 2.13.1) was an estimation of the degree of variability in weights/volumes of 
samples obtained using Weck Cels from the same woman at the same visit, between 
women and between visits and an assessment of the relationship between sample 
weight/volume and detected mAb concentration.  
Two Weck-Cel samples were performed on each of 28 women at each of five visits (Visits 
2, 3, 4, 6, and 7) as described in section 2.7.2.3. At one visit, Visit 2, two pairs of samples 
were taken, one before and one after the first dose of study gel was applied. Sample 
weights were obtained as described in section 3.6.1.1. MAB015 had some missing data as 
no samples were taken at Visit 4 and for this part of the analysis she has been omitted. 
Note that the analyses have been performed using the actual sample weights recorded on 
the balance (in grams).  
3.7.4.1 Variation in paired Weck-Cel sample weights obtained from the same woman 
at the same sampling time-point 
Prior to performing any statistical analyses,  variation in paired Weck-Cel sample weights 
obtained from the same participant at the same time-point was evaluated through 
presenting the data as a series of scatter diagrams.  
Firstly, to see how the variability of sample weights obtained was related to the 
magnitude of the weight, the difference between the weights of paired samples, taken at 
the same time-point in the same woman, was plotted against the mean of the two 
weights. As can be seen from Figure 3-18, there is a clear relationship with the heaviest 
samples (mostly those obtained at Visit 2, 1 hour post 1st dose (see section 3.7.4.4) having 
much greater variability than lighter ones. 
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Figure 3-18 Relationship between variability of weights of samples obtained at the 
same time-point in the same woman and magnitude of the mean sample weight (in 
grams) 
 
As can be seen in Figure 3-19, log transformation reduces the influence of the heaviest, 
most variable, samples on the overall distribution of the data and it is thus less skewed. 
This supports the decision to perform ANOVA of sample weights (see section 3.7.4.2) 
using log transformed data. 
 
Figure 3-19 Relationship between variability of weights of samples obtained at the 
same time-point in the same woman and log 10  of the mean sample weight 
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As Figure 3-20 shows, the weights for paired, repeat samples are clearly related i.e. 
samples taken at the same visit from the same woman show a trend towards having 
similar weights, however there is a degree of variability observed. 
Figure 3-20 Relationship Between the weights of paired samples obtained at the same 
time-point in the same woman 
 
3.7.4.2 Analysis of Variance (ANOVA)  
ANOVA is a statistical method which compares variation in repeated measurements 
obtained within a group of subjects to the variation between different groups [578]. It is 
often used to compare the means of samples from several different groups, e.g. 
participants in different study arms who have received different treatments or have 
different specific diagnoses i.e. where there are fixed effects, to see if there is a significant 
difference. In situations where ‘groups’ are actually individual members that can be 
considered to be a random sample from a larger population i.e. where there are random 
effects, e.g. individual participants on whom paired or serial measurements have been 
taken, it can also be used to estimate the variance between measurements in the same 
participant and between different participants, to look for sources of variability or 
measurement error, which is often of greater interest than comparing the means. 
There are two assumptions for ANOVA: firstly, that that the observations within groups 
(called residuals) follow a Normal distribution and secondly, that the variances of these 
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distributions are the same. Of these, the assumption of uniform variance is the most 
important [578]. 
As shown in Figure 3-21 below, the raw sample weights (the residuals in this analysis) 
have a roughly symmetrical distribution, but with tails too long for the Normal, and very 
different variability within visits (with the samples from Visit 2, 1hr post 1st dose being the 
most variable). 
The log transformed data (shown in Figure 3-22) have a more uniform variance, and 
although their distribution is slightly skewed, fit the ANOVA assumptions better. Thus, the 
analyses were conducted using the transformed data. 
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Figure 3-21a and b  Distribution and within visit variability of raw sample weights 
(residuals)  
 
Figure 3-22 Distribution and within visit variability of  log10 transformed sample weights 
(residuals) 
 
A comparison of means of different groups of subjects using ANOVA is conducted through 
first obtaining an estimate of the common variance  (S2) of the residuals within the groups 
(assuming the variances are the same for all of the populations represented by the 
groups), known as the within groups variance or residual variance. To do this, the mean 
for each group of residuals is estimated from the data and a sum of squares about the 
mean is calculated for each group and then added together to give the within groups 
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(residual) sum of squares. The degrees of freedom are obtained from the total number of 
residuals in all groups, minus the number of estimated means. In general, for m groups of 
size n each, there are nm - m = m(n-1) degrees of freedom. 
residual variance =  the within group sum of squares/the number of degrees of freedom 
An estimate of variance is also obtained from the variance of all the group means.  If 
there were no differences between any of the means in the populations from which the 
groups are derived, this between groups variance would be the variance of the sampling 
distribution of n observations, which is given by S2 /n (i.e. the square of the standard 
error) [578].  
The null hypothesis (H0) for the ANOVA is that the variance of residuals within the groups 
is the same as that between the groups. Thus, if this were true, n times the mean-derived 
(between groups) variance should be equal to the residual (within groups) variance. The 
ratio of these two variance estimates is called the variance ratio (F ratio, or F value).  If H0  
were true and if the residuals were all from the same Normal distribution with uniform 
variance, then the variance ratio would follow a known distribution, F, with m-1 and n-1 
degrees of freedom. If H0 were true, the variance ratio (F value) would be expected to 
equal 1.0. The larger the variance ratio, the smaller the probability of it being compatible 
with H0.  If P < 0.05 then H0  is rejected at the 95% confidence level. 
As mentioned above, in situations where ‘groups’ are in fact individual subjects from 
whom repeated samples/measurements have been  taken , ANOVA is most often used to 
provide estimates of both the within subject variance (σ2w) and the between subject 
variance (σ2b). This is known as the method of moments of components of variance. A 
single measurement observed from a single subject has variance σ2w + σ
2
b.  If there are n 
repeated measurements (replicate residuals) in each of m subjects; σ2w can be estimated 
directly from the within subjects mean square (MSw). The between subjects mean square 
(MSb) provides an estimate of mσ
2
b + σ
2
w. The variance ratio, (F value) = MSb/ MSw.  In this 
instance, H0 is that all subjects are the same, i.e. σ
2
b =0. As above, if H0 is true, the variance 
ratio would be expected to be 1.0. If P < 0.05 then H0 is rejected at the 95% confidence 
level [578].  
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ANOVAs can be conducted for a single source of variability i.e. different groups or 
subjects alone; a one-way ANOVA, or for multiple sources of variability; a multi-way 
ANOVA. 
3.7.4.3 Analysis of Variance (ANOVA) for log10 transformed Weck-Cel sample weights 
obtained at the same time-point (i.e. within the same woman and between 
different women within the same visit across all visits) 
The following table shows an ANOVA table where individual women are the ‘groups’; the 
row labelled ‘women’ represents the ‘between subjects’ terms and study visit is a second 
source of variation which was included in the analysis. The row labelled ‘visits’ represents 
the ‘between visits’ terms. The row labelled ‘residuals’ represents the ‘within subject and 
within visit’ terms. An assessment of the interaction between women and visits is also 
included to see whether there is any evidence to suggest that combining both potential 
sources of variation (i.e. comparing samples that have been taken both from different 
women and at different visits) produces greater variability than either factor on its own. 
For the purposes of this analysis each woman is considered to be a random member 
taken from a larger population and it has been assumed that each sample weight is 
uninfluenced by study treatment arm.  The latter assumption has been tested formally, as 
shown in section 3.7.4.4. 
Table 3-6 ANOVA table 1 for log10 transformed weights of repeated Weck-Cel samples 
Source of 
Variation 
Degrees of 
Freedom 
Sum of 
Squares 
Mean 
Square 
Variance 
Ratio (F) 
Probability 
Women 26 28.3966902     1.09218039       5.69 <0.0001 
Visits 5 47.523177       9.5046354       49.56 <0.0001 
Women x 
Visits 
130 80.6929978    0.620715368      3.24 <0.0001 
Residual 162 31.0714945    0.191799349      
Total 323 187.68436      0.581066129      
 
As can be seen from the table, there is a significant difference between the mean weights 
of Weck-Cel samples obtained from different women at the same visit and between those 
obtained from the same woman at different visits. The interaction term is also significant, 
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suggesting that weights of samples obtained from both different women and at different 
visits differ by a greater amount than samples obtained from either different women at 
the same visit or the same woman at different visits.  
As the interaction term is significant, the main effect can also be tested against the 
interaction mean square rather than the residual (within groups) mean square.  For visits 
we get P<0.0001, for women we get P = 0.02, so both main effects remain significant. 
The variances relating to the different sources of variation can be estimated using the 
method of moments for components of variance.  The residual (within groups) mean 
square gives us the within visit and woman variance, the variance of repeated 
measurements on the same woman at the same time-point.  This is 0.191799349.  The 
square root of this is the standard deviation, 0.43794903.  This is the standard deviation 
of log weights sampled from the same woman at the same visit.  The anti log of this is 
1.55.  This is approximately one plus the coefficient of variation on the natural scale, 0.55 
or 55% [582].  Hence repeated samples on the same woman at the same visit will have a 
standard deviation approximately 55% of the actual weight.  This great variability is 
reflected in Figure 3-18, where it can be seen that differences between pairs of weights 
can be as big as the average of the two. 
The variability between samples taken from different women on the same visit can also 
be estimated.  For this two estimates of variance are needed; for heterogeneity and 
between women [578].  For the heterogeneity variance, we have (0.620715368 − 
0.191799349)/2 = 0.21445801. Between women we have (1.09218039 − 
0.620715368)/(2×6) = 0.03928875. The total variance between samples taken from 
different women on the same visit is the sum of these three variances: 0.03928875 + 
0.21445801 + 0.191799349 = 0.44554611. The square root of this is 0.6674924 and the 
antilog is 1.95.  The coefficient of variation is 0.95 or 95%.  Hence sample weights are 
hugely variable between women. 
3.7.4.4 Variability between visits and by treatment arm   
In the analysis above, no estimate has been made of the variability between samples 
taken at different visits. This is because variability between visits is not random but 
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systematic as there are experimental differences between the visits, e.g. differences in 
the timing post gel application.   
As can be seen from Table 3-7, the mean weights of samples obtained at Visit 2, 1 hour 
post application of 1st gel dose are much higher than those obtained at other visits. There 
is little to suggest a difference in weights between study treatment arms, and this is 
demonstrated formally by the results of the ANOVA displayed in Table 3-8. 
Table 3-7 Mean (and standard deviation) of paired Weck-Cel sample weights, in grams, 
by visit and treatment arm 
Visit Treatment Arm 
Placebo Low Dose High Dose 
2 (pre) 0.063 (0.033) 0.084 (0.079) 0.047 (0.031) 
2 (post) 0.122 (0.047) 0.146 (0.056) 0.134 (0.036) 
3 0.062 (0.026) 0.063 (0.013) 0.053 (0.029) 
4 0.056 (0.018) 0.062 (0.025) 0.054 (0.043) 
6 0.072 (0.041) 0.068 (0.024) 0.079 (0.038) 
7 0.072 (0.072) 0.047 (0.029) 0.045 (0.020) 
Number 9 9 10 
 
Table 3-8 ANOVA table 2 for log10 transformed weights of repeated Weck-Cel samples 
Source of 
Variation 
Degrees of 
Freedom 
Sum of 
Squares 
Mean 
Square 
Variance 
Ratio (F) 
Probability 
Treatments 2 1.1732163 0.58660813 1.07 0.3583 
Women within 
Treatments 
25  13.7103164     0.54841266      
Visits 5 21.3408999      4.26817999       16.62 <0.0001 
Visits x 
Treatments 
10 1.9832618     0.19832618        0.77 0.6552 
Residual 124 31.8479446    0.25683826      
Total 166 70.0364077    0.42190607      
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Table 3-8 shows a two-way ANOVA where study treatment arm is the grouping factor. It is 
a split plot analysis, with women being the main units/source of variation, and visits being 
sub-units within these main units. The row labelled ‘treatments’ represents the ‘between 
treatment arms’ terms. The row labelled ‘women within treatments’ represents the 
‘between women within the same treatment arm’ terms and that labelled ‘visits’ the 
‘between different study visits’ terms. The ‘residual’ row represents the ‘within treatment 
arm, within woman and within visit’ terms.  
As can be seen from the ANOVA, there is no significant difference in the mean Weck-Cel 
sample weights between treatment arms (P = 0.36).  This is good for the internal validity 
of the study as it suggests there was no systematic error or bias occurring in sampling 
between the different arms. 
There is, however, a highly significant difference between sample weights obtained at 
different visits (P < 0.0001). The latter is largely driven by the much heavier samples from 
Visit 2 (1 hour post 1st dose). The samples obtained at this visit were visibly coated with 
gel, and it is this which has likely resulted in an increase in the recorded sample weight. 
By 8 hours post dose (Visit 3) there was very little gel visible in the vagina, hence less, if 
any would have likely been collected on the samples at other visits. 
The composition of the study gels was adjusted so that each different type, placebo, low 
dose mAbs and high dose mAbs, had approximately the same density. Thus, any present 
in Weck-Cel samples, particularly those taken at visit 2, 1 hour post dose, should have had 
the same weight for the same amount present (g/ml). This seems to be supported by the 
lack of a significant difference in the sample weights between study arms. 
3.7.4.5 Relationship between mAb concentrations detected in Weck-Cel samples and 
sample weights. 
The final analysis performed with regards to sample weights was to examine the 
relationship between weight of samples and concentration of each mAb detected by 
ELISA.  For this analysis data was only included from post-dose samples in participants 
receiving active treatment (low or high dose Mabgel). The few “not detectable” 
observations were set to 0.05 for this analysis, before transformation.  
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As shown in Figure 3-23 to Figure 3-28, in our study, there was an overall trend towards 
higher mAb levels being detected on heavier samples. However, as might have been 
predicted, the relationship was largely determined by the heavier, gel-laden, samples 
obtained at Visit 2 (1 hour post 1st dose), the time-point with peak mAb levels. A formal 
assessment of the relationship between sample weights, study visit, mAb concentration 
and treatment arm can be made through conducting a multiple regression analysis [577]. 
3.7.4.6 Multiple regression of log10 mAb concentration on log10 Weck-Cel  sample 
weight, with visit, subject and visit X treatment interaction as categorical 
factors 
In the following scatter diagrams, the symbol is the code number of the visit. 2.1 
represents Visit 2 (1 hour post 1st dose). The mAb concentrations are highly skewed so 
have been log-transformed in addition to the sample weights. For comparison, the 
untransformed mAb levels and sample weights have also been plotted. It is clear that 
there is some over-transformation occurring but that that the log transformed values are 
more appropriate for regression analysis, which assumes that residuals from both 
variables being compared are from a Normal distribution with uniform variance. 
Figure 3-23 Scatter plot of mean log10 Weck-Cel sample weight against log10 C2F5 
concentration detected by ELISA (unadjusted for dilution factor) 
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Figure 3-24 Scatter plot of mean Weck-Cel sample weight against C2F5 concentration 
detected by ELISA (unadjusted for dilution factor) 
  
 
Figure 3-25  Scatter plot of mean log10 Weck-Cel sample weight against log10 C4E10 
concentration detected by ELISA (unadjusted for dilution factor) 
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Figure 3-26 Scatter plot of mean Weck-Cel sample weight against C4E10 concentration 
detected by ELISA (unadjusted for dilution factor) 
  
 
Figure 3-27 Scatter plot of mean log10 Weck-Cel sample weight against log10 C2G12 
concentration detected by ELISA (unadjusted for dilution factor) 
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Figure 3-28 Scatter plot of mean Weck-Cel sample weight against C2G12 concentration 
detected by ELISA (unadjusted for dilution factor) 
  
Multiple regression of log10 antibody on log10 sample weight was performed with visit, 
treatment, woman (participant), and visit×treatment interaction as categorical factors 
[577]. Visit was included in the analysis because of its strong influence on mAb levels and 
sample weight.  Woman (participant) was included because it is a structural variable and 
it needed to be taken into account that the successive observations were on the same 
woman. 
Table 3-9 shows the regression slope of log antibody on log sample weight, first adjusted 
only for woman, then adjusted for woman and visit.  The table also shows the increase in 
R2 when sample weight is added, first to the model with woman only as the predictor, 
then to the model with woman and visit. R2 is the square of the multiple correlation 
coefficient (R) and represents the proportion of variability explained by the regression 
[577]. 
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Table 3-9 Regression slope of log10 mAb concentration on log10  Weck-Cel Sample 
Weight 
 
mAb 
Adjusted for woman only Adjusted for woman and visit 
Slope for sample 
weight (95% CI, P) 
R2 increase 
when sample 
weight added 
Slope for sample 
weight (95% CI, P) 
R2 increase 
when sample 
weight added 
C2F5 3.44 (2.63 to 4.26, 
P<0.001) 
0.439 1.10 (0.45 to 1.76, 
P=0.001) 
0.018 
C4E10 3.26 (2.44 to 4.07, 
P<0.001) 
0.411 0.90 (0.23 to 1.58, 
P=0.009) 
0.013 
C2G12 4.53 (3.73 to 5.32, 
P<0.001) 
0.560 1.67 (1.02 to 2.31, 
P<0.001) 
0.031 
 
For each mAb, there was a clear correlation between mAb concentration and sample 
weight overall, however, the slope was greatly reduced when visit was included in the 
model and the contribution of sample weight to the R2 was much smaller.  This showed 
that a large part of the relationship between mAb concentration and sample weight was 
explained by the influence of visit on both variables.  This was largely driven by Visit 2 (1 
hour post 1st dose), where both sample weights and mAb levels were at a maximum.  
However, it also showed that there was a small residual relationship which was not 
explained by visit i.e. that there was a slight general trend towards obtaining higher mAb 
concentrations from larger (heavier) samples independent of study visit.  
3.8 Summary and Discussion of Pharmacokinetic Results 
3.8.1 mAb Pharmacokinetics 
Pharmacokinetics is ‘the handling of a drug within the body, including its absorption, 
distribution, metabolism, and excretion’ [583]. Current knowledge of these processes 
with regards to mAbs has largely been derived from the study of naturally occurring 
antibodies or mAbs administered parenterally [468,584,585].  To date, almost all mAbs 
licensed for therapeutic use are administered either IV (the majority), or subcutaneously 
(SC), for systemic activity [468].  
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A few mAbs have been developed for localised administration in humans. These include 
Catumaxomab (TRION Pharma and Fresenius Biotech, Germany), a dually targeted IgG 
mAb against epithelial cell adhesion molecule (EpCAM) and the T Cell Co–Receptor, CD3, 
which is infused intra-peritoneally for the treatment of malignant ascites [586] and the 
vascular endothelial growth factor A (VEGF-A) binding Fab fragment Ranibizumab 
(Lucentis®, Genentech, San Francisco, CA, USA (owned by Roche, Basel, Switzerland), 
used intravitreally to treat neovasular age-related macular degeneration [587].  
Pulmonary delivery of mAbs for the treatment of lung cancer is also being explored [588]. 
Although humanized anti-HSV2 IgG mAbs have been developed, studies of vaginal 
application have thus far been confined to rodents, and  have primarily provided data on 
protective efficacy [589, 590].  To our knowledge, MABGEL 1 was the first study to look at 
the pharmacokinetics (and safety) of any mAbs in the human FGT. 
3.8.2 mAb Concentrations detected in vaginal secretions sampled using 
Weck-Cels  (primary study end-points) 
The primary end-points for the MABGEL 1 trial were the concentrations of the mAbs 
detected in vaginal secretions sampled using Weck-Cel sponges at 1, 8 and 24 hours post-
1st dose, and 12 and 36 hours post-12th dose of study gel. Median mAb levels (μg/ml)(as 
reported by Polymun) were found to be maximal at 1 hour post dose in the high dose 
(1505, C2F5; 987, C4E10; 1620, C2G12) and  low dose Mabgel (542, C2F5; 239, C4E10; 
619,  C2G12) groups  and still detectable at very low (nanogram range) levels at 36 hours 
(post 12th dose) in some participants. On average, adjustment to account for dilution 
factors during processing increased  mAb levels 5 fold at 1 hour post 1st dose, and 12 fold 
at other time-points. Although there were a couple of anomalous values in a small 
number of participants, the median levels are in keeping with application of a gel 
containing either 10mg/g or 20mg/g of each mAb. 
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3.8.3 mAb concentrations in other samples (secondary end points) 
3.8.3.1 CVL and aspirate samples 
CVL samples were taken at the last sampling time-point per gel dose, to allow direct 
comparison with the neat, self-aspirated secretions obtained by each participant as well 
as to those obtained by Weck -Cel. On visual inspection of the concentrations as reported 
by Polymun, in comparison with the values obtained from Weck-Cel samples (unadjusted 
for dilution factors) at the same time point and in the same woman, mAb levels obtained 
from CVL samples were generally lower (although by variable amounts).  As is reflected in 
the median levels in Table 3-4, differences were greatest for visit 4 samples (24 hours 
post 1st dose) for levels of C2F5 and C4E10, with smaller differences seen at visit 7 and for 
C2G12 in general, where mAb levels were measured as being < 1mg/μl in both sample 
types.  
Unfortunately, as discussed in section 3.8.6.5, there were difficulties encountered with 
using the self-aspirator, resulting in a paucity of analysable samples. A formal statistical 
comparison between the 3 methods was therefore not possible. 
3.8.3.2 Serum samples (systemic absorption) 
For C2F5, mAbs were undetectable or very close to the assay cut off (0.06 μg/ml) in most 
participants at most time-points. Levels  between 0.1 and 0.2 μg/ml were detected in 2 
participants ((MAB016) in the low dose and (MAB003) in the high dose Mabgel arms), 
however, in both participants, levels were greater at baseline (pre-1st gel dose) than at 
the 8 hour post 1st dose and 12 hour post 12th dose visits . There was no evidence of an 
overall difference in 2F5 levels between study arms. 
For C4E10 and C2G12, mAbs were detected at low levels (0.4 to 2.0 μg/ml) in all 
participants at all time-points (including samples taken at baseline and in placebo-users). 
Looking at the data recorded for individual women, similar levels (within  0.2 μg/ml) were 
detected across all 3 samples, with baseline values being higher, in many cases, than 
those taken at the 2 post dose visits. There was no evidence of a difference between 
study arms. As discussed in section 3.8.6.7, it seems likely that the levels reported 
represent non-specific background signal in the assay rather than actual mAbs. Thus, 
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there appears to be no overall evidence from our data to suggest that any systemic 
absorption of the mAbs occurs. 
3.8.4 mAb Half-lives 
The half-life (t ½) is the time required for half of an administered agent present to be 
eliminated from the body or a specified compartment. For t ½ to be valid, the decay in 
the concentration of the agent must be exponential i.e. the rate at which it is eliminated 
must be proportional to the amount present. In turn, this implies that processes 
responsible for elimination of the agent, i.e. distribution and clearance, must follow 1st 
order kinetics and not be subject to saturation [579].   
3.8.4.1 Estimates of the residence vaginal t ½ of C2F5, C4E10 and C2G12 obtained in 
our study 
Using the concentrations adjusted for dilution factors, for all participants in both the high 
and low dose Mabgel arms, residence half-lives in vaginal secretions (Weck-Cel samples) 
were estimated to be in the range of 4 to 5.5 hours for both of the MPER mAbs (4.7 hours 
(95% CI 4.2 to 5.5) for C4E10; 4.6 hours (95% CI 4.0 to 5.0) for C2F5). t ½ estimates were 
approximately an hour shorter using the unadjusted values, with both adjusted and 
unadjusted data fitting a exponential model. In contrast, vaginal levels of C2G12 did not 
conform to a single overall exponential decay, displaying a more rapid initial rate of 
decline than the other two mAbs, which then slowed at lower concentrations.  An 
estimate obtained for the early t ½ of C2G12, based on the 1 and 8 hour post 1st dose 
values, was 1.4 hours (95% CI 1.2 to 1.8).   
3.8.5 Variability in Weck- Cel sample volumes  
As demonstrated in section 3.7.4, there was a significant degree of variability in secretion 
weights/volumes between paired Weck-Cel samples obtained from the same woman at 
the same time-point (coefficient of variation 0.55 (i.e. standard deviation approximately 
55% of actual weight), although, as might be expected, this was much less than the 
variation between samples from different women at the same time-point (coefficient of 
variation 0.95).  
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In our study, measures taken to try to make sampling as uniform as possible included 
following SOPs, using the same brand of Weck-Cel throughout the study, utilizing 
different sampling methods in an order/at time-points designed to minimise their impact 
on subsequent samples and having the same clinician (the author) conduct all visits. 
However, as detailed in sections 3.8.5.1 and 3.8.5.2 below, variables arise both within the 
same woman and between participants which are beyond investigators’ control. In 
addition, as discussed in section 3.8.6, limitations with our sampling and laboratory 
processes, e.g. errors in recording weights, are also likely to have contributed to observed 
variability. 
3.8.5.1 Factors which could produce variability in the same woman at the same time-
point 
Provided Weck-Cels are held against the vaginal mucosa for a fixed period of time, the 
main factors influencing the volume/weight of sample collected will be the absorbance 
properties of the sponge and the amount and consistency of secretions/gel present in 
that area of the  vagina.  Although some variation in absorbance may exist between 
Weck-Cels, especially if from different batches, this is likely to be small. In contrast, 
differences related to secretions/gel and the vaginal environment are likely to be much 
greater. 
For anatomical reasons (see section 1.3) both gel and secretions may be more likely to 
pool in the upper vagina than the lower [51], therefore it is important to ensure sampling 
is consistently from the same region. In our study, all Weck-Cel samples were obtained 
from the lateral fornices (for paired Weck-Cels at the same visit, 1 was placed in each 
fornix on opposite sides). However, there is likely to be variation in the spread of gel and 
secretions even within this region. 
As shown in Figure 3-18, variability was greatest for the heaviest samples, obtained 1 
hour post 1st gel dose. This is unsurprising.  At this time-point, in contrast to all others, 
Weck-Cels were often visibly coated with gel, with gel covering the surface of the sponge 
as well as being absorbed within it. Thus, the weight/volume of sample collected was 
likely to be less determined by the absorbance properties of the Weck-Cel sponge and 
more dependent on the amount of gel/secretion present. As demonstrated by Barnhart 
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et al., using Magnetic Resonance Imaging (MRI) post vaginal application of gels of various 
compositions/formulations and volumes, gel distribution is rarely uniform (throughout  
the lower FGT), and complete, contiguous mucosal coverage is not always achieved 
[591,592].  Coverage would be expected to increase with time, as the gel spreads linearly 
and laterally and mixes with vaginal secretions, before being diluted out and/or lost 
through the introitus [591,592,593,594].  By 8 hours post dose very little gel remained 
visible in the vagina, thus it is likely to have had less influence over the weights/volumes 
of samples obtained at other visits. 
3.8.5.2 Additional factors which could produce variability in different women at the 
same time-point or the same woman at different time-points 
Variation with regards to reproductive hormone status, timing and technique of (non-1st 
dose) gel application, degree of ambulation and hygiene practices could all in theory 
affect the quantity, consistency and/or distribution of secretions/gel within the vagina, 
hence the volumes/weights of samples obtained between different participants and from 
the same woman at different visits. Of the above variables, only the first has been 
analysed using available data. 
As described in section 1.3, stage of menstrual cycle and use of hormonal contraceptives 
can influence the amount and composition of genital secretions. Endocervical mucus is at 
its most copious and stretchy at mid-cycle, due to the influence of rising levels of 
oestrogen, which peak and then fall prior to ovulation. In contrast, progestagens act to 
thicken the mucus and cause physiological sloughing of the vaginal epithelium, resulting 
in a heavier, more viscous vaginal discharge, containing exfoliated cells. The latter is seen 
in the luteal phase of the cycle and in those using progestagen dominant contraception 
[55,56]. In our trial, distribution of non-hormone (IUCD and/or condom) and hormone 
(IUS, DMPA, Cerazette or COCP) users was fairly balanced overall between study arms 
(see Table 3-1). In those women with a natural menstrual cycle, dosing was initiated in 
the follicular phase (between days 7 and 13) with visits 6 and 7 in the luteal phase. 
Median day for initial dose varied slightly between the arms (day 9, 11 and 12 for Mabgel 
high dose, Mabgel low dose and placebo respectively). However, as shown in Table 3-7, 
although some hormonal influence on individual sample variability is possible, there was 
little evidence of any difference in mean volumes/weights of samples obtained at visits 2 
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(pre-dose) and 3 compared with those collected later in the cycle (visits 6 and 7). There 
was also no evidence of any difference in mean Weck-Cel sample weights/volumes 
between treatment arms. 
Differences between women could also arise due to variation in the volume and surface 
area of the vaginal cavity. As Barnhart et al. have shown through MRI imaging, vaginal 
dimensions vary markedly between individuals. In their study of 28 vounteers, the length 
of the vagina (from external cervical os to introitus) ranged from approximately 4.1 to 9.5 
cm, transverse diameter (at the widest point, level with the vaginal fornices) varied from  
2.6 to 8.3cm and surface contact area ranged from 106.8 to 185.0 mm 2. Increasing age 
and parity were significantly associated with widening of the transverse diameter (due to 
laxity in the vaginal walls) and lengthening of the posterior and lateral fornices 
respectively.  A non-significant positive association was found between weight and overall 
vaginal length and a weak negative association between height and transverse diameter, 
with no associations between any parameter and ethnicity [51].  In our study, women in 
the low dose Mabgel arm were on average older than in the other 2 arms (32 compared 
with 25 years) and had had a greater number of children (Table 3-7), thus may have had a 
larger average vaginal surface contact area. This does not seem to have influenced the 
volumes/weights of collected Weck-Cel samples overall (since there was no evidence of a 
difference between the study arms (Table 3-7)) but may have increased the distribution 
of gel in-situ, with a subsequent reduction in detected mAb concentrations (see section 
3.8.5.3  below). 
3.8.5.3 Factors which could produce variability in mAb levels measured in different 
women at the same time-point  
As shown Table 3-2 the range of detected concentrations of C2F5, C4E10 and C2G12, 
across all time-points, was generally wide, reflecting the degree of variability in mAb 
levels in different participants. Many of the variables affecting the amount/ distribution of 
gel or secretions within the lower FGT will also influence detected mAb levels. In the 
multiple regression analysis (section 3.7.4.6), there was a clear positive correlation 
between detected concentrations of each mAb and Weck-Cel sample volume/weight. 
Although a large part of the relationship was explained by the influence of Visit 2 (1 hour 
post 1st dose), where both sample weights and mAb levels were at a maximum, there 
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was a small residual relationship, independent of study visit, suggesting a weak general 
trend for larger/heavier samples to give rise to higher mAb levels.  However, the 
relationship between sample volume/weight and mAb concentration is not a simple one.  
At the same (non- 1 hour post dose) time-point, secretion samples may be heavy because 
they consist of remnants of gel or viscous/mucoid secretion, containing high 
concentrations of relatively undiluted mAbs, or the Wecks-Cel may have absorbed a large 
amount of relatively dilute watery discharge/secretion containing lower levels of mAbs. 
Adjustment for ‘dilution factors’ corrects for the variation in mAb dilution by buffer 
during sample processing, due to the different weights/volumes collected, but it does not 
adjust for differences in in-situ dilution and mucosal spread. In theory, it provides a 
measure of ‘real-life’ mAb concentrations within the vaginal lumen, maintaining 
variability between individuals due to the presence of varying amounts of natural vaginal 
secretions and/or distribution e.g. differences in contact surface area, ambulation, 
hygiene practices etc. In our study, general trends in mAb concentrations were very 
similar both before and after ‘dilution factor’ adjustment and median levels obtained 
were in keeping with the quantity of mAbs applied in the gel (see section 3.7.2.3). Thus, 
its use appears to be valid. That said, the higher degree of variability in both sample 
weights/volumes and mAb levels observed at 1 hour post gel dose visit, and concerns 
regarding processing of these samples (see section 3.8.6.4) mean that we cannot be 
certain to what degree our findings at this time-point are accurate. 
Another potential influence on vaginal mAb levels is infection, in particular certain 
Candida species.  Pre-1st dose cultures  showed a heavy (+++) growth of Candida albicans 
in 3 participants in the low dose Mabgel arm (MAB014, 019 and 027). Of these, MAB019 
consistently had lower levels of all 3 mAbs compared to other participants in the same 
arm. This was not true of MAB014 and 027. Since cross-reactivity to Candida species’ 
surface glycoproteins is a feature of 2G12 alone, the low mAb levels in MAB019 are 
unlikely to be explained by this mechanism. Although, it is possible that the infection 
contributed in another way, e.g. through recruiting neutrophils (which release proteolytic 
enzymes) and/or increasing dilution through production of vaginal discharge, this 
participant was only mildly symptomatic and only one of the women (MAB027) had any 
objective signs of inflammation on examination (see sections 4.1.1.6 and 4.1.1.12). 
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3.8.6 Limitations of study design and procedures 
A number of limitations in the design and procedures employed in our study should be 
considered when assessing the accuracy and external validity of our findings.  
3.8.6.1 Sample size and study power 
Our study was the first time any of C2F5, C4E10 and C2G12 had been applied to the 
human FGT and although some data existed from the CEA macaque studies regarding the 
pharmacokinetics of the 20mg/g dose, there was insufficent data on which to base power 
calculations to determine the likely sample size required to demonstrate statistically 
significant differences in mAb levels across the 3 study arms and, in particular, between 
the 10mg/g and 20mg/g Mabgel arms. A sample size of 10 participants per arm was 
therefore seen as a reasonable target given the financial, time and personnel constraints 
that applied. Unfortunately, due to unforeseeable delays with obtaining study approval 
and the establishment of the EMU, there was only time to enrol 28 women prior to the 
expiry of the study gels. This sample size proved large enough to demonstrate statistically 
significant differences in the primary study end-point (levels of each mAb in the Weck Cel 
samples) across the 3 study arms at all time points, except 36 hours post 12th dose for 
C2G12 (Kruskal-Wallis rank). However, although observably higher median mAb 
concentrations were detected in the high dose Mabgel arm compared with the low dose 
arm at most time-points (except 36 hours (post 12th dose) when they were low (< 1mg/μl) 
in both arms) these only reached statistical significance at the 1 hour post 1st dose visit for 
2F5 and 4E10 and not at all for 2G12 (Man-Whitney U). Thus, although it seems probable 
that real differences were seen between the levels (detected on Weck Cel samples) 
achieved with the two Mabgel doses at most time-points, the small sample size, non-
parametric method of analysis, high degree of variability between individual participants 
and imprecision in the sampling and detection methods (see section 3.8.5) likely reduced 
the power of the study to show this. The ability of our study to demonstrate statistically 
significant differences in analyses of secondary end-points (CVL and serum samples) was 
even further reduced due to the generally lower mAb levels detected in these samples. 
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3.8.6.2 Number and timing of sampling time-points 
As discussed in section 2.3.1, sampling time-points were chosen in our trial to try to 
determine post-dose mAb concentrations at times of greatest relevance to the clinical use 
of the product whilst minimising the number of invasive examinations and sampling 
procedures required per participant. Sampling was performed at 1, 8 and 24 hours post 
1st dose and 12 and 36 hours post 12th dose; the split enabling the study to be conducted 
in a day-unit (such as the HYMS EMU) rather than an overnight research facility and aiding 
the recruitment of participants, who were able to fit dosing and sampling visits around 
existing family and work commitments. 
In terms of primary end-points, sufficient information was obtained from our study to 
provide an estimate of the peak levels of mAbs within an hour of gel application (of most 
relevance if the product were to be used just prior to coitus), concentrations at later time-
points (to provide information regarding possible duration of efficacy) and the likely time-
scale for complete clearance of mAbs from the FGT lumen. However, our sampling 
schedule was not ideally suited to estimating the t ½ of each mAb in the vaginal lumen. To 
be certain of timings and avoid the possibility of detecting residual mAbs from previous 
doses, only those samples obtained following the 1st gel dose were included in the t ½ 
analyses. Thus, estimates of t ½ for each mAb were based on data from 3 time-points only 
which limited their accuracy. In addition, the spacing of measurements meant that it was 
not possible to determine if 2G12 was truly eliminated in 2, bi-exponential, phases or if it 
was removed from the lumen through processes governed by non-linear kinetics. To 
obtain more reliable t ½ estimates and to investigate the linearity of the log curve more 
fully would ideally require at least hourly measurements for 8 hours then as many as 
could be carried out up to 24 hours. Such an intensive sampling regimen was beyond the 
scope of our study and would likely require the use of a reliable, acceptable, self-sampling 
method to avoid the need for repeated invasive clinical examinations. 
With regards to serum sampling, we are relatively confident that we have excluded any 
significant systemic absorption of the mAbs with the samples we obtained.  8 to 12 hours 
was the time-period post dose that we predicted that we might begin to detect mAbs in 
serum if they were absorbed through the mucosa, via the lymphatic drainage of the FGT, 
with the latter sample, taken following 12 gel doses, also able to detect any delayed 
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absorption.  However, with very limited data from previous research regarding uptake of 
antibodies from the FGT mucosa into the circulation (see section 3.8.8.4 ), it is difficult to 
be certain of this and further samples, at 4 hours, 24 hours and 36 hours post dose would 
perhaps have provided us with greater reassurance.  
3.8.6.3 Gel administration procedures 
Apart from the 1st dose of gel, which was administered under supervision on the EMU, all 
other doses, including the final dose, on which the 12 and 36 hour pharmarmacokinetic 
evaluations were based, were applied by women at home. Thus, although efforts were 
made by the research team to ensure that women adhered to the dosing protocol, there 
is an element of uncertainty as to whether the 12th doses were applied at the stated, pre-
arranged time. It is well-established that self-reported product adherence can be 
unreliable [595], but, the fact that women in the trial admitted to having applied earlier 
doses in the morning (rather than at night/bed-time as they had been instructed) (see 
section 3.5.1), and 3 women brought back unused syringes, could indicate that they were 
honest about when they actually used the gel. As described in section 3.5.2 , in a few 
cases, investigators were aware that samples had been taken outside of the allotted 
window either side of the pharmacokinetic time-point, due to participants arriving late 
for visits or mistakingly applying the final gel an hour before schedule. No sampling was 
performed, to our knowledge, beyond 1 hour of this window. 
Another potential limitation with the dosing procedure was the requirement to transfer 
the gel from its syringe into an applicator before administration.  Unfortunately, the fit 
between the luer-lock nozzle of the syringe and the Ortho applicator was not tight, thus, 
the potential existed for gel to be spilt during transfer.  Although no gel-spillage was 
reported by participants, several commented on the awkwardness of this procedure in 
the final interview (see section5.4.5.1 ), and with hind-sight, it would have been better to 
have pre-packaged the gel in an applicator device. 
3.8.6.4 Potential limitations of vaginal sampling by Weck-Cel and CVL 
Weck-Cel sponges have been established as a reliable way of obtaining vaginal and 
cervical secretions for measurement of naturally generated biological mediators 
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[525,526,527]. However, ours was the first study to use them to collect specimens for 
detection of mAbs which had been topically applied in a gel. In contrast to CVL, where the 
entire ectocervical-vaginal surface is washed with saline and any pooled secretions 
collected, Weck-Cel samples are obtained through direct contact of the sponge with a 
small area of the mucosal surface, enabling the site of collection, e.g. vagina, ectocervix or 
endocervix, to be determined.  In addition, the process of Weck-Cel sampling does not 
dilute vaginal secretions in situ, and there is no potential for error resulting from 
variability in absorption and recovery of lavage fluid. To normalize the latter requires 
measurement of total protein or the addition of a lithium tracer [528,529], neither of 
which was logistically possible in our study.  However, although neat, the volume of 
secretions collected by Weck-Cels is variable and centrifugation, following the addition of 
a known volume of extraction buffer, is required to elute fluid, containing antibodies, or 
other proteins of interest, from the sponge [523,524].  Adjustments can be made to 
correct for the dilution factor introduced during processing (see section 2.13.4.4), but 
only if an accurate record is obtained of the weight of the Weck-Cel both before and after 
sampling, to determine the amount of secretion absorbed by the sponge. 
In our study, rather than assume an average pre-sample weight (e.g. obtained from 
weighing 10 representative dry Weck-Cels as has been done by some previous 
researchers [526]) we measured both the pre and post-sample weights of each individual 
Weck-Cel using the same fine-balance.  For ease of measurement (as described in section 
2.11.2.3 and 2.11.2.4), weights were determined for the entire sample collection kit.  
However, although weighing each individual Weck-Cel pre- as well as post- sampling 
could in theory increase the accuracy of the calculated sample weights, increasing the 
number of occasions on which the balance was used and including the entire kit in 
measurements may have increased opportunities for measurement error. Unfortunately, 
on four occasions (MAB001 sample 1, Visit 2 (Pre-dose); MAB008 sample 1, Visit 4; 
MAB004 sample 1, Visit 7; MAB011 sample 2, Visit 7) the balance reading post-sampling 
was lower than the pre-sampling weight. This was possibly due to an error re-setting the 
fine balance or a failure to include the Weck sponge stem or other component of the kit 
in the post-sampling weight.  In view of these values being impossible, on the advice of 
the study statistician, Professor Martin Bland, they were converted to the lowest 
recorded weight observed of all other samples in the study which was 0.01g 
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(corresponding to 10 μl). Although these errors will reduce the accuracy of the dilution 
factor correction applied to the mAb concentrations detected by ELISA at these time-
points, the impact will be decreased by the fact that there were two Weck-Cel samples 
obtained per time-point (pooled prior to analysis) and the dilution factor is calculated 
using the mean of the 2 sample weights. 
In theory, applying a dilution factor correction provides a better in-vivo estimate of mAb 
concentrations present than the unadjusted values [525,526,527]. If standardized, it 
should also allow more accurate comparison of results between research groups.  
However, although the weight of the sponge is likely to give an indication of the volume 
absorbed, the assumption that 1mg of extra sample weight equates with 1ul of fluid that 
will be diluted by buffer may not always be precisely accurate, particularly in the presence 
of a vaginal gel. In addition, differences in consistency or constitution of genital secretions 
could have an influence on the efficiency of mAb extraction from the Weck-Cel sponge.   
In our study it was noted that the Visit 2 (1 hour post 1st dose) samples were much thicker 
in consistency than those taken at other visits as they contained visible quantities of gel. 
This is also likely to be responsible for the larger mean sample weights seen at this visit 
(as shown in Table 3-7). These samples were much harder to ‘spin down’ and elute fluid 
from than those from other time-points; thus, it is possible that, in some participants, 
mAbs may have remained stuck to the spin-filter. A similar phenomenon has been noted 
to occur in the presence of cervical mucus, but whether or not it impedes the elution of Ig 
or other immune factors has not been elucidated [524]. Thus, there is a degree of 
uncertainty as to how closely the adjusted mAb levels reported in our study, particularly 
at 1hr post 1st dose, reflect those present in the vaginal lumen. 
3.8.6.5 Self-taken vaginal aspirate sampling 
The ideal sampling method would provide a large, undiluted specimen from which 
concentrations of antibodies, cytokines or other molecules could be determined directly, 
per unit volume of secretion, without the need for processing using extraction buffers 
and subsequent dilution factor adjustment.  Unfortunately, use of the volumetric 
aspirator device, which had the potential to allow up to 1ml of neat secretion to be 
obtained through participant self-sampling, was not successful in our study. Eight women 
found them uncomfortable to use (see section 5.4.4.3) and when samples were obtained, 
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they were often of poor quality and/or low in volume with only 32% of possible samples 
suitable for ELISA. As mentioned in section 2.4.1, the aspirators were obtained from 
Professor Angela Kashuba, CFAR, Chapel Hill, USA, who has used them successfully on a 
number of ARV pharmacokinetic studies [538,539,596,597]. Although we are not 
experienced in using these devices, our participants were provided with face-to face 
verbal instruction in how to use them based on written information provided by Professor 
Kashuba and performed their first samples at the screening visit to allow greater time for 
explanation. With hindsight, it may have been useful to have obtained a ‘dummy’ pelvis 
for demonstration. The minimum time period of recumbency advised by Professor 
Kashuba prior to self-sampling is 15 minutes (A Kashuba, personal communication). In 
view of time constraints during study visits this is what was applied in the case of our 
participants. It is possible that extending this period may have resulted in improved 
comfort and sample collection by increasing the quantity of secretion pooled in the 
posterior fornix. However, this would have simultaneously reduced the convenience of 
using the device.  
Although outside of the aims of our sub-study, which was to compare the utility of self-
taken with clinician taken sampling for mAb measurement, the aspirator can also be used 
by clinicians to obtain samples. Although usually performed via direct vision at time of 
speculum examination [538,539,597], samples have recently been obtained without using 
a speculum [596,597]. Although there are no published direct comparisons, it may be that 
aspiration performed by a trained clinician may be less uncomfortable and more reliable 
than when self-performed. A comparison between clinician-obtained aspirates and Weck-
Cel sampling of vaginal secretions may be worth conducting in a future study. 
3.8.6.6 mAb degradation 
 The complex tertiary and quaternary conformation of immunoglobulins is susceptible to 
denaturation. As for other proteins, exposure to high temperature (> 60 °C), extreme pH, 
hydrophobic surfaces and shear forces can disrupt both covalent and non-covalent 
bonding,  resulting in cleavage and/or unfolding of constituent light and heavy chains 
[598].  In our trial, study gels were kept at 2-8°C prior to dispensing and participants were 
advised to keep them refrigerated until use. This was in accordance with the MHRA-
approved IMP dossier, based on data available at the time of initial submission. However, 
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by end-of-trial, the stability of each mAb in product buffer had been monitored for 60 
months at 2-8°C and for 12 months at 37 °C at pH 7.4 and 5.5 No decay of purity, 
aggregation or fragmentation was detected by size exclusion chromatography (SEC), SDS-
PAGE, and Western Blot, and neutralization activities were preserved (B Vcelar, personal 
communication).  Thus, despite having little control of gel storage conditions (for doses 2 
to 12) post dispensing, we can be reasonably certain that the mAbs were intact prior to 
administration. 
To try to limit any degradation of mAbs post sampling, all vaginal samples were required 
to be kept at 2 to 8 °C prior to processing, a PI cocktail was added to the extraction buffer 
(into which Weck-Cel sponges were placed immediately post sampling, but which was 
added later in processing of other vaginal samples) to inhibit naturally occurring 
proteases, and processing had to be completed within 2 hours of collection. Blood 
samples had a longer processing window of 4 hours, but were refrigerated, at 1 hour post 
collection, if they couldn’t be centrifuged at that time. Following processing, all samples 
were stored at -80 °C with temperature logging on freezers and during cold storage (dry-
ice) transportation to ensure they remained frozen until time of analysis at Polymun.   
However, although similar to those used in other studies [599,526], the above 
precautions do not guarantee the integrity of samples and we cannot exclude the 
possibility of mAb degradation between collection and analysis. In particular, it should be 
noted that the maximum collection-to-storage time-windows are somewhat arbitrary, 
being a compromise between optimal speed of sample processing, and feasibility in terms 
of available staff, transportation and equipment. 
3.8.6.7 ELISA 
An ideal ELISA should be specific for the antigen/antibody being detected (with low false 
positivity), sensitive to a low limit of detection (to limit false negativity) and give reliably 
reproducible results when repeated [600]. The ELISAs performed by Polymun were 
designed specifically for detecting C2F5, C4E10 and C2G12 and had been utilized 
successfully in a number of previous studies [501,502,503,504,505]. The assays were 
dependent on initial Fab binding, to specific epitopes (C2F5 and C4E10) or an anti-
idiotype antibody (2G12) on the pre-coated plate, followed by subsequent  recognition of 
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the Fc region (by a goat anti-human IgG gamma chain antibody),  and would thus be 
predicted to only detect mAbs which were largely conformationally intact. The lower limit 
of quantification of the assay was determined through the use of known, standard 
concentrations of purified C2F5, C4E10 and C2G12.  Concentrations in samples above this 
limit were then quantified through comparison of absorbance readings, using a computer 
programme, with a standard curve generated using the purified mAbs. Chromogenic 
substrates, such as OPD, tend to be less sensitive than chemifluorescent or 
chemiluminescent substrates but have the advantage of being directly visualisable and 
can be read by absorbance plate readers common to many laboratories. They are 
generally preferred in assays measuring proteins in the nanogram to microgram range (as 
opposed to the picogram or femtogram ranges) since they are easier to optimise and 
have a generally lower tendency to generate non-specific, background  signal than newer, 
more expensive substrates [600].  
In our trial, despite having the same pre-determined quantification limit and using similar 
methodologies, the assays for C4E10 and C2G12 had much more non-specific background 
detection than that for C2F5.  This was seen for all sample types, but was most apparent 
for serum.  The reason for this could not be ascertained by Polymun and, although efforts 
were made to remove any non-specifically bound IgG, e.g. through increasing washing 
steps or detergent (Tween) before addition of the anti –IgG antibody, the problem was 
not resolved.  As a result, any values close to the assay cut-off for C4E10 and C2G12 
(below about 1 μg) should be interpreted with caution as they may not reflect true levels.   
With respect to the Weck-Cel samples, applying a dilution factor correction to such values 
could artificially increase some low concentrations and potentially distort the data. In 
practice, this does not appear to have had much impact, with similar trends seen in both 
adjusted and unadjusted concentrations at all visits. With regards to the serum samples, 
it is possible that small amounts of absorption may have been masked by the imprecision 
of the lower cut-off of the ELISAs and we can be more confident of our findings with 2F5 
than with the other 2 mAbs. 
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3.8.7 Comparison of mAb concentrations and t ½ with those from other 
studies 
3.8.7.1 Comparison of mAb concentrations with those from the CEA macaque studies 
The median MAb levels detected in Weck-Cel obtained samples in the high dose (20mg/g) 
Mabgel group in our study can be compared to those seen in the macaque 20mg/g 
Mabgel pharmacokinetic studies conducted at the CEA (CEA study THE0703) (discussed in 
section 2.3). Since no correction was made for dilution factors in the reported results 
from the CEA studies, comparison will be made with our unadjusted values. It should be 
noted, therefore, that some difference in levels may result from variation in volumes of 
natural secretions between humans and macaques.  In the macaque studies sampling was 
performed using Weck-Cels and the same technique and volume of buffer was used for 
processing as in our trial. The constitution of the gel was also identical to that used in the 
high dose arm of our study. However, there were a few procedural differences between 
the human and macaque studies.  Firstly, relating to the smaller size of macaque vaginas 
compared to humans, a 2g application of the gel was used in macaques whereas in 
women the syringes dispensed approximately 2.5g of gel. Secondly, in macaques, all 
sampling was performed at serial time-points following a single application of the gel. In 
women, for reasons of comfort and logistics, samples at the 12 and 36 hour time points 
were performed after the 12th dose.  Thirdly, whereas all women were sampled at all time 
points in our trial, in the CEA studies, due to technical and staffing constraints, in addition 
to baseline, most of the 6 animals were only sampled 4 times over the duration of the 
study.  The median at each post-dose time-point was thus derived from levels obtained 
from an average of only 3 animals. Detection of mAbs by ELISA was performed at 
Polymun Scientific, using the same SOPs as for our trial. 
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Table 3-10  Median mAb Concentrations  (μg/ml) detected using Weck-Cels (before and 
after adjustment for dilution factors)  in participants in the High Dose (20mg/g) Mabgel 
arm compared with those in macaques in the CEA THE0703 study 
Sample
Time-
Point 
(hours 
Post 
dose) 
Median mAb concentrations (μg/ml) detected following application of        
20mg/g MABGEL 
THE0703 Macaques MABGEL 1 High Dose 
(unadjusted) 
MABGEL 1 High Dose 
(dilution factor adjusted) 
C2F5 C4E10 C2G12 C2F5 C4E10 C2G12 C2F5 C4E10 C2G12 
Pre 1st 
dose 
0.07 ND 0.25 ND 0.06 ND ND 0.2 ND 
1 1535 1505 2008 1505 987 1620 7737 5277 7479 
4 691 793 1046 - - - - - - 
8 91 181 153 220 148 23 3161 2505 538 
12 30 18 35 154 96 4.5 1376 870 52 
24 1.7 1.40 3.6 15.4 11 0.6 196 171 12 
36 - - - 0.3 0.5 ND 4.8 4.7 ND 
48 0.15 0.21 0.35 - - - - - - 
72 0.06 0.30 0.06 - - - - - - 
ND= Not detected, - = not performed in protocol 
As can be seen from Table 3-10, in the macaque studies, the median concentrations of all 
3 mAbs were of a similar magnitude to each other at each time point. Thus, all 3 mAbs 
seemed to decline at a similar rate.  Comparing the human and macaque data, C2F5 and 
C4E10 concentrations detected in our trial participants were similar to those seen in the 
macaques, with possibly even a slightly slower rate of decline. In contrast, C2G12 levels 
were lower in women than macaques at each time-point, suggesting a more rapid 
elimination from the human vaginal lumen.  
The apparent differences between macaques and humans, particularly with regards to 
C2G12 elimination, are intriguing and warrant more thorough investigation. However, it 
should be noted that there was a high degree of variability in detected mAb levels 
between participants within each of the Mabgel arms in our study, as borne out by the 
large reported ranges at each visit (Table 3-2). Thus, although clear trends in mAb levels 
were seen overall, there are likely to be marked differences in mAb elimination on an 
individual level. This could potentially also be the case with macaques. With this in mind, 
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the small number of animals studied and the fact that only a proportion of them were 
sampled at each visit might limit the reliability of any comparison. 
3.8.7.2 Comparison of our findings with vaginal IgG  t ½ estimates from other studies 
Very few other studies have investigated the t ½ of IgG after intravaginal application. 
Unfortunately, no t ½ estimates were derived in the CEA analysis of the concentrations 
detected in macaques following vaginal Mabgel administration. On review of the data, 
although six animals were sampled over a 72 hour period, due to technical and staffing 
constraints and faecal contamination, analysable samples were only obtained at three or 
more time-points in the first 24 hours, the period during which results were most reliably 
above the ELISA cut-off, in three individual animals, precluding robust t ½ estimates.  
In the only previous study of residence vaginal IgG t ½ in humans, which remains 
unpublished, human polyclonal IgG solution (RhoGam™, Ortho Diagnostic Systems) was 
applied to the posterior vaginal fornices of 10 women with a catheter [511]. Serial vaginal 
fluid samples were obtained using filter strips and anti- Rhoo D activity measured in a 
functional assay using Rhoo D
+ human red-blood cells.  Antibody levels were reported to 
have displayed a single phase, exponential decay, with t ½ = 8.85 hours.   
Studies conducted in mice used three different techniques (radioactivity detection, 
functional neutralization and ELISA) following lavage at various time-points, to measure 
elimination of antibody (125I- polyclonal mouse IgG, HSV2 specific monoclonal mouse 
IgG2a mAb and biotinylated polyclonal mouse IgG respectively) after intravaginal 
application [510].  Although the individual studies were small (n= 12, 3 and 6) and utilized 
a combination of cycling and DMPA-treated mice, they all provided generally similar 
estimates of t ½, increasing the robustness of the findings.  In contrast to the findings in 
women,  IgG was found to be eliminated bi-exponentially, in 2 separate phases; up to 90 
% was lost from the vagina in the first few hours (α phase, with t ½ = 0.7±0.1 hours) with 
the remainder eliminated  more slowly (β phase, with t ½ = 5±2 hours).  
There are a number of factors which must be taken into consideration when comparing 
our data with findings from the above studies. Firstly, the antibodies used were all 
applied in liquid solutions as opposed to a semi-solid, HEC-based, gel. As discussed in 
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section 3.8.8.1, this could alter their retention and distribution in a number of ways which 
could impact on vaginal t ½. Secondly, different techniques were employed for measuring 
IgG, with different assay sensitivities, dilution and processing requirements potentially 
impacting on the accuracy of IgG detection. However, since the same technique was used 
throughout each individual study, impact on t ½ estimates would be expected to small. 
Thirdly, as with our trial there were logistical restrictions on the number of serial samples 
that could be performed on each study subject. In the mouse studies, each animal could 
only be sampled at a single time-point since lavages were performed of the entire vagina, 
thus for each experiment, t ½ estimates were derived from concentrations detected in 
different animals at different time-points over a 25 hour period.  For the RhoGAM study, 
filter strips were used, enabling serial samples to be performed on the same individual. 
However, as this study was only presented as a conference poster, detailed information 
regarding methodology and t ½ calculation was not reported. Personal communication 
with one of the study investigators, R Cone, revealed that each woman was sampled 4 
times in a 72 hour period (1, 24, 48 and 72 hours post application) with t ½ estimates 
derived from log transformed data using a similar technique to us (see section 2.13.4.3). 
Confidence intervals were wider than for our study, given the smaller number of subjects, 
with the lower limit similar to our estimate (t ½= 8.85 95 % CI (5.1 to 11.2).  Stage of 
menstrual cycle, contraceptive use and parity of the participants is unknown.  
Given the above, the t ½ estimates derived from our data are in-keeping with those from 
previous studies, although it is possible this is by chance. All of the studies have 
limitations and many potential variables such as differences between IgG molecules, 
surface area: volume ratios between women and mice and effects of reproductive 
hormones have not been accounted for. 
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3.8.8 Putative mechanisms governing the elimination of the mAbs from 
the vaginal lumen 
Given the importance of antibody in the protection of mucosal surfaces from pathogens, 
including STIs, a surprising paucity of research has been conducted in relation to humoral 
immunity within the FGT. As a result, the source, distribution and clearance of natural IgG 
within the vaginal mucosa is incompletely understood [84, 601]. Based on what is known, 
the anatomy and physiology of the vagina, research using other tissues and agents, and 
the study of parenterally administered mAbs, the following mechanisms could be 
envisaged as having a role in the elimination of the mAbs C2F5, C4E10 and C2G12 from 
the vaginal lumen: 
1. Leakage 
2. Entrapment and loss in mucus 
3. Passage into the upper FGT 
4. Absorption /uptake from the vaginal lumen 
5. Metabolism/degradation 
Understanding these processes and their influence on the distribution and t ½ of the  
mAbs in the FGT, may help to elucidate mechanisms which play a key role in protective 
humoral immunity in the FGT and provide insights into ways in which the activity of the 
mAbs may be enhanced or reduced. 
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Figure 3-29 Putative mechanisms governing elimination of mAbs from the vaginal 
lumen 
 
3.8.8.1 Leakage 
The simplest way in which topically applied antibodies may be lost from the vaginal lumen 
is via leakage. In the mouse studies described above, loss during the initial 2 hours was 
increased by administering the antibody dose in a larger volume of PBS, and was virtually 
eliminated through anaesthesia, where the animals were laid on their backs and unable 
to move or groom [510]. It was thus hypothesised by the authors that the initial α phase 
was due to leakage from the vagina.   
If suitably formulated, applying mAbs within a semi-solid gel, rather than a liquid, should, 
in theory, reduce leakage whilst still allowing adequate distribution across the mucosal 
surface. As with mucus, the rheological properties of synthetic gels are largely 
determined by the nature of the matrix-forming polymer and its proportion relative to 
water and other constituents [602,603]. HEC is a non-ionic polysaccharide, produced 
through the expansion of cellulose, the major constituent of plant cell walls, by the 
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addition of sodium hydroxide and ethylene oxide [604].  A common gelling agent, it has a 
number of properties which make it highly suited for vaginal use and has been used in 
commercial lubricants, such as KY-Jelly (Johnson and Johnson, New Jersey, USA) and 
other microbicide formulations [512,513]. It displays pseudoplasticity and thermo  
reversible viscosity, becoming thinner and more stretchy at higher temperatures, 
enabling it to spread across the vaginal mucosa, whilst maintaining its integrity at low pH. 
In addition, it is mucoadhesive, forming cohesive interactions with the mucosal interface 
to increase retention (see section 3.8.8.2) [604].  However, producing a gel with ideal 
rheological properties is difficult, and even small changes in formulation can have a 
marked effect [602,603]. In comparison with the ‘universal’ HEC-based gel, developed 
and used by researchers from the International Partnership for Microbicides (IPM) and 
CONRAD [512,513], our gel vehicle contained a lower percentage of HEC (1.6 % vs 2.7%), 
different preservatives (methyl and propyl paraben vs sorbitol) and additional 
humectants (glycerin and maltose) to optimise the solubility and release of the mAbs. 
Thus, although the rheological suitability of our gel as a microbicide had been determined 
in-vitro, its behaviour within the complex physiological environment of the human vagina 
was uncertain prior to its use in the MABGEL 1 trial. 
In our trial, overt gel leakage was reported by 5 women, and 7 women reported using 
pads or underwear as a precaution to protect clothes or sheets from gel (see section 
5.4.6). Although difficult to quantify from history alone, most leakage was reported to 
occur on standing. This is unsurprising when considering the anatomy of the vagina (see 
section 1.3).  Thus, although there is likely to have been some early leakage of gel from 
the lower vagina, particularly in those women who stood up soon after application, gel 
administered to the upper vagina has a greater chance of having remained in situ.  
However, it is not possible to determine the extent to which leakage contributed to mAb 
elimination in our study. In addition, given that the 1st gel dose was applied in the EMU 
and women remained (largely seated) in the examination room (as a safety precaution), 
until after the 1 hour post-dose examination, it is possible that the potential impact of 
leakage was reduced on mAb levels obtained at this time-point. 
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3.8.8.2 Entrapment and loss in mucus 
As described in section 1.4.1, the vaginal mucosa is coated with secretions, including 
mucus. By adhering to mucus, polymers such as HEC not only increase the retention of 
gels but also the bioavailability of agents contained within them. HEC is water soluble and 
as it is spread and further hydrated at the mucosal interface, begins to swell and slowly 
dissociates. Interdiffusion and interpenetration can then occur between the chains of HEC 
polysaccharide and mucin polymers resulting in cross-linking, and the formation of 
hydrogen and/or electrostatic bonds [87, 604]. Such interactions open the gel matrix, 
allowing agents held within it to diffuse out.  Thus, the mAbs should, in theory, be 
released into mucus and held close to the vaginal mucosa, whilst the HEC slowly dissolves 
away. 
Naturally occurring antibodies are often found in mucus, having passed into it from the 
adjacent epithelium, and are thought to enhance protection against specific pathogens by 
trapping them and preventing their adherence to target cells [605,606].  This may be 
particularly important in the case of some nonenveloped capsid viruses (e.g, Human 
Papillomavirus (HPV), polio, adeno and rota viruses) which have evolved to pass 
efficiently through mucus and penetrate the underlying mucosa [87,607]. Although not 
fully understood, factors which influence the ability of a molecule or particle to diffuse 
through mucus include its size, hydrophobicity, its overall positive or negative charge and 
the thickness and viscosity of the mucus layer [87]. IgG mAbs, being approximately 20nm 
in diameter, should be relatively unimpeded by the mesh size of the mucin-matrix, which 
was originally estimated to be an average of 100nm in human ovulatory cervical mucus 
and may be even larger [607,608, 609]. However, antibodies contain multiple positive and 
negatively charged amino acids which, through both repelling and attracting the mostly 
negatively charged glycan moieties on mucin fibres, could enable them to form multiple 
transient, low affinity bonds. It has been proposed that these interactions may be 
sufficient to maintain antibody adhesion to mucus whilst allowing them enough freedom 
of movement to trap pathogens [607]. 
Since mucus is continuously produced, shed, and discarded from all mucosal epithelia, if 
the majority of the mAbs are retained in it post application then their residence time in 
the vagina would largely be determined by the clearance time for mucus. The typical 
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turnover time for mucus in the cervico-vaginal tract has not been elucidated, hence 
extrapolations must be made from other sites. In general, turnover appears to be fastest 
at surfaces with thin mucus layers, such as the nasal tract (20 mins) and slowest in the GI 
tract (4-6 hours), where there is a deep, ‘unstirred’ layer beneath the more rapidly 
cleared luminal mucus [610].  In addition, the mechanism of mucus transport will also 
have an influence. Mucus in the GI tract is dislodged by continuous peristaltic 
contractions, whereas in the respiratory tract it is wafted along by cilia. In the FGT, two 
processes act in opposing directions. Transport of sperm into and along the upper FGT is 
assisted through contractions of uterine smooth muscle (peristalsis) (triggered by 
endocrine and paracrine stmuli post coitus) and the ciliated secretory epithelium of the 
uterus and fallopian tubes. In contrast, mucus is mainly thought to be carried along the 
non-ciliated lower FGT mucosa to the introitus through the effects of gravity, the motion 
of the limbs and the activity of muscles in the pelvic floor and abdominal wall, which 
increase intra-abdominal pressure and/or squeeze the walls of the vagina together [611, 
612]. Taken altogether, it is difficult to determine an exact transit time for mucus in the 
vagina. Although likely to be several hours, it may be highly variable and influenced by 
activity, coitus, infections and other factors. 
3.8.8.3 Passage into the Upper FGT 
A study using MRI visualisation, following vaginal administration of 5ml N9 in a single 
woman, demonstrated passage of gel through the external cervical os and into the 
endocervical canal within 10 minutes of application. The amount reaching the internal 
cervical os and beyond was small and could not be accurately quantified [613]. In 
contrast, in another study, comparing the distribution of 3ml and 5ml of Gynol II 
spermicidal lubricant before and after simulated coitus (with a model phallus), gel was 
not visible in the endocervical canal in any participant within the first hour of use or prior 
to simulated intercourse. At 6 hours, it was seen in the endocervical canal in 33% (2/6) of 
women after using either volume of gel. Endocervical gel was also present in 20% (1/5) vs 
80% (4/5) of women, after using 5 and 3 mL, respectively, following simulated coitus 15-
30 mins post gel insertion [594].  The above findings suggest that although gel passage 
into the endocervical canal occurs, its incidence and timing is variable. Entry through the 
external cervical os may be increased by coitus and may be influenced by the nature and 
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volume of the product. Factors such as BMI, parity and activity/ambulation, may also 
have an effect [614].  Little is known regarding gel passage beyond the internal os and 
higher into the upper FGT. 
3.8.8.4 Absorption /uptake from the FGT lumen 
With its thick, multi-layered epithelium, the lower FGT mucosa is not primarily designed 
for absorption. However, its large surface area and the rich vascular and lymphatic 
network in the submucosa assist in the uptake of certain agents, which, if they enter the 
blood-stream, avoid first pass metabolism by the liver [615].  Although, the columnar 
epithelium of the upper FGT presents a thinner barrier, (as discussed in chapter 1), the 
movement of molecules are restricted through the presence of inter-cellular tight-
junctions [109].  Substances which are readily absorbed following vaginal application 
include small molecule drugs, such as atropine, morphine and vasopressin, and steroid 
hormones e.g. oestrogens and progestagens, for replacement or contraception [615].   In 
contrast to these molecules, which can diffuse transcellularly through most cell 
membranes, antibodies, being large and hydrophilic, must either pass between cells 
(paracellularly) or be ‘engulfed’ by cells via endocytosis [584,585,468]. Paracellular 
transport occurs through channels or ‘pores’ between adjacent cells, i.e. it is regulated by 
the ‘tightness‘ of the inter-cellular junctions, whereas endocytosis can either be receptor-
mediated or non-specific (pinocytosis) [584]. Despite IgG being the predominant antibody 
isotype found in human cervico-vaginal secretions, its source and the mechanisms of its 
distribution in the FGT have not been fully elucidated. However, as discussed below, 
there is some evidence to suggest that IgG may enter genital secretions via several routes 
and that some re-uptake by the epithelium may be possible. 
Given the absence of a large local immune inductive area in the FGT mucosa, unlike the 
Peyer’s patches in the GI tract, most IgG in the FGT lumen has historically been thought to 
be derived from the systemic circulation [601,616,617].  According to this model, IgG 
passes through the endothelium, into the submucosa, then through the cervico-vaginal 
epithelium via largely passive mechanisms, such as convection (paracellular carriage with 
fluid) and diffusion [584,585,617], with or without some additional active transport [616].  
However, despite being debated for almost 50 years, no direct evidence has yet been 
presented to confirm or refute the theory that genital tract IgG originates primarily from 
 206 
 
serum. Indirect support for a systemic origin includes the ability of IV administered anti-
HIV-1 IgG1mAbs to protect macaques from vaginal SHIV challenge [491,492,493]. Also in 
keeping, is the finding that following IM vaccination, including against the sexually-
acquired pathogens HBV and HPV, levels of specific IgG are detected in the same 
proportion (relative to total IgG) in both genital secretions and serum [618,619].  On the 
other hand, there are several lines of evidence which could suggest that at least some IgG 
is produced locally in the FGT. Higher specific:total IgG ratios have been detected in FGT 
secretions compared with serum following vaginal vaccination or genital infection [620, 
621] and IgG sub-class distribution has been shown to differ between serum and cervico-
vaginal secretions, with IgG1 predominating (>90% of IgG) in the latter [622]. In addition, 
IgG secreting plasma cells have been identified in the endocervical stroma, and to a lesser 
extent in that of the vagina and endometrium [616,623].  In support of an important role 
for the upper FGT in contributing to the antibody pool found in cervico-vaginal secretions, 
in post-menopausal women, levels of IgG decreased by half and  those of IgA by 15 fold 
following hysterectomy [624].  
What also remains unclear is whether IgG within the FGT sub-mucosa, either having been 
produced locally or extravasated,  passes into secretions via an active or a passive process 
and whether the transport mechanisms in operation are the same in the upper and lower 
FGT given their different epithelial characteristics. In contrast to IgG, the mechanism 
through which most locally produced IgA and, to a lesser extent, IgM enters mucosal 
secretions is well understood and involves active transport by the polymeric 
immunoglobulin receptor (pIgR) [616,625].  Unlike IgG, which is monomeric, secreted IgM 
and IgA are found as polymers, joined at their Fc regions by a J-chain. IgA forms mainly 
dimers whereas IgM is pentameric [73]. After production by plasma cells in the lamina 
propria adjacent to the mucosal surface, IgA or IgM polymers bind to pIgR, which is 
expressed on the basolateral membrane of the epithelial cell, and are taken up into an 
endosome, within the cell, via receptor mediated endocytosis. Through being bound to 
pIgR, the Ig polymer passes through the cell and is targeted to the luminal plasma 
membrane. Once on the outside of the cell, proteolysis of the receptor occurs, and the Ig 
polymer along with a portion of the receptor known as the secretory component (SC), is 
released to diffuse into the lumen [625].  
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A possible candidate transporter of IgG in the FGT is the neonatal Fc receptor (FcRn). This 
is a heterodimer composed of a membrane-bound major histocompatibility complex 
(MHC)- class 1-like heavy chain joined to β2 microglobulin (β2m)  [626,627]. It was first 
identified as the receptor which mediates the transport of IgG from mother to baby for 
passive immunity [628]. Expressed in the intestine of neonatal rodents, it transports IgG 
from ingested maternal milk across the intestinal epithelium [629]. In contrast, most 
passage occurs antenatally in humans, with FcRn transporting IgG from maternal blood to 
fetal capillaries through its expression on syncytiotrophoblast [630,631].  Although both 
systems involve FcRn-mediated transcytosis of IgG across a polarised epithelial cell layer, 
the mechanism by which this occurs is slightly different in each case. FcRn binds to the Fc 
portion of IgG in a pH dependant manner [632,633].  It can bind with high affinity at acidic 
pH (< 6.5) but not at physiological pH (7.4). Expressed on the brush border of enterocytes, 
it binds IgG in the acidic milieu of the lumen, internalises it, and releases it at neutral pH 
on the basolateral side [634,635].  In syncytiotrophoblasts, which are bathed in maternal 
blood (pH 7.4), IgG is instead internalised via pinocytosis, where it enters the endosomal 
pathway.  FcRn is expressed on the endosomal membrane and binds IgG as the contents 
acidify.  At the foetal side of the cell, the vesicle fuses with the membrane, and the 
physiological pH leads to the dissociation of IgG from FcRn [636,637].   
FcRn has now been shown to be expressed and functionally active in a range of adult 
human epithelial cells and tissues, including in the intestine [638,639], respiratory tract 
[640], renal tubule [641,642], liver [643] and vascular endothelium [644,645].  It is also 
found in cells of myeloid origin [646,647].  In some mucosal tissues, such as the intestine 
and lung, potential for bi-directional transport has been demonstrated [639,640]. Using a 
model in which adult FcRn α-chain-deficient mice express intestinal FcRn under the 
control of the human FcRn promoter, Yoshida et al. found that FcRn transcytosed 
submucosal IgG across the epithelial layer to the luminal side of the cells. Antibody then 
bound to cognate antigen, and the resulting immune complexes were then transcytosed 
back in the reverse direction, being released at the basolateral membrane. Immune 
complexes were taken up by submucosal DCs which were shown to migrate to the 
draining LN where they elicited antigen-specific T Cell responses. The researchers then 
extended their findings to the respiratory tract of mice [648]. Thus, they demonstrated an 
additional role for FcRn in immunosurveillance of mucosal surfaces.   
 208 
 
The above findings offered the potential that FcRn could be exploited for delivery of 
therapeutic proteins and vaccines across mucosal surfaces. Bitonti et al. demonstrated 
proof of concept by producing an Fc-fusion protein (a therapeutic protein fused to the Fc 
portion of IgG), depositing it in the lungs of NHPs by inhalation and detecting it in serum 
20 hours later [649].  They subsequently demonstrated similar findings in humans [650].  
Recently, Lu et al. have tested this strategy for vaccination.  Mice were immunized 
intranasally with IgG Fc fused to HIV-1 Gag protein (Gag-Fc fusion protein) as an 
immunogen and CpG oligodeoxynucleotides as an adjuvant. Animals developed local and 
systemic immunity, including durable B and T cell memory. Gag-specific immunity was 
sufficient to protect against subsequent intravaginal challenge with recombinant vaccinia 
virus expressing the HIV Gag protein [651].  
Recently, Li et al. have published data in support of a role for FcRn in the FGT [652]. They 
have demonstrated expression of FcRn mRNA (by RT-PCR) and protein (by Western blot) 
in 3 primary human female genital epithelial cell lines (End1, endocervical; Ect 1, 
ectocervical; and VK2, vaginal) and in HEC-1A, an endometrial adenocarcinoma cell line. 
In addition, they have shown, using immunohistochemistry, that it is present in human 
endometrial and vaginal tissue, with strong staining in the epithelium and weak scattered 
staining in the lamina propria, the latter, presumed to represent macrophages or 
dendritic cells, being more apparent in the endometrium. The authors were also able to 
demonstrate selective transcytosis of IgG in-vitro, using HEC-1A cells and a commercially 
available, primary human vaginal epithelial tissue (Human Epi-Vaginal Tissue Model 
(vaginal-ectocervical (VEC)-100 FT), and showed that it could occur in both basolateral-to-
apical and apical-to-basolateral directions.  
Experiments in mice appear to support these findings [652]. Using prepubertal mice, to 
minimise variation due to the estrus cycle, levels of biotin-labelled mouse IgG in vaginal 
washings were measured in both wild-type (WT) and FcRn knock-out (FcRn-KO) B6 mice 
12 hours after intra-peritoneal administration. To compensate for the reduction in 
circulating IgG that is seen in the absence of FcRn (see section 3.8.9.2), FcRn-KO mice 
received double the dose (200 vs 100 μg) of IgG. Although serum concentrations were 
similar in both sets of mice, biotin-labelled IgG was only detected in vaginal washings in 
WT mice, suggesting that FcRn is required for the transport of IgG from the blood into the 
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genital tract lumen. In a parallel experiment, biotin-labelled IgG was administered 
intravaginally into both WT (50 μg) and FcRn-KO (100 μg) mice in 30 μl PBS, and only 
detectable, at 12 hours, in the serum of WT mice, supporting the idea that FcRn also 
mediates transport in the opposite direction. However, the results of this research must 
be interpreted with caution.  Appropriate isotype and genetic controls were not shown 
for these experiments, and findings have not been corroborated by other researchers.  
Using both adult and pre-pubertal WT and FcRn-KO B6 mice, Schäfer found no evidence, 
from measuring relative titres of endogenous IgG, and IV administered biotinylated 
mouse IgG and human IgG, in serum and genital tract secretions, that IgG accumulates 
differently in the FGT in the presence and absence of FcRn. In addition, although FcRn 
expression was detected in stromal immune cells, by immunofluoresence, it was not 
found in vaginal, ectocervical, endocervical or uterine epithelium in WT mice.  
Intravaginal administration of biotinylated mouse IgG and human IgG did not result in any 
detectable translocation to serum at time-points between 1 and 24 hours post dose. As 
has been found by other researchers, in post-pubertal mice, levels of genital tract but not 
serum IgG (both endogenous and exogenous) varied markedly with the menstrual cycle, 
being highest during metestrous (post-ovulation) and lowest during proestrous (pre-
ovulation).  Similar patterns were seen in both WT and FcRn-KO animals suggesting that a 
local hormonal effect on FGT epithelial and/or vascular permeability, or on another as yet 
undiscovered transporter, may underlie this [K Schäfer, unpublished, PhD thesis, 2012]. 
Schäfer’s experiments have been confined to mice. However, due to differences in the 
structure of the promoters governing FcRn gene expression in humans compared with 
those of rodents and other mammals [653,654], significant inter-species variation is seen. 
For example, in humans FcRn is expressed by intestinal epithelial cells in both the fetus 
and adult whereas its presence diminishes in mice after the neonatal period [655,656]. 
Respiratory tract expression occurs mainly in the upper airways of humans and other 
primates and the bronchiolar and alveolar epithelium in cows and rats [640,657,658]. 
Thus, further investigation is needed to verify or refute the hypothesis that FcRn is 
present and mediates bi-directional transcytosis in-vivo in the human adult FGT. In 
addition, it is unclear if FcRn would have the same function at all sites in the FGT.  It is 
easy to visualise how IgG could be transported in both directions across the single-cell 
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thick, columnar epithelia of the endocervix and endometrium. At these sites, under 
normal conditions, the basolateral and luminal extracellular environments are at neutral 
pH, and IgG transcytosis could be conducted in a similar manner to that seen in 
syncitiotrophoblast. Such a mechanism is supported by the supplementary finding of Li et 
al. that in HEC-1A cells, FcRn co-localised with EEA1, a protein found in early endosomes 
[652]. In contrast, hypothesised transport across the multilayered, stratified epithelium of 
the vagina is more problematic. Although FcRn appears to be expressed in VK2 cells and 
in the mature, human vaginal epithelium [652], its localisation within the latter has not 
been clearly elucidated. The vaginal epithelium consists of cells at various stages of 
maturity, making it possible to identify four different layers, namely the basal, parabasal, 
intermediate, and superficial layers [659]. Full thickness transport of IgG would 
conceivably require the expression of FcRn in all of these layers but whether this occurs 
has not been ascertained.  Studies in skin have shown that FcRn is present intracellularly 
and is functional in cultured human keratinocytes, but its expression is confined mainly to 
the basal and suprabasal layers in normal human epidermis [660]. The fact that the 
human vaginal lumen is acidic (pH 4), under normal circumstances, would also present a 
barrier to the basolateral to luminal transport of IgG by FcRn. Although bidirectional 
transcytosis was possible in the Epi-Vaginal tissue model [652], the fact that this was 
grown as a monolayer and incubated in non-acidic culture medium renders it markedly 
different from the in-vivo environment. 
It has been proposed that, in the human vagina, rather than primarily mediating IgG 
transport across all of its many layers, FcRn may play a role in the sequestration of IgG 
near the lumen and/or in the delivery of IgG-antigen complexes to antigen presenting 
cells in the epithelium [652]. The acidic milieu of the vaginal lumen may enable FcRn to 
bind IgG for relatively long periods on the epithelial cell surface and allow it to capture 
cognate antigen whilst still holding onto it [661]. Such IgG could potentially be held ‘in-
reserve’ until a particular infection was encountered.  IgG-Ag complexes could then be 
recycled into the cell for transcytosis and gradually transported from cell to cell until a 
dendritic cell or macrophage was encountered. 
Our data, like that of Schäfer, shows no evidence of antibody uptake from the FGT lumen 
into the systemic circulation, and does not support the existence of bi-directional 
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transcytosis. However, the possibility of an IgG sequestration or surveillance role of FcRn 
in the vagina is not excluded. It is also possible, but unlikely, that luminal to basolateral 
mAb transport could have taken place and gone undetected  i.e. if the mAbs were passed 
into the sub-mucosa but did not get taken up by the lymphatic system or if only a low 
level of transport occurred. Interestingly, a different mechanism through which 
antibodies may be retained by the ectocervical-vaginal epithelium has recently been 
demonstrated by Blaskewicz et al.  In an experiment  in which Cy-3 conjugated human IgG 
was administered intraluminally to cultured cervical explant tissue, IgG was shown to 
permeate into the most superficial 3 to 4 cell layers of ectocervical epithelium (which are 
devoid of tight-junctions) but did not penetrate into deeper layers or through the 
endocervix [241]. It could thus be envisaged that antibodies may be sequestered in the 
most superficial layers of the ectocervico-vaginal epithelium, providing a potential zone 
for binding to micro-organisms and preventing them breaching deeper into the mucosa.  
Support for the retention of antibody by the mucosa is provided by findings from the 
mouse studies discussed in section 3.8.7.2. To determine the efficiency of lavage at 
removing IgG from the vagina, each individual mouse receiving topical 125I-IgG, had at 
least 4 lavages taken at a single time-point which were analysed separately in a gamma 
counter. The first lavage removed approximately 70 +/- 10% of the 125I-IgG from the 
lumen and the amount of 125I-IgG recovered in each subsequent lavage decreased by a 
factor of ten. Lavaging four times was sufficient for obtaining all of the 125I-IgG that could 
be removed from the vaginal lumen by lavage, which was 80 +/- 10% of the dose. Thus, 
this suggested that as much as 20% of the delivered antibody adhered to the vaginal 
mucosa in a way that resisted repeated lavaging.  The authors verified this by removing 
the reproductive organs from some of the animals and showed that most of the residual 
radio-activity remained associated with the vaginal tissue [510].  To demonstrate uptake 
of antibody into the FGT mucosa in our trial participants would have required vaginal 
biopsies to have been taken for analysis by immunohistochemistry. However, biopsies 
were not included in our study protocol. Although not yet done, it would be feasible to 
conduct another study using mice, perhaps with immunofluorescent-labelled antibodies, 
to evaluate their distribution in tissue post vaginal administration. 
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3.8.8.5 Metabolism/degradation 
IgG is susceptible to proteolysis by a number of enzymes including Plasmin, Pepsin, 
Trypsin, Papain, Cathepsins, elastases and metalloproteinases [598,662,663,664,665]. 
These mediate cleavage at or around the hinge region, which contains disulphide bonds 
between the Fab arms and the two carboxy-terminal domains (CH2 and CH3) of both 
heavy chains (see Figure 1-8). Cleavage at the hinge by Papain generates individual Fab 
and Fc fragments, whereas cleavage above (in CH2), by Pepsin and below (in CH3), by 
Plasmin, create (Fab)2 and Fabc (antigen and complement binding) molecules  
respectively. IgG subclasses vary in their susceptibility to these enzymes, with IgG3, which 
has a larger, more accessible hinge, being most susceptible, IgG2 most resistant and IgG1 
and IgG4 intermediate [666]. In addition to proteases, immunoglobulins, like all proteins, 
are also substrates of peptidases. These are a family of enzymes which act to remove 
amino acids from the amino (NH2) and carboxy (CHO) terminals of peptide chains, 
resulting in their modification or breakdown [667]. 
IgG breakdown can occur intra- and/or extracellularly in various body tissues and fluids.  A 
number of genital tract pathogens have been shown to produce proteases, which cleave 
immunoglobulins as a means of evading detection. These include Trichomonas vaginalis 
Neisseria gonorrhoea, BV-associated bacteria and the urinary tract pathogen Proteus 
mirabilis [668,669,670,671]. In addition, enzymes are released by polymorphonucleocytes 
(PMNs) [672], which although increased in number in the presence of STIs and 
candidiasis, are also found in the healthy vagina [72]. 
Intracellular IgG degradation in the FGT has not been formally studied. The extent to 
which it contributes to mAb elimination will depend on how much enters the epithelium 
and whether it is taken up by cells. One mechanism through which endogenous IgG may 
be catabolised is following FcγR–mediated endocytosis by macrophages and monocytes. 
However, only FcγRI is bound and activated by monomeric IgG; FcγRII and FcγRIII 
subtypes requiring interaction with multiple IgG molecules bound to antigen within an 
inmmune complex [143,147]. Given the relatively high affinity of IgG for FcγR and the high 
endogenous concentrations of IgG in plasma (around 10g/L) and genital secretions 
(around 1g/L), it has been argued that FcγR-mediated elimination is unlikely to occur to a 
significant degree for monomeric IgG, but becomes a more dominant mechanism for IgG 
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immune complexes [584,585]. Thus, although macrophages are commonly found within 
the cervico-vaginal mucosa, it seems probable that FcγR-mediated clearance contributed 
little to mAb elimination in our study. However, FcγRIII-triggered endocytosis of mAb-HIV 
virion complexes may have played a role in the elimination of the mAbs following i.v. 
administration to HIV infected individuals (see section 3.8.9), and could also potentially 
contribute to the efficacy of a mAb-based microbicide (see section 6.2.3.2). The latter 
possibility is strengthened through the finding that FcγRIII is expressed by a range of 
genital tract ECs [652]. 
Intracellular IgG catabolism in the FGT may also be influenced by the exact location and 
function of any FcRn present. Following endocytosis, proteins enter the endosomal 
pathway and are targeted for destruction in lysosomes.  However, as described earlier, in 
some tissues FcRn is located on the endosomal membrane where it acts to capture and 
return IgG to the surface.  In certain cell types, such as endothelium, hepatocytes, and 
those of myeloid origin, instead of transcytosing IgG, FcRn may simply return it to the 
same portion of the membrane, hence in effect, recycling it [643,647,673].  The same 
occurs with albumin. The long plasma t ½ of most endogenous IgG, and albumin, in 
comparison to other antibody classes and plasma proteins (21 vs < 7 days) is thought to 
largely result from this process [142, 674, 675]. Thus, if present in the vagina, FcRn could 
potentially both recycle and sequester IgG, resulting in a prolongation of its t ½. 
3.8.9 Possible explanations for the difference in pharmacokinetics 
between 2G12 and the MPER mAbs 
The apparent difference in rates of vaginal luminal elimination seen in our study between 
C2G12 and the MPER mAbs is intriguing. Whereas the concentrations of C4E10 and C2F5 
appeared to follow an exponential decay, with remarkably similar t ½s, levels of C2G12 
declined non-exponentially, with a more rapid decrease seen at higher concentrations, in 
the 1st 8 hours post dose, becoming slower thereafter. Differences in the pharmaco 
kinetics of the mAbs have also been observed previously when they were administered 
intravenously to HIV positive individuals [501,503,505,504,676]. In a long-term 
pharmacokinetic study, high doses (1g, 1g and 1.3g respectively) of C2G12, C4E10 and 
C2F5 were given in combination to 14 HIV-1-infected individuals at weekly intervals over 
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a 3 month period [676].  A slightly higher dose of C2F5 was administered because it had 
been shown to have the shortest t ½ of the 3 mAbs in previous studies [501,503].  In 
general, the distribution and elimination pharmacokinetics of all 3 mAbs appeared typical 
of systemically administered antibodies [584].  The plasma concentrations declined bi-
exponentially over time, compatible with a two-compartment pharmacokinetic model 
(plasma and tissues). Each antibody had a rapid distribution phase, followed by a log-
linear terminal elimination phase. Volumes of distribution were similar for all 3 mAbs, 
with a small central volume (Vc), equivalent to the assumed plasma volume, and a 3 times 
larger steady state volume (Vss), suggesting that significant amount of antibody entered 
the tissues.  Despite these apparent similarities, C2G12 was found to accumulate far more 
on multiple dosing than the other 2 mAbs, achieving significantly higher trough and peak 
plasma concentrations.  In contrast to the situation in the vagina, it was shown to display 
a much longer elimination t ½ (t ½ β) in plasma (21.8 +/- 7.2 days) compared to C4E10 
(5.5+/- 2.2 days) and C2F5 (4.3+/-1.1 days) [676].    
Analysis of the findings following both systemic and vaginal administration may help to 
elucidate the reason(s) behind the observed pharmacokinetic differences between the 
mAbs.  However, it should be borne in mind that the studies differed in the nature of 
their participants (HIV positive vs negative) and time-scales (3 months vs 12 days).  
Although this discussion will concentrate on factors that may influence mAb 
pharmacokinetics in general, such as variation in the intrinsic properties of the antibody 
molecules, differences in mAb-HIV interactions and clearance via the reticuloendothelial 
system (RES) may also have played a role in the IV dosing studies. 
3.8.9.1 Origin of constant (Fc) and variable (Fv) regions of the IgG1 mAbs 
It seems probable that most of the t ½ variation seen between the mAbs may be 
explained by differences in their physico-chemical properties.  It is thus important to fully 
understand what features are shared between the mAbs and which are not. In addition, 
any characteristics that make them atypical from usual IgG1 antibodies may also be of 
relevance. All 3 mAbs have fully human IgG1 sequences but were expressed in Chinese 
hamster ovary (CHO) cells. Their variable (Fab) regions are unique, each being derived 
from an individual hybridoma created through the fusion of peripheral blood lymphocytes 
from HIV-1 positive donors with the CB-F7 myeloma cell line [508]. In contrast, they are 
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thought to share identical, typically conserved IgG1 constant (Fc) regions [509].  However, 
whereas 2G12 was initially produced as an IgG1 antibody, hybridoma-derived 2F5 and 
4E10 mAbs were originally generated as IgG3 subtypes.  IgG3/G1 class-switched variants 
were subsequently generated in CHO cells through recombinant expression of the kappa 
light chain (ĸLC) and variable heavy chain (VH) mRNA sequences from the original 
hybridomas with those encoding IgG1 CH1-CH3 domains [509].  The IgG1 sequences  were 
obtained from an IgG1-producing human hybridoma cell line (known as 1B1) that had 
been created at the same time as those producing the other mAbs.   
3.8.9.2 Influence of both Fc and Fv regions on FcRn-IgG binding 
IgG3/G1 Isotype switching was primarily performed to increase plasma t ½. Typical IgG 
antibodies from sub-classes 1,2 and 4 have a t ½ of around 21 days whereas that for IgG3 
and other antibody classes is < 7 days [677].  As described in section 3.8.8.5, the relatively 
long serum t ½ of most IgG isotypes has been primarily attributed to recycling by FcRn in 
endothelium and other tissues [645]. The structural basis for the FcRn-IgG interaction has 
been well characterised. The binding site for FcRn is in the CH2-CH3 hinge region of the IgG 
Fc and is distinct from that of other Fcγ receptors [627,678]. Binding requires a 
hydrophobic interaction between an isoleucine residue at position 253 of IgG and a 
tryptophan at 133 on FcRn. Salt bridges between anionic residues on the α2 helix of FcRn 
and histidine residues on the CH2-CH3 of Fc are crucial for stabilizing the interaction 
[645,678]. These bonds depend on protonation of the histidines, thus explaining the pH 
dependence of binding. The exact number of histidines present varies between different 
antibody isotypes and between IgG from humans and other species, helping to explain 
different binding affinities to human FcRn [679]. Mutational analyses have shown that 
single or combinations of amino acid substitutions at or adjacent to these key sites can 
significantly enhance or reduce systemic IgG clearance by up to 3-fold [680,681,682,683].  
Since pH dependence is important for efficient recycling, mutations which improve 
binding at acidic pH alone result in much greater increases in plasma t ½ of the variant IgG 
than those which also increase affinity at neutral pH [684]. Enhanced binding or 
decreased dissociation at pH 7.4 may actually increase elimination, of the mutant and/or 
other IgG, through being degraded, after failing to be released at the cell surface, or 
competitively inhibiting the recycling pathway [685,686,687]. 
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It is interesting to note that whereas the plasma t ½ of C2G12 is similar to that of natural 
IgG1, despite being class-switched, those of C4E10 and C2F5 remain more in keeping with 
their original isotype, IgG3, which is not bound by FcRn. In addition, in the vagina, the 
initial rapid loss of C2G12 at high concentration (in the 1st 8 hours) with slower loss 
thereafter, might be in keeping with a saturable mechanism, like  receptor binding,  unlike 
the exponential reduction of the other 2 mAbs. The elimination of IgG from plasma is 
known to be concentration dependant, with the recycling capacity of FcRn exceeded, and 
IgG t½ reduced, following administration of high doses of IVIg [677]. However,  owing to 
the large quantity of endogenous IgG that is present in the body (around 10g/L in plasma; 
50 to 100g total body), total doses of 3.3g of the mAbs given iv would not be expected to 
increase the overall concentration of IgG sufficiently to lead to a significant reduction in 
plasma t½ [584].  In contrast, since IgG levels in vaginal secretions are lower 
(approximately 0.5 to 1mg/ml) it is possible that administering just 25 to 50mg of C2G12 
to the vaginal lumen may be sufficient to saturate any FcRn present in the mucosal 
epithelium. However, since all 3 mAbs possess the same Fc sequence, it might be 
expected that they would bind to FcRn with identical affinity. Although it is possible that 
mutations in the FcRn binding region may have arisen spontaneously during CHO cell 
expression, this is felt unlikely, and is not supported by amino acid sequencing performed 
by Polymun as part of their quality assurance analyses (B. Vcelar, personal 
communication).  Interestingly, recent observations suggest that the IgG Fv domain may 
also impact on the FcRn-IgG interaction. mAbs with the same wild-type human Fc 
sequences but different Fab domains have been shown to exhibit marked variation in 
their binding affinities for FcRn at acidic pH and in their dissociation at neutral pH [688]. 
This supports the earlier finding that Fc-fusion proteins bind with lower affinity to FcRn 
than mAbs which possess the same IgG1 Fc region [689]. Although the mechanism 
through which the Fv may influence FcRn binding has not yet been determined, it is 
hypothesised that the overall tertiary or quaternary structure of the IgG molecule may 
impact on the stability of the interaction or the ability of FcRn to form functional dimers 
[688]. To date, no direct assessment has been made of the relative affinities of C2F5, 
C4E10 or C2G12 for FcRn but it would be an important future investigation.  
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3.8.9.3 Unique structural characteristics of the mAbs 
The nature of the Fab regions or overall structure of the mAbs may be key to explaining 
their pharmacokinetic differences. 2G12 is a very unusual antibody. It has been shown to 
bind with nanomolar affinity to Man α1-2Man-linked moieties on oligomannose-type 
sugars that are covalently-attached, as a cluster, to gp120 [473,474]. This is interesting for 
three reasons: 1) oligosaccharides attached to the viral coat proteins are processed by the 
host and are, therefore, considered unlikely to be recognised as ‘foreign’ and 
immunogenic; 2) glycosylated proteins are normally synthesized as a collection of 
glycoforms, in which a range of different sugars can be present at a single site, which 
dilutes any potential antigenic response, and 3) because carbohydrate-protein 
interactions are usually much weaker (in the micro-molar range) than protein-protein 
interactions [690].  However, for reasons that are yet to be fully understood, intrinsic 
properties of the gp160 structure, together with steric constraints related to 
trimerisation, mean that the protein does not undergo the usual processing of sugar 
residues that occurs within the medial Golgi [691]. This gives rise to an unusual 
predominance of oligomannose-type glycans on gp120 including a particularly dense 
‘patch’ of residues, not normally found on mammalian proteins, in which the 2G12 
epitope is located [474].  
Studies have shown that 2G12 achieves its strong antigen affinity through possession of 
an atypical 3D conformation, which enables it to bind multiple adjacent carbohydrate 
epitopes in an array [692]. As shown in Figure 1-8, in a typical antibody molecule, the 2 
Fab domains are formed from the pairing of the light chain variable (VL) and constant (CL) 
domains with the variable and 1st constant domains of the heavy chain (VH and CH1).  
However, in 2G12 the two VH domains have swapped their VL partners (‘domain-
exchange’), resulting in a more tightly-packed, twisted orientation of the VH domains with 
respect to the CH1 domains compared to a standard Fab (see Figure 3-30).  As a result, 
rather than being free to rotate independently around the hinge region, the two 2G12 
Fabs are arranged side-by-side with their respective binding sites facing in the same 
direction. Thus, instead of containing 2 separate antigen binding sites separated by a 
variable distance (usually between 10 to 15nm), the two carbohydrate binding sites 
created by the VH and VL domains of 2G12 are separated by a fixed distance of only 
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3.5nm, with two additional binding sites created at the interface of the two VH domains 
[692].  Such an arrangement results in 2G12 possessing an extended linear conformation 
instead of the usual Y- or T-shape. 
Figure 3-30  Atypical structure of 2G12 
 
Figure reproduced from Calarese et al. Science, 2003 [692]. (A) Crystal structure of 
monomer of Fab 2G12 showing that the VH domain clearly separates from its typical interaction 
with the VL. The light and heavy chains are shown in cyan and red, respectively. (B) Crystal 
structure of the two domain-swapped Fab molecules assembled as a dimer. Both light chains 
are shown in cyan, with the heavy chains from Fab 1 and Fab 2 shown in red and purple. The 
fixed distance between the two combining sites is shown. (C) Elbow region between the CH and 
VH domains illustrating the domain exchange. The location of an unusual amino acid residue, 
ProH113, that may favor the domain exchange, is shown. (D) Close-up view of the VH/VH′ 
interface between the variable heavy domains. Potential hydrogen bonds are shown with 
dashed black lines.  
In comparison with 2G12, 2F5 and 4E10 exhibit much more typical antibody structures. 
However, they do show some adaptations which enable them to bind their epitopes, 
which lie on the portion of gp41 directly adjacent to the HIV viral membrane (the MPER).  
Both 2F5 and 4E10 possess longer and more hydrophobic (neutrally charged) third 
 219 
 
complementarity determining regions (CDR H3) on the variable part of their heavy chain 
than found in other IgG molecules, and have been shown to interact with a range of 
membrane-associated lipids [479,481,693].  This propensity is greatest for 4E10, which 
has been shown to bind with high affinity to cholesterol in addition to several glycolipids 
and phospholipids, including cardiolipin [694]. In contrast, studies have demonstrated 
mainly low affinity interactions between 2F5 and several anionic and neutral lipids, and 
no evidence of any lipid binding by 2G12 [506,518].  It has been shown, using phosholipid 
membrane model systems, that 4E10, and to a lesser extent 2F5, interact with 
zwitterionic and anionic lipid membranes before and/or during epitope binding and that 
whilst this is not essential for epitope binding, it is required for efficient neutralization 
[695,696]. Recent studies have been conducted to explain the apparent greater 
membrane affinity of 4E10 compared to 2F5, as well as its more potent neutralizing 
effect.  Although  the linear peptide epitopes recognised by each mAb lie close together 
on the MPER, the NWF(D/N)IT core (bound by 4E10) is more deeply  inserted into the 
lipid bilayer than the ELDKW core (bound by 2F5). In addition, 4E10 appears to interact 
more deeply within the membrane to promote the extraction of the MPER whereas 2F5 
binds on top of its epitope at the surface of the membrane, with only the tip of its CDR H3 
loop entering the bilayer [697,698]. 
Figure 3-31 Structures of 2F5 and 4E10 
 
Figure reproduced from Nabel GJ, Science 2005 [699]. 
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3.8.9.4 Effect of molecular charge on mAb pharmacokinetics 
As well as impacting on epitope recognition and FcRn binding, the overall structure and 
polarity of an antibody can also influence its non-specific interaction with cells and 
tissues.  A fundamental property of all proteins is their isoelectric point (pI) which is 
defined as the pH at which the molecule carries no net electrical charge [700].  Being 
mostly determined by the proportion and position of charged amino-acid residues within 
a molecule, the pI can largely be predicted from a protein’s mRNA sequence and overall 
structure [700]. However, certain chemical modifications, such as glycosylation, 
deamidation, isomerisation or oxidation, which can arise during production or storage of 
proteins, including antibodies, can give rise to charge heterogeneity even within a single 
mAb preparation [598]. Thus, when pIs are confirmed experimentally, using 
immunoelectrophoresis (IEF), it is not uncommon to see multiple bands, representing 
different isoforms of the same mAb with a range of slightly different pIs. Indeed this is 
what is seen with the anti-HIV mAbs: 2F5 produces bands in pI range 9-10; 4E10  close to 
9.5 and 2G12 in pI range 7.6- 8.6 (B. Vcelar, personal communication). Thus, although 
variable, 2G12 molecules generally have a lower, more anionic pI than the MPER mAbs. 
In general, the more basic (higher) isoelectric point of most antibodies compared with 
other serum proteins (pI 6.5 to 9 vs < 5.5) tends to favour their retention in tissues, as it 
renders them more likely to bind to negatively charged glycans on cell surfaces or within 
the extracellular matrix [700,701,702]. In addition, electrostatic interactions between 
positively charged antibodies and negatively charged cell membranes have been shown 
to enhance cellular uptake by pinocytosis [703,704].  Thus, in theory, mAbs with higher 
pIs would be predicted to be taken up more readily into tissues than those with lower 
ones. The effect of charge on systemic pharmacokinetics has been specifically studied 
using chemically modified IgG. Overall, there is indeed a trend for antibodies to show 
greater uptake and binding by tissues, and a resulting increase in their plasma clearance, 
with increasing  cationization.  In contrast, although anonized antibodies generally show 
less tissue uptake, they can display either increased or decreased plasma and total body 
clearance [700]. The latter may depend on the site and nature of the modifications and 
whether or not they impair binding to FcRn. To date, only one group have looked 
specifically at the effect of varying charge in the Fab region in antibodies which share 
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identical constant regions. Igawa et al. produced several charge-modified humanized IgG4 
antibodies through selective mutagenesis of amino acids in the Fv region and evaluated 
their pharmacokinetics in both normal and β2m KO mice [705].  In their studies, they saw 
a 2.4 fold increase in the plasma elimination t ½ and a 4.4 fold reduction in total body 
clearance between the  antibody with the highest pI (pI  9.2; t ½ 10.9 days) and the one 
with the lowest (pI 7.2; t ½ 26.1 days).  Similar results were seen in WT and β2m KO mice 
confirming they were independent of FcRn. This suggests that variation in charged 
residues in the IgG Fv region can produce pharmacokinetic changes of a similar 
magnitude as altering FcRn binding affinity.  
One might predict from their higher pIs, and possibly their greater affinity for lipids, that 
the MPER mAbs could be taken up more readily by tissues than 2G12. This could explain 
their more rapid plasma clearance. In addition, it could lead to them being retained in 
greater concentrations in the superficial layers of the vaginal epithelium from which they 
could later diffuse to the mucosal surface. However, in the long-term systemic dosing 
study, the Vss/Vc ratios were alike for all 3 mAbs, suggesting their tissue distribution 
kinetics were similar. However, as Joos et al. point out, there were a number of 
limitations to their two-compartment model [676].  Firstly, predicted values of Vss and Vc 
were derived from their data assuming that a rapid equilibrium in concentration was 
reached between the central (plasma) and peripheral (tissue) compartments for each 
mAb.  Any binding/retention of the mAbs in tissues would potentially invalidate this 
assumption and result in an underestimation of Vss. Secondly, when significant 
elimination occurs from peripheral compartments in addition to the central 
compartment, it is not possible to obtain accurate estimates of Vss unless tissue 
concentrations are measured in addition to those in plasma. This was not done in this 
particular study. Since the study was conducted in HIV positive individuals, at least some 
binding of mAbs to HIV virions and infected cells would be expected to take place in 
tissues in addition to in the systemic circulation, with resulting clearance by the RES.  
Thus, it is possible that differences occurred in the uptake and clearance of mAbs in 
tissues which could not be detected from the available study data. 
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3.8.9.5 Potential influence of structure and polarity on retention in mucus 
As mentioned in section 3.8.8.2, entrapment of antibodies in mucus is believed to result 
from their propensity to form low affinity bonds with mucin fibres.  Mucin fibres consist 
of long flexible strings of protein monomers, densely coated with short glycans, which are 
commonly tipped with a negative charge (carboxyl or sulfate groups). These glycosylated 
and highly hydrophilic regions are separated by “naked,” relatively hydrophobic regions 
of the protein that are believed to fold into globules. Thus, by presenting alternating 
hydrophilic and hydrophobic regions, an array of low-affinity bonds can develop between 
the flexible fibers of the gel and other molecules [87].  Whether antibodies bind mucin 
directly is a matter of contention.  Several researchers have tried and failed to 
demonstrate binding between immunoglobulins and purified mucins in-vitro 
[706,707,708] and  intermediaries,  such as SC (for s-IgA) or an IgG Fc binding protein, 
have been suggested to facilitate the interaction [709].  However, regardless of the 
mechanism, it is possible that the charge distribution and/or unusual linear configuration 
of 2G12 are less favourable for binding mucus than those of the MPER mAbs resulting in 
more rapid initial loss from the vaginal surface.   
3.8.9.6 Effect of structure on stability to degradation/metabolism 
Given its unconventional structure, it is possible that 2G12 has a greater susceptibility to 
degradation or enzymic breakdown within the vaginal environment than 2F5 and 4E10. In 
an immunochemical analysis, C2G12 was found to be more sensitive to low pH than 
typical IgG. In contrast to b12 and IVIg preparations, which were unaffected even after 4 
hour incubations, substantial aggregation of C2G12 molecules occurred after only 5 
minutes exposure to 0.2M glycine sulphate (pH 2.3); a reagent commonly used to elute 
proteins from affinity chromatography columns.  Acid-induced aggregates displayed large 
numbers of tightly-associated rings, with similar appearances on electron microscopy to 
C2G12 Fab arms generated after digestion by Papain [710]. The study authors suggested 
that acid treatment disrupts the normal VH-VL non-covalent interactions, but in contrast 
to typical IgG molecules, which re-associate rapidly upon a rise in pH, the twisted H-chain 
elbow region in C2G12 makes re-association less easy/favourable. Instead, unpaired VH 
and VL domains in one C2G12 molecule bind complementary partner domains in 2 other 
2G12 molecules leading to aggregation. Although a sample of the Mabgel product (pH 
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5.5) was tested and remained intact under ‘stressed’ temperature conditions (25 °C and 
37 °C for at least 3 months) prior to the start of the MABGEL 1 trial, the mAbs had not 
been evaluated at physiological vaginal pH (i.e. around pH 4.0). Nor had their stability 
been assessed in the presence of vaginal secretions. The plan had been to carry out such 
stability testing using the baseline samples of neat vaginal secretion obtained in the 
MABGEL trial using the aspirator (to which no buffer/PIs had been added). However, in 
view of the paucity of secretions in the aspirates, these analyses were only completed 
recently. Using vaginal secretions collected from 3 healthy women (as part of a vaginal 
flora study conducted by Dr Vicky Jespers, ITM), 1 ml of neat secretion from each 
participant (pool of 3 samples) was mixed with 1 ml of mAb preparation (mix of the 3 
mAbs containing 10 mg C2F5, 10 mg C2G12 and 10 mg C4E10 / ml plus 2 mM acetic acid, 
10 % maltose, pH 4). Samples were vortexed briefly and incubated at 37 °C. 100 μl 
samples were taken from this mixture at the following times: before incubation (mAb mix 
only), post incubation (mins): 15, 30, 60, 120, 240, 480, and 24 hours. 100 μl samples 
were diluted with 900 μl buffer (PBS 7.2-7.4 plus 1% bovine serum albumin) and frozen at 
– 70° C. Samples were shipped on dry ice to Polymun and analysed by specific mAb ELISAs 
(as per section 2.11.3) ( B. Vcelar, personal communication). Median mAb levels per time-
point are displayed in Figure 3-32 . As can clearly be seen, whereas concentrations of 
C2F5 and C4E10 were relatively stable in vaginal secretions, declining slowly over a 24 
hour incubation period, levels of C2G12 fell more rapidly, suggesting it is more susceptible 
to degradation by the low pH, proteolytic enzymes or both. Further investigation is 
needed to elucidate the exact mechanism.  
It would be interesting to determine whether a similar phenomenon occurs in vaginal 
secretions from cynomolgus macaques (Macaca fascicularis).  Comparisons of the vaginal 
microflora between humans and macaques, both cynomolgus and the larger pig-tailed 
macaque (Macaca nemestrina), have shown similarities in the range of bacterial species 
identified, through microscopy and culture, but differences in the proportion in which 
each is present. For example, Lactobacilli are generally found in lower density and 
Viridans streptococci in higher density in macaques than is usual for the healthy human 
vagina, with most hydrogen-peroxide production attributable to the latter rather than the 
former [711,712]. In general, vaginal pH is higher in macaques, being 5.5 to 8 in M. 
fascicularis, and 4 to 8.5 in M. nemestrina, with 6 to 7 being most common [712, 713].  
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This compares with 3.8 to 4.5 in healthy women (see section 4.3.3) [714]. Interspecies 
differences in vaginal pH, and perhaps in other, as yet undetermined, variables e.g. in the 
enzymic activity of mucosal secretions, could underly the observed differences in 2G12 
pharmacokinetics in the CEA studies compared with the Mabgel Trial. 
 
Figure 3-32 Concentrations of C2F5, C4E10 and C2G12 after incubation with human 
vaginal secretions at pH 4.0 
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4. SAFETY RESULTS AND ANALYSES 
4.1 Main Safety Data 
4.1.1 Adverse Events 
In total, 88 AEs were recorded for the 28 participants enrolled into the dosing phase of 
the Mabgel trial, of whom, 27 experienced at least one event. Only MAB026 was event-
free. 77 of the 88 events were assigned by the SP, in conjunction with the CI, as being 
possibly or probably related to use of the study gel (see section 2.8.2.2). 
Table 4-1   displays the distribution of AEs by study arm sub-divided according to Medical 
Dictionary for Regulatory Activities (MedDRA) category and nature of AE. 
4.1.1.1 Grade 3 AEs and SAEs 
There were no AEs occurring in the study that were graded as severe (grade 3) or higher 
and no serious AEs (SAEs) as defined in the UK Medicines for Human Use (Clinical Trials) 
Regulations 2004 [571]. 
4.1.1.2 Grading of other AEs 
Eighty four AEs (95.5 % of the total) were graded as mild (grade 1) in accordance with the 
protocol (see section 2.8.2.4). The remaining 4 AEs were graded as moderate (grade 2).  
Two of the moderate AEs occurred in a single participant in the placebo arm of the study 
(MAB006), the other 2 occurred in 2 separate participants, both in the low dose Mabgel 
arm (MAB001 and MAB014).  
MAB006 recorded 2 moderate AEs. These were intense vulval itching lasting 2 hours on a 
single occasion in the middle of the dosing period and PV bleeding like menses, at the end 
of the dosing period. These were both assigned as being possibly related to study gel use, 
although the participant reported that the latter started following a missed dose of her 
low dose COCP (Loestrin 20). Of note, this particular participant had 7 AEs recorded 
during the study, the most of any of the study participants. 
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MAB001 noticed light PV bleeding (reported initially as a brownish discharge and 
confirmed on examination (OE)) following the first dose of study gel. This settled after a 
couple of days but then returned later in the dosing period and was reported as 
intermittent between Visit 7 and the final visit (Visit 8). On the advice of the study 
Monitor, any AEs consisting of symptoms/signs that were intermittent or recurrent on > 2 
occasions during the study in the same participant with the same attributed causation 
were collected together and reported as a single AE of longer duration rather than 
multiple separate AEs. Thus, in view of its total duration, the bleeding was classified as a 
single moderate AE rather than multiple mild AEs. As this participant was using an 
etonogestrel implant as contraception, it is possible that her bleeding was related to this 
rather than the use of the study gel (and she had become more aware of it whilst taking 
part in the study). However, since the symptom was reported as being new in onset after 
the start of gel dosing, and was not observed OE at the screening or pre-dose Visit 2 
evaluations, it was attributed as being possibly related to the study gel. 
MAB014 reported feeling generally unwell and lethargic for <48 hours starting on the 3rd 
day of dosing. This was reported to the study team at Visit 5, by which point she reported 
feeling back to her usual self.  As this episode had resulted in her going to bed earlier than 
usual but had not prevented her from going to work or required any intervention apart 
from paracetamol, it was recorded as a moderate AE and assigned as being possibly 
related to the study gel.  
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Table 4-1  AE Distribution by Study Arm 
Organ system/Nature of Event Study Arm 
Placebo 
(n=9) 
10mg/g 
Mabgel (n=9) 
 
 
(n=9) 
20mg/g  
Mabgel (n=10) 
At least 1 adverse reaction 9 (100%) 9 (100%) 9 (90%) 
Reproductive System    
Non-menstrual bleeding 6 (67%) 5 (56%) 2 (20%) 
Discomfort (soreness, burning, 
pruritis) 
6 (67%) 2 (22%) 1 (10%) 
Vaginal discharge 3 (33%) 2 (22%) 2 (20%) 
Vulval or vaginal erythema 1 (11%) 3 (33%) 0 
Epithelial disruption 1 (11%) 0 0 
Constitutional Symptoms: Lethargy 1 (11%) 1 (11%) 0 
Headache 4 (44%) 3 (33%) 1 (10%) 
Gastrointestinal Disorder    
Abdominal pain (lower) 2 (22%) 1 (11%) 2 (20%) 
Abdominal pain (upper) 0 1 (11%) 0 
Nausea, bloating, vomiting or 
diarrhoea 
0 1 (11%) 2 (20%) 
Musculoskeletal: Back Pain 1 (11%) 1 (11%) 0 
Rash 0 0 1 (10%) 
Haematological Disorders    
Neutropenia 1 (11%) 1 (11%) 1 (10%) 
Low total WCC 1 (11%) 0 1 (10%) 
Increased PT 3 (33%) 0 3 (30%) 
Biochemical Investigations    
Increased blood bilirubin 0 0 1 (10%) 
Increased blood creatinine 0 1 (11%) 0 
Infections    
Vaginal candida 0 3 (33%) 0 
Bacterial vaginosis 0 1 (11%) 0 
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4.1.1.3 AEs Where There were Uncertainties as to Grade or Causation 
MAB004 experienced PV bleeding for 4 days beginning on the morning of visit 6 that she 
described as being ‘like a period’. According to the dates she gave us on the 1st dosing 
visit, the bleeding started on day 26 of her menstrual cycle and she reported having a 
regular cycle of around 28 to 30 days (she had a natural cycle as she was not using 
hormonal contraception). A decision was made by the study team, in conjunction with 
the CI, that this probably represented her normal menstrual period, as, when questioned, 
the participant had not been 100% certain regarding the start date of her previous period 
before study enrolment. However, on discussion with the Monitor, it was decided that it 
should be recorded as an AE as there was a chance that the bleeding could have been 
triggered by repeated examinations or use of the study gel. It was designated a mild AE 
but would have been assigned a moderate grading based on the duration and nature of 
the bleeding had it been felt to be non-menstrual in nature. This AE thus demonstrates 
two important points; firstly, the importance of the reliability of participant’s histories 
regarding menstrual cycle and symptomatology when assessing microbicide safety and 
secondly, the subjective nature of assigning severity grading and causality to AEs. 
Measures such as reviewing stored images after colposcopy, having clearly defined AE 
gradings in the study protocol, ensuring hospital emergency departments are informed 
about clinical trials (and alert study teams if any trial participant presents) and good study 
monitoring, all help to increase objectivity and prevent AEs from being missed. However 
there still remains a degree of reliance on participants reporting AEs accurately and them 
being documented and interpreted appropriately by investigators. 
4.1.1.4 AEs Resulting in Discontinuation of Study Gel 
As noted in section 2.13.5.2, according to the Trial Protocol, any AE graded as moderate 
(grade 2) should have resulted in a temporary discontinuation of dosing. However, in 
practice this only occurred for MAB014.  
The bleeding reported by MAB001 was only assigned as (cumulatively) being a moderate 
AE after the end of the dosing period and that experienced by MAB006 began on day 12 
of dosing, being reported to the study team at Visit 6.  The vulval itching episode occurred 
on day 3 of dosing and had resolved and not recurred following 2 more doses of gel 
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before it was reported to the study team at Visit 5. As there were neither any on-going 
symptoms nor any signs on examination, the CI decided that there was no clinical reason 
to suspend dosing in this participant. 
As a result of feeling unwell and going to bed early, MAB014 omitted 1 dose of study gel 
(Dose 3). However, by the time she attended for Visit 5, 2 days later, and reported her 
illness, she was feeling better and had already used the next dose of gel. Thus, again, the 
decision was taken that there was no clinical reason to omit any further doses. 
4.1.1.5 Follow up of AEs Continuing Beyond Visit 8 
There was no requirement in the study protocol to follow up any AE beyond Visit 8 unless 
it had been recorded as an SAE, in which case it would be followed up by the study 
team/CI until resolution. Likewise, any pregnancies in participants reported during the 
study period would have been followed up in accordance with the current North and East 
Yorkshire R & D Alliance procedure. All of the AEs which continued beyond Visit 8 were 
classified as mild (grade 1) and most were related to mildly abnormal blood parameters 
detected on samples taken at visit 8. In all cases, participants were informed of these 
results verbally by the SP and their GPs informed in the completion of study letter. Since 
none of these results were in the range likely to reflect significant pathology, it was left to 
the discretion of GPs as to whether they were followed up or repeated. GPs and 
participants were asked to notify us of any ongoing problems. 
4.1.1.6 Genital AEs 
AEs affecting the vulva, vagina and cervix are commonly seen in trials of vaginal products, 
such as microbicides, and their accurate recording and analysis is extremely important in 
assessing the safety and acceptability of the product. Hence, as discussed in section 2.8.3, 
genital AEs were specifically solicited through questioning at each visit and at telephone 
calls, and examination performed with the use of a colposcope to allow visualisation of 
the mucosa at higher magnification. Genital AEs are categorised in Table 4-1 according to 
the signs/symptoms presented in the study grading criteria for genital reactions and other 
commonly reported symptoms e.g. discharge. Discomfort includes descriptions of itching 
(pruritis), warmth/burning, dysuria, soreness and irritation. Where a single AE combines 2 
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of the above e.g. soreness and redness (i.e. a clinical sign and a symptom) the AE is listed 
under the sign only so as not to alter the total number of AEs from that recorded (only 1 
participant MAB027 had both). Non-menstrual per vaginal (PV) bleeding includes any 
bleeding or suggestion of previous bleeding, e.g. a brown discharge, reported by a 
participant or seen on genital examination. Other descriptions of discharge, including 
reports of stickiness, are included in the discharge category. 
There were 9 genital AEs in the high dose Mabgel arm (all at least possibly attributable to 
gel use), 13 in the low dose Mabgel arm (all at least possibly attributable to gel use) and 
19 in the placebo arm (17 at least possibly attributable to gel use). The 2 non-study gel 
related AEs in the placebo arm were folliculitis in participant MAB006 due to an in- 
growing hair and cervical trauma caused by the volumetric aspirator in MAB010. Both of 
these are discussed below in sections 4.1.1.10 and 4.1.1.11. 
The most common genital AE reported was non-menstrual vaginal bleeding, affecting 13 
of the 28 participants (46%) (2 in high dose, 5 in low dose, 6 in placebo arms). 2 of these 
cases (1 in low dose, 1 in placebo) were recorded as moderate AEs, based on duration or 
volume of bleeding, and are discussed above (section 4.1.1.2). Except for the case of 
MAB004, discussed in section 4.1.1.3, the remainder were clearly mild AEs: - PV 
spotting/brown discharge or slight bleeding from the cervical os, reported by participants 
and/or seen on examination, which lasted < 48 hours.  
Overall, there were 10 reports (4 in high dose, 3 in low dose, 3 in placebo arms) of 
unusual vaginal discharge in 7 women, with 3 women, 1 in each arm, (MAB016, MAB023, 
MAB024) reporting 2 episodes. The discharge reported varied in nature. 3 women 
(MAB001, MA008, MAB023) reported a white or pinkish white discharge that differed in 
appearance to what they usually experienced, but was not described as being heavy or 
thick. 2 participants described a thicker, heavier discharge than usual (MAB017, MAB023). 
The remaining 4 reports (MAB011, MAB024 (high dose) MAB016 x 2 (low dose)) were of 
stickiness and/or gel being noticed in underwear or coming out as discharge during the 
dosing period. The latter was also described by several participants in the interviews 
conducted at the end of the trial, with 7 women stating that they wore knickers, or pads 
when they normally would not to prevent gel leaking out on to bed clothes or underwear. 
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 In total 9 participants complained of discomfort (soreness, itching, irritation, 
warmth/burning); (1 in high dose arm, 2 in low dose arm, 6 in placebo arm). Only 1 
participant who complained of discomfort (MAB027), had erythema on examination. 
Interestingly, she was one of 3 women to have positive baseline candida cultures (see 
section 4.1.1.12).  
Findings suggestive of possible mucosal inflammation were seen on examination in 5 
participants: erythema - none in high dose, 3 in low dose, 1 in placebo arm; superficial 
epithelial disruption - 2 areas < 1 swab tip in diameter just inside the introitus in 1 
participant in placebo arm (MAB010). In all women, except MAB006 (see section 4.1.1.2) 
symptoms were easily tolerated and signs were mild and localised. All were self-limiting 
resolving within 4 days except for MAB021 who experienced intermittent small patches of 
dry skin that were mildly red but caused no discomfort between visit 6 and 8 (post gel 
dosing). There were no cases of visible swelling or mucosal oedema. 
Very few AEs were seen on colposcopy that would not have been detected by participant 
report or visual examination with the naked eye alone. MAB002 had a small area of 
erythema on her posterior vaginal wall that was not seen with the naked eye. The 
epithelial disruption in MAB010 was just visible with the naked eye but better delineated 
using the colposcope. Both of these findings were detected at visit 3 (8 hours post 1st 
dose) but had resolved by visit 4 (24 hours post 1st dose). Neither were visible at 
subsequent evaluations, although both were attributed as possibly related to use of the 
study gel. 
4.1.1.7 Other Clinical AEs 
Signs/symptoms that were reported by participants or detected on clinical examination 
that related to organ systems outside of the genital tract were designated as other clinical 
AEs. In general, the AEs reported were conditions that are seen commonly in the general 
population. Only 1 non-genital clinical AE was designated as moderate (grade 2) (see 
section 4.1.1.2), all the rest were mild (grade 1). 
For the most part, unless the AE was reported prior to the 1st dose of gel being 
administered, it was assigned as being at least possibly related to the study gel. The one 
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exception was a headache reported by MAB010 (placebo arm) during the dosing period 
that occurred on a morning following her having drunk an excessive amount of alcohol at 
a party. The participant described this as being exactly like a ‘hangover’ and felt better 
after taking ibuprofen. It was thus felt that it was more likely to be alcohol-related than 
caused by the study gel. Later in the dosing period, the same participant experienced 
another mild headache which was generalised and relieved by ibuprofen as before, but 
this time she had not drunk any alcohol. Thus, the second episode was attributed as being 
possibly related to the study gel.  
Headaches were in fact one of the most common AEs, reported by 8 participants (1 in 
high dose, 3 in low dose, 4 in placebo arm). All were mild and resolved spontaneously 
within 24 hours or with stat doses of non-prescription analgesics. Other frequently 
reported AEs were related to the gastro-intestinal tract. These included 4 cases of 
generalised abdominal pain (MAB012, MAB015, MAB016, MAB023), 1 case of diarrhoea 
and vomiting (MAB028), bloating and loose stools (MAB027), nausea (MAB004) and 
upper GI intolerance (indigestion/churning/heartburn) (MAB001). All of these symptoms 
resolved within 48 hours except for 1 case of lower abdominal pain and constipation 
(MAB011), which was reported just prior to the end of study follow up, and relieved by 
non-prescription suppositories after visit 8. Hence this was recorded as continuing 
beyond the end of the study. Other AEs seen included back pain (MAB021, MAB022) and 
rash (MAB015, localised to thigh, relieved with non-prescription antihistamine).  
4.1.1.8 Laboratory AEs 
In total there were 16 laboratory AEs recorded in the 28 participants enrolled:  6 in high 
dose, 4 in low dose and 6 in placebo arms. All laboratory AEs were mild. 
Most laboratory AEs recorded were results of tests of blood parameters that met the 
criteria for being an AE (as defined in the study AE grading tables). These are listed below.  
In addition, there were 3 baseline positive candida cultures, taken just prior to the first 
gel dosing at Visit 2, that were not associated with any clinical signs or symptoms at the 
time the swab was taken. These are discussed in section 4.1.1.12.  
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The blood results recorded as AEs were as follows: 
 MAB003 (High dose Mabgel arm): raised bilirubin (27 μmol/l; ULN = 19 μmol/l) in 
mild AE range (> 1.25 ≤ 2 X ULN) first detected at Visit 6 and resolved on re-
checking at visit 8. No elevations in other liver enzymes (alanine aminotransferase 
(ALT) or alkaline phosphatase (ALP)) were seen. 
 MAB014 (Low dose Mabgel arm):  raised serum creatinine (108 μmol/l; ULN = 90 
μmol/l) in mild AE range (> 1 < 1.5 x ULN). Detected at visit 8. Participant was 
contacted and returned for repeat 5 days later at which point it had returned to 
be within the normal range (64 μmol/l). 
These were the only two AEs involving biochemical abnormalities. The remainder 
involved haematological abnormalities of white blood cell counts (WBC), either total WBC 
or neutrophils alone, or a prolonged prothrombin time (PT). 
 MAB006 (placebo arm): low total WBC count (3.2 109/L) in mild AE range (<3.5 
>3.0 x 109/L) detected at visit 6, resolved by visit 8. 
 MAB007 (Low dose Mabgel arm): Low neutrophil count (1.4 x109/L) in mild AE 
range (≤ 1.5 > 1 x109/L) was detected at visit 6 but had returned to normal range 
when re-checked at visit 8. 
 MAB018 (high dose Mabgel arm)- low total WBC count (3.2 x109/L) and low 
neutrophils (1.1 x109/L) Detected on blood tests at Visit 8. Bloods rechecked 30 
days later (participant unable to attend sooner as on holiday) and had returned to 
within normal range for both parameters. 
 MAB021 (placebo arm): Low neutrophil count (1.5 x109/L) detected at visit 6, 
resolved by visit 8. 
All of the following had mildly elevated PT results (> 1 ≤ 1.25 x ULN) (at varying time-
points. Those with abnormalities remaining at visit 8 required no treatment but their GP 
was informed in the end of study letter. 
 MAB006 (placebo arm): Detected at Visit 6 and Visit 8. 
 234 
 
 MAB008 (high dose Mabgel arm):  Detected at Visit 3 (8 hours post 1st dose) and 
on subsequent blood tests including Visit 8. No treatment was required but the 
participant’s GP was informed of the ongoing mild blood abnormalities detected. 
 MAB012 (placebo arm): Detected at Visit 8. 
 MAB017 (placebo arm): First detected on Visit 2 pre-dose sample (but not  
increased on 8 hours post 1st dose sample) and at Visit 6, resolved by Visit 8. 
 MAB020 (high dose Mabgel arm): Elevated on Visit 2 pre- 1st dose and Visit 8 
samples but not in between. Considered to be unlikely to be related to study gel 
use by the CI as only elevated before and several weeks after mAb exposure. 
 MAB024 (high dose Mabgel arm): Raised on 8 hour post 1st dose sample but 
resolved on visit 6 sample. 
All of the above blood abnormalities (apart from MAB020 raised PT) were assigned as 
being possibly attributed to gel use during the trial and remained so for the statistical 
analyses. However, it is now felt unlikely that any of the non-genital laboratory AEs were 
caused by the use of the study gel given that there was no evidence of systemic 
absorption of the mAbs and no blood abnormalities have been associated with the use of 
other HEC-based placebo gels in other trials [399,400,415].  
4.1.1.9 Coagulation Assays and Anticardiolipin Titres 
The PT and APTT measure the extrinsic, and combined intrinsic (contact) and common 
pathways of blood coagulation respectively. The PT measures the activity of clotting 
factors produced by the liver (II, V, VII, and X) which require vitamin K for their 
manufacture and is often significantly elevated in people with vitamin K deficiency, e.g. 
due to poor diet or malabsorption, or in the presence of inhibitors, such as warfarin. It is 
also a measure of general liver synthetic function. The APTT, on the other hand, is much 
less specific, being elevated in deficiencies of all coagulation factors except VII and XIII. 
Apart from cases of hereditary isolated factor VII deficiency and early liver failure, it is 
unusual to have an elevated PT without accompanying derangement in the APTT. The 
APTT, on the other hand, is affected independently of the PT in most hereditary 
haemophilias and in the presence of heparin or anti phospholipid antibodies [715]. 
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In a previous human trial, transient elevations in APTT were temporally associated with 
the intravenous infusion of high doses of the mAbs [506]. In the 4 subjects tested, all of 
which had a normal APTT and PT at baseline, infusion of 5g of each of mAb in 
combination led to a mean increase in the APTT of 9.6 +/- 3.7 seconds at 30 min post 
infusion. This led to APTTs at peak serum mAb concentrations that were either still within 
the normal range or in the range which constituted a mild AE in that trial (>1.1 ≤ 1.25 x 
ULN). In contrast, there were minimal or no alterations to PT results and all remained 
within the normal range. In-vitro studies and retrospective analysis of samples from 
clinical trials in which participants received C2F5 and C2G12 or C4E10 alone, has 
determined that, unlike the other 2 mAbs, C4E10 displays cross-reactivity to the 
phospholipid cardiolipin (CL), with detectable elevations in serum aCL titres (105.7 +/- 
7.9) and it is this activity that increases the APTT. 
In our trial, we saw no elevations of APTT or any detectable rise in IgG anti-cardiolipin 
titres in any participants during the dosing or follow up periods. However, there were a 
number of women with elevated PT results recorded as mild AEs (range > 1 ≤ 1.25 x ULN). 
3 of these women were in the high dose Mabgel arm and 3 in the placebo arm, with none 
in the low dose Mabgel arm. There was no indication clinically or from results of other 
blood tests that any of the participants were significantly malnourished or had liver 
disease and no participants were taking warfarin or other anticoagulants. Thus, it is likely 
that the PT results were elevated due to another reason.  
There seems to be no clear pattern to the PT results that were above the normal range in 
relation to time point or study group. Two of three women in the high dose Mabgel arm 
who had elevations in PT first had this detected at Visit 3 (8 hours post 1st dose) which 
was when it was felt that peak systemic absorption of the mAbs might occur. However, in 
one of these women the PT results continued to be raised for the remainder of the trial 
whereas in the other they had fallen back to baseline when next measured at Visit 6 (12 
hours post 12th dose). In the third high dose participant, the elevated PT levels were 
deemed by the CI to be not related to gel use as they occurred on samples taken prior to 
use of the 1st dose of the gel and several weeks after (Visit 8), being normal in the dosing 
period. Three women who received placebo also had documented high PT results, and in 
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these participants they were again seen at pre-1st dose in one participant and at Visit 8 
alone in another, and none were at the 8 hours post 1st dose visit. 
Given the fact that there is no evidence of any systemic absorption of the mAbs, no rise in 
APTT (usually accompanying a PT rise) and PT values outside of normal range in blood 
samples taken before any doses of gel were given, and in the placebo arm, it would 
suggest that the elevated results may have arisen due to variables intrinsic to the blood 
collection process or to the PT assay itself. PT is measured on plasma from blood drawn 
into a tube containing citrate, which prevents clotting by binding calcium. For accurate 
measurement, the proportion of blood to citrate has to be fixed at a ratio of 9:1, and in 
York, as in most hospital laboratories, they will only process blood samples in tubes which 
look, on visual inspection, to have been filled to the correct level. In the laboratory, a 
known excess volume of calcium is added to the sample, together with a fixed amount of 
tissue factor (coagulation factor III) and the time taken for the sample to clot at 37 °C is 
assessed either by optical or mechanical means, depending on the exact methodology 
used. In most clinical laboratories, including York, this process is automated. It is well 
recognised that variations in the purity of tissue factor between different manufacturers, 
or even batches from the same manufacturer, or in the measuring equipment used can 
lead to variability in results [716]. Indeed, International Normalised Ratio (INR) was 
introduced by the World Health Organization (WHO) and the International Committee on 
Thrombosis and Hemostasis to try to standardise measurements between laboratories 
[717]. The INR is generated by comparing a patient’s sample with that of a normal control 
processed in the same way, with a correction factor applied reflecting the purity and 
source of tissue factor supplied by a particular manufacturer [716]. The INR is very useful 
in allowing the standardisation of the measurement of the anticoagulant effect of 
warfarin, as unlike the actual measurements and normal ranges for PT, it should remain 
relatively constant between laboratories. However, there is evidence to suggest, that this 
may not be the case in practice [718,719]. In our study, because 1) all of the participants 
were seen in the same centre with samples processed by the same laboratory, and 2) the 
DAIDS coagulation gradings are for PT (and APTT) rather than INR (and expressed as > 
ULN for the laboratory being used), it was decided to use the PT. Whether the INR would 
have resulted in fewer out of normal range results or variability between participants and 
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visits is felt unlikely, since the control PT time is laboratory specific and only altered if 
there is a change in equipment or processing procedures. 
It is interesting to note that the York Hospital laboratory changed their methodology for 
analysing PT and APTT samples on 27th April 2010. This was a planned upgrade to replace 
a Trinity Biotech MDA II optical analyser with a more modern IL ACL TOP500 model and 
also required a change in the thromboplastin used for PT analysis from Simplastin HTF 
(BioMerieux) to Recombiplastin 2G (Beckman Coulter).  Although the reference ranges for 
APTT and PT changed as a result of these modifications, these were clearly stated on the 
written laboratory reports for each result and graded in relation to the ULN as previously. 
Of the above, outside of normal range PT results detected, the Visit 8 sample for MAB020 
and all samples for MAB024 were processed using the new methods. Since the new 
methodology was only used for the last 3 months of the trial and in a relatively small 
number of enrolled and potential participants it was not possible to assess formally 
whether it had resulted in a change in the proportion of out of range PT values being 
reported. There were no AEs resulting from > ULN APTT values either before or after the 
change. 
4.1.1.10 AEs Not Related to Gel Use 
Of the 11 AEs assigned as being unrelated to use of the study gel, 7 arose in the time after 
consent was provided at the screening visit but before the first dose of study gel was 
administered and did not increase in severity with gel use (i.e. they were recorded as AEs 
in accordance with the North and East Yorkshire R&D Alliance SOP on Adverse Event 
Reporting, as required by the Sponsor, but were to be excluded from main analyses). The 
other 4 were assigned as being unrelated to gel use either because they were a 
recurrence of a mildly abnormal blood result detected at visit 2 (pre-1st dose), but not 
during the dosing period (e.g. MAB020, visit 8 PT result) or because another medical 
cause of the sign or symptom was felt to be more likely (e.g. MAB006, folliculitis related 
to an in-growing pubic hair; MAB010, headache related to drinking excess alcohol the 
night before).  
It is acknowledged that assigning causality can be subjective; thus, on the advice of 
Professor Bland, it was decided to statistically analyse the number of documented AEs per 
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study arm both including and excluding those AEs assigned as being not/unlikely to be 
related to gel use i.e. all reported AEs vs only those AEs possibly, probably or definitely 
attributed to gel use (see section 4.2). 
Two occurrences that were recorded as AEs not related to gel use deserve further 
discussion. These are: 1) AEs related to use of volumetric aspirator, and 2) positive 
baseline (visit 2 pre-dose) candida cultures. 
4.1.1.11 AEs related to use of the Volumetric Aspirator 
As detailed in section 2.8.3.1, genital examination, including evaluation by colposcopy, 
was generally performed prior to any sampling procedures, as advised in the 
CONRAD/WHO Manual for the Standardization of Colposcopy for the Evaluation of 
Vaginal Products (2004) [574]. This was to minimise the risk of epithelial abrasions and 
other injuries caused by swab taking being erroneously attributed to use of the study gel. 
In the course of the study, there was only 1 incidence where trauma was documented to 
have arisen as the direct result of a sampling procedure. This occurred in MAB010 (Visit 4) 
where no abnormalities were visible on initial colposcopic examination, but a circular 
indentation was visible on the cervix after performance of self-sampling using the 
volumetric aspirator. The participant experienced no pain during the procedure, and no 
epithelial disruption or disruption to blood vessels (e.g. echymosis or petechiae) was 
visible following a repeat colposcopic examination. The findings had resolved on review at 
Visit 5, which took place the following day. 
There were no other reports of pain or trauma arising from use of the aspirators during 
visits. However, as evidenced by the paucity of analysable data (section 3.6.1.3) and 
comments provided in the qualitative interviews (see Chapter 5), women found them 
difficult and uncomfortable to use. 
4.1.1.12 Positive Baseline Candida Cultures 
As discussed in section 2.7.2.6 baseline swabs for candida culture and speciation were 
performed on all participants at Visit 2, during the pre-1st dose evaluation. When the 
initial study protocol was written, in Summer 2008, there was no capacity at York Hospital 
to perform quantitative candida culture and speciation, thus, in line with the procedure 
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for processing similar samples from clinical settings in York, our study swabs were to be 
sent to the Mycology Reference Laboratory in Leeds. Since the primary intention was to 
examine for the presence of Candida species in asymptomatic women that could 
potentially impact on mAb pharmacokinetic results, the fact that there would be a delay 
in receiving the results of these swabs of around 10 days was not thought to pose any 
problem. Women were to be assessed clinically at each study visit, with the swab results 
analysed after the dosing period to aid interpretation of mAb and AE data.  
However, by the time the study was initiated, in September 2009, York Hospital 
Microbiology Laboratory had begun to perform in-house testing for Candida species. 
Thus, it was no longer necessary to forward the samples to Leeds and results became 
available to the study team within 3 to 4 days.  A potential dilemma was therefore 
created as to how to action any positive results that were received during the dosing 
period whilst minimising any impact on the conduct of the study and protecting 
participant’s well-being. A decision was made by the SP, in conjunction with the CI, that 
any positive results would be dealt with on a case by case basis, with treatment being 
administered according to presence of signs/symptoms that could be attributed to 
candidiasis or participant wishes. Since the application of topical treatments to the vagina 
such as pessaries and creams could affect the pharmacokinetics of the mAbs, oral 
treatment with fluconazole 150mg po stat was preferred. Women would be discontinued 
from dosing only in the event that they had signs/symptoms graded as 2 (moderate) or 
above in AE severity, in keeping with the study protocol. 
The management of participants with positive baseline candida results was discussed 
with the DSMC. It was deemed, by Professor George Kinghorn, that the above 
management was reasonable and would not impact on the integrity of study data or the 
safety of participants. 
No women seen at Visit 2 had any clinical signs of symptoms of genital tract inflammation 
or infection on the pre-dose evaluation, thus all women proceeded to receiving the 1st 
dose of study gel that day.  3 out of 28 women had positive baseline candida cultures 
(MAB014; MAB019; MAB027). All 3 of these cultures was positive for C. albicans and all at 
heavy growth (+++). All 3 of the women were randomised to the low dose Mabgel arm. 
Results were available for all 3 women in time for Visit 5 (day 5 to 7 of dosing) and were 
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communicated to them by the SP at this time. MAB019 reported symptoms of vaginal 
dryness and mild irritation lasting 3 days in total, but had no visible erythema or discharge 
on examination. She was offered treatment but her symptoms may just as easily have 
been caused by the study gel so were attributed as possibly related to gel. Neither of the 
other women displayed signs or symptoms associated with candida at this visit, but both 
were offered treatment as prophylaxis. MAB014 and MAB019 accepted treatment with 
fluconazole 150mg po stat when initially offered but MAB027 declined. However, she was 
eventually treated at Visit 6 after developing mild vulval soreness and redness. This was 
first noticed by the participant after 10 doses of gel, but not reported to the study team 
until Visit 6, and could have been related to candida or to the study gel. 
 
4.2 Statistical Analysis of Main Safety Data 
As with the pharmacokinetic data, all statistical analyses were performed in conjunction 
with Professor Martin Bland using STATA version SE 10.1, Stata Corp., College Station, 
Texas, released 1st October 2009. All analyses were performed on an intention-to treat 
basis unless specified otherwise.  
As described in section 4.1.1, AEs were recorded for nearly all participants. The number of 
AEs per woman was therefore deemed to be much more important and relevant than 
their presence or absence for a woman. It was therefore decided that it would be more 
meaningful to compare the safety data for each group in relation to the average number 
of AEs per participant, using the negative binomial distribution, as opposed to the 
proportion of women experiencing an AE, using Fisher’s exact test 
Analyses were performed both for AEs in their entirety and excluding those felt to be 
not/unlikely to be related to gel use. 
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4.2.1 Analyses of All AEs Regardless of Attribution to Study Gel Use 
Table 4-2 Severity of All AEs by Study Arm 
 
AE severity Study Arm Total 
 High Dose 
Mabgel 
Low Dose 
Mabgel 
Placebo  
Mild 
(grade1) 
24 26 34 84 
Moderate 
(grade 2) 
0 2 2 4 
Severe 
(grade 3) 
0 0 0 0 
 
The average numbers of AEs (including all AEs even if assigned as being not related to 
study gel use) reported in the three arms are displayed below 
 
Table 4-3 Mean and Standard Deviation of All AEs Per Study Arm 
Treatment group Number in group Mean number of 
events 
Standard deviation 
Placebo    9 4.00 1.94 
Low dose Mabgel    9 3.11 1.76 
High dose Mabgel  10 2.40 1.17 
 
The difference in reported AEs between study arms was not statistically significant,  
 P = 0.1 (negative binomial regression). 
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4.2.2 Analyses of AEs Attributed as Being At Least Possibly Related to 
Study Gel Use 
 
Table 4-4 Attribution of Likely Causality of AEs By Study Arm 
 
Relationship 
to Study Gel 
Use 
Study Arm Total 
 High Dose 
Mabgel 
Low Dose 
Mabgel 
Placebo  
Not Related 3 3 5 11 
Unlikely to 
Be Related 
0 0 0 0 
Possibly 
Related 
19 23 31 73 
Probably 
Related 
2 2 0 4 
Definitely 
Related 
0 0 0 0 
Any 24 28 36 88 
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Table 4-5 Severity of AEs Attributed as Being At Least Possibly Related to Study Gel Use 
by Study Arm 
AE severity Study Arm Total 
 High Dose 
Mabgel 
Low Dose 
Mabgel 
Placebo  
Mild 
(grade1) 
21 23 29 73 
Moderate 
(grade 2) 
0 2 2 4 
Severe 
(grade 3) 
0 0 0 0 
 
 
Table 4-6 Mean and Standard Deviation of  Number of AEs Attributed As Being At Least 
Possibly Related to Use of Study Gel Per Study Arm 
 
Treatment group Number in group Mean number of events Standard deviation 
Placebo 9 2.67 2.24 
Low dose Mabgel 9 2.11 1.69 
High dose Mabgel 10 1.80 1.40 
 
The difference in reported AEs between study arms was not statistically significant,  
P = 0.6 (negative binomial regression). There was nothing to suggest that recorded AEs 
were related to the application of mAbs.  
4.2.3 Summary and Discussion of Main Safety Results 
In general, daily vaginal application of up to 50g of each mAb over 12 days appeared safe. 
Although AEs were reported by all but 1 participant, 95 % were mild, none were serious 
and only 4 were moderate. There was no statistically significant difference in the number 
of AEs reported per participant between the 3 study arms, and this was true for all AEs 
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and those considered to be related to use of the study gel (i.e ARs). Thus, there was no 
evidence that the addition of either 10mg/g or 20mg/g of the mAb combination to the 
HEC gel vehicle resulted in increased toxicity. However, since there was no observation 
only group, i.e. all participants received either an ‘active’ or a placebo gel product, it is not 
possible to determine whether the reported AEs were related to use of the HEC gel 
vehicle or other causes. 
Clinical AEs not involving the genital tract were fairly evenly distributed between study 
arms and although attributed to the gel, likely reflect background morbidities.  As is 
typical for vaginal microbicide studies, over half (51 %) of reported ARs involved the 
genital tract. Non-menstrual bleeding (NMB) is a frequently reported event  and, as in our 
trial, is often at least as common in those using placebo as in users of active product 
[720].  However, for reasons which are not fully understood, rates are highly variable 
even between (and within) studies of the same product [721]. It has been suggested that 
variation in the processes for eliciting AEs, lack of uniformity in documentation, and 
differences in study populations,  in terms of their background rates of factors known to 
increase the incidence of (NMB) e.g. hormonal contraceptive use, sexually transmitted 
infections and willingness to report symptoms, may impact on results [721,722].  In our 
study, the relatively large number of pelvic examinations and an all-female clinical team 
[723] may have increased the number of recorded events.  In all but 2 cases the bleeding 
was very mild; spotting/brown discharge reported by participants and/ or visible fresh or 
old blood coming from the cervical os which resolved within 4 days even with continued 
gel use. Of note, 1 woman with moderate bleeding admitted missing a dose of her low-
oestrogen COCP, which could have triggered or contributed to the episode. Although a 
number of mildly elevated PT results were detected, none was temporally associated with 
a bleeding event. In view of the lack of evidence of mAb systemic absorption, the absence 
of a concomitant rise in aPTT or aCL, and lack of a biologically plausible explanation, these 
were felt to be most likely related to intrinsic variability in the laboratory PT assay rather 
than an indication of toxicity.  
In addition to PV bleeding, incidences of vaginal discharge (10 reports, in 7 (25 %) of 
participants) and genital discomfort (reported by 9 (32%) of participants) were also 
relatively common. However, apart from one report of severe vaginal itching > 2 hours, 
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these were mild and easily tolerated. Reports were fairly equally distributed across the 3 
study arms, except for symptoms of discomfort which were more common in placebo-
users. Examination findings suggestive of possible mucosal inflammation were seen in 5 
participants. There were 4 cases of erythema  (none in high dose, 3 in low dose, 1 in 
placebo arm) and 1 case of superficial epithelial disruption (< 1 swab tip) (placebo arm); 
all were mild and localised. One of the cases of erythema, associated with soreness, was 
attributed to C. albicans and treated with fluconazole; all others were self-limiting. 
Interestingly only 2 abnormalities were detected on colposcopy that would not have been 
seen with the naked eye.  This contrasts with results from a meta-analysis of 9 phase 1 
microbicide trials, where 43 % of abnormalities were only seen on colposcopy [724].  It is 
possible that some abnormalities may have gone undetected by the author, who is a 
trained but relatively inexperienced colposcopist. Although no new lesions were 
discovered on review of stored digital images, only two images were captured using the 
colposcope camera per visit, thus it was not possible for the CI to visualise the entire 
ectocervical and vaginal mucosae.  Some abnormalities may also have been difficult to 
detect from a digital photograph. However, the utility of colposcopy in assessing 
microbicide safety has recently been questioned.  The significance of findings, other than 
deep epithelial disruption (which was not seen in any of our participants),  in relation to 
HIV transmission is unclear and, in a prospective evaluation, colposcopy was found to be 
no better than naked-eye examination alone at detecting toxicity related to use of N9 vs 
HEC placebo [725].  
Overall, as was highlighted in section 4.2.3, the current process of identifying and 
recording AEs is largely subjective, being reliant on the accuracy of participants’ reports of 
symptoms and the interviewing, examination and interpretation skills of study clinicians.  
As discussed in section 6.2.2, efforts are being made to develop more objective methods 
of evaluating microbicide toxicity which can be validated directly against HIV transmission 
risk.  In the meantime, it is important to be aware of the limitations of current clinical 
safety assessments, which may be poorly predictive of ‘real-world’ effects. 
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4.3 Results and Analyses From the Vaginal Flora Sub-Study 
4.3.1 Data Relating to Quantitative PCR for Lactobacillus Species, Nugent 
Scores and Vaginal pH  
Data regarding Lactobacillus Species concentrations and Nugent scores were provided by 
Dr Vicky Jespers, Institute of Tropical Medicine, Antwerp, Belgium. Vaginal pH was 
measured and recorded on the HYMS EMU.  
4.3.2 Evaluation and Statistical Analysis of Lactobacillus PCR Results 
The primary objective of the vaginal flora sub-study was to identify whether there were 
any differences between the study arms with regards to changes in concentrations of 
specific Lactobacillus species, detected by real-time, quantitative PCR. 
Statistical testing was performed in conjunction with Professor Martin Bland using STATA 
(version SE 10.1, Stata Corp., College Station, Texas, released 1st October 2009). 
4.3.2.1 Analysis of Lactobacillus species according to presence or absence in 
participants  within each study arm at each visit 
Table 4-7 shows the % of women in each study arm at each visit who had detectable 
Lactobacillus species by PCR.  P values given in Table 4-7 in were obtained using Fisher’s 
Exact test, which compares the number of participants with and without each 
Lactobacillus species in each study arm at each visit. This test was chosen over the Chi-
square test in view of the small sample sizes in each group. 
Lactobacilli were detected in all women at all visits using the generic PCR primers.  In 
general, the presence or absence of a particular Lactobacillus species appeared to 
remain constant throughout the study. At the screening visit, L. crispatus was 
detectable in 56, 89 and 70 % of participants in the placebo, low dose and high dose arms 
respectively. At Visit 7, the respective percentages were 67, 89 and 70 and at Visit 8 they 
were 67, 89 and 80. A similar picture was seen for L. jensenii, which was found in 78, 78 
and 70 % of participants in placebo, low dose and high dose arms respectively at both 
screening and Visit7, and 78, 78 and 60 % at Visit 8.  
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 For L. iners, the percentages of participants with detectable counts at screening was 78, 
22 and 50 % for placebo, low dose and high dose arms respectively. For placebo, the 
percentage reduced slightly to 67 % for both Visits 7 and 8, however, for both Mabgel 
arms, the percentage was the same at all visits.  
The Lactobacillus species present in the fewest participants overall was L. gasserii. This 
was present in 33, 44 and 10 % of women in placebo, low dose and high dose arms at 
screening, 44, 44 and 30 % in the same groups at Visit 7 and 44, 33 and 30 at Visit 8. This 
is broadly consistent from findings of other studies, which suggest it may be less 
abundant than the other strains.  However,  the percentage of healthy women found to 
be colonized by each species varies with technique used and population sampled [541, 
726,727]. 
Overall, there was no evidence to suggest that the presence or absence of any 
Lactobacillus species was affected by the application of study gel, and no statistically 
significant differences were seen across the groups. The lower percentage detection of L. 
iners in the low dose arm was present from screening, where it was of borderline 
statistical significance, thus was independent of study gel use.  
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Table 4-7 Number (%) of women with specific Lactobacillus species by visit and study 
arm   
P-values were obtained using Fisher’s Exact test 
Visit and  
Study Arm 
 Lactobacillus Species 
N L. crispatus L. iners L. jensenii L. gasseri Lactobacillus 
(generic)  
  Screening  
Placebo 
Low dose 
High dose  
P-value  
 
9 
9 
10 
 
5 (56%) 
8 (89%) 
7 (70%) 
0.343 
 
7 (78%) 
2 (22%) 
5 (50%) 
0.080 
 
7 (78%) 
7 (78%) 
7 (70%) 
1.00 
 
4 (44%) 
3 (33%) 
1 (10%) 
0.256 
 
 9 (100%) 
 9 (100%) 
  10 (100%) 
 
   Visit 7 
Placebo 
Low dose 
High dose  
P-value  
 
9 
9 
10 
 
6 (67%) 
8 (89%) 
7 (70%) 
0.639 
 
6 (67%) 
2 (22%) 
5 (50%) 
0.183 
 
7 (78%) 
7 (78%) 
7 (70%) 
1.00 
 
4(44%) 
 4 (44%) 
 3 (30%) 
0.793 
 
      9 (100%) 
      9 (100%) 
     10 (100%) 
   Visit 8 
Placebo 
Low dose 
High dose 
   P-value 
 
 
9 
9 
10 
 
6 (67%) 
8 (89%) 
8 (80%) 
0.639 
 
6 (67%) 
2 (22%) 
5 (50%) 
0.161 
 
7 (78%) 
7 (78%) 
6 (60%) 
0.664 
 
3 (33%) 
4 (44%) 
3 (30%) 
0.887 
 
9 (100%) 
9 (100%) 
10 (100%) 
 
4.3.2.2 Analysis of quantitative Lactobacillus species counts by study arm and visit  
Table 4-8 shows the average counts detected by PCR of each Lactobacillus species. Both 
the arithmetic mean and the median have been given. The data are highly skewed, 
reflecting the large range of values, so the latter is likely to be more representative of a 
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central value. In view of the large number of zero values, it was felt inappropriate to 
perform a log transformation of the data or calculate the geometric mean. 
Values > 100 are given to zero decimal places, values > 10 < 100 to 1 decimal place, and 
those < 10 to 2 decimal places. 
P-values were obtained using the Kruskal Wallis rank test, allowing for ties, comparing 
ranked data across all 3 study arms. 
In keeping with the findings from the previous analysis (see section 4.3.2.1), the only time 
point and Lactobacillus species where there was a significant difference in counts 
detected between the study arms was at screening for L. iners. However, since this was 
seen prior to the application of the 1st dose of study gel it is unrelated to gel use. There 
was no evidence of any adverse effect of the Mabgel on Lactobacillus species counts. 
Analysis was not performed for the counts recorded using the lactobacilli generic primers 
as it was apparent that the counts they detected were lower than the total counts found 
using the species-specific primers. It therefore appears that their amplification efficiency 
is lower than those of the species-specific primers at detecting individual species and it is 
unclear whether these primers amplify all species with equal efficiency. It was felt that 
formally analysing these counts would add little to the overall conclusions from the sub-
study and could even be potentially misleading. 
Lactobacillus species counts by study visit and arm are represented graphically in Figure 
4-1 to Figure 4-4. Note: the bottom and top of each box  represent the 25th and 75th 
percentile (the lower and upper quartiles, respectively), and the band near the middle of 
the box represents the median (50th percentile). In most cases, the ends of the whiskers 
represent the minimum and maximum of all the data. However, where there is a single 
outlier this has been excluded and is represented by a dot. 
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Table 4-8 Average (mean and median) Lactobacillus species counts per ml of elution 
buffer by study arm and visit 
Visit and  
Study Arm 
 Lactobacillus Species (x 106/ml) 
N L. crispatus L. iners L. jensenii L. gasseri 
    Mean Med Mean Med Mean Med Mean Med 
Screening 
Placebo 
Low dose 
High dose 
 
 
9 
9 
10 
 
161 
213 
99.8 
 
97.9 
243 
35.7 
 
191 
3.52 
49.1 
 
16.9 
0.00 
1.61 
 
5.97 
1.99 
2.24 
 
1.81 
0.02 
0.12 
 
0.43 
0.01 
0.01 
 
0.00 
0.00 
0.00 
P-value    0.45     0.04    0.54    0.26 
Visit 7 
Placebo 
Low dose 
High dose 
 
 
9 
9 
10 
 
121 
125 
150 
 
126 
109 
71.7 
 
  31.4 
36.7 
30.3 
 
    0.69 
0.00 
0.17 
 
49.2 
22.9 
2.13 
 
22.9 
0.37 
0.49 
 
0.07 
5.22 
0.00 
 
0.00 
0.00 
0.00 
P-value 
 
   0.96      0.21    0.21     0.64 
Visit 8 
Placebo 
Low dose 
High dose 
 
 
9 
9 
10 
 
201 
190 
204 
 
42.2 
139 
144 
 
   88.0 
243 
48.1 
 
    24.6 
0.00 
2.00 
 
8.15 
7.76 
2.13 
 
2.04 
1.21 
0.43 
 
0.01 
0.15 
0.09 
 
0.00 
0.00 
0.00 
P-value 
 
 
 
    0.86     0.43   0.23    0.69 
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Figure 4-1 Box Plot of L. crispatus Counts By Study Arm and Visit 
 
Figure 4-2 Box Plot of L. iners Counts By Study Arm and Visit 
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Figure 4-3 Box Plot of L. jensenii Counts By Study Arm and Visit 
 
Figure 4-4 Box Plot of L. gasseri Counts By Study Arm and Visit 
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4.3.3 Discussion of Methods Used to Assess Vaginal Flora 
In 1983, Amsel et al. proposed clinical criteria for the diagnosis of BV. The presence of 
three of the following four criteria is considered to be consistent with the presence of BV: 
vaginal pH of > 4.5, clue cells on saline wet mount, release of a fishy amine odour on 
addition of 10% potassium hydroxide to a drop of vaginal discharge, and a characteristic 
thin, homogenous vaginal discharge [728]. Of these, vaginal pH has been shown to be the 
most sensitive of the individual criteria, and amine odour the most specific [729]. 
Unfortunately, however, it is often difficult to perform a ‘whiff test’ in practice due to the 
need to apply the potassium hydroxide rapidly before the sample dries and health and 
safety issues preventing its use in the consultation room.  
A healthy, normal vaginal pH is generally accepted as being < 4.5, however, studies have 
demonstrated that a pH of > 5.0 provides a more specific indicator of BV [729,730] and a 
cut-off of ≥ 4.7 is employed in some clinical and research settings [714,731].  Many 
factors, other than the absence of lactobacilli/presence of BV associated organisms, 
influence the pH of vaginal fluid. These include presence of other infections, in particular 
Trichomonas vaginalis, hormonal status, size of cervical ectopy and menstruation 
[732,733,734]. Cervical secretions have a higher pH (around 8.0) than those in the vagina 
thus it is imperative to take pH readings from the lateral vaginal wall [735]. Presence of 
alkaline seminal fluid and vaginal products, including lubricating gel, can also alter the pH 
of the vagina. In our trial, no participants admitted to having had vaginal intercourse 
during the study, and mimimal aqueous lubricant was used for speculum insertion. The 
study gels were buffered to pH 5.5 in their formulation hence it is possible that if some 
residual were present in the vagina it may increase the recorded pH. The latter is unlikely, 
however, given the timings of pH and vaginal flora evaluations in relation to dosing 
(screening, 36 hours post 12th dose, next menstrual cycle post gel use).  
In 1991, Nugent et al. described a system for scoring Gram-stained vaginal smears to 
diagnose BV (see section 2.11.4.2 for methodology) [561]. In contrast to clinical methods, 
and the earlier Gram-stain method devised by Spiegel et al. the Nugent scoring system 
allows assessment of vaginal flora on a continuous scale, providing more information than 
just a positive or negative BV diagnosis. Although still commonly used to diagnose BV in 
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clinical practice, the reliability of the Amsel criteria is dependent on the clinical expertise 
of the examiner and has been shown to have reduced sensitivity and inter-observer 
reproducibility compared to the Nugent score [558, 736,737,738,739]. In addition, Gram-
stain methods have the advantage of providing a specimen, in the form of a slide, that 
can be archived for subsequent verification. The Nugent score has thus become the gold 
standard method for diagnosing BV in research studies.  However, like all Gram-stain 
methods, Nugent scoring is highly dependent on the quality of slide preparation and 
factors such as small specimen volume and poor gram-stain uptake can greatly influence 
interpretation. In our study, despite all specimens being taken by a single clinician and 
Gram-stained by experienced personnel at a single centre, there were unfortunately a 
few slides which could not be read due to inadequate preparation. 
Alternatives to Gram-stain and clinical methods for assessing vaginal flora include both 
quantitative culture and PCR techniques. The former has been used to demonstrate 
increases in log10 counts of the BV associated bacteria Gardnerella vaginalis and 
Mycoplasma hominis and decreases in Lactobacillus species in women diagnosed as 
having BV by Nugent score [740,741]. One advantage of culture is that Lactobacillus 
colonies can be directly assessed for hydrogen peroxide production using 
tetramethylbenzidine agar plates [742]. 
The advent of molecular techniques has enabled accurate differentiation and 
identification of lactobacilli to the individual species level. Studies using qPCR to quantify 
differences in particular Lactobacillus species have yielded interesting and sometimes 
conflicting results, suggesting that the changes associated with BV are far more 
complicated than a simple reduction in numbers. As mentioned in section 2.4.2, L. 
crispatus and to a lesser extent, L. jensenii are the most commonly detected species in 
women with normal flora, but L. iners is most abundant in women with BV and L. gasseri 
in women with intermediate flora [542, 543]. Interestingly, nearly all strains of L. crispatus 
and L. jensenii have been reported to produce hydrogen peroxide, whereas this is true for 
only 9% of the strains of L. iners [541]. Until recently, L. iners was an underappreciated 
member of the vaginal microbiota, since it does not grow on the Rogosa agar traditionally 
used to isolate lactobacilli [743]. However, there is now evidence that it may be the most 
abundant Lactobacillus species overall, being isolated from 2/3 of black and Caucasion 
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women in one US study, and dominating the vaginal flora in 1/3 of women from a range 
of ethnic backgrounds [726,727].  
Indeed, what is classed as a ‘normal’ flora has itself been called into question. Verhelst et 
al., on the basis of Gram stain, terminal restriction fragment length polymorphism 
analysis of the 16S rRNA gene (T-RFLP) and molecular identification (tDNA-PCR) of 
cultured isolates, have suggested a new classification of the normal vaginal microflora 
[744]. Referring to the Ison-Hay grading system, a simplification of the Nugent scoring 
method used in clinical settings, whereby Gram-stained slides are classified according to 
the estimated proportions of various bacterial morphotypes rather than actual counts 
[745], they suggested that the normal, lactobacillus-predominant (grade I) microflora 
could be split up into four categories, designated grade Ia, Ib, Iab and I-like. Grade Ia was 
shown to contain predominantly L. crispatus, grade Ib predominantly L. gasseri and L. 
iners, and grade Iab a mixture of these three species. Surprisingly, grade I-like flora was 
shown to consist of Bifidobacterium species rather than Lactobacillus species. Grade I-like 
flora has been suggested to represent an unrecognized type of disturbed vaginal 
microflora that has previously not been distinguished from a healthy vaginal microflora 
[746].  
Support for the notion of a limited range of background vaginal microbiota has come 
from recent studies which have used high-throughput molecular methods based on 
pyrosequencing of barcoded 16S rRNA genes. A US study of 396 assymptomatic American 
women identified five clusters of vaginal microflora; four of which were dominated by 
Lactobacillus iners, L. crispatus, L. gasseri, or L. jensenii, while the fifth had lower 
proportions of lactic acid bacteria and higher proportions of strict and facultative 
anaerobes [727]. This low-Lactobacillus group accounted for about 25% of the women 
sampled and was over-represented in Hispanic (34.3%) and black (38.9%) women as 
compared with Asian (17.6%) and white (9.3%) women. In addition, Zhou et al. have 
shown that microbial communities dominated by > 1 species of Lactobacillus are less 
common in black women than those of white or Japanese ethnicity, perhaps rendering 
them more susceptible to BV and other sexually transmitted infections, including HIV 
[726,747]. 
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4.3.4 Comparison Between Clinical Assessment, Nugent Score and PCR 
Methodologies in Our Trial 
Although the primary method for evaluating vaginal flora in our study was qPCR, clinical 
assessments (appearance of discharge and vaginal pH) and Gram-stained slides were also 
performed at the same time-points. Consistent with the PCR data, overall, there was no 
microscopic evidence from the Nugent scores to suggest that either dose of the Mabgel 
or the placebo caused a detrimental change in vaginal flora. The majority of all vaginal 
smears were Nugent scored as 0, i.e. there was a preponderance of lactobacillus 
morphotypes and no other gradable organisms. Of the 4 smears which were scored 
higher than 0, 2 were obtained at the screening visit, none at visit 7 and 2 at visit 8. 
MAB003 (high dose Mabgel arm) had a grade 4 flora at screening (intermediate between 
normal and BV), with a high pH of 6.4. Clinically, there was no evidence of any heavy or 
malodorous discharge at this visit, thus she met eligibility criteria for study enrolment, 
having neither microscopic nor clinically defined BV. Unfortunately her Visit 7 slide was 
judged to be inadequate for interpretation. However, her flora had returned to normal at 
Visit 8, with a slightly high pH of 4.9. Interestingly, PCR results showed that L. iners 
dominated this participant’s flora at all 3 visits and L. gasseri was not detected.  
These data are in contrast to the findings of de Backer et al. but support those of others, 
in indicating a possible ‘role’ for L. iners as a marker of transition in the vaginal flora 
[542,748]. They also highlight the paucity of published data on how quickly changes in the 
composition of the vaginal microflora occur and how much represents ‘natural’ flux 
rather than pathology. Until recently, research assessing vaginal flora by PCR techniques 
has mostly taken a ‘snap shot’ view, evaluating the microbiome at a single moment in 
time. In a recent small study, fluctuations in the levels of Lactobacillus species and BV 
associated organisms were evaluated over the menstrual cycle and following antibiotic 
treatment in women diagnosed clinically with BV [749]. Levels of L. crispatus and L. 
jensenii declined with onset of menstruation, whereas those of G. vaginalis and L. iners 
increased. Spontaneous reversal beginning at the end of menses occurred in most 
individuals subsequently. In women with BV, in contrast to most BV associated bacteria, 
L. iners levels did not decline post treatment, but remained constant or increased, and 
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some women became re-colonised with other Lactobacillus species. These findings 
concord with observations from studies using Gram-stain methods, which detected 
transient changes in vaginal flora at the start of the menstrual cycle and rapid resolution 
of BV, within 3 days in around half of episodes, even without treatment [750,751]. 
MAB007 (low dose Mabgel arm) had a grade 8 (BV) flora at screening, as judged by Dr 
Jespers, thus would not have been eligible for the study based on this evaluation. 
However, on the screening slide reviewed by Dr Morris at EMU she was judged as having 
2+ short lactobacillus morphotypes and 1+ gram-variable rods per high powered field and 
was given a score of 3. Clinically she had only a scanty, inoffensive white discharge with a 
pH of 4.3, thus was not judged to have BV in York. Subsequent slides at Visits 7 and 8 
were both graded as showing normal flora.  
This example demonstrates the fact that, although more reliable than clinical criteria, 
inter-observer disagreement over Nugent gradings can still exist.  Indeed, in their original 
study, Nugent et al. found an inter-centre correlation of 0.82, which although better than 
with the previously used Spiegel criteria, indicates an element of subjectivity in slide 
interpretation [561]. Molecular methods, such as PCR, offer a more objective approach. 
PCR results for this participant showed that her vaginal flora was dominated by L. iners, 
which increased 10 fold with each subsequent visit. L. jensenii and L. gasseri were also 
present, increasing from being barely detectable at screening, to a peak at visit 7. L. iners 
has been noted to cause confounding on microscopy as it often stains Gram-negative and 
is coccobacillar in appearance in contrast to the longer, Gram-positive appearance of the 
classical lactobacillus morphotype [743]. This may explain the discrepant Nugent scores 
assigned on the screening visit smears. 
MAB017 (placebo) had a grade 4 flora at visit 8. This lady had a normal vaginal pH (4.3) 
and no clinically apparent discharge at this visit. As with MAB003 discussed above, this 
lady had a pre-dominance of L. iners and a relative paucity of other Lactobacillus species 
in her flora. 
MAB014 (low dose Mabgel) was given a Nugent score of 7 on her vaginal flora smear 
from Visit 8. Clinically, this lady had quite a heavy, homogenous white discharge and an 
elevated vaginal pH of 6.4 at this visit. A diagnostic slide was not performed, as this was 
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outside of the study protocol. However, the putative BV diagnosis was discussed with the 
patient and an offer made of evaluation and treatment at the York GUM clinic. 
Interestingly, unlike the other participants with abnormal Nugent scores, this lady had an 
absence on L. iners on PCR and her flora was dominated by L. crispatus. However, her 
Visit 8 sample had the lowest levels of L. crispatus and highest detectable L. gasseri levels 
of her 3 visits. 
In our study, excluding the 2 occasions where there was no pH value recorded, 50/74 
(67.5 %) of vaginal smears given a Nugent score of 0 had an accompanying pH < 4.5. Of 
those > 4.5, 17/24 (70.8 %) had a pH of 4.6 and 7/24 (29.2%) a pH in the range 4.9 to 5.9. 
Interestingly the highest pH readings (5.8, 5.9 and 4.9) were seen in MAB021, in whom 
neither L. crispatus nor L jensenii were detected on PCR, but in whom there were high 
levels of L. iners.  
MAB008 also had high pH readings (5.2 x2 and 4.6) with an absence of a vaginal discharge 
consistent with BV at any visit. This participant is intriguing as slides from all 3 visits were 
graded as Nugent 0 (indicating that 4+ lactobacilli morphotypes were visible 
microscopically) but she had the lowest detectable Lactobacilli counts on PCR of any 
participant. Of note, only the non-specific Lactobacillus genus primers produced 
detectable counts suggesting that any Lactobacilli present were likely to have been from a 
species other than those detectable with the species-specific primers. The generic 
primers were designed based on sequences conserved between L. Jensenii and L. 
crispatus [560] and it is possible that they may not detect all Lactobacillus species that 
exist with equal efficiency. Another possibility is that this participant had a microflora 
dominated by Bifidobacteria or another organism that can resemble lactobacilli 
microscopically [744]. 
Although our study was not designed to directly compare methodologies for assessing the 
vaginal flora, it is reassuring to note that in general there was agreement between 
clinical, microscopic and PCR assessments and this increases the validity of our findings. 
However, it should be noted that since we currently only have PCR data from our study 
related to Lactobacillus species and not BV associated organisms, we only have a partial 
analysis of the flora by molecular methods.  Results of further analyses by Dr Jespers are 
awaited.  
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As we have found, PCR is a useful and reliable tool for assessing changes in the vaginal 
flora in the context of microbicide safety studies and It is likely to be increasingly used to 
detect subtle changes and provide additional information to microscopy in other areas of 
research. However, it is unlikely that it will replace clinical and Gram stain methods for 
initial participant screening or evaluation of vaginal discharge due to cost and time 
needed to process samples. 
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5. QUALITATIVE INTERVIEW SUB-STUDY 
5.1 Rationale behind the qualitative interview sub-study 
The initial planning for the interview sub-study was carried out by Sarah Woodhall, non-
clinical Research Fellow, HYMS with advice from Dr Yvonne Birks, Senior Lecturer, 
Department of Health Sciences, University of York and Dr Susan Rosenthal, Assistant 
Professor of Pediatrics, Columbia University, New York, USA. 
The overall aim of the sub-study was to evaluate participants’ experience of taking part in 
the MABGEL 1 trial.   
As with many Phase 1 trials, MABGEL 1 participants were required to attend for several 
visits and undergo multiple examinations. The proposed purpose of Mabgel, however, 
meant that product use and examinations were of a far more intimate nature than would 
be experienced in many studies.  Women were also required to abstain from sexual 
intercourse and use devices such as the gel applicator and vaginal self-sampling aspirator, 
which may have incurred difficulties.  
Since MABGEL 1 was the first study to be conducted on the HYMS EMU, it was felt that 
feedback from participants, regarding their motivation for volunteering and their 
interactions with the research team, would be useful for optimising recruitment and 
retention in future clinical trials. In addition, it was considered important to obtain 
participants’ views of the conduct of the study: to identify any procedures and/or 
features of the IMP that could be altered to improve acceptability. 
5.2 Research Objectives 
The following were identified as being the main objectives of the sub-study: 
1. To determine participants’ motivation for volunteering 
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2. To ascertain whether participants’ rights and dignity were being respected whilst 
taking part in the clinical trial 
3. To identify any areas of study conduct which could be improved in future trials 
4. To determine the utility and acceptability of the self-sampling aspirator 
5. To identify any features of Mabgel which should be altered as part of product 
development 
5.3 Methodology 
5.3.1 General conduct of the interviews 
A semi-structured interview was carried out with each of the 28 Mabgel trial participants 
at their final study visit (Visit 8). In order to create a relaxed and open environment, in 
which the participant felt that they were able to give honest answers, it was important 
that the interviewer was not someone they had met previously during the trial. Because 
some of the questions being asked were of an intimate nature e.g. pertaining to sexual 
activity, application of gel, vaginal examinations, and to better enable the interviewer to 
establish a rapport with the participant, it was decided that the interviewer should be 
female. It was initially envisaged that the interviews would be conducted by Sarah 
Woodhall, however,   she was no longer working in York by the time the study took place. 
The interviews were instead conducted by three female members of clinical research 
staff, none of whom were otherwise involved in the MABGEL 1 Trial. These were Dr 
Victoria Ledgar, F2 Doctor on a 4 month placement with Professor Lacey’s research group, 
Sarah Russell-Sharpe, Senior Research Nurse and Sarah Douglas, Clinical Trials Assistant 
and MSc Student in Heath Sciences. Interviews took place in the consulting rooms of the 
EMU. Guidance and training on conducting the interviews was provided by Dr Birks.   
Participants were informed of the interviews in the PIS that they were asked to read 
before consenting to take part in the trial. They were permitted to decline to take part in 
the sub-study whilst still being able to take part in the main trial if they wished. Written 
consent was sought and obtained for the sub-study from all participants at the screening 
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visit. Prior to commencing each interview, the interviewer reaffirmed verbally that the 
participant remained happy to consent to being interviewed and that they agreed to the 
interview being audio-recorded. Each participant was given a short briefing at the start of 
the interview explaining the general aims and nature of the questions. All interviews were 
digitally recorded and transcribed verbatim by a trained Medical Secretary.  
Participants were reassured that their comments would be treated confidentially. All 
interviews were conducted and documented anonymously; no personal identifiable 
information was included on the recording or transcript. Instead, each interviewee was 
given a new interview ID independent from their subject number for the main trial. All 
interview transcripts have been archived in the Trial Master File (TMF). 
5.3.2 Interview topic guide 
A topic guide was produced by Sarah Woodhall and Susan Rosenthal to aid the 
interviewer in focusing the discussion on relevant areas. This was loosely based on a 
guide used by Dr Rosenthal in a previous study [752]. 
The following topic areas were listed: 
1. Motivation for taking part in the trial 
 
2. Adequacy and suitability of information provided before and during the trial 
 
3. Experience of clinical trial visits and procedures 
 
4. Compliance with study procedures  
 
5. Experience of using the gel and self-sampling device 
 
In addition, some sample questions were included. These were meant to be used as 
guidance only and there was no requirement to use the exact wording or order given in 
the guide. It was envisaged that all interviews would be different and scope remained for 
further issues to be raised by either the interviewer or the participant during the 
conversation. 
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For example: 
 Opening questions 
 Where did you find out about the trial? 
 How long did you take to decide whether or not you wanted to take part? 
 If a friend asked you what it was like to take part in the study, what would you tell 
them? 
 
Motivation for taking part in the trial 
 Why did you decide to take part in the study? / What interested you in taking part in 
the study?  
 
Adequacy and suitability of information provided before and during the trial 
 What did you think about the information you received about the trial before you 
decided to take part? 
o Initial advertisement 
o Information leaflet 
o Consent form 
o Website 
o Did you read the information leaflet?- If so, was it easy to understand? Any 
suggested changes? 
 Did the information you received at the start of the trial give you a good idea of what 
the trial involved?  
o What was different to expectations? Any surprises? 
o Did anything make you feel uncomfortable? 
o Anything you were unsure about? 
o Any questions at start of the trial? - if so, what were they? 
o Were your questions answered adequately at the start of the trial? 
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Experience of clinical trial visits, procedures and use of self-sampling device 
 What was the hardest part of the study for you? 
o Anything you disliked? 
o Any concerns about taking part? 
 What was your experience of attending for the trial visits? 
o Ease of fitting in round own life 
o Samples and investigations 
o Blood tests, vaginal examination, general examinations 
o Use of self-sampling device 
 Easy or hard to use? 
 Would you prefer to take your own samples or have a doctor/nurse 
do it? 
 
Compliance with study procedures  
 Did you find it easy or hard to follow the trial procedures (self-administering the study 
gel, remaining sexually abstinent)? 
o Did you use all doses of the study gel? 
 When did you use the gel? 
 What was it like to use? 
 Any problems using it? 
o Understanding of what was required during the trial 
 When to use gel 
 When to come in for visits 
 When allowed to have sex 
 Completing the diary card 
 Did you remain sexually abstinent during the dosing period of the study? 
o Was this easy or hard to do? 
o Did you inform the study nurse? 
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Experience of using the gel  
 What was your experience of using the gel? 
o Feel 
o Leakage 
o Appearance 
o Ease of use 
 
5.3.3 Data Analysis 
Transcripts were analysed by the author and Sarah Douglas with advice and guidance 
from Dr Yvonne Birks and Dr Catherine Montgomery, Postdoctoral Research Fellow, 
Department of Sociology, University of York. Data were analysed using a ‘framework’ 
approach similar to that described by Ritchie and Spencer [753].  
Transcripts were read several times and initial themes identified by consensus. 
Unsurprisingly, given the semi-structured nature of the interviews, these broadly 
matched the topic areas suggested in the topic guide. Further themes and sub-themes 
emerged as transcripts were coded and coding schemes were refined as the process 
developed. Analysis was carried out manually as there had been no plans to use a 
software package e.g. NVivo, and access to such programmes was unavailable in York 
Hospital or the Monkgate Clinic, which was where the research team were based. 
The purpose of the analysis was to try to identify recurring concepts to develop and 
explain hypotheses but efforts were made to ensure the diversity of view-points were 
represented, especially any that were contradictory.  
Since the author had been involved in the co-ordination and clinical aspects of the trial, 
there was the potential for this to have had an influence on the interpretation of the 
data, particularly with regards to comments relating to study conduct. For this reason, the 
results and conclusions generated were reviewed by Dr Montgomery, together with the 
transcripts, to verify that they accurately reflected the content and breadth of the data. 
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Quotes from the original transcribed interviews have been used to try to support the 
development of theories and findings. Quotation marks have been used to indicate when 
a participant has been quoted directly otherwise the author has used reported speech, 
aiming to keep as close to the original speech as possible.  
5.4 Results 
Interviews were completed and recorded for all 28 participants. Interviews ranged in 
duration from 10 minutes to 20 minutes 20 seconds. The mean duration was 13 minutes 
27 seconds. 
5.4.1 Trial Recruitment 
5.4.1.1 Awareness of the existence of the study 
All participants were asked how they first found out about the trial. 13 of the 28 
participants (46%) reported that they became aware of the trial through word of mouth. 
Interviewee 20 said that she knew a member of staff from the EMU and Interviewee 26 
confirmed that her friend had already participated in the trial and had told her all about 
it.  2 of the 28 participants stated that they found out about the trial through York 
Hospital’s intranet site therefore indicating that they were themselves NHS staff. 4 
participants said that there was information about it on the University of York’s Intranet, 
implying that they worked or studied there. 4 of the participants mentioned Local Link 
magazine which is a free magazine that is delivered around the York area and an 
additional participant referred to a local magazine but did not provide the name of it. This 
again may have been the Local Link magazine, since this was the only magazine in which 
adverts were placed. 1 woman said that there was an advert in her local newspaper (the 
York Press) and the remaining 2 participants had seen posters displayed at York Hospital 
that were advertising the trial. 
5.4.1.2 Motivation for taking part in the study 
Participants were asked what it was that interested them in the trial in the first place and 
made them want to take part. 3 of the 28 participants stated that their sole motivation 
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for taking part in the trial was the financial remuneration. A further 15 participants said 
that the money had played a part but in addition they had other reasons for wanting to 
take part. 20 of the participants saw value in the research being undertaken either 
because they were particularly interested in HIV or because they had an interest in 
research in general. Interviewee 10 commented that she was interested in the concept of 
using a gel as a preventative measure against HIV. Interviewee 16 expressed a desire to 
help others as she said that she was a nurse herself. In addition to the financial 
motivation and being able to see value in the research 3 participants highlighted a 
different reason for wanting to be a part of the trial. Interviewee 13 reported that it was 
the opportunity of having a ‘full sexually transmitted infection check-up’ that appealed to 
her. Interviewee 26 also stated that she thought that through the screening tests, blood 
tests and examinations that would be performed she would also be getting something out 
of the trial. A unique comment was made by Interviewee 19, whose interest in the trial 
was partly due to the time commitment of it. She told the interviewer that her hours had 
been cut at work and her son was at school so she saw the trial as something to do part- 
time to fill her day.  
5.4.2 Discussing the trial with others 
It was clear from some participants’ responses as to how they had become aware of the 
study that some of the women who were already enrolled in the trial had talked about it 
to their friends, family or work colleagues and this had sparked further interest in the 
trial. All participants who were asked if their decision to take part in the trial had been 
influenced by any additional factors such as friends or family stated that the decision was 
ultimately their own, however a number referred to discussions they had had with others 
which had played a role in their decision making. 
Interviewee 10 and Interviewee 26 had friends who were already enrolled on the trial, 
therefore their friends’ experiences had partly influenced them. Interviewee 10 said that 
her friend ‘was quite positive about it (the trial)’ and commented that ‘if she had said 
anything particularly negative about it, it probably would have put me off but she didn’t 
have anything bad to say’. 
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5 participants mentioned that they had discussed the trial with their partners first before 
signing up. Interviewee 13 said that this was due to the need for sexual abstinence.  
One woman (Interviewee 9) expressed an initially negative or apprehensive view of 
discussing her participation with others. ‘I kept it quite quiet because I didn’t know how 
people would react’.  However, in her experience, this was unfounded: ‘after I’d signed up 
and I was accepted then I started to tell people and nobody was negative or worried about 
it so everyone was quite like “Tell me a bit more about it” ’. 
Several participants found it awkward discussing the trial in view of the ‘intimate’ nature 
of the product and procedures. Interviewee 6 told the interviewer that there was one 
occasion when her partner had had some friends round and she did not want to explain 
to them about the trial and so found it a bit awkward ‘disappearing’ to use the gel. 
Interviewee 26 found it slightly uncomfortable telling her friends what the gel was when 
she was on holiday with them. Similarly, Interviewee 25 had to explain what the gels were 
to her housemate as she lives in a shared house and had to store them in a communal 
fridge. 
The question ‘If a friend asked you what it was like to take part in the study what would 
you tell them?’ was also posed. All of the responses to this question were predominantly 
positive: ‘Everyone was going out of their way to help you’ (Interviewee 3); Interviewee 
19 described the trial as ‘fantastic’. Interviewee 11 however advised that the trial 
probably would not be suitable for women who hate having smear tests performed. 
Similarly, Interviewee 12 said that she thought that the trial would be better suited to 
women in their 30s or 40s who are used to smear tests or who have already had children 
as they would find the examinations and procedures less embarrassing. 9 out of the 28 
participants reported that either they would recommend the trial to their friends, family 
or colleagues or that they had already told others about it. 
5.4.3 Adequacy and suitability of information provided before and during 
the trial 
The question ‘What did you think about the information that you received before you 
started the trial?’ was posed to participants. The discussions around this topic chiefly 
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focused on the written information provided in the PIS which all participants read before 
consenting to be involved in the MABGEL1 trial. The majority of participants were very 
positive about the information they had read. Interviewee 1 responded with ‘Everything 
that I wanted to know was there’. Other participants described the information as 
‘thorough’ (Interviewee 4, Interviewee 2). Interviewee 20 said that she was a nurse but 
thought that the information could be understood by anyone. Similarly, Interviewee 15 
described the information as being written in ‘lay terms’ and ‘not too medical’. 
Interviewee 18 mentioned that she found the chart of what happened and when during 
the trial particularly useful. Interviewee 10 liked that there was so much information and 
said ‘You can really get a picture before having to speak to anyone’. She thought this took 
away the feeling of being under pressure to take part in the trial just because one of the 
team had taken so much time to explain all about it to you. In contrast Interviewee 2 was 
unsure if potential participants would read all the information due to the sheer volume of 
it and did comment that she did not understand some of the technical terms used in the 
PIS such as ‘colposcopy’ and thought a bit more explanation of such terms was needed in 
the literature. Interviewee 16 commented that the information was ‘initially quite 
boggling’ but then said that she found it easier to understand once a member of the 
research team had talked her through it. Similarly, Interviewee 11 stated that the verbal 
information that had been disseminated from the team and her friend made the written 
information easier to digest. Interviewee 17 had a more negative evaluation of the 
information and said that she found it ‘slightly difficult to understand’. 
During the discussion the participants were asked if they remembered having any 
questions or concerns about the trial after having read all the information that was 
available to them. 4 of the participants recalled expressing concern over the possible side 
effects associated with using the gel, for example, Interviewee 3 ‘did not remember the 
issue of fertility being raised at any point and if involvement in the trial could affect it in 
any way.’ 2 participants had questions relating to the availability of parking at the hospital 
and the costs of this. Other concerns raised were participants who were anxious about 
being able to fit in the appointments around their working life.  Interviewee 28 said that 
she would have liked to have known in advance how long each visit would last. 
Interviewee 13 was worried that the trial might be ‘too invasive’. 
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An additional question posed was ‘Did you (the participant) feel that anything unexpected 
happened in the trial that had not been mentioned in the PIS? or ‘Could you suggest 
anything which might have been added or changed to  improve the PIS? ’. Interviewee 11 
suggested that advising participants to ensure they had had something to eat or drink 
before coming in for an early morning appointment would make giving blood easier. 2 
participants said that they had not been aware that they would have to take some of their 
own samples during the trial. Interviewee 23 reported that she had not expected the gel 
to be so cold and said that it had not been suggested to her that she take the gel out of 
the fridge for a short while first to allow it to get up to room temperature.  
In contrast, Interviewee 19 said ‘When I’d actually been and done it it’s a lot easier than it 
looks on paper’. Similarly, Interviewee 20 said there were fewer visits than she first 
thought. She had expected that she would have had to come in for visits everyday.  
5.4.4 Experience of Clinical Trial Visits and Procedures 
When participants were asked ‘what was the hardest part of the trial for you?’ the 
responses were quite varied.  Several of the participants identified more than one specific 
aspect of the trial as being difficult. Most of the difficulties surrounded genital 
examinations, sampling, and fitting study visits and gel use into their normal routine.  
Interviewee 1 recalled being daunted at first by the prospect of a speculum being used 
during the vaginal examinations but she stated that it became easier after the first time. 
She was also apprehensive about a camera being used to take photographs during these 
examinations but she did say that she was asked if she wanted to see the screen or not. 2 
additional participants also felt uncomfortable about the camera being used. 4 
participants identified the self-sampling procedure as being the most challenging part of 
the trial. 3 participants found it difficult fitting trial visits in around either their family or 
working life. Remembering to put the gel in everyday at roughly the same time was 
described as being problematic for 3 of the participants. Interviewee 17 said that using 
the gel in general was the hardest part for her as she was conscious of the gel inside her 
all the time she was using it and had to wear knickers to bed which she would not 
normally do. A couple of the participants were uneasy about having blood tests, finding 
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them uncomfortable and having concerns regarding the volume of blood taken. 1 
participant stated that she had not found anything difficult during her time in the trial.  
Some of these aspects are explored further below.  
5.4.4.1 Ease of Attending Study Visits 
Participants were asked specifically to comment on how easily they fitted trial visits in 
around their normal life. None of the women reported any major problems with regards 
to this. However, Interviewee 2 said that it was a struggle when there were 3 visits that 
were very close together. Similarly, Interviewee 16 described her first day of dosing as 
being ‘quite intense’. She scheduled this specifically for her day off but said she was 
doubtful that she would have managed to fit in both of the visits if she had been at work. 
Interviewee 12 had also scheduled the first day of dosing to occur on her day off.  
Interviewee 5 commented that she did have to change her routine a bit while she was 
involved in the trial. 4 of the participants worked flexi-time and reported that they found 
it very easy to attend for the visits. There were 9 references made to the flexibility of the 
research team which participants stated made it easier for them to fit in the visits and to 
not have to change their routines too much. Interviewee 1 suggested that it would be 
good if the research team could offer early evening appointments for those people that 
finish work at around 4 or 5pm. Interviewee 25 said that she did not get the impression 
that there were appointments available outside of normal 9am-5pm office hours but she 
commented that there were no issues for her coming in for appointments within that 
time frame.  
5.4.4.2 Experience of undergoing intimate examinations 
Only one of the participants recalled any really negative experiences relating to the 
intimate examinations which were performed as part of the trial. Interviewee 17 said that 
the research staff had presumed that because she had already taken part in a similar 
clinical trial that she would be familiar with all the procedures that would be performed. 
She commented that ‘I prefer being more looked after’, suggesting that she believed her 
quality of care could have been higher.  In contrast, Interviewee 9 reported that ‘the 
doctor and nurses always talked through all of the procedures with her before they did 
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them’. Interviewee 24 commented that the examinations were ‘sometimes quite 
uncomfortable’ but highlighted that the research staff had made her feel as comfortable 
as possible. Several further references were made to the quality of care provided by the 
research staff. Interviewee 1 said that the staff were always very considerate during 
examinations and procedures and Interviewee 9 stated that the staff always respected 
her privacy. Interviewee 5 had never had an examination using a speculum before and 
found the procedure uncomfortable at first but then got used to it. Interviewee 8 
commented that she was ‘well used to intimate examinations’ as she had had 4 children 
and therefore had no issues with the examinations being performed. As previously stated, 
3 of the participants were slightly uncomfortable with photographs being taken during 
some of the internal examinations however Interviewee 26 said that she was actually 
really interested in seeing the images that were taken.  
5.4.4.3 Experience of using the self-sampling vaginal aspirator 
Participants’ experiences of the self-sampling device were also discussed specifically 
during the interview. 8 of the participants described the procedure as either ‘easy’ or 
‘fine’. Interviewee 2 said that she found the device simple to use but stated that by doing 
the procedure herself she was unsure if she was collecting an adequate sample. A further 
3 participants reported that they had doubts regarding whether they had managed to 
collect a good enough sample or if they were performing the procedure correctly. 
Interviewee 8 said that the device became easier to use once she had had a couple of 
goes at using it. Similarly, Interviewee 13 stated that she found the procedure ‘strange’ 
the first time but then she felt comfortable with using the device after that. 2 of the 
participants compared the self-sampling device to like using a tampon. Interviewee 9 said 
that the device was easy to use but slightly uncomfortable. A further 7 participants 
reported that they had experienced some kind of discomfort during the procedure, most 
commonly the device catching on the vaginal wall. As stated previously, 4 of the 
participants identified this procedure as being the most challenging aspect of the trial for 
them. The most negative experience of self-sampling seems to have been for Interviewee 
27 who described the procedure as ‘horrible’ and she stated ‘I would never want to do 
that again’. 
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Following on from the discussion about the self-sampling device participants were then 
asked which sampling method they preferred: having their samples taken by a clinician or 
taking the samples themselves. 10 out of the 28 participants stated that they preferred 
taking the samples themselves. Some of the reasons given were: ‘it was less intrusive’ 
(Interviewee 23); ‘it did not involve using a speculum’ (Interviewee 2); ‘it was less 
embarrassing‘ (Interviewee 25). Interviewee 3 said that by doing the samples herself she 
felt more involved in the trial and it gave her a sense of being in control. 11 of the 
participants reported that they preferred having their genital samples taken by the trial’s 
doctor. Of those, Interviewee 9 and Interviewee 1 said that it made more sense for the 
clinician to take the samples since they were already performing other examinations. A 
further 3 said that they found it less painful when the clinician took samples. One 
interviewee stated ‘I did 2 self samples and the first one it was quite painful. The second 
one wasn’t painful but because the first one had been I was really dubious when I was 
doing it. That first experience of it just put me off really’.  
 6 participants commented that the doctor was more knowledgeable about the procedure 
and could see more clearly what they were doing and would therefore obtain better 
samples. Interviewee 22 expressed a strong preference for the doctor taking samples so 
that she would not have to see what was happening herself. When she was able to see 
she stated ‘I felt quite disgusted really’. 2 of the participants had no preference for either 
of the 2 sampling methods however Interviewee 26 reported that if it meant that she 
didn’t have to come in for examinations then being able to take the samples herself 
would be nicer. 
5.4.4.4 Experience of venepuncture 
When the subject of blood tests arose, 11 of the participants shared some negative 
experiences with the interviewer. 6 of those 11 reported that they had had to go to 
Phlebotomy at least once during the trial as the research team were unable to obtain a 
blood sample. Interviewee 5 experienced some bruising after having given blood and 
stated that the first time was quite painful. Interviewee 13 also reported that she had 
bruised once. However, as previously stated only 2 participants identified the blood tests 
as being the most difficult part of the trial for them. None of the participants suggested 
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that their venepuncture problems were in any way caused by the research staff and 
seemed to view their difficulties as just being unfortunate or even expected. 
5.4.5 Compliance with study procedures 
5.4.5.1 Compliance with gel usage 
Participants were asked if they had successfully managed to use all of the doses of the 
study gel. Interviewee 12 reported that she had missed one dose as she had been unwell. 
Interviewee 15 also said that she had missed one dose. She explained that on one 
occasion she had returned home after midnight and she thought that she should not use 
the gel because she said that the team had been quite specific about the timings of when 
to use the gel and it was after that time frame. Interviewee 23 stated that she had one gel 
left at the end of the trial but was unsure why this was the case as she claimed she was 
certain that she had used one every day. Interviewee 8 commented that if the gel had 
had to be used at a specific time each day then she would have struggled complying with 
the trial but because there was some flexibility she managed to successfully complete the 
dosing schedule.  
No participants reported having spilt any of the gel. However, 3 women commented that 
they had found transferring the gel from the syringe to the applicator “a bit fiddly” and 
that transfer would have been made easier if the fit between the end of the syringe and 
the applicator had been tighter. 
5.4.5.2 Completion of the diary card 
The diary card that participants had to complete during the dosing period of the study 
was also discussed during the interview. The majority of participants reported that the 
diary card was very easy to fill in. Interviewee 5 and Interviewee 15 both said that they 
found it a useful way of keeping track that they had actually used the gels. Interviewee 3 
suggested that a column could be added so that participants could list any problems or 
side effects that they had experienced as otherwise she said it can be sometimes difficult 
to remember specific things that have happened.  Interviewee 2 thought that the 
importance of the diary card could have been emphasised more as she thought she 
recalled being told that it was not an important part of the trial at the start. 2 of the 
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participants stated that they were unsure if they had to fill in the first box on the diary 
card themselves or if the research staff should have completed this as their first dosage 
was at York Hospital.  
5.4.5.3 Sexual abstinence 
The issue of remaining abstinent during the dosing period of the trial was also raised. No 
participant stated that they had had oral or vaginal sex during the dosing period of the 
study. 24 of the participants reported that they had not had any problems with remaining 
abstinent. Interviewee 12 commented that she found it easy to remain abstinent as she 
had been married for a while. Interviewee 28 stated that she did not have a boyfriend so 
had no problems with the abstinence side of the trial.  Interviewee 1 however 
commented that it may have become an issue if the period she had had to remain 
abstinent was any longer. Interviewee 10 also was not in a relationship but reported that 
had she been in one then not being able to have sex maybe would have been an issue. 
Interviewee 13 said the abstinence was not challenging for her as she was in a 
relationship and had talked it through with her boyfriend but she imagined that 
remaining abstinent may have been a problem for women who were not in a serious 
relationship, especially if they went out and got drunk.   
The remaining 4 participants did find the abstinence side of the trial quite difficult. 
Interviewee 2 reported that she found it ‘a bit frustrating towards the end of the trial’. 
Interviewee 20 described it as ‘tough’. Interviewee 17 told the interviewer that she met 
up with a former partner during the dosing period of the trial and was unsure whether 
she could have sex or not.  She stated that she did not have intercourse with him but that 
her reasons for not doing so were not due to the trial and that being in the trial probably 
would not have stopped her from having sex had she wanted to.  
5.4.6 Experience of using the gel 
Women were asked to comment on the appearance and consistency of the gel. None of 
the participants expressed any strong feelings on this subject. Interviewee 9 stated  ‘It 
was a clear gel; it was absolutely fine. It was easy to use; it wasn’t sticky or problematic’. 
Interviewee 3 stated ‘it didn’t look like anything particularly scary’. 
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Participants shared their experiences of using the gel and were specifically asked if they 
had had any problems with leakage. 4 participants reported that they had not 
experienced any leakage when they used the gel. 2 of those 4 stated that they had 
expected there to be some leakage and were surprised when there was not any. 5 of the 
participants mentioned that they had used either sanitary pads or panty liners whilst 
using the gel, and 2 that they wore knickers at night when they wouldn’t normally. 
Interviewee 24 said that she felt uncomfortable at having to wear panty liners as she 
would not usually use them. Interviewee 20 had not experienced any leakage whilst using 
the gel but reported some bleeding between doses and therefore had had to wear a 
sanitary pad as the trial rules stated that she could not use tampons. She commented that 
she did not like having to use a pad. Interviewee 8 told the interviewer that she had been 
given a pad to wear on her first visit but that she had not needed to wear one after that. 3 
participants compared the sensation of using the gel to being like ‘as if you’d just come on 
your period’ (Interviewee 1, Interviewee 5, Interviewee 18). 5 of the participants 
mentioned that the gel leaked out when they were standing up but that they had 
experienced no leakage when they were lying down. Interviewee 16 was one of those 
participants and commented that ‘I think sometimes it depends where you put it as to 
how long it stays there’. Interviewee 9 said that one night she had used the gel before 
going to the pub and had felt like the gel was trickling down her leg whilst she was there.  
Interviewee 5 and Interviewee 17 reported some itchiness whilst using the gel. 
Interviewee 23 told the interviewer that a couple of times during the dosing period she 
had had a pale pink discharge but she said that she had been assured by the research 
staff that this was not harmful. Interviewee 27 reported that she found the gel a bit cold 
when she used it but in contrast Interviewee 13 said that she experienced a warming 
sensation after applying it. Interviewee 4 stated that she had to take the gel out of the 
fridge an hour before using it otherwise it was too cold to use.  
5.4.7 Closing comments and suggestions to improve future trials 
At the end of the interview all participants were asked if there were any other points 
which they would like to raise about taking part in the trial. At this point 8 of the 
participants were complimentary towards the research staff. Interviewee 3 said that the 
research team were a really nice group of people who helped her to relax. Interviewee 1 
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stated that she was made to feel welcome by the staff. Interviewee 22 described the staff 
as ‘very respectable’ and ‘very considerate’ and she commented that ‘they put my mind at 
rest’. Interviewee 27 liked that she saw the same nurses and doctor at her visits and was 
able to build a rapport with them. Interviewee 8 mentioned that the staff always made 
sure that she knew exactly what was happening at each stage of the trial.  Interviewee 10 
commented that the trial was not the easiest of things to do as it was ‘quite invasive’ but 
she said that once she was used to the procedures and examinations it became more 
tolerable. Interviewee 4 described the first few days of the visits as ‘intense’ as there 
were lots of examinations and blood tests and she mentioned that she had developed 
some bruising as a result.  
A few suggestions about what could be done to improve future trials were proposed. 
Interviewee 3 suggested that a radio or television playing in the background would help 
participants to relax more and suggested that gowns (rather than paper sheets) could be 
provided to participants so that they would feel less exposed during the examinations. 
Interviewee 18 reported that she did not think that any changes needed to be made to 
the trial except for the self-sampling part. Interviewee 20 suggested that panty liners 
could be provided to the participants as she said ‘I got through them like nobody’s 
business’. Interviewee 10 suggested that ‘some sort of pre-filled (application) device or 
better fitting ends between the syringe and applicator would have made it easier to apply 
the gel’. Interviewee 14 was unsure about why she had to keep the syringes from the trial 
and was asked to bring them back. She would have liked this to have been explained to 
her.  
5.4.8 Discussion and conclusions 
Overall, participants gave a very positive account of their experience of taking part in the 
MABGEL 1 trial. Women were generally satisfied with the information they had received 
before they decided to take part, and most found it informative and easy to understand. 
The participants were complimentary towards the research team, reporting that staff 
were friendly and helped put them at ease. 
Although the intimate nature of the examinations and the photographic images were 
uncomfortable for a minority of women, overall, these were well-tolerated. The self-
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sampling procedure was identified by 12 participants as being problematic, however, 
partly because some of the women found it painful to use but also because others 
worried that they were not obtaining an adequate sample. However, 10 participants said 
that if given the choice between taking samples themselves or having the clinician taking 
them they would prefer to take their own samples.  
Fitting in study visits and adhering to study procedures/ requirements did not appear to 
pose any difficulties for the majority of participants. Being single or in a long-standing 
relationship and discussing the study with partners initially, before deciding to enrol, 
were identified as being helpful in facilitating sexual abstinence. 
There was some suggestion that the gel consistency was too runny, with 5 participants 
reporting that they had experienced the gel leaking out when they were standing up, and 
7 women stating that they wore pads, panty-liners or underwear to avoid the gel leaking 
onto sheets or clothing. However, it is possible that the requirement for sexual 
abstinence contributed to any leakage through not enabling the product to be spread 
throughout the vagina as it would if used prior to penile intercourse [594]. If the product 
were to be developed further then attention would need to be given to ensuring that the 
gel was the optimum consistency to maximise delivery and retention of the mAbs and 
that any leakage was acceptable to potential users. 
Trying to ensure that trial participants have as good an experience as possible is clearly 
very important. Not only should clinicians act in the best interests of individuals already 
enrolled in a study, but they should also have a view to future recruitment.  One of the 
clearest findings from the MABGEL 1 interviews is the importance of word of mouth. 
Some of the women who were already taking part in the trial talked about it to their 
friends, family and work colleagues and this led to further recruitment. Indeed, almost 
half of all MABGEL 1 participants found out about the trial this way.  
Although not enquired about specifically, none of the participants reported experiencing 
any social stigma or undue resistance from friends or partners towards their taking part in 
the study. Only one participant reported feeling apprehensive about discussing the study 
with others through fear of a negative response, although several expressed 
awkwardness due to the intimate nature of the product. Importantly, 3 of the participants 
 279 
 
explicitly stated that they would be keen to take part in another clinical trial if a similar 
study was recruiting in the future. 
Our study has several limitations. Firstly, the sample was restricted to women enrolled in 
a Phase 1, pharmacokinetic and safety study who were all considered to be at low risk of 
acquiring HIV infection. In addition, the participants were of majority white British 
ethnicity (28/29). In these respects, they were a different population from that which 
would be likely to use a microbicide if one became available. The setting of product use 
was also artificial, with participants being required to abstain from sexual intercourse. 
Although there has been debate about the appropriateness of incorporating research 
surrounding acceptability into clinical trials in which participants or settings are unlikely to 
be representative of ‘real life’ use [754], participants in Phase 1 clinical trials are the first 
to experience daily use of a product and can offer important early insights into its 
consistency, feel and smell [755].  In addition, as we have found, integration of qualitative 
and quantitative approaches can facilitate fuller evaluation and interpretation of safety 
and pharmacokinetic data.  In our study, participants’ opinions and experience with 
regards to using the gel were only a small part of what we wished to ascertain. Much of 
the interview focused on areas of specific relevance to the conduct of clinical trials, both 
in helping to assess the utility and acceptability of self-taken sampling and in determining 
the effectiveness of particular recruitment strategies and study information. Overall, the 
aim was to gauge an over-view of participants’ experience in taking part in the trial and 
identify any areas which should be modified or improved. Since the MABGEL 1 trial was 
the first study to take place on a newly opened research facility, such information will be 
invaluable in the planning and conduct of future studies. 
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6. SUMMARY, OVERALL CONCLUSIONS, AND FUTURE 
DIRECTIONS 
6.1 Summary 
As described in chapter 1, significant advances have recently been made in the 
development and evaluation of biomedical HIV prevention strategies.  Although there is 
now clear evidence that treating those already infected with HIV prevents onward 
transmission, particularly in motivated, stable sero-discordant partnerships [310], 
additional interventions are still required for use by HIV negative individuals. Young 
women are especially vulnerable to acquiring HIV infection and may lack control over 
their partners’ behaviour [4,16]. Thus, interventions that women can use themselves, 
such as oral or topical PrEP, would be potentially beneficial.   
However, implementing current ARV-based prevention approaches will be a challenge, 
even in richer nations, especially in view of recent reductions in global funding for HIV 
treatment for individuals’ health [756,336,339].  In addition, over-reliance on the same 
classes of agent for both prevention and treatment is not ideal, particularly with the 
emergence of increasing ARV resistance in low income countries [454,455]. Use of 
protective, non-ARV based anti-HIV agents may therefore be advantageous. 
One potential strategy is the topical use of anti-HIV-1 mAbs.  2F5, 4E10 and 2G12 were 
among the 1st generation of broadly neutralizing mAbs to be identified in the sera of HIV 
positive individuals, and have been shown both to have potential to prevent HIV-1 
transmission in NHP SHIV challenge studies [486,487,488,489,490,491,492,494, 
495,496,497,498,499] and be safe when given IV to humans [501,502,503,504,505,506].  
They were therefore considered to be suitable candidates for a prototype, combination 
mAb-based microbicide.  
MABGEL 1 was a Phase 1 clinical trial involving 28 healthy, female volunteers.  It was both 
the first study of intravaginally administered mAbs in humans and the first to be 
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conducted in the HYMS EMU.  It was designed, primarily, to assess the pharmacokinetics 
of C2F5, C2G12, and C4E10 (produced in CHO-cells) when applied to the vagina in a HEC-
based gel (Mabgel).  In addition, data was obtained on a number of secondary outcomes: 
local and systemic toxicity of the Mabgel, including effects on the vaginal flora; utility of 
using Weck-Cels and a self taken vaginal aspirator for sampling genital secretions; and 
participants’ experiences of taking part in the trial.  Study conduct and results have been 
presented and discussed in Chapters 2 to 5. 
This final chapter will evaluate the potential viability of the concept of using combination 
HIV-1 NAbs as a global microbicide, discuss the contribution our research has made to the 
microbicide development field and propose ideas for future investigation. 
6.2 Mabgel: a feasible microbicide for the ‘real-world’? 
To be successful at preventing HIV transmission in the ‘real-world’ a microbicide 
formulation would need to be stable, both at high ambient temperatures and in the 
presence of  male and female genital secretions, safe, efficacious, acceptable and cheap 
to produce [388,389]. At present, whether a combination NAb-based product could fulfil 
all of these criteria is yet to be determined. Studies of C2F5, C4E10, C2G12, and the 
existing Mabgel, have provided important early insights, including identification of several 
pitfalls. However, as will be discussed in sections 6.2.4 and 6.2.6, some current problems 
may potentially be overcome through the use of novel NAbs and technologies. 
6.2.1 Stability 
At time of writing, stability of the mAbs in product buffer has now been established for 
over 2 years at 37 °C and 1 year at 45°C, with no evidence of significant mAb degradation 
(B Vcelar, personal communication).  Thus, it would appear that the Mabgel would be 
suitable for use in regions with high ambient temperatures, with no reliable access to 
refrigeration. However, as discussed in 3.8.9.6, there is evidence to suggest that the 
atypical structure of C2G12 may render it susceptible to rapid enzymatic and/or acid 
induced cleavage on exposure to cervico-vaginal secretions, accounting, at least in part, 
for its more rapid elimination after vaginal application. Although generally possessing 
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more typical Ig conformations, based on these findings, we would recommend all future 
NAbs be evaluated in the presence of both female genital secretions and semen prior to 
animal or clinical studies. 
6.2.2 Safety 
As reported in chapter 4, there was little to indicate from our study that the mAbs or gel 
vehicle were toxic to the cervico-vaginal mucosa or disturbed the normal bacterial flora.  
That said, there is now a general consensus that the relatively crude and subjective 
assessments undertaken in early phase microbicide safety trials to date are inadequate at 
predicting potential enhancement of HIV-1 transmission, and that most studies, involving 
2 weeks or less of product exposure, are too short to elucidate toxicities that develop 
slowly or with cumulative exposure [418].  Indeed, as Poynten et al. point out, we have 
reached a stage at which HIV-1 incidence in Phase III trials has become the ultimate safety 
end-point as well as the only end-point that can be used to assess effectiveness of 
potential microbicide.  Recommendations have been made for improvements to safety 
evaluations (at both preclinical and clinical stages) to facillitate the earlier detection of 
more subtle pro-inflammatory effects [392].  Suggestions include the use of new imaging 
techniques, e.g. optical coherence tomography [757,758,759], the measurement of 
cytokines and innate antimicrobial peptides in addition to perturbations of vaginal flora 
[760] and performance of biopsies (vaginal, cervical  +/- endometrial (with lavage)) pre 
and post microbicide exposure [761,762]. However, the complexities of the female genital 
mucosal environment, including the effects of hormones, infections and semen, and 
variation in sampling methods between studies, have thus far impeded attempts at 
identifying any specific biomarkers predictive of clinically relevant toxicity [99,265,763].  
Although the data we have obtained to date regarding the safety of Mabgel are 
reassuring, it is clear that if the product were to be taken into further development, 
additional safety assessments would be needed in line with current recommendations 
[391,392]. These would include evaluation of cytokine generation, both in explants and in 
animal studies, teratogenicity assessments in rodents and extended safety studies in 
women, incorporating mucosal biopsies and measurement of antimicrobial and 
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inflammatory mediators.  Safety trials involving sexually active and HIV positive 
populations and male penile tolerance studies should also be conducted [764]. 
6.2.3 Effectiveness 
Assuming that a microbicide is safe, to be efficacious it would need to deliver: 1) an agent 
capable of protecting against all circulating HIV-1 strains; 2) to the right anatomical site; 
3) in a high enough concentration; and 4) for an adequate duration to mediate 
preventative effects [765].  In deciding whether to continue to develop the Mabgel in its 
current form, its potential to achieve these should be considered. 
 
6.2.3.1 Breadth of protection 
 As mentioned in chapter 1, the mAbs differ in the breadth of their in-vitro neutralization 
capabilities, with 4E10 mediating cross-clade neutralization of virtually all isolates tested 
to date, with more limited coverage by 2F5 and, in particular, 2G12 [484,485,486,766].  
The neutralization breadth mediated by 4E10 is highly unusual and has not been equalled 
by any other HIV-1 NAb discovered to date (see section 6.2.6). The 4E10 MPER epitope 
appears to be highly conserved whereas glycan residues recognised by 2G12 are often 
absent, particularly from viruses belonging to Clades A, C and CRF01 AE [484]. 
Unfortunately, Clade C viruses are also neutralized poorly by 2F5 [484,766]. Given that 
Clade C isolates account for > 50 % of HIV-1 infections world-wide and are the most 
prevalent viruses in Southern Africa, India and China [24], the fact that they are 
neutralized well by only one of the mAbs in the current microbicide is not ideal and may 
compromise its global effectiveness. 
 
6.2.3.2 Site and mechanism of action  
Even if theoretically capable of neutralizing the HIV strains present in the donor inoculum 
(i.e. they can prevent infection of target cells, such as TZM-bl cells in-vitro) the success of 
the mAbs in-vivo will depend on complex pharmacodynamic interactions which are more 
difficult to evaluate.  
 284 
 
To inhibit the establishment of HIV infection in the FGT, an anti-HIV agent must either 
prevent active virions from crossing the epithelium, or interfere with their entry into, 
replication or early spread within target cells. The exact site(s) and speed of onset of 
activity of the agent depend on its mode of action. Those which inactivate virions or 
interfere non-specifically with binding to cells, such as surfactants and polyanions, are 
predicted to act rapidly, and mainly in the lumen/mucosal surface, whereas those which 
block an intermediary stage in viral entry, viral integration or replication, e.g. CCR5 
inhibitors, NRTIs/NtRTIs, integrase inhibitors, protease inhibitors, and/ or mediate 
destruction of infected cells, act within the mucosa after a short delay.  However, in the 
case of NAbs, which can have a range of effects, the situation may be complicated [767]. 
In general, antibody-mediated neutralization of HIV-1 has been attributed to binding of 
antibody to sites on Env trimers and interfering with virion attachment to host cell 
receptors and/or fusion and cell entry. However, with a few exceptions, the precise 
molecular mechanisms through which individual antibodies mediate their effects have 
been poorly understood [768]. Recently, important mechanistic differences have been 
identified between the MPER mAbs, 2G12 and b12 which could impact on their in-vivo 
efficacy.  It has long been recognised that maximal in-vitro neutralization of susceptible 
isolates by 2G12 occurs rapidly (within 1 hour) whereas that mediated by b12 and the 
MPER mAbs develops over a number of hours [484]. This is partly due to differences in 
epitope accessibility; the 2G12 binding site consists of glycated residues on the external 
surface of gp120, whereas the CD4bs epitope of b12 is deeply recessed and the MPER is 
partially buried in the viral membrane [472,473,476,477]. Resistance to neutralization by 
b12, 2F5 and 4E10 can arise even in the presence of their cognate amino acid residues, 
due to variations in the 3-dimensional structure of the Env trimer which preclude access 
to their epitopes [769,770]. In addition, whereas the primary mechanism of virus 
neutralization by 2G12 appears to be competitive inhibition of virion-host cell attachment 
(by binding V3 in a way which blocks conformational changes required for efficient 
binding of CD4 and CCR5) [475] that for the MPER mAbs is much more complex.  Evidence 
to date suggests that whilst 2F5 and 4E10 can bind to their epitopes, within their lipid 
environment, on free virions prior to target cell engagement (and this enhances 
neutralization), they interact with gp41 more strongly once it forms a hairpin 
intermediate on binding CD4 [479,481,482,483,770]. This action likely prevents formation 
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of the fusion peptide hence blocks virus entry.  Recently, Trkola et al.  have shown that 
the MPER mAbs and b12, but not 2G12,  can also induce shedding of Env from the surface 
of virions resulting in irreversible neutralization [771].  In contrast, although much more 
rapid, neutralization mediated through 2G12 binding was shown to be reversible; viable 
virions being released once excess antibody was removed [475,771].  However, Env 
shedding is a slow process, requiring prolonged incubation of the mAbs with free virions 
or the continued presence of antibody at the time of contact with target cells.  For the 
MPER mAbs, high concordance between the degree of observed shedding and 
neutralization, and similarities in the kinetics of the two processes, suggest they are 
functionally linked.  In contrast, the primary mechanism of b12 neutralization appears to 
be independent of shedding. The exact time required for 100 % shedding was variable, 
dependent on both mAb concentration and temperature, but took a minimum of 16 
hours using 100μg/ml MPER mAb (sufficient to neutralize 70% of challenge JR-FL 
pseudovirus stock at  20 hours) at 37 °C [771].   
In addition to direct neutralization, both NAbs and non-NAbs can mediate other activities 
in the mucosa which may contribute to HIV clearance [146,147,345]. These include 
binding of virions to prevent trancytosis, and Fc mediated functions, e.g. phagocytosis, 
ADCC and ADCVI of infected cells and complement activation.  Large, multimeric 
antibodies (IgM and IgA) can aggregate virions, and impede their passage through 
epithelial layers [345]. However, although most antibodies (isolated mainly from highly-
exposed HIV-1 unifected individuals) that have been shown to block transcytosis in-vitro 
have been of the IgA class [772,773,774,775], HIV-1 binding to syndecans, which is 
dependent on a conserved arginine in gp120 [260, 776], can be blocked by the IgG1 NAb 
b12, inhibiting its uptake by epithelial cells [777]. 
For b12, there is in-vitro and in-vivo evidence to suggest that Fc-mediated effector 
functions, but not complement activation, play a role in its protective effects when it is 
given IV [778,779]. To date, the ability of other anti-HIV NAbs to perform non-neutralizing 
activities has been studied less extensively and has been confined to in-vitro analyses. In 
contrast to b12, both 2G12 and the MPER mAbs have been shown to be inefficient when 
assessed using antibody-dependent cell-mediated viral inhibition assays (ADCVI) [499, 
778, 780].  However, antibodies may differ in their individual abilities to elicit particular 
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cell-mediated effector functions.  Both ADCVI and ADCC depend on interactions between 
the antibody, FcR-bearing effector cells and an infected target cell. However, whereas 
ADCVI assays measure the quantity of HIV virions released by infected target cells (which 
may be influenced by a number of both cytotoxic and noncytotoxic inhibitory 
mechanisms), those for ADCC detect cell lysis [148].  When focusing only on ADCC, 2F5 
has been shown to have potent activity, acting in an FcγRI-dependent manner [781].  
Interestingly, FcγRI interactions have also been reported to increase the neutralization 
potency of both 2F5 and 4E10, but not b12 and 2G12, when expressed on TZM-bl target 
cells [782]. In contrast, for both b12 and 2G12, ADCC activity can be boosted in-vitro 
through mutations which enhance Fc binding to FcγRIIIa [783,784].  In general, antibody 
concentrations needed to elicit Fc-mediated effector functions are much higher than 
those required for neutralization [499,779,781]. 
The implications of the above findings for in-vivo protection are poorly understood. FcγRI 
binds monomeric IgG with high affinity; thus, given the high concentration of IgG in serum 
and genital secretions, is thought to be saturated under physiological conditions. In 
contrast, FcγRIIa, FcγRIIb, and FcγRIIIa bind monomeric IgG with low affinity and probably 
require the formation of immune complexes for efficient IgG binding; the latter being 
more compatible with a role in pathogen clearance and immunoregulation [143,147,784]. 
However, although antibody-FcγRIIIa mediated effector functions have been correlated 
with protection from HIV and SIV in vaccine studies [785,786,787], and with enhanced VL 
control in infected individuals [788,789,790], a direct relationship has not been proven. 
Despite displaying enhanced affinity for human and macaque FcγRIIIa, and demonstrating 
significantly (at least 10-fold) greater ADCVI, ADCC and NK activation abilities in-vitro, a 
non-fucosylated variant of b12 (administered IV) produced no difference in protection or 
post infection VL in macaques, following repeated low-dose vaginal SHIV162P3 challenge, 
compared to wild-type b12 [791]. Thus, it may be that other Fc-mediated activities were 
behind the previously observed increased efficacy of wild-type b12 compared with Fc-
deficient (LALA mutant) b12 [778,779] or that enhancement of FcγIIIa binding and NK 
stimulation, beyond that which occurs naturally, has little observable impact in the 
context of the antibody, SHIV challenge dose/strain and small numbers of animals 
studied. 
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Overall, with respect to anti-CD4bs antibodies, mAb concentration and ability to 
neutralize SHIV challenge virus (i.e. to both bind virus and inhibit virus-target cell 
attachment) have been shown to be the critical determinants of protection in macaques 
(following vaginal exposure), with non-neutralizing activities offering additional, but 
limited, benefits [500,778,779,791,792].  This appears to be true both for IV and topically 
administered antibodies. Whether such findings can be generalised to other mAbs and to 
human/HIV-1 contexts, has not yet been definitively established. However, they are 
consistent with the inability of IV administered polyclonal anti-HIV Ig preparations 
(containing non-neutralizing anti-Env antibodies) to protect macaques against challenge 
with several different SHIVs [490,491] and with the lack of efficacy demonstrated by 
recombinant monomeric HIV-1 gp120 vaccines in phase III trials, despite them frequently 
eliciting non-neutralizing, gp120-binding antibodies in serum [343,344 ,352]. That said, as 
highlighted by a recent vaccine study in macaques [793], antibody responses and effects 
in blood may differ from those at the mucosal interface. 
A current important question for microbicide research is whether intracellularly acting 
anti-HIV agents, e.g. tenofovir, can target HIV once it has been endocytosed by mDCs or if 
this is a potential route for HIV to escape and enable dissemination and T cell infection 
beyond the FGT [248].  Trans-infection has also been proposed as a means for pathogens 
to evade immune system recognition and avoid neutralization by antibody. However, in 
the context of the T cell-T cell VS, HIV transfer has been shown to be sensitive to blockade 
by a range of entry inhibitors, including  b12, CCR5 inhibitors, PRO 2000 and T20 [279].  
Whether this is  also true for mDC-T cell transmission is uncertain but SDF production by 
mDCs has been shown to inhibit R4 using virus transfer by VS and may help explain the 
preferential transmission of R5 virus [794]. Given that they would likely have sufficient 
time to act, mAbs which can neutralize irreversibly at low concentrations, inhibit cell-cell 
spread and mediate destruction of infected cells (via Fc mediated effects) could clearly be 
of benefit. 
Enhancements in knowledge regarding the mechanism of action of 2F5, 4E10 and 2G12 
have raised a number of questions regarding their potential efficacy as a vaginal 
microbicide. 
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1. Could virions be bound rapidly enough by 2G12 in the vaginal lumen to become 
trapped in mucus or lost in vaginal secretions  before they either pass beyond 
reach of the antibody (e.g. into the submucosa or upper FGT) or antibody 
concentrations fall to levels where they became viable again? 
2. Do 2F5 and 4E10 concentrations remain high enough for long enough on the 
mucosal surface to irreversibly neutralize virions through Env shedding?  
3. Are sufficient mAbs taken up into the mucosa to a) prevent binding of virions to 
initial target cells, b) inhibit transinfection and c) elicit Fc-mediated effects?  
Such questions will not be easy to answer. Pharmacokinetic data obtained from the 
Mabgel trial (see Chapter 3) provides a direct indication of the concentration of each mAb 
present on the vaginal surface over time, following gel application, including dilutional 
effects of vaginal secretions.  Thus, it would be possible to see if corresponding mAb 
concentrations were capable of neutralizing a range of viral isolates at likely physiological 
concentrations in-vitro. Ideally, such pharmacodynamic assessments would be conducted 
using mAbs obtained in neat vaginal secretions, and if possible, semen, to try to mimic 
the physiological situation. Unfortunately, due to the paucity of time-points where self-
aspiration was performed and the difficulties encountered with the sampling device, such 
experiments were not possible using the Mabgel samples. However, if future 
pharmacokinetic studies were conducted, neat samples, perhaps obtained using an 
INSTEAD® Soft Cup (Evofem, San Diego, California, USA) [536], could be collected at 
multiple time-points.   Such studies could also include biopsies, which would enable mAbs 
to be detected in the mucosa, and also provide tissue for explant challenge.  An ex-vivo 
technique has recently been developed whereby tissue biopsies, performed in humans at 
fixed time-points post application of a microbicide, are infected in-vitro with low-dose 
HIV-1 isolates and compared with those from untreated controls through the 
measurement of levels of p24 and integrated provirus [386].  Adaptation of such models 
may eventually enable the study of more detailed mAb-cellular interactions, although 
mimicking the exact virus: mAb concentrations and complex pharmacodynamic 
interactions that occur in natural infection would be extremely challenging. 
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6.2.3.3 mAb concentrations required for protection in-vivo 
In the absence of any direct human pharmacodynamic and efficacy data, an indication of 
whether, and for how long post application, the Mabgel could offer protection from HIV-1 
can be gained by comparing the vaginal mAb concentrations (from Weck-Cels) in our trial 
with those shown to block SHIV vaginal transmission in NHP studies. Comparisons can be 
made with vaginal concentrations of (a) transudative mAbs present after IV infusion, or 
(b) directly vaginally administered mAbs; the latter being more directly relevant to our 
study and proposed vaginal microbicide development.  
 
Unfortunately, for the initial high dose (≥ 300 TCID50) vaginal SHIV NHP challenge studies 
(using IV administered mAbs) [491,492,493], limited data was published regarding 
antibody titres in vaginal secretions at the time of challenge.  In addition, comparison 
between studies was complicated by differences in sampling methodologies and lack of 
adjustment for dilution factors [492,792].  Like other early mucosal challenge studies (see 
Table 1-8), being primarily designed to inform development of vaccines, they were largely 
concerned with identifying systemic, serological correlates of protection. Although the 
exact mAb concentrations vary, (depending on the antibody, neutralization assay, route 
of challenge, and SHIV subtype used) the majority of data suggest that sterilizing 
protective effects in-vivo require serum mAb levels in the challenged animal 30 to >100 
times higher than those needed to produce 90% neutralization in standard in-vitro 
peripheral blood mononuclear cell assays (i.e. the PBMC IC90) [493,795]. The exception to 
this is 2G12, which has been shown to mediate significant protection at serum levels close 
to the PBMC IC90 (although relatively high 2G12 concentrations are needed to attain IC90) 
[491,780].  
Encouragingly for the ‘real-world’ setting, recent NHP studies suggest that protection 
from multiple low dose (3 to 10 TCID50 SHIV) vaginal exposures may be achieved with 
serum and mucosal antibody levels around 20-fold lower than needed to prevent 
transmission from a single high dose challenge [779, 784].  Using 1mg/kg of b12 IV, in a 
multiple bi-weekly 10 TCID50 vaginal SHIV162P3 challenge model, rhesus macaques were 
protected in 104 out of 108 challenges, with median vaginal concentrations at challenge 
time points of approximately 20 and 5 μg/ml [784].  
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Unfortunately, no data is yet available regarding the vaginal levels of 2G12, 2F5 or 4E10 
that might be capable of protecting from such ‘physiological’ viral inoculae. However, for 
2F5, an idea of the concentrations needed to protect from a single high dose challenge is 
known. In a study conducted by Veasey et al, 5 macaques received a 300 TCID50 vaginal 
challenge of SHIV162P3 following a 25mg/kg IV infusion of 2F5. The challenge inoculum was 
administered at the time of peak vaginal 2F5 concentration, which was found to be 350 to 
500 μg/ml at 6 hours post infusion. No animals became infected (R Veasey and R 
Shattock, personal communication). As these researchers used the same dilution factor 
correction and ELISA methodology as we did, extrapolating to the corrected 
concentrations found in our study would suggest that the median levels of 2F5 detected 
in both the high and low dose Mabgel arms at 8 hours (post 1st dose) and 12 hours (post 
12th dose) would be sufficient to offer protection.  However, such extrapolations should 
be treated with caution. There was a wide range of mAb levels detected at all time-points 
in our study, even within each of the high and low dose groups, so all women might not 
be equally protected. In addition, mAbs detected from Weck-Cels applied to the vaginal 
wall following systemic administration reflect not only those antibodies present in the 
vagina but also those in the submucosa, i.e. the systemic to mucosal compartment 
gradient.  Since it is likely that the mAbs would be distributed more widely within the FGT 
following systemic rather than topical application it is possible that they would have a 
broader range of effects and/or a longer duration of action for the same measured 
luminal concentration. 
A more direct reflection of whether the vaginal mAb levels detected in our trial would 
offer protection from some HIV-1 strains can be gained from comparing our data with 
that from NHP challenge studies conducted by the CEA. In a study designed to investigate 
the prophylactic efficacy of 20mg/g Mabgel (2ml), 22 macaques in 4 groups (untreated 
controls, placebo-treatment 1 hour before challenge, Mabgel 1 hour before challenge and 
Mabgel 4 hours before challenge) were exposed intravaginally to 3 AID50  (50 % animal 
infectious doses) of SHIV162P3 in 50 % human seminal plasma following treatment with 
DMPA.   5/6 untreated control animals were infected, as were 4/5 animals who received 
placebo. Of the animals who received Mabgel, 1/5 became infected when challenged at 1 
hour post application and 2/6 animals at 4 hours post application [Dereuddre-Bosquet 
and R Le-Grande personal communication].  As mAb concentrations detected in our study 
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were similar in magnitude over time to those found in the macaques (see Table 3-10), 
there is potential for a similar protective effect to also be shown in women.  That said, 
physiological differences between women and macaques, and the ‘atypical’ nature of the 
challenge (SHIV162P3 is relatively susceptible to neutralization by all 3 mAbs and 3 AID50 is a 
relatively low dose challenge stock for a single exposure study) mean it is difficult to 
predict with any certainty.  In addition, as with most microbicide candidates to date, all 
animal studies have been conducted using free virions; potential efficacy against cell-
associated viral transmission is thus as yet unexplored.  Advances in the development of 
even more ‘realistic’ repeated low-dose SHIV challenge models [233,234], and in the 
establishment of reliable NHP cell-associated transmission systems [796] will hopefully 
improve the predictive accuracy of pre-clinical efficacy studies in future. 
6.2.4 Production Costs 
One disadvantage of using biological molecules produced in mammalian cells as 
therapeutic agents is their high manufacturing cost.  At present, the estimated cost of 
producing C2F5, C4E10 and C2G12 using CHO cells is 50 to 100 Euros/g of mAb (B. Vcelar, 
personal communication). Thus, each single 2.5g dose of 20mg/g Mabgel, containing a 
total of 150mg of mAbs, would cost between 7.5 and 15 Euros to manufacture, not 
including the cost of the gel vehicle. In addition, the quantities of mAbs that can be 
produced using mamalian cell-culture systems are relatively small (3 to 75 pg/cell/day 
with high-producing clones), due to the limited transcriptional and translational capacities 
of the cells [797].  Although feasible for generating therapeutic mAbs, for use in small 
numbers of individuals in wealthy nations, CHO-cell based production systems are too 
expensive and constrained for viable scale-up of a global microbicide.  Alternative 
manufacturing strategies would therefore need to be found. One potential option that is 
currently being explored is production of mAbs in plants (‘plantibodies’)[798, 799]. Viral 
vector constructs have been generated that achieve transient, rapid, high-yield 
expression of mAbs in tobacco (Nicotiana benthamiana) [800,801].  Entire mature plants 
are infiltrated with a diluted Agrobacterium suspension containing T-DNAs encoding viral 
replicons with IgG light and/or heavy chain gene inserts.  mAbs can be harvested from 
leaves within 4 to 10 days (0.5 mg of mAb per g leaf fresh weight), with production being 
directly scaleable to the volume of biomass infected [800,801,802].  Since no genes are 
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incorporated into the plant genome (unlike with transgenic plants) and no replication-
competent virus is produced, there is no risk of the transgene being spread via pollen, 
seeds, or virus [802].   
2G12, 2F5 and 4E10 have all been produced successfully in tobacco plants [803, 804, 805] 
and 2G12 has also been produced in transgenic maize [806,807]. Such mAbs have been 
shown in-vitro to demonstrate antigen recognition, FcγR binding, and HIV-1 neutralization 
capabilities that are at least as good as their CHO- cell produced counterparts, despite 
differences in glycosylation [804, 805,806, 807, 808].  IgG has an oligosaccharide 
covalently attached to a single asparagine residue (Asn 297) on the CH2 domain of each 
of its heavy chains which appears to be integral to maintaining the correct structural 
conformation of Fc [809].  Additional glycans may also be added to the Fab region. The 
nature and range of sugar moieties added varies between species, with CHO cell-derived 
glycans being more similar to those found in humans than those derived from plants 
[810,811]. However, both CHO and plant –specific oligosaccharides can potentially be 
immunogenic in humans and can influence IgG pharmacokinetics and effector functions 
[810,811, 812]. In view of their molecular differences, and the potential for 
contamination with herbicides and pesticides, plantibodies require separate evaluation 
and regulatory approval to those produced in CHO cells [798,799].  A phase 1 clinical trial 
of the safety and pharmacokinetics of  N. Benthamiana – derived, GMP grade 2G12 as a 
vaginal microbicide is due to be conducted at the University of Surry (CI Professor David 
Lewis) in 2012 as part of the EU funded Planta-Pharma project [813].  
6.2.5 Acceptability 
Predicting whether an efficacious microbicide will be used in the ‘real-world’ is a 
developing but inexact science. Historically, two approaches have been used to try to 
understand the factors that influence ‘acceptability.’  One method is to use surrogate 
products (those with similar formulation and application characteristics to candidate 
microbicides being developed) and ask women whether they would use ‘a product like 
this one’ in the future. The second method is to assess acceptability during clinical trials. 
However, as in the MABGEL1 trial, volunteers who take part in acceptibility studies or 
early phase trials are not always representative of the eventual target group for the 
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product and its evaluation is independent of sexual activity. In contrast, assessments of 
acceptability performed during efficacy studies, involving sexually active women from 
high risk populations, have greater applicability to the ‘real-life’ setting. That said, it is 
important not to equate product adherence with acceptibility, since the two are 
imperfectly related [765]. 
A woman’s decision to use a microbicide has been found to be influenced by multiple 
factors, related to herself, the product and the context [765]. User-related characteristics 
which may have an impact include ethnicity, socioeconomic status, and prior experience 
of using prevention products [814].  Contextual factors, include nature and dynamics of 
the sexual partnership, perception of HIV risk and socio-cultural influences [815,816].  
Features of the product which may impact on its acceptibility include colour, smell, 
consistency, propensity for leakage, timing and frequency of use in relation to coitus and 
overall effect on sexual pleasure [720,817,818].  
Whilst the colourless and odourless nature of the Mabgel attracted no negative 
comments, in common with other semi-solid gels, it was prone to leakage. However, as 
has also been found with other products, reports and experience of leakage varied 
markedly between women (see section 5.4.6).  In acceptability studies for cellulose 
sulphate vaginal gel and KY lubricant, 20% of participants reported gel leakage to an 
extent that it would discourage them from future use [818,819]. In research addressing 
the application of BufferGel, a significant minority of women described leakage, 
messiness and an overall negative experience [817]. When used in the context of sex, 
women’s perceptions of a product’s characteristics are often different to when used 
during sexual abstinence [817,818].  In an acceptability  study of cellulose sulphate gel 
involving sexually active women, while 40% of participants stated that the product leaked 
out during sex, 100% reported that their vagina felt ‘more wet’ which was considered a 
positive feature [720]. Experiences of South African women enrolled in the MDP 301 trial 
of PRO2000 were also positive; up to 60% reported that sex became ‘wetter’ and more 
enjoyable when using the gel and only 1% felt it had a negative impact [820]. 
Coital-dependent gel use may not be convenient for women in all parts of the world. 
Women may have little warning that sex is going to take place, or live in regions where 
‘dry sex’ is the norm [821]. In addition, frequent insertion of gel or applicators may cause 
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trauma or be associated with adverse events. In the MABGEL 1 trial, intermenstrual 
bleeding was experienced by almost half of all participants across the three study arms 
(see section 4.1.1.6).  Although it is difficult to determine whether this was related to 
background incidence, or caused / increased by the gel vehicle, gel insertion or 
examination, it was perceived to be related to product use by participants.  Even if not 
felt to be a sign of toxicity, such common AEs can be problematic, since they may deter 
women from using the product. 
As mentioned in section 1.6.6, intravaginal rings (IVR) are an alternative dosing form 
which offer long-term coitally-independent release of active agents and avoid the 
leakage, and other problems, associated with gels.  They have been shown to be 
acceptable in several studies [822,823]. However, until recently, they were only suitable 
for releasing small molecule, hydrophobic agents, such as contraceptive hormones or the 
NNRTI Dapivirine [440].   A new ring device (the insert vaginal ring (InVR®)) has now been 
developed that is capable of releasing mAbs and other proteins over an extended period, 
thus opening up possibilities for using this method in the future [824].  
An even more novel approach is the use of adeno-associated viruses (AAVs) to transfer 
genes encoding “minibodies” to cells to enable them to secrete NAbs constitutively. A 
“minibody” is a single-chain variable fragment: Fc fusion molecule which dimerizes to 
form a protein which is shorter than a full-length IgG, but with similar neutralizing 
capabilities.  To date, this strategy has been assessed in mice and NHPs, where systemic 
b12 minibodies (mice) and SIV-specific immunoadhesins (i.e. anti-SIV Fabs) (macaques) 
were produced continuously for > 1 year through transduction of muscle tissue [825,826]. 
However, although the latter afforded some protection from IV SIV challenge, this was 
hampered by transgene immunogenicity (i.e. antibodies elicited against the 
immunoadhesins).  Recently, the ability of AAVs to transduce cervico-vaginal epithelial 
stem cells has been demonstrated in-vitro, with the resulting b12 minibodies able to 
inhibit HIV-1 infectivity and transfer of cell-free virus through VEC tissues [827]. Further 
research is needed to examine the effectiveness of such a ‘self-generating microbicide’ in 
NHPs before testing in humans. 
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6.2.6 Novel anti-HIV-1 NAbs 
A growing number of novel, cross-clade HIV-1 neutralizing mAbs are being identified 
through efficient, high-throughput screening of sera from a range of HIV-1 infected 
individuals [158,485,828,829,830].  Among the first of these ‘new generation’ broadly- 
neutralizing mAbs to be discovered , PG9 and PG16 bind conserved, glycosylated epitopes 
on the V2 and V3 loops of ‘native’ trimeric gp120 or uncleaved gp160 [485]. VRCO1 and 
PGV04, recognise the gp120 CD4 binding-site [828,830]. These 4 mAbs display an overall 
greater breadth of neutralization than 2F5, 2G12 and b12, particularly to Clades A and C,  
and can inhibit most isolates at concentrations around 10 fold lower than 2F5, 2G12, b12 
and 4E10.  Thus, although none are as broadly neutralizing as 4E10 at high concentrations 
(i.e. VRC01 and PGV04 neutralize approximately 90 % of tested isolates, PG9 and 16 
around 70 % and 4E10 > 95% at IC50 < 50 μg ml
–1) at low concentrations they can 
neutralize a larger range of global HIV-1 strains than any of the four 1st generation mAbs 
[485, 828].  Recent in-vitro data has confirmed the potential for additive coverage if used 
in combination [831]. 
Recently, a range of anti-HIV-1mAbs (PGT 121-123, 125-128 130-131, 135-137 and 141-
145) have been isolated with potencies which are 10 times greater still (i.e. the median 
antibody concentrations required to inhibit HIV activity by 50% or 90% (IC50 and IC90 
values) are 100-fold lower than for the original broadly neutralizing mAbs)[828].  Several 
of these, including the broadest (PGT 128), recognise mannose (Man8/9) epitopes  on the 
gp120 glycan shield and, unlike 2G12, may mediate cross-linking of adjacent Env trimers, 
accelerating decay in viral infectivity [832].  Although individually having less broad 
maximal coverage than earlier NAbs (e.g. PGT 128 neutralized 73 % of strains at IC50 < 50 
μg ml–1), if present at the time of exposure, certain combinations have the potential to 
provide protection from the majority of circulating HIV-1 isolates at very low 
concentrations (e.g. PGT 128 + PGT 145 could neutralize 63 % of viruses at IC50 < 0.1 μg 
ml–1, compared with 1% for 4E10) [829]. Thus, their induction through vaccination or 
application as a microbicide could be highly efficacious.  However, further research is 
needed to confirm their activity and safety in-vivo and fully understand their mechanism 
(s) of neutralization. 
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6.2.7 Conclusion 
Unfortunately, given its relatively limited coverage of clade C isolates, high manufacturing 
costs, and possible need for re-formulation, the Mabgel is unlikely to be a viable global 
HIV microbicide in its current form.  However, in the light of advances in antibody 
production in plants and the ongoing discovery of novel, increasingly potent, cross-clade 
HIV-1 NAbs, the general concept of using combinations of mAbs for HIV prevention looks 
increasingly promising.  For example, a microbicide containing high concentrations of 
4E10 as a ‘backbone’ combined with 2 of the newer, more potent gp120 binding NAbs 
may have potential. Combining plantibodies with other biopharmaceuticals, e.g. lectins, is 
another way of potentially enhancing coverage breadth and efficacy [833].  The concept 
of combining microbicides with mucosally-delivered vaccines is also being explored [834]. 
Although the existing Mabgel is unlikely to be progressed further, data regarding its 
pharmacokinetics and safety will be useful in the development of future mAb-based 
products.  As calculated from the MABGEL 1 trial, the vaginal residence t ½ of the MPER 
mAbs would be compatible with their application as a coitally-dependent microbicide, 
thus demonstrating ‘proof of principle’. However, the more rapid decay of 2G12, has 
highlighted potential differences between the vaginal environment of macaques and 
humans and provided a caveat to investigate the effects of genital secretions early in 
future product development.  Results from MABGEL 1 have been considered by the 
MHRA in granting permission to conduct the 1st trial of tobacco-derived 2G12 in women 
(T Cole, personal communication, 2011). Experience gained from the trial has also 
influenced the design and conduct of a subsequent HIV vaccine study conducted on the 
EMU, including its recruitment strategy and the choice of the INSTEAD® Soft Cup, rather 
than an aspirator, for self-sampling vaginal secretions.  In addition, having had its utility 
demonstrated both in our trial, and subsequently in a trial of a dapivirine-releasing IVR 
[835], the use of PCR in the analysis of vaginal flora is gaining acceptance and has been 
incorporated into a number of planned microbicide studies. 
In spite of recent progress, we are still a long way from controlling the HIV-1 pandemic. 
Given the current economic down-turn it is now even more important that we continue 
to strive to limit the number of new HIV infections and reduce the global cost of 
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healthcare and treatment.  However, it is vital that only the most promising microbicide, 
PrEP and vaccine candidates are advanced to avoid squandering time and resources. 
Although of crucial importance, efficacious biomedical interventions will be insufficient 
on their own to reduce the sexual transmission of HIV. Ideally, they should be used as an 
adjunct to behavioural strategies, aimed at reducing numbers and concurrency of 
partners, encouraging condom use and increasing HIV testing [17]. Structural changes will 
also be required at both national and community levels to provide the financial and 
infrastructural support needed for successful implementation of behavioural and 
biomedical interventions and address policies and societial norms that pose barriers to 
HIV prevention [17,295]. A “combination prevention” approach (using multiple, co-
ordinated, evidence-based interventions operating  at individual, relationship, community 
and national levels) which is tailored to the  specific needs of each particular population, 
is  generally considered to be the only route likely to achieve a large and sustainable 
reduction in global HIV incidence [836]. 
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